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Abstract 
Electronic medical record databases (e.g. the Clinical Practice Research 
Datalink, CPRD) are increasingly used in epidemiological research. The CPRD 
has two formats of data: coded, which is the sole format used in almost all 
research; and free-text (or ‘hidden’), which may contain much clinical 
information but is generally unavailable to researchers. This thesis examines 
the ramifications of omitting free-text records from research. 
Cases with bladder (n=4,915) or pancreatic (n=3,635) cancer were matched to 
controls (n=21,718, bladder; n=16,459, pancreas) on age, sex and GP practice. 
Coded and text-only records of attendance for haematuria, jaundice and 
abdominal pain in the year before cancer diagnosis were identified. The number 
of patients whose entire attendance record for a symptom/sign existed solely in 
the text was quantified. Associations between recording method (coded or text-
only) and case/control status were estimated (χ2 test). For each symptom/sign, 
the positive predictive value (PPV, Bayes' Theorem) and odds ratio (OR, 
conditional logistic regression) for cancer were estimated before and after 
supplementation with text-only records.  
Text-only recording was considerable, with 7,951/20,958 (37%) of symptom 
records being in that format. For individual patients, text-only recording was 
more likely in controls (140/336=42%) than cases (556/3,147=18%) for visible 
haematuria in bladder cancer (χ2 test, p<0.001), and for jaundice (21/31=67% 
vs 463/1,565=30%, p<0.0001) and abdominal pain (323/1,126=29% vs 
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397/1,789=22%, p<0.001) in pancreatic cancer. Adding text records reduced 
PPVs of visible haematuria for bladder cancer from 4.0% (95% CI: 3.5–4.6%) to 
2.9% (2.6–3.2%) and of jaundice for pancreatic cancer from 12.8% (7.3–21.6%) 
to 6.3% (4.5–8.7%).  
Coded records suggested that non-visible haematuria occurred in 127/4,915 
(2.6%) cases, a figure below that generally used for study. Supplementation 
with text-only records increased this to 312/4,915 (6.4%), permitting the first 
estimation of its OR (28.0, 95% CI: 20.7–37.9, p<0.0001) and PPV (1.60%, 
1.22–2.10%, p<0.0001) for bladder cancer.  
The results suggest that GPs make strong clinical judgements about the 
probable significance of symptoms – preferentially coding clinical features they 
consider significant to a diagnosis, while using text to record those that they 
think are not.  
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1 Introduction  
The Clinical Practice Research Datalink (CPRD) is a UK-based research 
service providing anonymised copies of primary care records. It is considered 
the gold standard of primary care databases, partly because of its large size 
and generalisability to the UK population. Though created for pharmacological 
research, the database is now used extensively in epidemiological studies.1,2  
One concern for researchers using the CPRD arises from the way clinical 
events are recorded electronically. Most CPRD practices use ViSion (ViSion 
INPS, London, UK), in which GPs must choose a Read codea first to begin a 
record, after which a comments box opens.  Here, GPs can type freely and are 
not limited to elaborating on the code.3 From clinical and medico-legal 
standpoints, codes and text are equally accessible. The same cannot be said 
for research – while codes are fully and routinely available to researchers, text 
records are not. Furthermore, a moratorium on collection of CPRD text data 
was introduced in 2013. It remains possible to access text recorded before then, 
although this is complex, expensive, limited and, therefore, rarely done.b Thus, 
the clinician’s recording style may generate bias – researchers being oblivious 
                                            
a
 Read codes are a coded thesaurus of clinical terms that have been in common use in the NHS 
since 1985.  
b
 Note: on 31 March 2016, shortly after my viva, the CPRD stopped providing historical free text 
(that collected before 2013). 
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to anything that is only recorded as an inaccessible comment (henceforth called 
‘hidden text’).  
The objective of this thesis is to investigate the evidence for recording style bias 
in the CPRD, using, as an example, recently developed research methods 
underpinning risk assessment tools for GPs to assess cancer risk in 
symptomatic patients.4,5 The implications of the results for another cancer 
prediction tool, QCancer, are also discussed.6,7  
The objectives are achieved by re-creating datasets from case–control studies 
characterising the presentation of cancer in primary care, and supplementing 
them with text records for known symptoms of cancer. Three symptoms and two 
cancers were chosen to exemplify recording style bias. Haematuria and 
jaundice are high-risk 'alarm' symptoms of bladder and pancreatic cancer, 
respectively, and abdominal pain is a 'low-risk but not no-risk' feature common 
to both cancer sites.4,5  
To meet the objectives, my study addresses five specific research questions: 
1. How much symptom information is documented in electronic medical 
records using text rather than a code? 
2. Are studies of coded data vulnerable to bias arising from the differential 
use of text and codes between comparison groups? 
3. Does recording style vary with type of symptom? 
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4. Does the recording style vary with the clinical context of a symptom's 
presentation?  
5. Do text data provide additional value to coded data? 
To answer these questions, I quantify recording style bias and its effect on 
measures of association between the symptoms and cancer and on risk 
estimates for cancer (such as the positive predictive value).  
The thesis begins with an overview of the CPRD, including its history, data 
formats, strengths and limitations, and its use in research. Chapter 3 reviews 
the literature on the types of information recorded in the CPRD as hidden text. 
Chapter 4 describes the background to this work – including the Discovery 
Programme, within which this project is set. It also gives brief overviews of 
bladder and pancreatic cancer, and of the three symptoms – haematuria, 
jaundice and abdominal pain. Chapter 5 summarises the main background to 
the project and identifies the research questions addressed by my thesis. 
The methods are described in Chapter 6 and the results in Chapters 7 to 12. 
Chapter 13 is the discussion, and conclusion forms Chapter 14. The thesis ends 
with a number of appendices containing reference materials. These materials 
include my publication in The British Journal of General Practice, conveying my 
clinical findings about the risk of bladder cancer in patients with non-visible 
haematuria.8 These results were used by The National Institute of Health and 
Care Excellence in their revision of the guidelines for recognition of cancer in 
primary care and referral for investigation.9  
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2 The Clinical Practice Research Datalink  
2.1 History  
The Clinical Practice Research Datalink (CPRD) (www.cprd.com) is a UK-based 
research service that maintains a database of anonymised, electronic copies of 
longitudinal patient records in primary care. Set up for pharmacological 
research, the database was originally called the Value Added Medical Products 
(VAMP) research databank, but was renamed the General Practice Research 
Database (GPRD) in 1993 when VAMP was bought out by Reuters Health 
Information. A year later the GPRD was donated to the Department of Health.10  
The rebrand to CRPD occurred in 2012 when the NHS National Institute for 
Health Research and the Medicines and Healthcare products Regulatory 
Agency assumed a joint funding role.  For simplicity’s sake, I shall use the term 
CPRD consistently throughout this thesis, regardless of the name by which the 
database was known at the time of the study under discussion. 
2.2 Data recording  
Since the 1990s, clinical data in the CPRD have been recorded within 
contributing GP practices during patient consultations using ViSion software. 
ViSion contains Structured Data Areas, in which Read codes are used to 
describe clinical information, ‘to aid rapid and more complete recording of 
presenting symptom(s), [and] significant physical findings (positive and 
negative)…’.3 Clinical data that are not entered as Read codes are captured as 
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text, primarily in the notes written by GPs to supplement or clarify Read codes 
(Figure 2.1), and in communications to and from other healthcare providers (for 
example, hospital letters). When writing the former, GPs are not limited to 
elaborating solely upon the clinical event that prompted their particular choice of 
code; hence, the text is commonly described as ‘free’. Use of codes rather than 
text fields is encouraged, not only to fulfil the CPRD’s commitment to provide 
high-quality data for research, but also because it enables automation of clinical 
audit within a practice.3 
Figure 2.1 Screenshot showing the comments box that becomes available (red arrow) once a 
Read code has been selected in ViSion 
 
2.2.1 Use of codes versus text 
It is worth mentioning at this point that little is known about the risks and 
benefits of coding the patient history in electronic health records, or indeed 
about what motivates GPs in their choice of recording style, i.e. codes or text. 
Since the 1960s, advances in medical bioinformatics have resulted in a number 
of systems that enable structured (i.e. coded) entry of clinical information, but 
the data on their dissemination and use are scarce. Hamilton et al (2003) 
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reported on the quality of individual consultation recording in paper-only, 
computer-only and in hybrid systems (i.e. a combination of both). The quality of 
consultation recording was highest for paper-only systems, particularly 
regarding symptom recording.11 A qualitative study published 8 years later 
suggested that structured data entry remained less flexible and more time-
consuming than traditional text entry. 12 Advances in technology that address 
these objections will broaden the use of coding, as will improvements in the IT 
skills of doctors as younger generations progress through the system.  
Furthermore, a systematic review of secondary care records concluded that 
structuring the medical history increases the amount of clinical information 
gathered and makes it more amenable to being coded. However, there was 
only poor evidence that coding is associated with improved clinical decision-
making and no evidence that it is accompanied by an improvement in patient 
outcomes.13 The review noted that the lack of evidence from primary care was a 
limitation, recognising that early presentation of illness is most likely in that 
setting, arguably making it the one in which most could be gained from 
structuring and coding the patient record. Finally, no studies were identified that 
investigated the influences on choice of codes or text, highlighting the paucity of 
research into this topic.13  
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2.3 Data storage and format 
Data are uploaded to the CPRD electronically from participating surgeries 
approximately every 4 weeks via the secure NHS intranet. Once uploaded, data 
are processed into two main storage formats, medcodes or text, depending on 
the original style of data recording. The alphanumeric Read codes are 
converted to numeric medcodes in direct 1:1 mapping, such that the two terms 
are essentially interchangeable.a The purpose of this mapping is twofold: first, to 
reduce the database’s size; and secondly, to render the data more amenable to 
manipulation by information technology packages such as Stata (StataCorp, 
College Station, Texas, USA) or SPSS (IBM Software, Portsmouth, UK).14  
Any notes GPs make to supplement the codes are stored in text fields within the 
CPRD. Hospital letters sent electronically are also imported into text fields; 
however, letters on paper are scanned to a PDF file, which is attached to the 
medical record but remains inaccessible to researchers. Storage in PDF format 
is reducing hand-in-hand with IT developments that encourage paper-based 
communication to be abandoned in favour of electronic methods. Indeed, the 
electronic record (incorporating both codes and text) is viewed as the complete 
legal record.15  
                                            
a
 In this thesis, I retain the term that is appropriate to the setting; therefore, I use 'Read code' 
when discussing events during consultations with GPs, and 'medcode' in relation to analysis. 
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2.4 Strengths and limitations 
An excellent summary of advances in the utility and use of the GPRD at the 
time of transition to the CPRD can be found in Williams et al1 A recent profile of 
the CPRD was published in 2015.2   
2.4.1 Size 
An undeniable strength of the CPRD is its size. As of August 2014, 684 GP 
practices in England, Northern Ireland, Scotland and Wales were registered 
with the CPRD, covering approximately 8.8% of the UK population. At that time, 
the database contained records on 13.56 million patients whose data fulfilled 
quality criteria specified for research, of whom 5.68 million remained registered 
with a contributing GP practice.  
2.4.2 Probability sample 
A further strength relates both to the database’s size and the way that health 
care is provided in the UK. Virtually all UK nationals are registered with a GP, 
who provides primary care and acts as a gatekeeper to secondary care 
provided by the National Health Service (mainly hospital-based care). If patients 
do access secondary care directly, for example by attending the emergency 
department, this information is shared with the GP. The integration of the 
systems ensures continuity of the medical record at one point: the GP. It is a fair 
assumption that virtually all UK citizens have a chance (greater than zero) of 
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being included in the CPRD, which can therefore be viewed as a ‘probability 
sample’ of the UK population.  
A recent review reported the demographic characteristics of acceptable CPRD 
patients (as of January 2014), and the subset of those active on 2 July 2013. Of 
the 4,425,016 active patients, 2,183,161 (49.3%) were men and 2,241,855 
(50.7%) were women, reflecting national data. However, the geographical 
distribution of patients was not even across the regions. For example, 600,824 
(13.6%) of patients were in London compared with 29,954 (0.7%) in the East 
Midlands. Some of this will be accounted for by variations in population density, 
and some by the requirement of some Clinical Commissioning Groups to use 
GP systems other than ViSion.2 Despite these caveats, it is generally accepted 
that studies using CPRD data may draw inferences from their results to the UK 
population as a whole, which accounts for much of the database’s appeal.1,2  
2.4.3 Prospective data collection 
As described above (Section 2.2), clinical data are recorded during the 
consultation, i.e. prospectively. Consequently, exposure and outcome data have 
limited vulnerability to information bias.  In addition, any information transmitted 
automatically and electronically, such as test results and prescriptions, is free 
from recording bias.   
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2.4.4 Data quality 
Once uploaded to the CPRD, data are subjected to stringent quality checks for 
continuity and completeness to ensure that only data of a quality acceptable for 
research are released. Reports are sent to contributing GP practices 
highlighting any deficiencies or inconsistencies in the patient records, and 
subsequent data are refused by the CPRD if the identified shortcomings have 
not been addressed satisfactorily. A single metric, the ‘up-to-standard date’, is 
used to indicate the overall quality of data within GP practices. In essence, this 
is the last date on which the practice was considered to have provided 
continuous data of a quality high enough for research.1 One limitation to note is 
that these quality assurances are only applicable to the coded data, not the text. 
The internal CPRD metrics are unable to illuminate the uncertainty inherent in 
the text record, such as spelling and typographical errors or abbreviations 
whose definition may be either obscure or ambiguous; for example, MVR could 
be mitral valve repair or mitral valve regurgitation. Therefore, researchers must 
ensure their search criteria are broad enough to maximise the capture of entries 
made using shorthand or acronyms. Furthermore, researchers including text 
data need to devise their own quality checks to quantify the errors associated 
with any variables they generate from this part of the CPRD.  
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2.5 Data access and use in research 
The CPRD is widely used in epidemiological research, resulting in over 850 
research papers to date (www.cprd.com/Bibliography/Researchpapers.asp, 
accessed 25 September 2015). 
Researchers wanting to use CPRD codes as their data source can purchase 
online access to the most recent version of the primary care datasets via the 
CPRD GP online data subscription service, aptly known by the acronym CPRD 
GOLD. Access to powerful query and extraction tools enables these 
researchers to build their own datasets. An alternative, cheaper, option is to buy 
ad hoc datasets assembled by the CPRD according to the researcher’s 
specified criteria. 
Information stored in text fields is not routinely available to researchers, 
primarily because it may contain information that identifies the patient. This has 
always been the case; indeed, since the inception of the CPRD, as shown in my 
literature search, researchers have never routinely requested supplementary 
text data. Furthermore, a moratorium on collection of CPRD text data was 
introduced in October 2013, owing to an unspecified governance requirement. 
The CPRD are working to remove this restriction, so that text data collection 
can recommence. Until then, the CPRD will provide access to extracts of the 
text collected before October 2013, in line with a researcher’s specified search 
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terms, although this service is fairly costly owing to the extensive manual 
checks required to ensure complete anonymisation of the record.a   
Once the study participants have been identified and their raw data files have 
been extracted from the CPRD, researchers use statistical software or data 
management software for further processing and analysis. Codes require a 
minimum of pre-processing for conversion to variables suitable for analysis.15 In 
contrast, manual interpretation and other work-up, all costly and time-
consuming, are required before the information stored in text fields can be used 
in research. The extra cost and analytical complexity of including text data in 
research present such barriers that the default position is for researchers to 
restrict their analysis to codes. The ramifications of this data loss are poorly 
investigated and form the subject of this thesis. 
2.6 Other electronic databases 
The CPRD is one of three main electronic databases of medical records 
collected as part of everyday clinical care in the UK. The others are The Health 
Improvement Network (THIN) and QResearch,16 which are briefly discussed 
below.  
                                            
a
 Note: On 31 March 2016, shortly after my PhD viva, the CPRD stopped providing historical 
free text (i.e. that collected before 2013).  
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2.6.1 The Health Improvement Network 
The Health Improvement Network (THIN) is a large database of primary care 
records collected as part of routine clinical care provided by general practices 
throughout the UK. It was established in 2003 in a collaborative project between 
In Practice Systems Ltd (INPS, London, UK) and Cegedim Healthcare Software 
(Boulogne-Billancourt, France), which was later acquired by IMS Health 
(London, UK). It is primarily used for pharmacoepidemiological research.17 
THIN shares many of its strengths and limitations (see Section 2.4) with the 
CPRD, not least because they both collect data using ViSion (INPS). Indeed, a 
validation study reports that there is considerable overlap between the two 
databases, with some THIN practices previously contributing, or still currently 
contributing, data to the CPRD.17  
Most recent data indicate that 587 general practices currently contribute data to 
THIN, and that the database holds copies of records for 12.4 million patients, of 
whom 3.6 million are still active. As this amounts to ~5.7% of the population, the 
database is generally perceived to be a representative sample of the UK; 
however, no geographical distribution data for THIN have been published in 
order to assess the validity of this assumption.a    
As with the CPRD, data are recorded using a code or in the free text, and the 
latter are available to researchers at additional cost. THIN is widely used in 
                                            
a
 See http://www.csdmruk.imshealth.com/our-data/statistics.shtml (accessed 17 May 2016). 
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research and has generated more than 500 publications to date, with an 
emphasis on pharmacoepidemiological studies.a 
The main difference between the CPRD and THIN is one of governance – the 
CPRD is funded and managed jointly by NHS National Institute for Health 
Research and the Medicines and Healthcare products Regulatory Agency, 
whereas THIN is owned by IMS Health and managed via University College 
London.b 
2.6.2 QResearch 
QResearch is a not-for-profit partnership between University of Nottingham and 
EMIS Health (Leeds, UK) that was established in 2004.18 No database profile 
for QResearch has been published and the following information is taken from 
either the QResearch website (www.qresearch.org) or from a recent paper 
published by QResearch co-director, Professor Julia Hippisley-Cox.19 
QResearch currently holds copies of the electronic medical records from 
approximately 1,000 general practices throughout the UK covering a population 
of more than 20 million people. Data are collected as part of routine care using 
                                            
a
 See 'Primary Care Database Publications List' at http://www.ucl.ac.uk/pcph/research-groups-
themes/thin-pub/publications (accessed 17 May 2016). 
b
 See 'THIN Database Research Team' at http://www.ucl.ac.uk/pcph/research-groups-
themes/thin-pub (accessed 17 May 2016). 
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EMIS software.a Like the CPRD and THIN, QResearch data include 
demographic information, diagnoses, prescriptions, referral information as well 
as laboratory and clinical test results. Diagnoses, symptoms and other clinical 
information is recorded using Read codes or text.  
QResearch shares many of the strengths and limitations of the CPRD (see 
Section 2.4); however, it is likely that data loss in hidden text is likely to be even 
greater than in the CPRD because, unlike ViSion, EMIS does not insist on use 
of Read codes to initiate a medical record. Thus identification of specific 
diseases and symptoms is more complex than in the CPRD or THIN. It's not 
clear whether all the record is stored in a free text field, or whether there are 
separate 'coded' and free text sections. For the purposes of this thesis, there is 
no available free text section allowing study of missing data. 
Various American databases exist, such as Kaiser and UW Medicine. These 
are created predominately for billing purposes and so have limited applicability 
for epidemiological research. Similar to QResearch, it is not clear whether there 
are two tiers of recording. 
                                            
a
 See 'What is QResearch?' at 
http://www.qresearch.org/SitePages/What%20Is%20QResearch.aspx (accessed 17 May 2016). 
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3 Literature review: what is stored as text in the CPRD 
and what is its value?  
A literature review was conducted to identify the type and value of information 
recorded as text within the CPRD, as this is the first step in clarifying the 
methodological consequences of omitting text data from analysis. Potential 
methodological concerns include under-reporting, with attendant 
underestimation of prevalence. Under-reporting that is not random – for 
example, being associated with a particular patient subgroup – will lead to bias. 
These errors are of specific concern for not only the research community but 
also the policy-makers and health service providers whose decision-making 
hinges on the quality of the evidence base.  
3.1 Literature search criteria 
The research question posed was, ‘What type of information is stored solely as 
uncoded free text in the UK-based Clinical Practice Research Datalink (formerly 
General Practice Research Database), a database of electronic health 
records?’ EBSCOHost was used to identify pertinent literature from the Medline 
database, including e-Journals. The search terms chosen and number and 
details of references found are displayed in Table 15.1 (see Appendix 1: 
Literature search tables): 51 papers of potential relevance to the research 
question were identified. After review, 10 published papers were retained for the 
final review. Reference lists within the retained publications were checked, 
which identified one relevant conference proceedings report. Citations of all 
49 
 
selected publications were found using Web of Science, but identified no further 
papers for inclusion in this review. Reasons for exclusion are given in Table 
15.2. 
3.2 Findings from use of text in validation studies  
In systematic reviews, Herrett et al20 and Khan et al 21 reported on the value of 
text data as a tool for ‘validating’ clinical data recorded elsewhere in the CPRD. 
Nicholson et al15 defined validation in this context to mean not only how 
accurately the selected code reflected the GP’s thinking at the time but also 
whether the correct diagnosis was made. Internal validation, against the 
patient’s medical record or by separate GP questionnaire, is a standard way of 
checking agreement between a code and the GP’s opinion. Confirming whether 
the correct diagnosis was made involves external validation against a gold 
standard, often the opinion of a hospital specialist. Increasing integration of the 
entire medical record (including communications from secondary care) into text 
fields illustrates the significance of this part of the CPRD to validation, and 
hence to research.  
Seven validation studies were identified whose results suggest the type of 
information that is stored solely as text in the CPRD. Their findings also 
illuminate how to optimise access to, and use of, information in text fields and 
hint at the ramifications of ignoring this part of the CPRD in terms of identifying 
cases, outcomes and exposures.  
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3.2.1 Pregnancy and pregnancy outcome validation studies  
The CPRD is an excellent database for examining pregnancies and pregnancy 
outcomes, because its research information requirements were designed to 
enable the data to be captured in sufficient detail for use in drug safety studies.3 
The current CPRD’s data recording guidelines for ViSion, published in 2004, 
recommend that Read codes are used to record live births, spontaneous 
abortions and terminations in the mother’s record.3 Foetal abnormalities and 
serious congenital malformations should also be noted in the mother’s record. 
This is to protect against data loss in the event of a prolonged hospital stay or 
early death, as a result of which the infant may never register with the mother’s 
GP practice. The guidelines stress the importance of making it clear that such 
outcomes relate to the foetus/infant and not the mother. To achieve this, they 
suggest input of a ‘general’ Read code indicating contact with the health service 
for something other than illness (often denoted with the prefix [V]), and using 
the text field to note the details of the anomaly. Therefore, text has the potential 
to be a rich source of information for studies of adverse pregnancy outcomes. 
Three studies have examined the CPRD’s utility as a validation tool, as 
described below. 
First, Wurst et al22 carried out a validation study of CPRD data recorded 
between January 1992 and February 2005 for three specific congenital heart 
defects: ventral septal defect, coarctation of the aorta and tetralogy of Fallot. 
Case records are commonly validated by questionnaire in conventional 
research projects, in an expensive and time-consuming procedure. The authors 
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sought to find whether information in the mothers’ and infants’ text fields in the 
CPRD could be extracted and used for validation in place of questionnaires. A 
thesaurus of codes pertaining to the congenital heart defects was drawn up, 
reflecting codes used by GPs during the time of the study. Read codes and their 
forerunner Oxford Medical Information System (OXMIS) codes, which were 
used in VAMP, identified 24 cases of coarctation of the aorta, 72 cases of 
tetralogy of Fallot and 373 cases of ventral septal defect in the CPRD. Of these, 
104 were randomly selected for inclusion in the study. Text fields in the infant 
record paired with the first occurrence of a Read or OXMIS code were searched 
for keywords relating to congenital heart defects, such as ‘congen*’, ‘heart’, 
‘Fallot’, ‘tetra’, ‘cardiac’, ‘defect’, ‘anomal*’ and ‘septal’. All text fields in the 
maternal record were searched for the same terms in the year before and 2 
years following the infant’s delivery date. Outcome measures included 
concordance between information in text fields and that obtained from a 
practitioner questionnaire. Text records were available for only about 50% of the 
infants in the study. Nevertheless, concordance with questionnaires was high 
(ranging from 92% to 100% on the various measures), leading the authors to 
conclude that infant text fields have potential for case report validation. Text 
from the maternal record yielded no information that was not otherwise 
available through the medical record or the infants’ text fields. Indeed, only 31% 
of mothers’ records contained any information at all about the infant’s heart 
defect. This is perhaps unsurprising, given that the guidelines recommending 
use of mothers’ text fields to record details of anomalies were published in 
2004, near the end of the study period. The authors recommended that future 
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studies should examine infant text fields paired with every occurrence of the 
Read/OXMIS code rather than just the first, to maximise the amount of 
information retrieved and minimise the need for questionnaire validation. 
However, in light of the updated recommendations in force since 2004, it would 
be unwise not to include the mothers’ text records in future studies as well. 
Secondly, Devine et al23 developed an algorithm to identify pregnancies within 
the CPRD and subsequent outcomes over the period 1 January 1987 to 31 
December 2006. A thesaurus of pregnancy codes (Read and OXMIS codes) 
was compiled and each code was categorised in relation to an end-of-
pregnancy event or pregnancy care. Two tools were used to validate the 
algorithm. In the first, live birth and miscarriage counts generated from the 
algorithm were compared with data held in the additional clinical details 
maternity (ACDM) file, which contains information on completed births and 
miscarriages in the CPRD. In the second, text fields recorded 2 weeks either 
side of the end-of-pregnancy date were searched for a list of terms chosen to 
optimise the identification of a wide range of possible pregnancy outcomes. The 
presence of one of these terms was taken as validation of the algorithm. 
Concordance between the algorithm and information in text fields was reported 
in terms of percentage agreement and kappa score. Both validation tools were 
consistent with the algorithm for the outcome of live births. However, for 
spontaneous abortion and miscarriage, while the ACDM file did validate the 
algorithm, the text did not (percentage agreement 77%, kappa score 0.36). 
Similarly low kappa scores were found for other pregnancy outcomes, such as 
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elective termination and multiple births. The authors suggested that use of less 
specific search terms for live births compared with other possible pregnancy 
outcomes explained their results. They concluded that future studies should 
examine the entire text field rather than search for particular terms to remove 
dependence on search term specificity. It is worth considering whether the 
choice of study period can shed further light on the authors’ results. The chosen 
study period (1987-2006) coincides with the initiation and early development of 
VAMP, during which time recommendations regarding use of codes and text 
were being refined. It would be interesting to re-examine the performance of the 
validation tools during a period of consistent recording practice. In mitigation, 
the number of pregnancies identified early on was relatively small (271 in 1987, 
15,750 in 1990) compared with later on (43,408 in 2006).  
Thirdly, Charlton et al24 studied the utility of the CPRD in the surveillance of 
pregnancy outcomes to identify potential teratogens. The study population was 
derived from women in the CPRD with a live pregnancy outcome between 1 
January 1990 and 31 December 2006 and a medcode for a diagnosis of 
epilepsy, seizure or convulsion. The offspring of these mothers were identified 
and mother-baby pairs included in the study sample (n = 3,869) if the baby 
remained registered within the CPRD for 3 months after birth. Using a 
thesaurus of pertinent medcodes, 188 potentially major congenital 
malformations in 161 children were identified. Verification of the congenital 
malformation was carried out by manual review of a photocopy of the child’s 
complete medical record (n = 109 malformations) or, where this was not 
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available, the entire text (n = 77). The medical record verified the coding of 100 
of the 109 (91.7%) congenital malformations, whereas text performed less well, 
verifying 60 out of 77 (77.9%). The authors reported that text was less reliable 
than the medical record as a verification tool and presumed this was partly 
because it omits paper communications, which are not available to researchers. 
As noted above, this is likely to reduce as a problem in the long term, because 
increased use of electronic communication between other healthcare providers 
and GPs will enhance the level of detail recorded in searchable text fields. 
However, the study was limited by not examining the mothers’ text records, as 
this may have been a valuable source of information about congenital 
malformations.  
3.2.2 Other validation studies 
In response to concerns over the completeness and accuracy of information 
held in cancer registries, Boggon et al25 carried out a validation study to 
compare information held in the National Cancer Data Repository (NCDR) and 
the CPRD. Concordance between the two datasets was taken as confirmation 
of cancer. If cases were identified on the NCDR but not the CPRD, text was 
searched for a thesaurus of terms validated separately by manual inspection of 
a small sample of CPRD records. Overall the level of concordance between the 
two databases was high. Across all cancers combined, the CPRD identified 
2.1% more cases than the NCDR; however, for colorectal, lung, urinary tract 
and pancreatic cancers the converse was true. Of the 5,676 cases identified in 
the NCDR, 5,335 (94%) were recorded in the CPRD, 624 of which were stored 
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in text fields only, amounting to 11.0% of the NCDR figure. The authors 
considered a number of possible reasons for the apparent disagreement 
between the data, including the fact that the CPRD and NCDR use different 
coding thesauri, and the stage of disease at diagnosis. For lung and pancreatic 
cancers in particular, which have a poor prognosis, some patients present as 
emergency admissions to hospital and are diagnosed with cancer shortly before 
their death. It is feasible that such diagnoses are never recorded in the patient's 
primary care record.  
Boggon et al's study indicated not only the importance of verifying diagnostic 
code thesauri, but also the potential use of text for case ascertainment, 
particularly for the two cancers investigated as part of my PhD, bladder and 
pancreatic cancer. 
Close et al26 estimated the relative risk of renal failure or impairment in patients 
with bipolar disorder according to age, gender and exposure to lithium. The 
study also attempted to validate recording of lithium use in Prescription Pricing 
Authority (PPA) codes within the CPRD. Internal validation procedures included 
examination of the complete text field, although this was only available for 44 of 
the 77 (57%) confirmed cases of renal failure. Of these 44 patients, all 28 who 
had PPA codes for lithium were validated by text. Lithium exposure duration 
was confirmed for 22 of these 28 patients; for the remaining 6 patients, duration 
was reportedly underestimated by between 4 and 32 years (mean 12.3 years, 
SD 10.3 years). However, the large size of the standard deviation relative to the 
mean suggests that the data were not normally distributed and that a non-
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parametric measure of central tendency would have been more appropriate. 
Letters from secondary care for 16 patients who did not have PPA codes for 
lithium indicated that they had indeed been prescribed the drug. The authors 
concluded that exposure to lithium and potentially other medications may be 
underestimated in studies using CPRD data, especially if uncoded data are 
ignored. The study can be criticised not only for its choice of descriptive 
statistics, but also for its approach to determining both renal failure and lithium 
use. For renal failure, diagnostic and referral codes were used, but laboratory 
test results of kidney function, objective markers of renal failure, were omitted. 
For lithium use, using the therapy file rather than PPA codes would have 
captured all prescriptions originating in primary care and, in theory although 
maybe not in practice, those in secondary care. This is important because 
lithium is a specialist drug, and it is plausible that not all prescriptions were 
issued by the GP. Therefore, one could argue that the authors did not choose 
the optimal validation tool available to them. 
Thomas et al27 reported on the validation of suicide and self-harm recording in 
the CPRD between 1 January 1998 and 31 December 2010 by comparison with 
Office for National Statistics (ONS) and Health Episode Statistics (HES), 
respectively. Coded CPRD data failed to identify 1,670 (74%) out of 2,260 ONS-
confirmed suicides between these dates. Using wild cards to allow for variation 
in terms, they searched the text fields for pertinent phrases, for example 
‘suicid*’, and picked up an additional 179 completed suicides, accounting for 
10.7% of the missed cases. Coded CPRD data on self-harm failed to identify 
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622 patients admitted to hospital (HES data) with self-harm in 2010. Searching 
the text for phrases such as ‘overdose’, ‘self*harm*’ and ‘self*injur*’ identified 
101 (16.2%) of these missed cases of non-fatal self-harm. Thomas et al 
concluded that CPRD codes underestimate the incidence of both completed 
suicide and self-harm and that information stored in the text accounts for only 
part of this under-recording. Initially, one might be unsurprised to discover that 
the CPRD under-reports suicide, an event that generally occurs outside a GP’s 
surgery. However, this finding should be considered in terms of the current 
recording guidelines for ViSion3 (while recognising that they only came into 
force in the middle of study period). The CPRD emphasise the need to record 
the date, fact and cause of death, as all are extremely important outcomes for 
research; indeed, it is a contractual requirement for practices to notify their 
Health Authority of a patient’s death. Consequently, the CPRD designed a 
Death Administrative Management Plan specifically to collect this information 
using Read codes. The guidelines list specific codes that might be selected and 
do not specify any circumstances where text should be used instead. It would 
be valuable to know whether the fact of death was also under-recorded in the 
CPRD for those patients whose suicide was not identified, but regrettably these 
data were not reported.  
Finally, Shah et al28 analysed text fields to validate an algorithm for identifying 
cause of death in a random sample of 3,310 patients who died in 2001. The 
algorithm performed with a positive predictive value of 98.4% (95% CI: 97.2–
99.2) and sensitivity of 92.9% (95% CI: 90.8–94.7). Cause of death was 
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recorded solely as text in 19.4% of a random sample of 3,310 patients 
registered in the CPRD who died in 2001, suggesting that coded data alone 
under-report this outcome. Again, it would be valuable to know whether the fact 
of death was similarly under-reported.  
3.3 Findings from studies into automated text processing 
As indicated by the validation studies discussed above, valuable information 
can be obtained from studying the text fields and progress is steadily being 
made to overcome the aforementioned barriers to routine use of these data. 
Indeed, techniques are available to automate the interpretation of text, ranging 
from simple searches for key terms, through computer-based algorithms, to 
natural language processing (NLP).  NLP is roughly defined as intelligent 
processing of human language by computers; it has application in both 
information extraction and the automated interpretation of text.29 There is 
understandable interest in applying NLP techniques to research using electronic 
health records. The Patient Records Enhancement Programme (PREP), funded 
by the Wellcome Trust and based at the Universities of Brighton and Sussex, 
aims to enhance access to text fields and is working closely with the CPRD. 
The findings of studies published as part of this programme are discussed 
below, in terms of information ‘hidden’ in the text.  
3.3.1 The PREP studies  
Tate et al30 focused on how accurately coded diagnosis dates matched the 
actual dates on which the diagnoses were received. Participants were 344 
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women with a coded diagnosis of ovarian cancer recorded between 1 June 
2002 and 31 May 2007. The group obtained the entire text record for these 
patients recorded in the year prior to their diagnosis. The results suggested that 
omitting to examine the text may mislead researchers into thinking that a 
diagnosis was made later than it actually was: for 22% of 344 women in the 
study, evidence of the diagnosis was recorded in the text before the diagnostic 
code was assigned. The median time difference was 24 days (interquartile 
range: 8–67 days), but for 34 (10%) of patients, the diagnosis was recorded in 
the text more than 4 weeks before it was coded. The authors acknowledged the 
limitation that they did not investigate whether ignoring the text causes 
information to be missed completely (i.e. false-negative misclassification), 
because they did not identify patients whose diagnosis was recorded solely as 
text.  
Nicholson et al31 picked up on the aforementioned limitation and analysed text 
fields in an attempt to maximise the probability of identifying all patients with a 
diagnosis of rheumatoid arthritis within the CPRD. The authors proposed that 
evidence of the disease should be sought from three sources: level 1, 
diagnostic codes for rheumatoid arthritis; level 2, codes from other domains, 
such as symptoms or test results; and level 3, text. The amount of information 
recorded solely in the text was not reported; nevertheless, the authors 
concluded that using codes alone for case definition carried the potential both to 
miss patients diagnosed with the disease and to assign an incorrect date on 
which the diagnosis was made. 
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Ford et al32 examined CPRD medcodes and text on 6,387 patients aged 30 
years and older who had a first coded diagnosis of rheumatoid arthritis between 
2005 and 2008. They searched all text recorded in the year before the medcode 
was entered and found key words indicating a diagnosis of rheumatoid arthritis 
in 29% of these patients. Additionally, text contained key words suggesting a 
diagnosis of inflammatory arthritis in 14% of patients but only 706 (11%) 
actually had a diagnostic code for the disease. Codes for synovitis were 
recorded for just 179 (3%) of patients, but a search of the text revealed that an 
additional 1,168 (18%) of the patients had keywords related to this condition. 
Finally, a positive test result for rheumatoid factor was found in text alone in 
13% of the patients. The text note was most likely to be associated with 
medcodes for letters and communications. The authors acknowledged that a 
major limitation of their work is that they did not identify negation of their key 
words; therefore, a proportion of the uncoded records may denote the absence 
of a symptom of inflammatory arthritis, or its presentation by someone other 
than the patient. The authors conceded that they may have overestimated the 
extent of information hidden to studies restricted to codes.  
As noted in a conference proceedings report, Koeling et al33 analysed the same 
dataset as Tate et al30 and searched the text fields (GP supplementary notes 
and hospital letters) of all 344 patients in the year prior to their diagnosis of 
ovarian cancer for references to five commonly occurring symptoms. Negation 
of symptom reporting was identified using an algorithm. The incidence of each 
symptom was increased markedly by inclusion of information recorded in the 
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text: abdominal pain rose from 147/344 (43%) to 208/344 (60%); urogenitary 
problems, 87 (25%) to 140 (41%); abdominal distension/bloating, 86 (25%) to 
190 (55%); constipation, 57 (17%) to 127 (37%); and diarrhoea, 28 (8%) to 87 
(25%). To the best of my knowledge this is the only CPRD study to have 
examined symptom recording restricted to text fields.  
3.4 Conclusions  
This review confirms that few studies include information recorded in text in the 
CPRD, with the majority restricting their analysis to coded data. Therefore, even 
if the effects of attendant data loss are small, the impact will be pervasive. 
Indirect evidence from validation studies suggested that ignoring text fields 
incurs data loss, leading most notably to inaccuracies in patient outcomes and 
case ascertainment. Validation studies revealed nothing about loss of symptom 
information and the evidence regarding loss of data on drug exposure was 
rather weak. Nevertheless, it is apparent that valuable information can be 
obtained from studying the text fields and that CPRD codes alone do not reflect 
the complete medical record.  The PREP studies provided stronger evidence of 
data loss, and suggested that restricting analysis to coded data will lead to 
errors in diagnosis date and case ascertainment as well as underestimation of 
symptom prevalence.  
To the best of my knowledge, no studies have attempted to quantify any bias 
introduced by this data loss. This is important not least because CPRD data are 
increasingly used in primary care research studies, whose findings have the 
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potential to influence public health policy and practice within the National Health 
Service. As this review highlights, an unknown quantity of potentially valuable 
information is held solely in text format within the CPRD, with barriers to access 
meaning that it is generally ignored by research.  Rapid advances in the 
automated interpretation of text are being made, such that the inclusion of text 
into research studies may become routine in the future, but only if governance 
restrictions on the collection of such data are lifted (see Section 2.5). However, 
until such time arrives, it is important to investigate and quantify the impact of 
ignoring this section of the CPRD on research outcomes. These topics form the 
basis of my PhD studies. 
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4 Using symptoms of cancer to study the impact of 
data loss in ‘hidden’ text  
4.1 Introduction 
Cancer is a significant source of morbidity and mortality in the UK. For example, 
the latest data summarised by Cancer Research UK indicate that, in 2012, over 
338,000 people in the UK were diagnosed with a form of the disease, and that 
there were approximately 162,000 cancer deaths.34 Survival of most adult 
cancers in the UK has generally been poorer than that in comparable western 
European countries.35 This observation prompted a number of UK Government 
policies, including The NHS Cancer Plan36 in 2010 and its successor The 
National Cancer Strategy37 in 2011. The clinical evidence to support policy 
decisions has been provided by a number of research programmes, including 
the National Awareness and Early Diagnosis Initiative (NAEDI) and the 
Discovery Programme.  
Discovery was a UK-based programme funded by the National Institute for 
Health Research whose aim was to expedite the diagnosis of cancer in 
symptomatic patients who present in primary care. The Universities of Bristol, 
Cambridge, Bangor, Durham, Oxford and Exeter as well as Bristol NHS Clinical 
Commissioning Group all contributed to the programme, which officially ended 
in June 2015. Theme 2 of the Discovery Programme analysed CPRD data to 
model the presentation of cancer in primary care; therefore, it was selected as 
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an ideal forum for investigating the potential impact of symptom data loss in 
‘hidden’ text.  
4.2 Theme 2, the CAPER Studies 
In Theme 2, the Cancer Prediction in Exeter (CAPER) Studies determined how 
cancer – 13 sites to be studied in total – typically presents in primary care. 
Observational studies for each cancer were conducted with data from the 
CPRD (see review in Section 2). Using a variant of the case–control study 
design, the main clinical features of cancer presentation were identified and 
their associated risk of cancer quantified, singly and in pairs. The main outputs 
of this work are risk assessment tools, which describe the risk of cancer with 
symptom combinations.  
An evaluation of risk assessment tools was conducted in a cohort study of 614 
GPs from 165 practices in England. The results suggested that use of risk 
assessment tools was accompanied by increased diagnostic activity and 
additional cancer diagnoses. However, the study was not designed to determine 
whether these changes were wholly attributable to implementation of the risk 
assessment tool.38   
A review of risk prediction tools for cancer in primary care was published 
recently. It highlighted the uncertainty that remains over their clinical utility, and 
called for further research into their implementation in primary care, so that their 
use maximises benefits while minimising harm.39 This requires knowledge of the 
risk assessment tool's accuracy to predict the chances of cancer in symptomatic 
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patients. My study is designed specifically to address one aspect of this – the 
introduction of errors associated with restricting analysis to clinical information 
recorded by GPs using Read codes, and ignoring anything noted in the text. 
4.3 Selection of cancer and symptoms to be studied 
At the time of writing, the CAPER Studies had published their findings on the 
main features of nine cancers in primary care – bladder,4 pancreatic,5 kidney,40 
oesophago-gastric,41 breast42 and uterine43 cancers, as well as myeloma44 and 
non-Hodgkin45 and Hodgkin46 lymphomas.  
Bladder and pancreatic cancer were chosen to be the exemplars, because they 
share a common symptom, abdominal pain, thus permitting comparison of its 
recording between cancers. In addition, each of these cancers has a 
characteristic headline or ‘alarm’ feature. Text recording was examined for three 
features; namely, haematuria (the alarm symptom for bladder cancer), jaundice 
(the alarm feature for pancreatic cancer) and abdominal pain. Additional 
reasons for their selection included the fact that they are not part of the Quality 
and Outcomes Framework initiative; therefore, their recording is unlikely to be 
influenced by financial incentives.47 Finally, uncertainty around their presence 
and severity varies, which may affect GPs’ recording style. Abdominal pain has 
many causes and is assessed by both clinical examination and subjective 
patient reporting. In contrast, jaundice and visible haematuria are determined 
objectively and both arouse a strong clinical suspicion of serious pathology. 
 
66 
 
The cancers and symptoms chosen for this study are now discussed in detail, to 
give sufficient context for interpretation of the clinical and methodological 
findings of the study.   
4.4 The cancers 
4.4.1 Pancreatic cancer 
4.4.1.1 The pancreas 
The pancreas is a soft, lobulated gland that lies between the posterior 
abdominal wall and the peritoneum at the level of the lumbar spine (L1–L2). The 
organ is 12–15 cm long and, shaped like the letter J, consists of a head, neck, 
body and tail. Its head sits in a curved loop of duodenum, from which point the 
body extends superiorly and to the left. Its tail – forming the bulk of the 
pancreas – lies adjacent to the spleen, close to the posterior abdominal wall. 
The pancreas functions as an exocrine gland, secreting digestive enzymes, and 
as an endocrine gland, secreting the hormones insulin and glucagon.48  
4.4.1.1.1 Exocrine function 
The exocrine portion makes up 98% of the pancreas. It produces enzymes 
essential for the breakdown of carbohydrates, proteins and fats ingested as 
food into smaller molecules that can be absorbed from the small intestine into 
the blood stream.  
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Enzyme synthesis occurs in acinar cells in the pancreatic tail. In brief, three 
main types of enzyme are produced: protease (to digest protein), lipase (to 
digest fat) and amylase (to digest carbohydrate).  
Acinar cells are clustered into lobules around a central lumen that forms the 
beginning of a ductule. The ductules draining these lobules form a network of 
ducts that feed into the main pancreatic duct (duct of Wirsung) that runs from 
the tail of the pancreas to its head. Cuboidal epithelial cells lining the pancreatic 
ducts release a bicarbonate-rich fluid, which forms an alkaline pancreatic juice 
in which the digestive enzymes flow along the ductule system. The main 
pancreatic duct joins the common bile duct, which originates in the gallbladder, 
and together they drain into the duodenum at the ampulla of Vater. Thus, there 
is a clear delivery pathway from the place of digestive enzyme production, the 
acinar cell, to the site of action in the duodenum.48,49 
4.4.1.1.2 Endocrine function 
The endocrine portion makes up 2% of the pancreas, in the form of cells called 
Islets of Langerhans. These cells secrete hormones, most of which are 
essential for the control of blood glucose; for example, insulin and glucagon. 
Islets cells are highly vascularised; even though they make up just 2% of all 
pancreatic tissue, they receive a disproportionate 10–15% of the organ’s overall 
blood supply. This facilitates the release of their hormones directly into the 
blood supply – the distribution of endocrine pancreatic hormones does not take 
place via the exocrine pancreatic duct system. 
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4.4.1.2 Definition of pancreatic cancer 
Malignant neoplasms can arise in the head, neck, body or tail of the pancreas. 
According to the International Classification of Disease, pancreatic cancer falls 
under the category C25.  
4.4.1.3 Risk factors 
Parkin et al50 estimated that 28.7% and 12.2% of the incident pancreatic cancer 
cases in the UK in 2010 were due to tobacco smoking and obesity, respectively. 
In a review article, Hidalgo cites evidence that the risk of pancreatic cancer in 
smokers is 2.5 to 3.6 times that in non-smokers, with the risk increasing the 
greater the exposure.51  
Aside from these lifestyle factors, there is some evidence to suggest a familial 
cause in some cases. For example, in a collaborative case–control study, the 
Pancreatic Cancer Cohort Consortium found evidence of a moderate 
association between a family history of pancreatic cancer and risk of developing 
the malignancy (odds ratio 1.76, 95% CI: 1.19–2.61). The association may arise 
from shared genetic risk factors, such as inherited mutations, although these 
are rare. The association may also arise from shared environmental risk 
factors.52  
Other lifestyle factors, such as alcohol, red meat consumption and exposure to 
radiation, have been investigated but the evidence for their association with 
pancreatic cancer is limited.53  
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4.4.1.4 Incidence 
The latest statistics summarised by Cancer Research UK report that 8,773 
people (4,328 new cases in men; 4,445 in women) were diagnosed with 
pancreatic cancer in the UK in 2011. These figures equate to age-standardised 
incidence rates of 10.8 (95% CI: 10.4–11.1) per 100,000 men and 8.7 (95% CI: 
8.5–9.0) per 100,000 women. In terms of ranking, pancreatic cancer is the 13th 
most common cancer in men and the 9th most common cancer in women.53 
The incidence of pancreatic cancer rises with age. Current incidence rates are 
low and similar in men and women below the age of 40 years. The incidence in 
men and in women rises sharply as age increases above 50 years; for example, 
from 5 to 9.2 per 100,000 men and from 3.3 to 7.3 per 100,000 women in the 
age bands 45–49 years and 50–54 years, respectively. Incidence then 
increases steadily, to peak in those aged 85 years or older, at 109.4 per 
100,000 men and 92.6 per 100,000 women.53 
Aggregate incidence data for pancreatic cancer in each year of the recruitment 
period of my study are plotted in Figure 4.1. The incidence in men was fairly 
stable throughout the study period at between 10 and 11 cases per 100,000 
men. In women the incidence fluctuated above and below 8 per 100,000 women 
between 2000 and 2004, after which it tended to rise to reach a value of 8.7 per 
100,000 women in 2009.53  
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Figure 4.1 European age-standardised incidence rates for pancreatic cancer per 100,000 
population; UK data 2000–2009 
 
Note: Adapted from a graph prepared by Cancer Research UK 
Original data sources: 
1. Office for National Statistics. Cancer Statistics: Registrations Series MB1. 
http://www.statistics.gov.uk/statbase/Product.asp?vlnk= 8843. 
2. Welsh Cancer Intelligence and Surveillance Unit. http://www.wcisu.wales.nhs.uk. 
3. Information Services Division Scotland. Cancer Information Programme. 
www.isdscotland.org/cancer. 
4.4.1.5 Diagnosis  
Pancreatic cancer only becomes clinically apparent after the malignancy has 
advanced enough to invade surrounding organs, or has metastasised. 
Unfortunately, there is no effective screening tool for pancreatic cancer, 
meaning that it is usually diagnosed when patients become symptomatic, in 
other words at an advanced stage of the disease.54  
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In a recent meta-analysis of the association between symptoms and pancreatic 
cancer, Schmidt-Hansen et al55 concluded that the only high-risk feature of 
pancreatic cancer in primary care was jaundice. Meta-analysis of the positive 
predictive value of jaundice for pancreatic cancer was not possible owing to the 
lack of suitably designed studies.  
Stapley et al – whose CAPER study I extend in my PhD – reported a positive 
predictive value of jaundice for pancreatic cancer of 12.9% (95% CI: 7.9–7.1%) 
in patients aged over 40 years.5 Based on Stapley et al’s study, The National 
Institute for Health and Care Excellence (NICE) recommend referral of patients 
who are 40 years or older and who have jaundice for investigation for suspected 
pancreatic cancer. The guidelines also recommend GPs to consider referral in 
patients who are 60 years or older with weight loss plus any of the following 
symptoms: diarrhoea, back pain, abdominal pain, nausea, vomiting, new-onset 
diabetesa or constipation.9  
The National Cancer Intelligence Network56 identified routes to diagnosis for the 
57,566 pancreatic cancer diagnoses made in the period 2006 to 2010, at a time 
when there were no specific recommendations for referral if GPs suspected a 
patient may have pancreatic cancer.57 The data indicate that 27,056 (47%, 95% 
CI: 47–48%) were diagnosed following an emergency presentation. A further 
                                            
a
 New-onset diabetes was determined as the first ever occurrence of a diagnostic Read code for 
diabetes in the patient's medical record, or as the first ever occurrence of a raised blood glucose 
level above the local laboratory’s normal range.  
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12,089 (21%, 95% CI: 20–21%) were diagnosed following referral by the GP, 
but not under the auspices of the two-week-wait rule. This latter pathway, which 
was introduced in December 2000, led to the diagnosis of 8,060 (14%, 95% CI: 
14–14%) patients with pancreatic cancer.  
These results are supported by Lyratzopoulos et al’s58 findings from the 2010 
National Cancer Experience Survey in England. Of the 24 cancers studied, 
pancreatic cancer was ranked the second highest in terms of percentage of 
patients who consulted their GP three or more times before a referral was made 
(193 of 467, 41.3%).a  
Pancreatic cancer is commonly diagnosed using computed tomography. The 
majority of tumours originate in the exocrine pancreas, and are known as ductal 
adenocarcinoma.54 Tumours originating in the endocrine pancreas – 
neuroendocrine tumours such as insulinomas and glucagonomas – are 
relatively rare, and most are benign.53     
4.4.1.6 Stage at diagnosis 
Once diagnosed, cancer is staged to assess the size of the original tumour and 
whether it has spread in the body – this is generally the case for all cancer 
types, not just pancreatic cancer. A commonly used staging system is TNM 
(tumour, node, metastases): 
                                            
a
 Only multiple myeloma was greater, with 939 of 1,854 (50.6%) of patients consulting their GP 
three or more times before referral. 
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 T indicates the size of the cancer and how far it has spread into nearby 
tissue. T can take a value of between 1 (small) and 4 (large) 
 N indicates whether the cancer has spread to the lymph nodes. N can 
take a value between 0 (no lymph node involvement) and 3 (lots of lymph 
nodes are involved) 
 M indicates whether the cancer has spread to another part of the body. 
M can be 0 (no spread) or 1 (the cancer has spread) 
Once this TNM stage has been established, cancer diagnoses are assigned a 
general stage of between I and IV (Table 4.1).  
Table 4.1 Staging of cancers  
Stage Description 
0 Carcinoma in situ 
I  Relatively small cancers, contained within the organ of origin 
II  Cancers larger than stage I cancer, but which have not started to 
spread to surrounding tissue. Sometimes cancer cells may have spread 
into lymph nodes close to the tumour (depending on the cancer type) 
III  Relatively large cancers that may have started to spread to surrounding 
tissues. Cancer cells have usually spread to lymph nodes in the area 
IV  The cancer has spread from its organ of origin to another organ within 
the body – also known as secondary or metastatic cancer 
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The National Cancer Intelligence Network extracted staging data from the 
English National Cancer Registration Service for cancers diagnosed in 2013a; 
however, data specific to pancreatic cancer were not reported.  
In a US-based study to validate the staging of pancreatic cancer, Bilimoria et 
al59 identified the stage at diagnosis of 121,713 patients in the US National 
Cancer Data Base registered in the period 1992–1998. Of these patients, 
67,192 (55.2%) were diagnosed at stage IV, and 15,831 (13.0%) at stage III. 
As described above (see Section 4.4.1.5), in the period of 2006–2010 in the UK, 
nearly half of all pancreatic cancers were diagnosed following emergency 
admission. This reflects the fact that pancreatic cancer remains asymptomatic 
for a long while, and only becomes symptomatic once it has spread to other 
regions of the body. Even then, the initial symptoms are vague and common to 
a number of diseases, such that by the time the symptoms are thought to be 
attributable to pancreatic cancer, the disease has progressed to a late stage.54  
4.4.1.7 Mortality 
The Office for National Statistics report that 7,546 deaths attributable to 
pancreatic cancer (C25) were registered in England and Wales in 2013, 
accounting for 5% of the 145,344 deaths from cancer registered that year. 
Gender-specific data indicate that similar numbers of men (n = 3,767) and 
women (n = 3,779) died from pancreatic cancer in 2013, equating to just under 
                                            
a
 See http://www.ncin.org.uk/publications/survival_by_stage, accessed 12 November 2015. 
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5% of the 76,962 cancer deaths in men, and to just over 5% of the 68,382 
cancer deaths in women. The majority (6,629/7,546= 88%) of all pancreatic 
cancer deaths occurred in patients who were 60 years of age or older.60 
Pancreatic cancer was the fifth most common cancer cause of death in men, 
and the fourth most common cancer cause of death in women in the UK in the 
previous year, 2012. Correspondingly, the European age-standardised mortality 
rate from pancreatic cancer in the UK in 2012 was 10.2 (95% CI: 9.9–10.6) per 
100,000 men and 8.2 (95% CI: 7.9–8.4) per 100,000 women.53 
Aggregate mortality data for pancreatic cancer in each year of the recruitment 
period of my study are plotted in Figure 4.2. The pattern was similar to that of 
incidence, because survival (see Section 4.4.1.8) is so poor. Mortality in men 
was fairly steady, at between 9.5 and 10.0 per 100,000 men, whereas in women 
it was stable between 2000 and 2003, at about 7.3 per 100,000 women, after 
which it rose to reach 8.0 per 100,000 women in 2009.53 
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Figure 4.2 European age-standardised mortality rates for pancreatic cancer (C25) per 
100,000 population; UK data 2000–2009 
 
Note: adapted from a graph prepared by Cancer Research UK 
Original data sources: 
1. Office for National Statistics, Mortality Statistics: Deaths registered in England and Wales: 
http://www.ons.gov.uk/ons/search/index.html?newquery= series+dr 
2. General Register Office for Scotland, Deaths Time Series Data, Deaths in Scotland: 
http://www.gro-scotland.gov.uk/statistics/theme/vital-events/deaths/time-series.html 
3. Northern Ireland Statistics and Research Agency, Deaths by cause: 
http://www.nisra.gov.uk/demography/default.asp14.htm 
4.4.1.8 Survival 
The terminology of survival data is complex and requires clear definition. I follow 
the definitions used by Cancer Research UK – the source of the data discussed 
in this section. Namely, ‘net survival estimates the number of people who 
survive their cancer rather than calculating the number of people diagnosed 
with cancer who are still alive. In other words, it is the survival of cancer patients 
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after taking into account the background mortality that they would have 
experienced if they had not had cancer.’ In contrast, ‘relative survival compares 
the survival of individuals with cancer to those in the general population. Ideally 
it would be to those without cancer, but this baseline is difficult to obtain. It is 
similar to the probability of survival from cancer without including any other 
cause of death.’61 
The 1-year, age-standardised, net survival rates for men and women diagnosed 
with pancreatic cancer in England and Wales during 2010–2011 are reported in 
Table 4.2. In this time period, survival at 1 year was similar in men (21.6%, 95% 
CI: 20.6–22.5%) and women (20.1%, 95% CI: 19.1–21.2%). Survival of patients 
diagnosed in 2010–2011 was predicted to be very poor in men and women at 
both 5 and 10 years (Table 4.2); indeed, pancreatic cancer ranks the lowest of 
all cancers in terms of 10-year survival.53 
Table 4.2 Pancreatic cancer, age-standardised 1-, 5- and 10-year net survival, in adults aged 
15–99 years), England and Wales, 2010-2011 
  Net survival (%, 95% CI) at 
1 Year  5 Years a 10 Years a 
Men 21.6 (20.6–22.5) 3.5 (1.7–6.5) 1.1 (0.1–6.5) 
Women 20.1 (19.1–21.2) 3.1 (1.3–6.2) 1.1 (0.1–6.4) 
a
 Predicted using an excess hazards model. 
Note: Prepared by Cancer Research UK 
Original data sources: 
Survival estimates were provided on request by the Cancer Research UK Cancer Survival 
Group at the London School of Hygiene and Tropical Medicine. 
http://www.lshtm.ac.uk/eph/ncde/cancersurvival/ 
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Net survival trends over time are plotted in Figure 4.3, from data provided by the 
London School of Hygiene and Tropical Medicine, summarised by Cancer 
Research UK. One-year, age-standardised net survival for pancreatic cancer 
increased from 15.3% in men and 14% in women in 2000–2001 to 21.6% and 
20.1%, respectively, in 2010–2011. Longer-term survival figures are stable and 
poor; for example, 5-year survival in 2000–2001 was 3% in men and 2.4% in 
women, and 3.2% and 2.7%, respectively, in 2005–2006. Predicted 5-year 
survival for cancers diagnosed in 2010–2011 is 3.5% in men and 3.1% in 
women. Figures for 10-year survival suggest that approximately 1% of patients 
diagnosed with pancreatic cancer will survive their disease for at least 10 
years.53  
Figure 4.3 Pancreatic cancer age-standardised, net survival at 1 year, 5 years and 10 
years, England and Wales, 2000–2011 
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Note: 
Adapted from graphs prepared by Cancer Research UK 
Original data sources: 
Survival estimates were provided on request by the Cancer Research UK Cancer Survival 
Group at the London School of Hygiene and Tropical Medicine. 
http://www.lshtm.ac.uk/eph/ncde/cancersurvival/ 
 
4.4.1.9 Conclusion 
Pancreatic cancer is the tenth most common cancer in the UK, accounting for 
3% of all new cases of cancer in 2012. In that year, it was the 13th most 
common cancer in men and the ninth most common cancer in women. The 
incidence of pancreatic cancer in the UK is rising, which may reflect the 
increased prevalence of obesity. Most patients with pancreatic cancer are 
diagnosed following emergency admission and have late-stage disease. This 
has consequences for both mortality and survival. Mortality is high, such that 
pancreatic cancer was the fifth most common cancer cause of death in the UK 
in 2012. Survival from pancreatic cancer remains poor – the 10-year net 
survival figure of 1% has remained unchanged since the 1970s.   
4.4.2 Bladder cancer 
4.4.2.1 The bladder 
The urinary bladder is located in the pelvic cavity, immediately behind the pubic 
bones. Its function is to store urine that has been formed in the kidneys and, 
typically, it has a capacity of 500 ml. The urethra is far longer in men (20 cm) 
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than it is in women (just under 4 cm).48 This is one of the main reasons why 
women are more susceptible than men to bladder infections. 
4.4.2.2 Change in the definition of bladder cancer 
Significantly, the definition of ‘bladder cancer’ changed in 1998, when the 
International Classification of Disease (ICD) for Oncology created separate 
diagnostic codes for carcinoma in situ of bladder (D09.0) and neoplasm of 
uncertain behaviour of bladder (D41.4), removing them from code C67 (bladder 
cancer).62  
The change in definition has consequences for my study, as the bladder cancer 
cases were selected according to the pre-1998 definition of the disease. 
Subanalysis was conducted on cases that met the post-1998 definition of 
bladder cancer and their matched controls, and the risk estimates reported in 
Appendix 6. 
The risk factors for bladder cancer (C67) are now discussed, as are its 
incidence, diagnosis, stage at diagnosis, mortality and survival. 
4.4.2.3 Risk factors  
Excluding genetic predisposition, there are a number of known external lifestyle 
factors that increase the risk of developing bladder cancer, the main ones in the 
UK being age (as reflected by the age-specific incidence rates discussed below) 
and tobacco smoke. In regions of the world where Schistosoma haematobium is 
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endemic, at least 41% of patients with bladder cancer have schistosomiasis; 
however, this infection is not a significant risk factor in the UK.61  
According to government statistics, tobacco smoking is in decline. 63 The data 
were first collected in 1948 and showed that tobacco smoking was more 
prevalent among men (65%) than women (41%) (raw data not available). Both 
the overall prevalence of smoking and the gender gap have fallen steadily since 
then, with figures of 42% of men and 36% of women in 1980, and 31% of men 
and 28% of women in 1990. The latest data (2010) suggest that similar 
proportions of men (20%) and women (19%) smoke tobacco. This suggests that 
while smoking patterns will have contributed to historical gender-specific 
differences in the incidence of bladder cancer, this is likely to reduce in the 
future. Indeed, the percentage of incident cases of bladder cancer in the UK in 
2010 attributable to tobacco smoking was estimated to be 37.5% in men and 
34.4% in women.50  
Other known risk factors for bladder cancer include occupational exposure, 
such as occurs in aluminium and in rubber production and in painting and 
decorating – industries traditionally dominated by men.61,64 
4.4.2.4 Incidence 
The latest statistics summarised by Cancer Research UK report that 
approximately 10,400 people (7,452 new cases in men; 2,947 in women) were 
diagnosed with bladder cancer (C67) in the UK in 2011. These figures equate to 
age-standardised incidence rates of 17.7 (95% CI: 17.3–18.1) per 100,000 men 
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and 5.4 (95% CI: 5.2–5.6) per 100,000 women. In terms of ranking, bladder 
cancer is the fourth most common cancer in men and the 13th most common 
cancer in women.61  
Current incidence rates are low and similar in men and women below the age of 
40 years. A gender difference in incidence develops as age increases above 50 
years. After 60 years of age, bladder cancer incidence rises much more steeply 
in men than in women. Indeed, the gender difference in incidence rate peaks in 
the 65- to 69-year-old age group, at 70.5 per 100,000 men compared with 18.8 
per 100,000 women. The absolute peak in age-specific incidence occurs in 
patients 85 years of age or older, at 264.3 per 100,000 men and 76.3 per 
100,000 women.61  
Aggregate incidence data for bladder cancer in each year of the recruitment 
period of my study are plotted in Figure 4.4. Cancer Research UK report that 
the incidence fell during this period, from 22.6 per 100,000 men and 6.5 per 
100,000 women in the year 2000, to 18.9 per 100,000 men and 5.4 per 100,000 
women in 2009. The decline in incidence over time is attributed to reductions in 
both exposure to occupational risk factors and tobacco smoking.61  
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Figure 4.4 European age-standardised incidence rates for bladder cancer (C67) per 
100,000 population; UK data 2000–2009 
 
 Note: Adapted from a graph prepared by Cancer Research UK. Original data sources: 
1. Office for National Statistics. Cancer Statistics: Registrations Series MB1: 
http://www.ons.gov.uk/ons/search/index.html?newquery= series+mb1 
2. Welsh Cancer Intelligence and Surveillance Unit: http://www.wcisu.wales.nhs.uk 
3. Information Services Division Scotland. Cancer Information Programme: 
www.isdscotland.org/cancer 
4. N. Ireland Cancer Registry: www.qub.ac.uk/nicr. 
4.4.2.5 Diagnosis 
There is no effective screening tool for bladder cancer, meaning that it is usually 
diagnosed when patients become symptomatic. In a recent meta-analysis of the 
association between symptoms and bladder or renal cancer in the primary care 
setting, Schmidt-Hansen et al65 concluded that the only high-risk feature was 
visible haematuria. Five studies6,66,67,68,69 were included in the meta-analysis, 
which reported a summary estimate of the positive predictive value of visible 
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haematuria for bladder or renal cancer of 5.1% (95% CI: 3.2–8.0%) in patients 
aged 15 to 100 years old. Drawing on this meta-analysis, The National Institute 
for Health and Care Excellence (NICE) recommend referral for investigation on 
a suspected cancer pathway for patients who are 45 years or older who have 
unexplained visible haematuria without a urinary tract infection, or visible 
haematuria that persists or recurs after successful treatment of a urinary tract 
infection.9 
The National Cancer Intelligence Network56 identified routes to diagnosis for the 
42,924 bladder cancer diagnoses made in the period 2006 to 2010, i.e. under 
the previousa NICE referral guidelines.57 The data indicate that 13,306 (31%, 
95% CI: 31–32%) of the patients were diagnosed following referral via the two-
week wait pathway. A further 12,349 patients (29%, 95% CI: 28–29%) were 
diagnosed following a routine or urgent referral made by the GP but not under 
the two-week wait route. Approximately one-fifth of patients (7,954/42,924= 
19%, 95% CI: 18–19%) were diagnosed following emergency presentation.56 
                                            
a
 Previous NICE guidelines were subtly different to the current ones, and recommended urgent 
referral for suspected urological cancer for patients of any age who presented with painless 
visible haematuria, once a urinary tract infection had been excluded. Urgent referral was also 
recommended for patients aged 40 years and older who presented with recurrent or persistent 
urinary tract infection accompanied by visible haematuria.  
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Cancer Research UK report a gender difference in emergency presentation, 
with a greater proportion of women (25%, raw data not reported) presenting via 
this route compared with men (16%, raw data not reported).61  
Typically, bladder cancer is diagnosed in secondary care by flexible cystoscopy 
(see Section 4.5.1.6.2), with or without ultrasonography of the renal tract.70  
4.4.2.6 Stage at diagnosis 
The latest bladder cancer staging data summarised by Cancer Research UK 
relate to cancers diagnosed in England in 2013,61 using data from the National 
Cancer Intelligence Network (see Table 4.3). Staging data were not complete, 
with the stage at diagnosis reported as ‘unknown’ for approximately one-quarter 
of all new diagnoses (2,228/8,775= 25.4%) in the analysis period. Over half 
(4,865/8,775= 55.4%) of all new bladder cancer cases were diagnosed at an 
early stage (i.e. stage I or II), leaving just under one-fifth being diagnosed at an 
advanced stage (i.e. stage III or IV) in England in 2013.  
Table 4.3 Bladder cancer staging data, England 2013 (figures provided by the National 
Cancer Intelligence Network) 
Stage at diagnosis Number of new diagnoses (%) (n = 8,775 in total) 
I 3,061 (34.9) 
II 1,804 (20.6) 
III 488 (5.6) 
IV 1,194 (13.6) 
Unknown 2,228 (25.4) 
Total 8,775 
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4.4.2.7 Mortality 
The Office for National Statistics report that 4,536 deaths attributable to bladder 
cancer (C67) were registered in England and Wales in 2013, accounting for 3% 
of the 145,344 deaths from cancer registered that year. Gender-specific data 
indicate that roughly twice as many men (n = 3,039) as women (n = 1,497) died 
from bladder cancer in 2013, equating to approximately 4% of the 76,962 
cancer deaths in men, and to 2% of the 68,382 cancer deaths in women. The 
majority (3,217/4,536= 70.9%) of all bladder cancer deaths occurred in patients 
who were 75 years of age or older.60  
Bladder cancer was the 7th most common cancer cause of death in men, and 
the 13th most common in women in the UK in the previous year, 2012. 
Correspondingly, the European age-standardised mortality rate from bladder 
cancer in the UK in 2012 was 7.7 (95% CI 7.4–7.9) per 100,000 men and 2.8 
(95% CI: 2.6–2.9) per 100,000 women.61 Aggregate mortality data for bladder 
cancer in each year of the recruitment period of my study are plotted in Figure 
4.5. The trend is downward, from initial values of 9.2 per 100,000 men and 3.2 
per 100,000 women in 2000, to 7.9 per 100,000 men and 2.7 per 100,000 
women in 2009. Indeed, Cancer Research UK report that age-standardised 
bladder cancer mortality rates fell in the UK between 2001–2003 and 2010–
2012 by 15% in men and 11% in women. They attribute this to the decline in 
numbers of people who smoke tobacco, presumably reflecting the decline in 
bladder cancer incidence.61 However, it is important to consider trends in 
survival before making such an interpretation, as trends in mortality only closely 
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mirror those in incidence when the majority of patients die shortly after 
diagnosis.62  
Figure 4.5 European age-standardised mortality rates for bladder cancer (C67) per 
100,000 population; UK data 2000–2009 
 
Note: Adapted from a graph prepared by Cancer Research UK 
Original data sources: 
1. Office for National Statistics, Mortality Statistics: Deaths registered in England and Wales: 
http://www.ons.gov.uk/ons/search/index.html?newquery= series+dr 
2. General Register Office for Scotland, Deaths Time Series Data, Deaths in Scotland: 
http://www.gro-scotland.gov.uk/statistics/theme/vital-events/deaths/time-series.html 
3. Northern Ireland Statistics and Research Agency, Deaths by cause: 
http://www.nisra.gov.uk/demography/default.asp14.htm 
4.4.2.8 Survival 
The 1-year, age-standardised, net survival rates for men and women diagnosed 
with bladder cancer (C67) in England and Wales during 2010–2011 are 
reported in Table 4.4. In this time period, survival at 1 year was considerably 
better in men (76.6%, 95% CI: 76.6–76.6%) than in women (61.6%, 95% CI: 
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61.5–62.8%). Predicted survival both at 5 and at 10 years is anticipated to be 
better in men than in women (Table 4.4). 
Table 4.4 Bladder cancer (C67), age-standardised 1-, 5- and 10-year net survival, in adults 
aged 15–99 years, England and Wales, 2010-2011
61
 
  Net survival (%, 95% CI) at 
1 Year  5 Years a 10 Years a 
Men 76.6 (76.6–76.6) 56.9 (56.7–57.1) 54.3 (53.9–54.8) 
Women 61.6 (61.5–62.8) 45.6 (45.2–46.1) 39.5 (38.8–40.2) 
a
 Predicted using an excess hazards model. 
Note: Prepared by Cancer Research UK 
Original data sources: Survival estimates were provided on request by the Cancer Research UK 
Cancer Survival Group at the London School of Hygiene and Tropical Medicine. 
ttp://www.lshtm.ac.uk/eph/ncde/cancersurvival/ 
The chances of surviving bladder cancer are strongly dependent on the stage at 
which it is diagnosed. Cancer Research UK provide relative survival data 
grouped by stage at diagnosis, estimated using data from The National Cancer 
Registration Service Eastern Office (formerly known as the Anglia Cancer 
Network). The data were collected during 2006 to 2010, coincident with much of 
my study period. Note, however, that these deaths relate to bladder cancer 
diagnoses that also included diagnostic codes D09.0 (carcinoma in situ of 
bladder) and D41.4 (neoplasm of uncertain behaviour of bladder). These 
cancers have a much better prognosis than cancers included in diagnostic code 
C67.  
Relative survival was very high in those diagnosed with stage I disease, with 
97% of men and 96% of women surviving for at least 1 year. Survival for at 
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least 5 years with a stage I diagnosis was also high, at 89% of men and 86% of 
women.  
Relative survival decreased both in men and women the more advanced the 
stage at diagnosis, with the worst figures in those patients diagnosed at stage 
IV. Here, 26% and 9% of men reached 1-year and 5-year survival, respectively, 
compared with 25% and 11% of women. In general, relative survival was the 
same in men as in women, except at 1 year following a stage II diagnosis. Here, 
a higher percentage of men (74%) than women (57%) were alive at 1 year. 
It is difficult to interpret the trends in bladder cancer survival over time, because 
of the above-described (see Section 4.4.2.2) change in definition of the disease 
in 1998. One-year age-standardised net survival data for bladder cancer 
suggest that survival has decreased since the 1990s; however, this is likely to 
be an artefact related to the exclusion of carcinoma in situ of bladder and 
neoplasm of uncertain behaviour of bladder, which are low-risk, benign tumours 
with a far better prognosis than cancers included in ICD10 code C67.   
4.4.2.9 Conclusion 
Bladder cancer is relatively common (it was the seventh most common cancer 
in the UK in 2011), but the incidence is higher in men than in women. The 
incidence has been falling both in men and women since the year 2000, some 
of which may be attributed to historical reductions in the prevalence of smoking. 
Most cases of bladder cancer are diagnosed at an early stage, and are 
associated with a high chance of survival. Despite this, bladder cancer was the 
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seventh most common cause of death in the UK in 2012, the majority of which 
occurred in patients aged 75 years or older. Mortality from bladder cancer is 
falling, partly a reflection of the reduced incidence. Trends in survival are 
difficult to interpret, because the definition of bladder cancer changed in 1998.   
4.5 The symptoms 
4.5.1 Haematuria 
4.5.1.1 Formation of urine 
Urine is formed by the kidneys and then transported via the ureter to the 
bladder, where it is stored prior to being expelled from the body during 
micturition. The first step in urine formation is the ultrafiltration of a plasma-like 
fluid from the blood into functional units called nephrons, of which the kidney 
contains approximately 1.2 million. In a healthy adult, the rate of ultrafiltrate 
formation is approximately 125 ml per minute or 180 litres per day, which 
equates to approximately 20% of renal blood flow. In healthy people, the 
ultrafiltrate from which urine is formed contains few red blood cells. The loss of 
around one million red blood cells in the urine daily, equating to about one cell 
per high-power field, is considered normal.71  
4.5.1.2 Definition 
Haematuria is defined as the abnormal presence of red blood cells in urine, 
either in sufficient quantities to be readily recognised by the patient (visible) or 
in an amount so small that it requires detection by urine dipstick testing or 
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microscopy (non-visible).72 Visible and non-visible are the terms currently 
recommended to describe the two types of haematuria and so have been 
adopted consistently throughout this thesis in preference to other descriptors 
such as ‘frank’, ‘gross’ or ‘macroscopic’ (visible) and ‘invisible’, ‘microscopic’ or 
‘dipstick-positive’ (non-visible).73  
The threshold for definition of non-visible haematuria is three or more red blood 
cells in urine per high-power field on microscopy, in the absence of infection or 
proteinuria.72,74 Non-visible haematuria is described as symptomatic when it is 
accompanied by lower urinary tract symptoms such as hesitancy, frequency, 
urgency or dysuria, whereas it is called asymptomatic when discovered 
incidentally in the absence of any accompanying symptoms.73  
4.5.1.3 Background rate 
The background rate of visible haematuria in the general population is unclear. 
Summerton estimated that a UK GP will encounter less than one case per year, 
but it is not clear how this figure was calculated. He also quoted a figure of 0.6 
cases per year per GP in a standard practice in the Netherlands, according to 
morbidity figures from general practice.75 
There is also a great deal of uncertainty about the prevalence of non-visible 
haematuria in the general population.76 This may relate to the small number of 
studies conducted and heterogeneity in both the method of detection (dipstick 
test alone or in combination with microscopy) and the number of tests carried 
out to confirm the diagnosis.77 Four screening studies are discussed below; 
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however, it is important to note that any inferences about the prevalence of non-
visible haematuria in the general population should be drawn with caution, 
because all these studies used non-probability sampling methods.  
In a sample of 20,751 men and women in the USA undergoing dipstick 
urinalysis screening as part of a private health assessment, the overall 
frequency of asymptomatic non-visible haematuria was 2.9%. The study 
investigated the relationship of non-visible haematuria with gender and age: it 
tended to decrease with age, being 5.0% in women aged 55–75 years, falling to 
3.4% in women >75 compared with respective values of 1.8% and 1.08% in 
men. Non-visible haematuria also tended to be more prevalent in women than 
men overall. It should be noted, however, that the sample included different age 
ranges for the two genders (men ≥35 years; women ≥55 years), women aged 
<55 years being excluded owing to problems associated with misattribution of 
vaginal bleeding.78  
In a UK retrospective study of 10,050 men attending a private clinic for health 
screening between February 1983 and January 1984, the prevalence of non-
visible haematuria was 2.5%. Haematuria was detected in freshly collected 
midstream urine sample using dipsticks sensitive to haemoglobin, and 
confirmed by re-testing and microscopy within 4 hours. The age range of men 
discovered to have haematuria was 21–72 years (summary statistics not 
reported).79   
In a prospective study, 855 elderly men (aged 60–85 years) were invited to 
attend an inner city health centre in Leeds, UK, for urine screening as part of 
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general health check. In total, 578 men responded, of whom 78 (13%) had 
dipstick-positive haematuria on the initial test conducted by a nursing sister. All 
participants were asked to test their urine weekly for 10 weeks, which resulted 
in a further 54 men (9%) reporting a positive result. The authors combined 
these results to report an overall prevalence of 132/578, or 23%, in men >60 
years.80  
Finally, a retrospective screening study examined 1000 healthy Israeli military 
male recruits, aged 18–33 years at the beginning of a 15-year investigation.76 
Non-visible haematuria was defined as two to four or more red blood cells per 
high-powered field on microscopical examination of urine. The point prevalence 
of non-visible haematuria was 5.2% (results from 12,227 urinalyses conducted 
over the 15-year study). The study reported a cumulative incidence of non-
visible haematuria of 387 in the 1000 men (38.7%) on one or more occasion, 
and of 161/1000 (16.1%) on two or more occasions. The authors acknowledged 
the limitation that the sampling of young adult men from the military prevents 
inferences to be made about the general population. This value may 
overestimate the frequency of non-visible haematuria in the general population, 
which tends to be more sedentary than military recruits, given the known 
association between non-visible haematuria and vigorous exercise.81  
4.5.1.4 Detection  
Detection of haematuria relies on both observation and urinalysis, including 
visual inspection, chemical dipstick testing and microscopy.  
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4.5.1.4.1 Visual inspection of urine 
Visible haematuria is an alarming symptom, and presents as smoky, bright red 
or reddish-brown urine, which may or may not contain blood clots.82 The overt 
nature of visible haematuria means that it has a very low false-positive rate of 
detection. However, patients may mistake other conditions as being 
haematuria, such as rectal or vaginal bleeding, haemoglobinuria (excretion of 
free haemoglobin in the urine), myoglobinuria (urinary excretion of myoglobin 
from broken down muscle cells) and acute intermittent porphyria (fresh urine 
appears normal, but develops a dark-red colour if left to stand). Finally, red/pink 
or orange coloration of urine may occur after ingesting beetroot, blackberries 
and some medications (e.g. rifampicin).82 Misattribution as haematuria can be 
avoided by careful dietary and medication history-taking, as well as by a 
selection of tests (Table 4.5).49  
Table 4.5 Tests to distinguish true visible haematuria from conditions that mimic it
49,82
  
Condition Test to distinguish it from visible haematuria  
Haemoglobinuria Microscopy of a fresh urine sample – red blood cells 
are not present in the urine 
Myoglobinuria Microscopy of a fresh urine sample –  red blood 
cells not present in the urine 
Specific laboratory tests are available to distinguish 
myoglobin from haemoglobin  
Acute intermittent 
porphyria 
Examine fresh urine samples 
Red blood cells not detected in urine  
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Non-visible haematuria is not detectable on visual inspection, but relies on 
examination of urine using chemical dipsticks sensitive to haem or, less 
frequently, by urine microscopy. 
4.5.1.4.2 Chemical dipstick testing 
Dipstick tests detect the presence of haem, which is a prosthetic group that 
forms the non-protein part of haemoglobin and myoglobin, enabling both to bind 
oxygen.83 Therefore, chemical dipsticks detect intact red blood cells (shown as 
green spots on the reagent strip), haemoglobin (green-coloured fields) or free 
myoglobin (also as green-coloured fields).82 They are calibrated to give a 
negative finding at the normal level of blood loss in urine. Several chemical 
dipsticks are available commercially, and all give a result immediately in GP 
surgeries.  
There are few reliable data available for calculating dipstick performance 
characteristics. Sensitivity is reported to range between 91% and 100%, but 
with a specificity ranging from 65% to 99% for two to five red blood cells per 
high-power field, the potential for false-positives may be as great as 35%.84 
Causes of false-positive readings for haematuria include contamination with 
menstrual blood or with bleach, patient dehydration (conserving water inevitably 
increases the concentration but not the overall number of red blood cells), 
myoglobinuria (e.g. following breakdown of muscle tissue, such as can occur in 
patients taking statins or recreational drugs, or following trauma) and using a 
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stale urine sample.82,85  Inappropriate storage of dipsticks increases the 
likelihood of false-negative readings, as does an acidic urine and bacteriuria.85 
Table 4.6 Indications for chemical dipstick testing 
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 Type of use Indication Of value in 
Screening Random Diabetes mellitus 
Asymptomatic bacteriuria 
Selective Antenatal care 
Hypertension 
Diagnosis Primary renal disease Glomerulonephritis 
Secondary renal disease Bacterial endocarditis 
Non-renal disorders Diabetes mellitus 
Monitoring Disease progression Diabetic nephropathy 
Drug toxicity Gold therapy 
Drug compliance Rifampicin therapy 
Illicit drug use Opioids, benzodiazepines 
This table was reproduced, with permission, from Macleod’s Clinical Examination, 12th edn., 
Douglas, G., Nicol, F., Robertson, C. (eds.), pp.1–476, Copyright Elsevier (2009).  
Despite the potential for inaccuracy, a recent systematic review concluded that 
dipsticks are a reasonable method to use in isolation to detect non-visible 
haematuria. Data from 17 studies evaluating the accuracy of dipstick tests in the 
diagnosis of haematuria, compared with the reference standard of microscopy, 
were pooled. The positive likelihood ratio of dipsticks to diagnose haematuria 
was estimated to be 5.99 (95% CI: 4.04–8.89) and the negative likelihood ratio 
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0.21 (95% CI: 0.17–0.26), with the proviso that the figures should be interpreted 
cautiously, owing to significant heterogeneity between studies.72 Clinically, 
dipstick testing is widely indicated in screening, diagnosis and monitoring of 
disease (Table 4.6).82 
4.5.1.4.3 Urine microscopy  
On visual inspection, the colour of urine varies with the patient’s hydration 
status – the lighter the colour, the more hydrated the patient. Regardless of its 
colour, normal fresh urine is clear, but cloudiness may develop in a sample that 
has been left to stand for long enough that phosphate and urate salts precipitate 
out of solution. For this and other reasons, it is important to conduct urinalysis 
on fresh samples. Cloudiness of a freshly collected urine sample is abnormal, 
and indicates the presence of pus and/or bacteria.82  
Early morning, midstream urine samples need careful preparation before 
examination. Best practice is as follows: centrifuge a 10-ml sample at 2,000 rpm 
for 5 min, discard the supernatant and re-suspend the sediment in 0.5–1.0 ml of 
the original urine sample. Examine a single drop of the freshly prepared sample 
under a microscope.84,86 Urine microscopy detects non-visible haematuria far 
more accurately than chemical dipsticks, with a very low false-positive rate, but 
only when performed by trained technicians or nephrologists as described 
above.73 It is utterly impractical to provide this level of service in primary care, 
and so urine microscopy is rarely carried out in this setting.  
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4.5.1.5 Causes  
Blood in urine can originate from anywhere along the urinary tract, but sources 
are generally grouped according to the potential underlying pathology as being 
glomerular (nephrological) or non-glomerular (urological).72  
Visible haematuria usually has a non-glomerular source of blood, such as the 
ureter, bladder or urethra. Visible haematuria associated with loin pain (renal 
colic) is often caused by a kidney stone as it is passed from the body in the 
urine. Blood that clears before the urine is fully voided usually indicates an 
origin in the urethra, whereas an association with frequency or dysuria 
commonly indicates the bladder as being the source.82 Tumours themselves are 
liable to bleed because they have a fragile blood supply. When they become 
large enough to invade surrounding tissue, tumours may damage healthy 
vasculature and also result in bleeding. For tumours sited anywhere along the 
urinary tract, the blood is expelled in the urine and is apparent to the patient as 
visible haematuria.  
Causes of non-visible haematuria, without proteinuria, can be either glomerular 
(nephrological) or non-glomerular (urological) (see Table 4.7).  
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Table 4.7 Causes of isolated non-visible haematuria (causes are listed in order of descending 
frequency of presentation, according to available data) 
Origin Age 
< 50 years ≥50 years 
Glomerular IgA nephropathy IgA nephropathy 
Thin basement membrane disease 
(also known as benign familiar 
haematuria) 
Hereditary nephritis (also 
known as Alport syndrome) 
Hereditary nephritis (also known as 
Alport syndrome) 
Mild focal glomerulonephritis 
of other causes 
Mild focal glomerulonephritis of other 
causes 
 
Non-
glomerular 
  
Upper urinary 
tract 
Nephrolithiasis Nephrolithiasis 
Pyelonephritis Renal-cell cancer 
Polycystic kidney disease Polycystic kidney disease 
Medullary sponge kidney Pyelonephritis 
Hypercalciuria, hyperuricosuria, or 
both, without documented stones 
Renal-pelvis or ureteral 
transitional-cell cancer 
Renal trauma Papillary necrosis 
Papillary necrosis Renal infarction 
Ureteral stricture and hydronephrosis Ureteral stricture and 
hydronephrosis 
Sickle cell trait or disease in blacks Renal tuberculosis 
Renal infarction or arteriovenous 
malformation 
 
Renal tuberculosis in endemic areas 
or in patients with HIV infection 
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Origin Age 
< 50 years ≥50 years 
Lower 
urinary tract  
Cystitis, prostatitis and urethritis Cystitis, prostatitis and 
urethritis 
Benign bladder and ureteral polyps 
and tumours 
Bladder cancer 
Bladder cancer Prostate cancer 
Prostate cancer Benign bladder and ureteral 
polyps and tumours 
Urethral and meatal strictures  
Schistosoma haematobium in North 
Africans 
 
Uncertain Exercise Exercise 
‘Benign’ (unexplained) Over-anticoagulation (usually 
with warfarin) 
Over-anticoagulation (usually with 
warfarin) 
 
Factitious haematuria (usually 
presents with visible haematuria) 
 
HIV, human immunodeficiency virus. 
Reproduced with permission from Cohen and Brown (2003), Copyright Massachusetts Medical 
Society.
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Causes of haematuria are classified as renal (e.g. neoplasia, 
glomerulonephritis, tubulointerstitial nephritis, polycystic kidney disease, 
papillary necrosis, infection and trauma) or extrarenal (e.g. calculi, infection, 
neoplasia and trauma), each group consisting of a mix of benign and serious 
conditions.85 Infection and calculi are the most common non-malignant causes 
in the over 40s – the patient group included in our study. Urinary tract infection 
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(UTI) is very common – more so in women than men owing to their short 
urethra.  
Completing menopause further increases the risk in older women, as loss of 
oestrogen renders the urinary tract more vulnerable to infection. Calculi are less 
common than UTI (lifetime incidence up to 15%) and presentation peaks in a 
younger age group (20–40 years) than is included in my study.85 Therefore, the 
most common benign cause of haematuria in the over 40s is UTI. In addition, in 
women, vaginal bleeding may be mistaken for haematuria.  
Serious pathology resulting in haematuria includes neoplasms such as bladder 
cancer. Bladder cancer is more common in men than in women (see Section 
4.4.2.4).34 The most highly predictive symptom of bladder cancer is visible 
haematuria.4,6,67,69 This is reflected by current UK referral guidelines published 
in 2015 by the National Institute of Health and Care Excellence (NICE), which 
recommend referral for patients over 45 years of age who have unexplained 
visible haematuria without UTI, or visible haematuria that persists or recurs after 
successful treatment of UTI.9    
4.5.1.6 Investigation 
A systematic review conducted in 2006 to determine an effective diagnostic 
strategy for the investigation of visible and non-visible haematuria concluded 
that there were ‘insufficient data currently available to derive an evidence-based 
algorithm’. The authors presented a diagnostic algorithm based on the opinion 
and practice of clinical experts.72 Urological referral and investigation for 
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urological cancer using ultrasound (US), cystoscopy and cytology was 
recommended for: 
 All patients with visible haematuria 
 Patients with asymptomatic non-visible haematuria accompanied by risk 
factors for cancer (such as smoking)  
 All patients with persistent symptomatic non-visible haematuria  
4.5.1.6.1 Ultrasound 
Ultrasound (US) is a non-invasive imaging technique that is used in the 
investigation of haematuria. It is excellent at identifying renal cysts but has 
limited usefulness in detecting solid renal masses that are smaller than 3 cm in 
size.87 Its performance is highly dependent on the expertise of the 
ultrasonographer,72 and its sensitivity at detecting bladder cancer in patients 
was reported to be 19%.87,88   
4.5.1.6.2 Cystoscopy 
Cystoscopy is an invasive investigation carried out by urologists in secondary 
care. It is indicated when a non-glomerular cause of haematuria is suspected, to 
identify malignancy – particularly bladder cancer.87 The sensitivity of cystoscopy 
to detect bladder cancer, as indicated by haematuria alone, was reported to be 
95.6% (95% CI: 87.2–98.6%), which equates to a positive predictive value of 
haematuria for bladder cancer of 65.0% (95% CI: 55.2–73.7%). The specificity 
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was 94.3% (95% CI: 92.1–95.9%), which is reassuringly high for an 
investigation used to rule out malignancy.89 
4.5.1.6.3 Cytology 
Cells sloughed from urothelial tumours are excreted in the urine and can be 
detected by cytology. However, the reliability of this technique depends greatly 
on the technical proficiency of the pathologist examining the samples. The 
sensitivity of cytology to detect bladder cancer ranges from 40% to 70%; 
therefore, while a positive result is considered diagnostic of the presence of 
urothelial cancer, a negative result cannot rule out a malignancy, owing to the 
test’s high false-negative rate.87 
4.5.1.7 Conclusion 
There are two forms of haematuria: visible and non-visible. Visible haematuria 
may have a benign or a malignant underlying pathology. However, for patients 
and GPs alike, it is an alarming symptom not least because of its strong 
association with urological tumours. Non-visible haematuria is only apparent on 
testing of urine, and the majority of cases have an underlying benign pathology. 
Neither form of haematuria has an association with pancreatic cancer. 
4.5.2 Jaundice 
4.5.2.1 Introduction 
Jaundice, also known as icterus, occurs when plasma levels of bilirubin, 
normally 3–17 µmol/l, rise in excess of 40 µmol/l.90,91 Bilirubin is a by-product of 
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the breakdown of red blood cells, is yellow in colour, and is excreted in both bile 
and urine.83  
4.5.2.2 Detection 
Moderately raised levels of plasma bilirubin require detection by liver function 
blood tests. As its plasma levels rise in excess of 40 µmol/l, the yellow-coloured 
bilirubin becomes noticeably visible in the whites of the eyes, the mucous 
membranes and eventually the skin and urine.90  
4.5.2.3 Background rate 
In a cohort study of 186,814 adults aged over 45 years, Taylor et al92 reported 
an annual incidence of jaundice of 0.74 per 1,000 patients. An acknowledged 
limitation of the Taylor study is that their cohort was not a random selection of 
all adults aged over 45 years, as it over-represented the age group who suffer 
cancer. This is because it was carried out as part of the Discovery Programme,a 
and the cohort was selected from the group of control patients from the CAPER 
studies, who were matched on age, sex and GP practice to cancer cases.92  
4.5.2.4 Causes  
There are three main mechanisms by which hyperbilirubinaemia can lead to 
jaundice. First, excess production of bilirubin at a rate that overwhelms the 
                                            
a
 As described in Section 4.2, the Discovery Programme used CPRD data in case–control 
studies to characterise the presentation of 13 common cancers in primary care in the UK. 
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liver's ability to process it for excretion (termed pre-hepatic jaundice). Secondly, 
liver malfunction (hepatic jaundice), and, finally, obstruction of the bile duct, one 
of the main routes of bilirubin excretion (post-hepatic jaundice).91 
4.5.2.4.1 Causes of pre-hepatic jaundice  
The most common cause of pre-hepatic jaundice is excessive breakdown of red 
blood cells, such as occurs in haemolytic anaemia, Gilbert syndrome, 
spherocytosis, sickle cell disease and thalassaemia major.90  
4.5.2.4.2 Causes of hepatic jaundice 
Common forms of hepatic jaundice include viral hepatitis and alcoholic hepatitis, 
and it may also be associated with alcoholic cirrhosis, primary biliary cirrhosis 
and the ingestion of certain drugs.90 
4.5.2.4.3 Causes of post-hepatic jaundice 
Post-hepatic jaundice commonly arises when the common bile duct becomes 
obstructed. The obstruction is commonly caused by a benign gallstone; 
however, it may be caused by an impinging malignancy of pancreatic origin.90,93 
4.5.2.5 Investigations 
In brief, initial investigations in suspected jaundice include urine and blood tests 
to determine whether the patient has hyperbilirubinaemia and to assess liver 
function. Investigations escalate to include abdominal imaging using a variety of 
modalities to determine whether the bile duct is obstructed.93 
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4.5.2.6 Conclusion 
Jaundice has a variety of causes in adults, ranging from benign conditions such 
as gallstones to life-threatening malignancies such as pancreatic cancer. As it 
may indicate the presence of a serious condition, it is viewed as a worrying 
symptom in adults, particularly in those confirmed as not having gallstones or in 
those with other features suggestive of pancreatic cancer.93 It has no known 
association with bladder cancer.  
4.5.3 Abdominal pain 
4.5.3.1 Introduction 
Pain has been described as ‘an unpleasant sensory and emotional experience 
resulting from a stimulus that has already caused, is causing, or is likely to 
cause tissue damage’.94 The abdomen is defined as the region of the trunk 
between the diaphragm and the inlet of the pelvis. It contains vital organs 
(viscera, such as the gastrointestinal tract, the liver, biliary ducts and pancreas), 
parts of the urinary system, as well the aorta and its branches, the inferior vena 
cava and its tributaries and the portal vein.48 Therefore, it was reasonable to 
assume that both pancreatic and bladder cancer may present with abdominal 
pain in the design of the studies. 
In a clinical examination, pain is characterised by its severity, nature and 
location, each of which is discussed below in more detail.  
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4.5.3.2 Assessment of pain severity 
Assessment of pain severity relies on how it is perceived and reported, both of 
which depend on the patient’s subjective and emotional responses to it. Indeed, 
pain severity is such an individual experience that some regard attempts to 
categorise it as unhelpful and counterproductive.94,95 Despite this, various 
methods have been developed to measure pain severity, including scales that 
require patients to match it to a number, to a visual image or to a verbal 
description. For chronic pain, methods must be extended to include a measure 
of the pain’s impact on the patient’s physical and emotional well-being, as well 
as their social functioning.96 There are no Read codes for severity of pain, 
although there are codes to indicate when a patient has completed a McGill, 
Oswestry or Dallas pain scale, a visual analogue pain scale or a pain diary. 
Indeed, a retrospective, cohort study of the quality of medical record keeping 
conducted in 18 general practices in Exeter, UK, reported that the recording of 
symptom severity is poor in computerised systems. Of 2,444 individual 
symptom codes documented in electronic medical records, only 290 (11.9%, 
95% CI: 10.6–13.2%) included an indication of its severity.11 
Given the highly individual and subjective nature of pain perception, and the 
poor documentation of its severity, information about pain severity as a marker 
of bladder or pancreatic cancer was not sought. 
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4.5.3.3 The nature of abdominal pain  
In broad terms, the nature of abdominal pain is determined by whether it arises 
from inflammation or obstruction. Abdominal pain associated with inflammation 
tends to be constant, of varying severity and is exacerbated by physical 
disturbance. In contrast, pain arising from obstruction of a muscular tube (such 
as the bowel or ureter) is ‘colicky’, i.e. it fluctuates in severity and comes in 
waves, and is described as ‘gripping’. Prolonged obstruction can lead to 
distension of the bowel or ureter, at which point the pain is described not as 
colicky, but as constant and ‘stretching’.91  
4.5.3.4 The significance of pain location  
4.5.3.4.1 Introduction 
The abdominal organs are closely positioned within the abdominal cavity; 
therefore, disease in one organ readily affects the others. In addition, many of 
the abdominal organs are inaccessible to palpation, because either they lie 
deep within the abdominal cavity, or are afforded bony protection by the ribs, 
pelvis or spine. Despite these limitations, vital diagnostic information can be 
obtained from a thorough clinical examination and history.91  
4.5.3.4.2 Anatomy 
Anatomically, the abdomen is divided into three zones horizontally (upper, 
central and lower) and three vertically (right, central and left), as depicted 
schematically Figure 4.6.  
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Figure 4.6 Schematic diagram to show the regions of the abdomen and the zones where pain 
from the pancreas and bladder (underlined) is experienced 
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bladder, uterus & 
adnexae 
Left iliac fossa 
 
 
Sigmoid colon 
 
A common alternative to the terms described above is to divide the abdomen 
into four quadrants – upper and lower, left and right – demarcated by the 
midline vertically and the umbilicus horizontally. GPs may use any of these 
terms to describe the location of abdominal pain, a fact that needs to be borne 
in mind when searching for abdominal pain records. 
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4.5.3.4.3 Visceral pain 
While much visceral pain is simply felt ‘centrally’, the pain arising from some 
visceral structures is perceived in characteristic locations; for example, pain 
from the pancreas is felt in the left hypochondrium and centrally in the 
epigastrium, whereas a painful bladder is located in the hypogastrium.  
Pain may radiate away from these specific sites in characteristic ways as 
surrounding structures become affected by the disease; for example, pain 
originating in the pancreas radiates through to the back and to the left. 
Therefore, patterns of pain radiation are helpful for identifying not just the 
source of pain but also the extent of underlying disease.91   
4.5.3.4.4 Referred abdominal pain 
Pain from abdominal structures may also be referred to other parts of the body 
that share the same nerve supply, as shown in Figure 4.7. Referral of pain in 
this way derives from neural connections that develop in the embryo, good 
knowledge of which permits clinicians to identify where the underlying disease 
is likely to be.48,91  
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Figure 4.7 Some important skin areas involved in referred visceral pain (Figure 5-70 
reproduced with permission from Richard S. Snell, Clinical Anatomy for Medical Students, 5th 
edition, © Richard S. Snell MD PhD, 1995
48
) 
 
For example, visceral pain from the gallbladder is not just perceived in the right 
hypochondrium and radiating right and through to the back – it also may be 
referred up to the right shoulder tip, where it is perceived by the patient as an 
entirely dissociated pain.48  
Consequently, the signature locations of abdominal pain associated with 
pancreatic cancer generally differ from those that might be experienced by a 
patient with bladder cancer.  This was important when deciding which pain 
codes GPs might choose to record abdominal pain, and therefore which pain 
codes to select for study (see Section 6.8.1). 
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4.5.3.4.5 Pain from abdominal wall structures (somatic pain) 
Pain arising in abdominal wall structures is described as ‘somatic’. Relevant 
structures include the skin, fascia, muscles and, importantly, the outer layer of 
the membrane lining the abdomen – known as the parietal peritoneum. The 
nerves transmitting pain from the parietal peritoneum also innervate the 
overlying skin and mediate local reflexes. Therefore, abdominal pain arising 
from an inflamed parietal peritoneum may present with hyperaesthesia 
(excessive physical sensitivity), tenderness of the skin and increased abdominal 
tone, called ‘guarding’. It may also be characterised by tenderness experienced 
upon sudden release of an abdominal wall stretch induced by deep palpation – 
so-called rebound tenderness.48  
Bladder and pancreatic cancer are not reported as being associated with 
somatic abdominal pain.  
4.5.3.5 Investigation for abdominal pain 
In cancer diagnosis, abdominal pain is a ‘low-risk but not no-risk’ symptom. It 
has a high enough positive predictive value for colorectal, oesophageal, 
stomach, ovarian or pancreatic cancer to warrant either investigation in primary 
care or referral. For suspected pancreatic cancer, the advice relating to patients 
aged 60 years and older, who have abdominal pain in conjunction with weight 
loss, is to consider an urgent computed tomography scan – to be performed 
within 2 weeks – or an urgent ultrasound scan if the former is not available.9  
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4.5.3.6 Conclusion 
Determining the location, nature and patterns of radiation of abdominal pain is 
helpful for identifying the source of pain and the extent and nature of underlying 
disease. While abdominal pain is a feature of both bladder and pancreatic 
cancer, its characteristics vary with the cancer site.  
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5 The research questions 
To round out the introductory part of this thesis, I thought it would be helpful to 
draw together the various strands that have informed the research questions 
that this thesis is designed to address.  
First, there is existing evidence to suggest that GPs use text fields to record a 
lot of information about symptoms, and that this is hidden to the majority of 
CPRD-based studies because they restrict their analysis to codes. Therefore, at 
the very least, CPRD studies are likely to under-report symptom prevalence. 
Secondly, little is known about GPs’ choice of recording style and whether this 
varies with the type of patient, the type of symptom or the context in which it 
presents – all of which have the potential to introduce bias. Thirdly, policy 
decisions that decide the allocation of public money to healthcare provision are 
based on evidence provided by primary care research, an increasing amount of 
which is conducted using CPRD data. Therefore, such decisions need to be 
made in full knowledge of any under-reporting or bias introduced by the 
omission of text data. With this in mind, the following research questions were 
formulated. 
1. How much symptom information is documented in electronic 
medical records using text rather than a code? 
Most CPRD practices use ViSion (ViSion INPS, London, UK) to record the 
electronic medical record, in which GPs must choose a Read code first, after 
which a comments box opens.  Here, GPs can type freely and are not limited to 
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elaborating on the code. From clinical and medico-legal standpoints, codes and 
text are equally accessible. The same cannot be said for research – while 
codes are fully and routinely available to researchers, text records are not. 
Therefore, researchers are oblivious to anything that is recorded only as an 
inaccessible comment (henceforth called ‘text-only records’).  
2. Are studies of coded data vulnerable to bias arising from the 
differential use of text and codes between comparison groups? 
Systematic differences in the use of text rather than code to record clinical 
events between comparison groups will lead to bias in studies restricting 
analysis to codes, because of unequal data collection. For example, if text-only 
recording is greater for controls than cases, outcome measures will be 
artificially inflated because clinical events experienced by the control group will 
be consistently under-reported. Conversely, outcome measures will be 
artificially reduced if text-only recording is greater for cases than controls.  
3. Does recording style vary with type of symptom? 
Some symptoms are known ‘alarms’ for disease, whereas other symptoms may 
not trigger such a high level of clinical suspicion. To the best of my knowledge 
the effect of a symptom’s clinical significance on GPs’ choice of recording style 
(codes or text) has not been quantified.13,15  
Presenting with an alarm symptom increases the likelihood that a GP will 
instigate an investigation, carry out some tests or perhaps make a referral. Such 
actions tend to require GPs to use codes in their record-keeping.3,97 Therefore, 
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it is feasible that GPs are more likely to use codes for alarm symptoms than 
they are for symptoms perceived to be of little clinical significance. If this were 
the case, studies conducted using coded data only would be biased towards 
alarm symptoms and, conversely, against relatively innocuous ones.  
4. Does the recording style vary with the clinical context of 
presentation of a symptom? 
During a consultation GPs draw on their knowledge and experience to formulate 
a working diagnosis that best fits the patient’s presentation, taking into account 
patient characteristics such as their gender, age and lifestyle. The dual-process 
model of diagnostic reasoning has been proposed relatively recently, involving a 
mixture of intuitive and analytical thought processes.98  It may be hypothesised 
that this process leads doctors to record preferentially any clinical features 
substantiating what they think is the correct clinical diagnosis, rather than to 
record absolutely everything reported by the patient. This may muddy the 
interpretation of how alarm symptoms are treated – after all, a symptom may be 
considered a red flag when presented with a constellation of other symptoms 
that ‘fit’ the working diagnosis, but a red herring when it is incongruous. Such 
recording behaviour would lead to bias in the capture of information about 
symptoms based on their perceived likelihood of presentation in a particular 
context.  
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5. Do the text data provide additional value to coded data? 
Research questions 1–4 address the issue of bias introduced by ignoring text 
data within the CPRD. However, it is also important to investigate whether there 
is a difference in the ‘research quality’ of code- and text-based variables. For 
example, do code- and text-based variables give similar measures of 
association between symptoms and cancer in regression analysis?  
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6 Methods 
These case–control studies extended two recent CAPER studies of CPRD data 
that reported the main features of bladder4 and pancreatic5 cancer presentation 
in primary care. The extension was in the form of supplementation with text 
records for three features – haematuria, abdominal pain and jaundice – to 
identify what information had been missed because it had not been coded. This 
required cross-checking of dates to establish whether the text note was 
elaborating on an event already recorded by the GP using a Read code or 
indeed was the sole documentation of the symptom. This date matching could 
not be done if the new text-based variables were simply bolted on to existing 
datasets4,5; instead, the datasets had to be re-created using the same study 
participants.  
It was decided to extend the original studies conducted in the CPRD rather than 
start afresh with a completely new dataset or change to a different dataset (e.g. 
QResearch or THIN, see Section 2.6). This is because the original studies, 
along with others also using CPRD data collected between 1 January 2000 and 
31 December 2009 under the same design,41,42,43,44 were used as evidence in 
2015 revision of the National Institute of Health and Care Excellence referral 
guidelines for suspected cancer.9 This enabled my study to identify and quantify 
bias arising from data loss in the original studies and to revise the risk estimates 
for bladder and pancreatic cancer accordingly. 
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The methods specific to this study, including pre-analysis work-up, dataset re-
creation and identification of text-only recording, are detailed below. For 
completeness, the setting, methods of recruitment, and design of the original 
studies are also described.  
6.1 The setting  
Participants for both studies were selected from the CPRD at a time when it 
was collecting data on approximately 12 million patients across the UK, 
equating to 8% of the population. The CPRD’s probability sampling methods 
and geographical representativeness allow inferences about the UK population 
as a whole to be drawn from these studies’ results.  
6.2 The recruitment period  
The recruitment period was 1 January, 2000 to 31 December, 2009 inclusive for 
both studies. The end point was determined as the last date for which the Office 
for National Statistics for England and Wales had complete data for the 
numbers of cases of bladder and pancreatic cancer at the time the original 
studies were devised.4,5 Ten years was considered an adequate length of time 
to study the two cancers.  
This recruitment period also coincided with increased automation of test result 
transmission from the laboratory to the GP surgery. Laboratory test results used 
to be transferred manually into the patient record, but ‘drag-and-drop’ from an 
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email was introduced in 2003. However, since 2007 data entry of all laboratory 
results has been fully automated, linked through the patient’s NHS number.99 
6.3 Study participants  
Participants were eligible for potential inclusion in the studies if they were 
registered during the recruitment period with a CPRD practice whose data met 
‘up-to-date standard’ quality criteria (see Section 2.4.4). As the CPRD is a 
probability sample of the UK population (see Section 2.4.2), it is fair to assume 
that the cases are representative of typical cancer patients. In addition, cases 
and controls are all drawn from the same underlying population. For these 
reasons, the study design minimises, if not eliminates, selection bias. 
6.3.1 Case ascertainment 
Potential cases were identified as those patients with a clinical or referral record 
of incident bladder or pancreatic cancer in the recruitment period. Incident 
cancer was defined by the Read code list provided by the primary investigator 
(Professor Willie Hamilton) and agreed with the CPRD research team (complete 
lists in Appendix 15.2).  
The definition of bladder cancer reflected that used before the change in 
disease definition introduced by International Classification of Disease (ICD) for 
Oncology in 1998, i.e. it included carcinoma in situ of bladder and neoplasm of 
uncertain behaviour of bladder (see Section 4.4.2.2). 
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Read codes are mapped 1:1 to medcodes by the CPRD purely to facilitate 
analysis in Stata and essentially the terms are interchangeable.a The list was 
used to create a ‘disease thesaurus’ of medcodes in Stata, in which each 
cancer site was assigned a unique number. Medcodes pertaining to the 
diagnosis of a specific cancer could therefore be extracted by searching on the 
cancer site code. 
6.3.2 Inclusion criteria for cases 
Inclusion criteria for cases consisted of: 
 Being aged ≥40 years at diagnosis  
 Being registered at the practice for at least 1 year before diagnosis 
 Having gender clearly recorded as either ‘male’ or ‘female’ 
6.3.3 Exclusion criteria for cases 
Exclusion criteria for cases consisted of: 
 Having a secondary cancer 
 Being diagnosed with any cancer before 1 January, 2000  
                                            
a
 In this thesis, I use Read codes in the context of the GP consultation, as these are what the 
GPs use to create the medical record, whereas I use medcode in the context of research; 
however, I should emphasise that the two terms are completely interchangeable.  
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 Not consulting in primary care in the year before the cancer diagnosis 
 Not having any matched controls 
6.3.4 Final selection of cases 
Inclusion and exclusion criteria were applied, after which a maximum of 5,000 
cases with the relevant cancer diagnosis were recruited to the bladder cancer 
study using random sampling. The limit of 5,000 cases was set, in order to keep 
within the financial resources of the original studies.4,5 Fewer than 5,000 
patients received a diagnosis of pancreatic cancer; therefore, all those who both 
met the inclusion criteria and were not ruled out because of the exclusion 
criteria were recruited. 
6.3.5 Inclusion criteria for controls 
Controls were selected from the same baseline population that yielded the 
cases. Up to five controls were selected per case, as this increased the power 
of the study.100 Cases and controls were matched on sex, age and GP practice. 
Inclusion criteria for controls consisted of: 
 Being registered with the same GP practice as their matched case when 
the latter was diagnosed with cancer 
 Being aged ≥40 years when their case was diagnosed with cancer  
 Having at least one entry in the clinical or referral files (see below, 
Section 6.5.2) in the year prior to cancer diagnosis in the case 
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 Being alive on the date on which their case was diagnosed with cancer 
6.3.6 Exclusion criteria for controls 
Exclusion criteria for controls consisted of: 
 Exclusion of their matched case for any reason 
 Being diagnosed with the same cancer as their matched case before 1 
January, 2000 
 Being diagnosed with the same cancer as their matched case after 1 
January, 2000 – as this would mean they were eligible to be a case 
themselves 
 Being a control for another case 
6.3.6.1 Subanalysis of bladder cancer dataset 
In separate sub-analyses, the bladder cancer dataset was restricted to just 
those cases with diagnostic codes included in ICD category C67. In other 
words, cases (and their matched controls) were dropped if they had received a 
diagnosis of carcinoma in situ or of neoplasm of uncertain behaviour of bladder. 
This was carried out in order to estimate the risk of bladder cancer in 
symptomatic patients commensurate with the post-1998 ICD definition of the 
disease. The risk estimate results of this analysis are reported in Appendix 6: 
Risk estimates for the post-1998 definition of bladder cancer (C67). 
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6.4 Matching 
Cases were matched on sex, age and GP practice, using observation window 
matching, with up to five controls. Conventionally, matching is used to control 
for confounding. In CAPER studies, confounders would have: (1) a causative 
association with the disease (albeit ‘caused by’ rather than ‘causing’) and (2) a 
non-causative association with the risk marker under investigation. It is hard to 
envisage a framework for confounding between two risk markers, given their 
dependence on causative pathology. Equally, it is reasonable to assume that 
there is no mechanism by which a risk factor could have a non-causative 
association with a risk marker, since risk factors exert their effect before cancer 
develops whereas risk markers only become apparent after cancer is 
established. Therefore, smoking, alcohol consumption and obesity – all 
commonly considered confounders in conventional case–control studies – do 
not fulfil these criteria in CAPER studies. The purpose of matching here was not 
to control for confounding; rather, it was to minimise bias as described below.100   
6.4.1 Matching on sex 
Matching on sex was carried out to mitigate any reporting bias caused by 
differential consulting patterns and behaviour between men and women. A 
study of consultation rates in England between 1995 and 2008 using 
QResearch® data reported that women tended to visit the GP more frequently 
than men between the ages of 19 and 60 years. Aggregated data on crude 
consultation rates indicated that men aged 15–19 years attended twice per 
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year, rising to 5 times at the age of 55–59 years, whereas attendances by 
women at the same time points were just under 5, rising to nearly 7. In contrast, 
there was no observable difference in attendance patterns between men and 
women in the very young or very elderly; for example, in 2008 the highest 
median practice consultation rates were 12.9 (IQR: 10.2–16.1) per person-year 
for men aged 85–89 years and 12.5 (IQR: 9.9–15.2) per person-year for women 
of the same age.101 A study of nearly 4 million patients in 2010 in The Health 
Improvement Network (THIN) database reported that overall consultation rates 
in primary care were 30% lower for men than women. The size of the difference 
varied with age, being greatest among 21- to 39-year-olds (ratio of male to 
female consultations = 0.40, 95% CI: 0.39–0.40). Of more relevance to CAPER 
studies, in patients aged >40 to 57 years, the male : female ratio was 0.62 (95% 
CI: 0.62–0.63), and in those older than 58 any difference had largely 
disappeared (0.92, 95% CI: 0.91–0.93).102 The same authors then investigated 
consulting patterns in the 24 months prior to a diagnosis of colorectal or lung 
cancer or malignant melanoma. Participants included all patients over 16 years 
permanently registered in THIN with an incident diagnosis of lung (n = 11,081) 
or colorectal (n = 12,189) cancer or malignant melanoma (n = 4,352) between 
1997 and 2006. Interestingly, the authors found no evidence that consulting 
patterns varied between men and women, although it should be noted that they 
recorded just the number of consultations, investigating neither their content nor 
their nature.103  Nevertheless, matching on gender remains prudent given that 
the propensity for women to consult more than men is retained in the control 
group. 
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6.4.2 Matching on age 
As reported above, consultation rates vary with age, reflecting how disease – 
and therefore symptom – profiles change throughout life.101 The latest statistics 
summarised by Cancer Research UK indicate that roughly half of all incident 
cases of both pancreatic and bladder cancer were in people older than 75,53,61 
whereas the median age of over 40s that consult their GP was reported to be 
62 years.104 Therefore, without matching on age, cases would be an average of 
>10 years older than controls, leading to comparisons being made between two 
groups with different symptom profiles.  
To protect against patient identification, the CPRD did not release exact dates 
of birth, only the year. For the purposes of matching, all participants were 
assumed to have been born on 1 July as this falls midway through the year. 
6.4.3 Matching on GP practice 
Matching on GP practice was used as a proxy to control for the known 
dependence of consulting patterns on socioeconomic status and location. A 
study of 60 GP practices in England and Wales including half a million patients 
reported that a higher proportion of people in social classes IV and V consulted 
their GP compared with those in classes I and II. Consultation rates also varied 
with geographical location.105    
Matching on GP practice was also done to avoid potential recording bias due to 
variations in the documentation of clinical information between GP practices. All 
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data submitted to the CPRD are subjected to stringent quality controls and the 
majority of participating GP practices use ViSion software to generate the 
electronic health record (see Section 2). In addition, GP practices are strongly 
encouraged to follow ViSion recording guidelines.3 All of this, in theory, 
minimises between-practice variation in data collection. Nevertheless, some 
variation in adherence to the recording guidelines will remain, not least because 
ViSion can be customised; for example, by creating thesauri of Read codes that 
appear automatically when GPs start to type in certain symptoms. In addition, 
GPs themselves will vary, not only in terms of what they decide to include in the 
notes but also how they record it – as a Read code or in the text. While the 
CPRD variable ‘staffid’ allows identification of the practice staff member who 
entered the data, it does not necessarily follow that this person is the actual GP. 
Therefore, as a pragmatic compromise, matching on GP practice was carried 
out to minimise recording bias between participants in the study.100  
6.5 Data collection and data work-up  
6.5.1 Data collection 
Data were collected by GPs as part of routine primary care. The mechanism of 
data recording is described in detail in Section 2.2 and will not be repeated 
here.  
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6.5.1.1 Reporting bias 
Matching on sex, age and GP practice all minimise the potential for reporting 
bias. One could also argue, however, that patients in the early presentation 
stage of cancer might be starting to become worried about their health and have 
a lower threshold than controls for attending the GP. In the original CAPER 
studies, this was examined by looking for differences in attendance for fractures 
as a proxy for general attendance patterns between comparison groups. This 
was chosen as fractures were thought to be equally likely across the entire 
study population, given that incident rather than metastatic cancer was 
investigated. Limitations of this approach are discussed in the next section 
(Section 6.5.1.2). 
Reporting bias may also occur owing to differences between what the patient 
tells the GP and what the GP hears and records. This is discussed below in 
Section 6.5.1.2, Recording bias. 
6.5.1.2 Recording bias 
The two main potential sources of recording bias in observational studies of 
data recorded as part of everyday clinical care are discussed below. 
6.5.1.2.1 Consistency of recording between comparison groups 
Unbiased estimates of clinical features in cases and controls require that GPs 
are equally likely to record information reported by the two comparison groups. 
Indeed, the assumption made by all researchers using CPRD data is that GPs 
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have no systematic tendency to alter the information that they record according 
to a patient’s ultimate diagnosis. However, when making a diagnosis, GPs will 
test alternative hypotheses iteratively when taking the history. They will focus on 
those symptoms reported by the patient that fit with their working diagnosis, and 
use these to inform the tests and referrals they decide to request. This heuristic 
approach – in effect 'framing' by the working diagnosis – will influence which 
information reported by the patient is subsequently recorded by the GP.106 
107,108,109,110 This calls into question the validity of the above assumption about 
consistency of recording style between comparison groups, because the cases 
are shortly to be diagnosed with cancer whereas the controls are free of the 
disease. It is conceivable that preference is given to recording those signs and 
symptoms that justify the clinical management, introducing recording bias in 
accordance with the clinical significance of a symptom for the cancer under 
investigation.  
6.5.1.2.2 Use of codes versus text 
In my study, unbiased estimates of clinical features in cases and controls also 
require that the accessibility of information within the electronic medical record 
is the same for cases as for controls. The assumption made by all researchers 
using CPRD data is that GPs have no systematic tendency to alter their 
recording style according to a patient's ultimate diagnosis. There is evidence 
that paper-based systems are more amenable than computerised systems to 
the recording and quantification of symptoms.11 By analogy, it is conceivable 
that GPs may find it easier to record symptoms in the 'comments box' rather 
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than as a Read code. Differential use of text-only recording between cases and 
controls would introduce a recording bias because, as described above (see 
Section 2.5), Read codes are readily and routinely available to researchers 
using CPRD data, whereas the text is generally withheld. Therefore, symptom 
information recorded only in text and not as a code will be ‘hidden’ to 
conventional studies and result in false-negative assignment of patients to 
symptom-free status. 
This was tested in the original CAPER studies by studying fracture rate and so 
far no evidence of bias has been unearthed. However, the choice of fractures 
may be criticised because they are unambiguous diagnoses requiring treatment 
and follow-up in fracture clinic. Arguably, a fracture is unrepresentative of 
symptoms or signs suggestive of more than one possible diagnosis that may or 
may not require referral. It is possible that recording styles may differ in these 
two scenarios. Therefore, this study specifically addresses the validity of 
assumptions made about GPs’ recording style.  
6.5.2 Raw data  
Raw data were received from the CPRD in the generic American Standard 
Code for Information Interchange (ASCII) format, on multiple CD-ROMs. In 
total, 12 file types were provided, of which 7 (6 of coded and 1 of text data) 
were used. Their contents are described briefly below.  
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6.5.2.1 Matching files 
The CPRD provided a complete list of potential cases and controls in separate 
‘matching’ files for each cancer site. Each file consisted of three variables, the 
first two being unique identifiers for cases (capatid) and for controls (copatid), 
respectively; the third, an ordinal number that took a value of 0 for cases and of 
between 1 and 5 for controls.  
6.5.2.2 Patient files  
The patient files contained basic demographic data and patient registration 
details. Data were held in 21 variables, including a unique patient identifier 
(patid, derived from capatid and copatid in the matching files), gender and year 
of birth and an indicator stating whether the patient’s data met quality 
standards. 
6.5.2.3 Practice files 
The practice files contained details about the GP surgeries that contribute to the 
CPRD, including their region and collection information. Data were held in four 
variables, including a unique identifier for each practice (pracid) and the up-to-
standard date, i.e. the date at which the practice data were last deemed to be of 
research quality. 
6.5.2.4 Clinical files  
These files contained the entire medical history, including clinical signs, 
symptoms, diagnoses and deaths, entered into the GP system using Read 
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codes. Data were stored in 11 variables, including: the unique patient identifier 
patid; the event date; the medcode identifying the clinical eventa; and a text 
identifier (textid) to allow linkage of the medcode with its paired free text record. 
Patients may have had more than one row of data.  
6.5.2.5 Referral files  
These files contained referral details recorded on the GP system. Information 
pertained to patient referrals to external care centres (normally to secondary 
care, such as hospitals for inpatient or outpatient care), and included speciality 
and referral type. Data were held in 14 variables including patid, event date, 
textid, medcode and others indicating the referral speciality. 
Clinical and referral files were regarded as essentially equivalent, so they were 
appended into a master ‘clinical and referral’ dataset of medcodes. 
6.5.2.6 Test files  
These files contained the patients’ test results recorded in the GP system. The 
data were held in 13 core variables, plus a variable number of data fields for the 
test results themselves. The data were coded using a Read code, chosen by 
the GP, identifying the type of test used. Data were stored differently according 
to the test that was carried out and denoted either qualitative text-based (for 
                                            
a
 Mapped 1:1 by the CPRD from the Read code, purely to facilitate data handling. 
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example 'Normal' or Abnormal') or quantitative (i.e. a numeric value that needs 
to be compared to the normal range – also provided) results. 
6.5.2.7 Text files  
The text files were not routinely available to CAPER studies, but were 
specifically requested for this investigation. Text fields in the medical records of 
participants in the bladder4 and pancreatic5 cancer studies were searched for 
evidence that the patient attended the GP for abdominal pain, jaundice or 
haematuria. The CPRD were asked to extract all the following word strings: 
 abdominal pain: 'bdominal pai' or 'bdo pai' or 'ain in abdo' or finally 
'pigastric pai'  – if searches were not case sensitive, the obvious first 
letter was added 
 jaundice: 'aundice' or 'cterus' or 'cteric' 
 haematuria: 'aematuria' or 'lood in urine' 
CPRD staff examined the strings and redacted any information that could 
identify the patient. String variables were created, consisting of the extracted 
search term plus the three words either side to aid interpretation.a  
                                            
a
 The CPRD advised that limiting the accompanying text to three words either side of the search 
term would be the most cost-effective way of obtaining interpretable data (the data are charged 
by the word). 
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Data were held in four variables; namely, patid, pracid, textid and the text itself. 
Patients may have had more than one row of data.   
Visual inspection suggested that sorting of extracts into the appropriate 
symptom categories at the CPRD had introduced some errors; for example, 
some extracts relating to haematuria were sorted to the abdominal pain group. 
Therefore, all extracts were combined into a single dataset and re-sorted into 
the appropriate category by identifying the original search terms given to the 
CPRD. Some extracts contained search terms for more than one symptom, and 
so duplicate copies were sorted into each symptom dataset. 
6.5.3 Variables extracted from the raw data  
The variables extracted from the raw data files and used in this study are listed 
in Table 6.1.  
6.5.4 Raw data processing and work-up 
The raw data files supplied by the CPRD were imported individually into Stata 
(version 11 in the original studies; version 13 in this PhD). The variables listed 
in Table 6.1 were extracted and used to construct the final dataset.  
This section describes the raw data processing and work-up carried out in 
readiness for dataset construction in CAPER studies.4,5 Not all steps were 
repeated when re-creating the datasets for this study; instead, some variables 
from the original studies were imported. Such variables are clearly identified 
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and explanations given as to why it was necessary to do this rather than re-
create them from scratch.  
Table 6.1 Variables extracted from the raw data files 
Raw data file Variables used 
Patient file Unique patient identifier Year of birth† 
Gender Date of death† 
Clinical file Unique patient identifier  Event date 
Medcode Additional clinical details code 
Unique text identifier  
Referral file Unique patient identifier Unique text identifier 
Medcode Event date† 
Test file Unique patient identifier Test value 
Medcode Lower limit of normal range 
Event date† Upper limit of normal range 
Text file‽ Unique patient identifier The text string# 
Unique text identifier  
Matching file Unique case identifier‡ Ordinal within patient group‡ 
Unique control identifier‡  
Notes:  
‽Data clean-up required. 
†Raw data provided in string format and required conversion to elapsed date format for analysis 
in Stata. 
#Raw data provided in string format and required conversion to binary variable for analysis in 
Stata. 
‡Raw data used to derive variables essential for analysis of matched data. 
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Most of the variables in the data files could be used as provided, while others 
required conversion to a format suitable for analysis in Stata, and this is also 
described below. 
6.5.4.1 Text file data clean-up 
The validity of each observation within its symptom group was checked by 
searching for and identifying the original search terms sent to the CPRD. 
Incongruous observations were reassigned to their correct symptom dataset, 
after which duplicate observations were identified and surplus records dropped.  
The text records were supplied as sequences of characters in ‘string’ variable 
format and were converted to binary variables (symptom present or absent) 
suitable for analysis. This was a lengthy process and unique to my PhD; 
therefore, the details are described in a separate section (see Section 6.6). 
6.5.4.2 Deriving variables essential for analysis of matched data  
The study population contained a maximum of 5,000 patients with a particular 
cancer, plus up to five matched controls per case. Each case and their controls 
formed a 'group'. The data in the matching files (see Section 6.5.2.1) were used 
to create variables that uniquely identified each patient (patid), their case/control 
status and the group to which they were assigned. These variables were 
essential for analysis of matched data.  The patient identifier variable, patid, 
was similarly generated by the CPRD and is the same as that referred to 
throughout Section 6.5.2.  
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6.5.4.3  Patient age 
A variable ‘age’ was generated, assuming that all participants were born on 1 
July, as this falls midway through the year.  
6.5.4.4 Date of diagnosis  
The diagnosis date was taken to be the first occurrence in the patient’s 
electronic medical record (the ‘clinical and referral’ master) of a medcode listed 
in the cancer’s diagnostic thesaurus (see Appendix 2: Disease thesauri). 
Diagnosis dates were imported from the original studies, because these 
determined the period over which text records were examined for evidence that 
the patient was attending with haematuria, jaundice or abdominal pain.  
6.5.4.5 Age at diagnosis 
Age at diagnosis was calculated, as were binary variables that assigned 
patients to the following age groups at diagnosis: >60 and ≤60 years. 
6.5.4.6 Determining the analysis period within patient groups 
The aim of analysis was to identify how cancer presents in the year before 
diagnosis. Therefore, all controls were assigned their case’s diagnosis date, in 
order to anchor the end point of the analysis period within patient groups. To 
ensure that data were restricted to the analysis period, all events in the ‘clinical 
and referral’ master dataset occurring either after, or more than a year before, a 
patient group’s diagnosis date were dropped. Duplicate observations were 
identified and surplus copies deleted. The resulting dataset was saved and 
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used as the source of coded evidence of possible features of cancer, as 
described in Section 6.8. Data in the test files were similarly restricted to the 
analysis period within patient groups.  
The CPRD created a ‘redundant’ date of 1/1/2500 and any observations 
assigned this date were dropped from the study. Also dropped were any 
observations whose date of recording was not provided.  
6.6 Construction and application of the algorithm to 
convert text strings to binary variables 
6.6.1 Introduction 
Pre-analysis work-up was required to convert the strings in the text files (see 
Sections 6.5.2.7 and 6.8.2) to a format suitable for analysis. Binary variables 
were generated indicating whether or not each text record included evidence 
that the patient had attended for abdominal pain, haematuria (visible or non-
visible) or jaundice in the year prior to diagnosis in the case. Reference to a 
symptom in an observation should not be interpreted as confirmation that the 
patient has the clinical condition in question; indeed, doctors will also document 
when particular signs and symptoms are absent to demonstrate that they have 
taken a thorough history.111  
6.6.2 Using an algorithm to interpret the meaning of text strings  
CPRD databases can include thousands of observations. Reading and 
interpreting each one by hand is time consuming to the point of impracticality; 
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furthermore, it renders the process vulnerable to inconsistencies in decision-
making. To enhance the accessibility and utility of the text data, a ‘triage’ 
algorithm was devised to increase the automation of this process in a way that 
was reliable and also quantified the uncertainty inherent in the resulting 
variables.  
6.6.2.1 Theory of negation 
Arguments in the algorithm were underpinned by the theory of negation in 
natural language, which is a complex area and touched on only very lightly 
here. For an in-depth discussion of the structure, use and meaning of negation 
in natural language, I referred to A Natural History of Negation.112 The type of 
negation applicable here is ‘contradictory opposition’, which has two 
distinguishing criteria112: it applies to pairs of statements and the pairs are 
mutually exclusive, i.e. one must be true and the other false. This fits well with 
the nature of symptoms, which are also binary entities in that they are either 
present or they are not at the time of the consultation.  
6.6.2.2 Construction of the algorithm 
The arguments of the algorithm were derived from the rules governing sentence 
construction (syntax) as applied to the theory of negation. Full details are given 
in Appendix 3: Algorithm construction. Code for the algorithm that converted the 
text strings to discrete variables was created in Stata (version 13).   
A preliminary assessment of the data revealed that binary classification, 
‘symptom present’ and ‘symptom absent’, was not sufficient, and that a third 
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category ‘meaning unclear’ was required, at least in the interim. Sometimes this 
was because of uncertainty over timing and sometimes because the text was 
nonsensical (some examples are shown in Table 6.2).  
Table 6.2 Examples of text strings relating to haematuria 
String of text Interpretation 
AFTERNOON HAS HAD HAEMATURIA 
AND NOT FEELING 
Symptom positive 
CLOTS BLOOD IN URINE Symptom positive 
PAINFUL HAEMATURIA; MSU 
PENDING; TEL 
Symptom positive 
. HELPFUL IN STOPPING 
HAEMATURIA IN THE PAST 
Unclear – uncertainty over timing of 
haematuria 
TAKEN. NO SOME HAEMATURIA 
OVER LAST 1/52 
Uninterpretable 
HAS HAD NO HAEMATURIA. SHE HAS 
HAD 
Symptom negative 
Therefore, the decision was taken to classify each observation initially into one 
of the following groups: 
1. ‘Symptom negative’ – used to describe those observations in which 
symptoms were explicitly or implicitly described as absent at the time the 
patient consulted the GP.  
2. ‘Symptom positive’ – used to describe those observations in which 
symptoms were contemporary.  
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3. ‘Meaning unclear’ – used to describe when the patient’s status 
regarding the symptom could not be ascertained with certainty. 
Identification of those observations whose meaning was unclear was difficult to 
automate since there are few rules on which to base decision-making. I decided 
to search for trigger words and highlight those observations as potentially 
unclear (see Appendix 3: Algorithm construction).   
6.6.3 Application of the algorithm  
Semi-automated classification of observations was carried out to reduce the 
number requiring manual assessment:  
1. All observations were initially classed by the algorithm as symptom-
positive.  
2. The algorithm identified the negation of symptoms and reclassified 
those observations as ‘symptom negative’.  
3. The algorithm identified potentially ambiguous observations, based 
on the presence of trigger words, and reclassified them as ‘meaning 
unclear’. These observations required later manual assessment to 
see if they could be reclassified as either symptom-negative or 
symptom-positive.  
4. Observations that were not picked up by the algorithm in steps 2 and 
3 remained classified as symptom-positive by default. This was later 
verified by manual assessment.  
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The accuracy of this process was assessed by comparing the output with that of 
a specially constructed reference standard (see Section 6.7). 
6.6.4 Generation of variables for analysis 
The classified text strings were converted to binary variables suitable for 
analysis. Unclear observations were deemed to provide insufficient evidence 
that the symptom was present, and so were reclassified as ‘symptom absent’ to 
achieve binary classification.  
Variables were created for abdominal pain, jaundice and the two types of 
haematuria – visible and non-visible.  
6.6.5 Missing data 
Missing data occurred where the text fields did not contain any mention of the 
symptom in question. The lack of either reporting or recording of the symptom 
was interpreted as no evidence that the symptom occurred.  
Missing data may also arise from misspelling and typographical errors, as 
affected text strings would not have been picked up by the CPRD’s search 
criteria. To get a measure of the potential for this type of error, I exported a 
random sample of the text record received from the CPRD into Word and 
proofread them. The rate of spelling and typographical errors was reported. 
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6.7 Validating the classification procedure using the 
diagnostic test model 
Text data are inherently noisy and it was important to assess the accuracy with 
which observations were categorised, to get a measure of classification error. In 
the diagnostic test model, accuracy is reported in terms of sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) in 
comparison with a gold standard. In this context, the gold standard would be the 
true meaning of the free text being categorised.  
6.7.1 Applicability criteria of the diagnostic test model 
For the diagnostic test model to be applicable to the semi-automated procedure 
for classifying free text observations, several criteria need to be fulfilled113:  
1. The final classification system must be binary.  
2. A gold standard must be used to assess the free text observations and to 
establish the true category of each one. (The classification procedure’s 
output is then compared with that of the gold standard in a contingency 
table. As the gold standard provides error-free classification, all false-
positives and false-negatives can be attributed with certainty to error in 
the classification procedure.) 
3. The same gold standard is used to assess all observations. 
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4. Assessments made using the gold standard and the semi-automated 
classification procedure should be made at the same time, to eliminate 
changes that occur over time.  
Criteria 3 and 4 were readily met and did not pose a problem in this scenario; 
however, the same cannot be said of criteria 1 and 2. 
6.7.1.1 Criterion 1: alternatives when classification is not binary  
As described above, we had the problem of observations whose meaning 
remained unclear. There were three possible approaches to dealing with this, 
as described below.  
6.7.1.1.1 Receiver operating characteristic curve 
Where ordinal categories have been derived from underlying numerical 
variables, observations can be classified into a binary system based on a 
threshold or cut-off value. The performance of the threshold value can be 
quantified by plotting sensitivity against (1 – specificity), to give a receiver 
operating characteristic curve.114 This method can be applied to string data by 
assigning a numerical score to each observation, such as is used in information 
retrieval systems. For example, using a Bayesian inference network approach, 
Aranow115 developed an ad hoc method for classifying radiology reports 
according to the level of evidence that mammograms belonged to one of three 
categories regarding the presence of suspicious conditions: positive, negative 
or uncertain. It was proposed that if the system accurately categorised 
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mammograms as positive or negative, only those categorised as uncertain 
would require manual review. 
Developing a similar system for scoring our free text observations and setting 
cut-off values to enable a binary classification system would not be trivial and so 
alternatives were explored.   
6.7.1.1.2 Correction for misclassification of binary exposure variables 
Correction for misclassification of binary exposure variables is complex because 
the errors, unlike those on numerical variables, correlate with the true value of 
the binary variable. In essence, the error can only take a value of 0, −1 or +1: it 
is always 0 when the classification is correct, but when the classification is 
incorrect the error is +1 when the true value is 0, and −1 when the true value is 
1.114 Making repeated measurements is suggested as a way of imputing 
missing values, but this option was not available in our study.  
6.7.1.1.3 Sensitivity analysis 
In the absence of an observation scoring system, a binary classification system 
can be imposed on data. This is achieved by taking the view that there is 
insufficient evidence to classify ‘unclear’ observations as ‘symptom positive’, 
instead assigning them to the category ‘symptom negative’. Subsequent 
sensitivity analysis would be required, first merging the ‘uncertain’ category with 
the ‘positive’ category, and then with the ‘negative’ category, to create the 
following binary classification systems: 
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a. Symptom negative + Symptom not negative (i.e. merged groups 
‘symptom positive’ and ‘meaning unclear’).   
b. Symptom positive + Symptom not positive (i.e. merged groups 
‘symptom negative’ and ‘meaning unclear’). 
Calculating the metrics sensitivity, specificity, PPV and NPV for each of these 
two groups would give their maximum and minimum values, with the true value 
for our data set lying somewhere in between. 
Sensitivity analysis was the preferred option in this study. 
6.7.1.2 Criterion 2: alternatives when there is no gold standard 
The absolute gold standard for interpreting the free text would be to ask the GP 
who wrote the note to review the entire free text content and confirm the 
meaning. Clearly, this was impossible, so we had to seek an alternative.  
6.7.1.2.1 Manual assessment by a single expert 
Some authors have taken manual assessment by an expert as a proxy for the 
gold standard of free text interpretation.116,117,118 For example, Wang used 
manual assessment by a single medical practitioner blinded to the output of an 
algorithm written to classify documents in a fully automated process.118 
However, this does not allow any assessment of reliability (i.e. the 
reproducibility of the measurement), which is particularly important in this 
setting as the interpretation of free text observations is so subjective. Therefore, 
alternatives were explored.  
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6.7.1.2.2 Constructing a reference standard 
The evaluation of index tests when there is no gold standard was the subject of 
a review by Rutjes.113 Of the four main methods identified, constructing a 
reference standard using the panel of consensus method was chosen as the 
most appropriate. The methods used to achieve this are now described. 
6.7.2 Constructing and validating the reference standard 
A panel of two raters was formed, both practising GPs and both supervisors of 
my thesis. A random sample of 100 observations about haematuria was 
extracted from the text files using Stata.  
6.7.2.1 The pilot trial 
The text strings were exported to Excel and sent to each rater independently. 
Using a drop-down list, each rater was asked to select the category they felt 
most accurately reflected the meaning of the text: symptom present, symptom 
absent or meaning unclear. The raters worked independently, and no conferring 
was allowed.  
I collated the results, and identified and reported the level of agreement 
between the two raters. I chose to use the weighted kappa statistic, as it gives a 
measure of agreement over and above that due to chance alone. The formula 
used to calculate the quadratic weights (w) was: 
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wij = 1 – [(i – j)
2/(k – 1)2], 
where i and j are the individual categories and k is the total number of 
categories (i.e. 3). 
‘Symptom present’ was denoted as category 1; ‘meaning unclear’, category 2; 
and ‘symptom absent’, category 3. The quadratic weights were calculated as: 
w11 = w22 = w33 = 1 – [(0)
2/ (3 – 1)2] = 1 (i.e. complete agreement) 
w12 = w21 = 1 – [(1)
2/ (3 – 1)2] = 0.75 (i.e. partial agreement) 
w13 = w31 = 1 – [2
2/ (3 – 1)2] = 0 (i.e. complete disagreement) 
The kappa score is known to be sensitive to marginal inhomogeneity, being 
reduced by symmetrical imbalance and enhanced by asymmetrical 
imbalance.119 Therefore, the marginal totals were calculated and reported as an 
indication of the degree of homogeneity.  
6.7.2.2 Category definitions 
The results of the pilot trial were shared with both raters and definitions agreed 
for each category (see Section 6.6.2.2). 
6.7.2.3 Finalising the reference standard  
The raters were then asked to re-assess the same random sample of 100 
observations, independently, according to the agreed definitions. The raters 
subsequently discussed the discrepancies, in a bid to maximise agreement in 
the reference standard to near gold standard status. If observations remained 
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stubbornly indecipherable by both raters, or the raters disagreed as to their 
meaning, their classification as unclear was retained. The percentage defined in 
this category was reported.  
6.7.2.4 Validating the reference standard 
The reference standard was validated to provide a measure of its potential as a 
source of error, by reporting final levels of inter-rater agreement using the kappa 
statistic.113  While the interpretation of the kappa statistic is variable (see Table 
6.3), there is general agreement that a value >0.8 indicates very good or almost 
perfect agreement. A kappa value of 1 would indicate that a true gold standard 
had been established.  
Table 6.3 Interpretation of the kappa statistic 
Kappa 
value 
Interpretation 
of strength of 
agreement 
by Altman120 
Kappa 
value 
Interpretation 
of strength of 
agreement by 
Landis121 
Kappa 
value 
Interpretation 
of strength of 
agreement by 
McGinn122 
<0.20 Poor <0.40 Moderate or 
poor 
0 None 
0–0.2 Slight 
0.21–
0.40 
Fair 0.2–0.4 Fair 
0.41–
0.6 
Moderate 0.4–
0.75 
Fair to good 0.4–0.6 Moderate 
0.61–
0.80 
Good >0.75 Excellent 0.6–0.8 Substantial 
0.81–
1.00 
Very good 0.8–1.0 Almost perfect 
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6.7.2.5 Finalising the reference standard 
To finalise the reference standard, observations were dropped if agreement 
could not be reached as to their meaning, or the raters agreed that they were 
uninterpretable. The weighted kappa was calculated and reported. 
6.7.3 Validating the classification process  
The purpose of constructing the reference standard was to validate the 
classification process, to provide a measure of its potential as a source of 
misclassification of free text observations.113 To that end, the classification 
process was used to categorise the same random sample of observations as 
was used to construct the reference standard. Validation was reported in terms 
of the weighted kappa statistic, as above, along with marginal totals. 
Summary 
Having cleaned-up the raw data and converted the text strings to variables 
suitable for analysis, using a validated classification method, I moved on to 
identifying evidence that patients attended their GP in the analysis period for 
risk markers of cancer. 
6.8 Identifying records of attendance for possible 
features of cancer  
This section describes how both coded and text records of attendance for 
possible features of cancer were extracted from the patients’ electronic records.  
151 
 
Recap 
Figure 2.1 is repeated here as a timely reminder of what I mean by ‘coded’ and 
‘text’ records. During the consultation, GPs are obliged to select a Read code 
first to make a clinical entry in the patient’s record (the coded record), after 
which they are free to write in the comments box (the text record). The text may 
or may not relate to the Read code.  
Figure 2.1 (repeated) Screenshot showing the comments box that becomes 
available (red arrow) once a Read code has been selected in ViSion 
 
The CPRD subsequently map the alphanumeric Read codes 1:1 to numeric 
medcodes, purely to facilitate analysis. As discussed earlier (see Section 2.5), 
the majority of studies restrict their analysis to the coded record. However, in 
this study, the text record was also examined for evidence that patients 
attended for abdominal pain, haematuria or jaundice (see Sections 5 and 
6.5.2.7).  
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6.8.1 Identifying coded records of patient attendance for 
symptoms possibly indicative of cancer  
A three-step process was used to extract coded records of patient attendance 
for all those symptoms identified in the original studies as being the most 
strongly associated with cancer.4,5 This involved creating a separate thesaurus 
of medcodes for each possible symptom of cancer, and identifying when 
medcodes from a thesaurus had been recorded in the electronic medical record 
(the ‘clinical and referral’ master, see Section 6.5.2.5).  
Step 1 – finding synonyms for potential features of cancer  
Step 1 was included to maximise data capture and involved finding synonyms 
for each potential feature of cancer. A variety of resources were used, the main 
one being the latest version of the coding system International Classification of 
Primary Care, ICPC-2.123 This classification system was chosen because, 
compared with Read codes, it has greater emphasis on symptoms. Other 
resources consulted included literature from patient support groups, the internet 
(e.g. medical education websites, patient information websites and discussion 
forums) as well as amenable medical practitioners.  
Step 2 – creating symptom thesauri for each potential feature of cancer 
In step 2, the descriptions of all medcodes were searched for any occurrence of 
synonyms identified in step 1. A shortlist of medcodes containing these 
synonyms was saved as a Stata dataset. The final list of pertinent medcodes 
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was selected manually from the shortlist to create a symptom thesaurus. Codes 
were omitted if they pertained only to treatment, to diagnostic procedures or to a 
family or past history. Codes for diseases characterised by the symptom of 
interest were considered carefully; for example, a thesaurus for ‘diarrhoea’ 
might include ‘gastroenteritis’. Each symptom thesaurus was agreed with the 
primary investigator and practising clinician, Professor Willie Hamilton. 
When re-creating the datasets for my PhD, the bespoke symptom thesauri of 
the bladder4 and pancreatic5 cancer studies were re-used to ensure the 
accurate identification of information that had been missed because it had been 
recorded solely in text.  
In a separate strand of analysis, I wanted to compare how symptoms were 
recorded across the bladder and pancreatic cancer datasets. For this I could re-
use the haematuria and jaundice symptom thesauri from the bladder and 
pancreatic cancer studies, respectively, as these symptoms were not common 
to both cancers. However, abdominal pain was a shared feature, for which each 
study had derived a unique symptom thesaurus.a While both included 
medcodes for general abdominal pain, the bladder cancer thesaurus included 
codes for features such as abdominal tenderness, rigidity and colic. In contrast, 
the pancreatic cancer thesaurus had included codes for epigastric pain, 
indigestion and dyspepsia. Therefore, I used the generic symptom thesaurus for 
                                            
a
 This ‘customising’ was done to ensure that each thesaurus was optimised for the synonyms 
described in step 1, to match the pattern of abdominal pain experienced in each cancer. 
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abdominal pain created by the research group for the distinct purpose of 
comparing how abdominal pain was recorded across both cancer sets.  
When creating the generic symptom thesaurus, the definition of abdominal pain 
was deliberately kept tight. Tenderness was not considered as a synonym for 
pain, because it is elicited on examination and is classified as a sign rather than 
a symptom.91 Discomfort was also omitted as a synonym for pain, because it 
was thought to be at or below the lower limit of the spectrum of pain severity, 
which, as discussed above, is very subjective and unreliable (see Section 
4.5.3.2). I could have used a Delphi process to select the codes for inclusion in 
the thesaurus; however, I did not have unlimited access to my clinical 
supervisors' time, and chose to prioritise their input for the classification of text 
records over the choice of symptom codes. Furthermore, a Delphi process was 
not used in the selection of codes for the jaundice and haematuria thesauri, so 
its introduction would have been inconsistent with the methodology of the 
original studies.4,5 
All symptom thesaurus codes are reported in Appendix 4: Symptom thesauri. 
Step 3 – identifying if and when the patients’ records contained symptom 
thesaurus codes  
Step 3 identified if and when symptom thesaurus codes were recorded in the 
patients’ records. This was done by merging the symptom thesaurus with the 
master dataset of clinical and referral files (see Sections 6.5.2.4 and 6.5.2.5) 
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and extracting those observations that were common to both to a new dataset 
of coded records of patient attendance for that symptom.  
The individual codes used by the GP to record the symptom were noted, after 
which a single binary variable was created simply to denote that there was a 
coded record of patient attendance for the symptom in the analysis period.  
The dataset was truncated just to three variables, one each for patient 
identification, patient attendance for the symptom and the event date. Data 
were excluded if the date of recording was not available.  Multiple records of a 
symptom on the same day were assumed to refer to a single event; therefore, 
surplus entries were dropped to avoid duplicate reporting. In the dataset, 
patients had more than one row of data – one for every date on which they 
presented with the symptom.  
This process was repeated for each symptom separately and individual 
datasets were later combined to construct the final dataset.  
6.8.2 Identifying text records of attendances for haematuria, 
abdominal pain or jaundice 
A three-step process was used to identify where haematuria (visible or non-
visible), abdominal pain or jaundice was recorded solely in the text and not as a 
code.  
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Step 1: Identifying the event date and the medcode paired with the text 
record 
In ViSion, the option to enter information as text is only available once a Read 
code has been selected; therefore, every text record will have a matched Read 
code that is subsequently mapped to a medcode.  
All text records that had been classified as symptom-positive (see Section 
6.6.3) were put forward for Step 1.  
Step 1 identified the Read Code and medcode paired with each text observation 
and the date of recording (see Figure 2.1, repeated above, for a reminder of 
how GPs enter clinical information). The text records in the raw text files for 
each of haematuria, abdominal pain and jaundice (see Section 6.5.2.7) could be 
uniquely identified by a combination of two variables: the patient identifier 
(patid) and the text identifier (textid). This allowed accurate mapping of each 
text record to its paired medcode and event date in the electronic medical 
record (the ‘clinical and referral’ master dataset of medcodes, see Sections 
6.5.2.4 and 6.5.2.5).  
Step 2: Identifying whether the paired medcode is related to the symptom 
discussed in the text 
Step 2 looked at the relationship between the text record and its paired 
medcode. If the paired medcode was related to the symptom discussed in the 
text (see Figure 6.1), the text record was classed as code-complementary; if 
not, it was considered to be a potentially text-only record.  
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Figure 6.1 Step 2: Discriminating between code-complementary and potentially text-only 
records 
 
To do this, the dataset of symptom-positive text records with their paired 
medcode created in step 1 was merged with that symptom’s thesaurus of 
medcodes. Text records that matched with a medcode in the symptom 
thesaurus were classified as code-complementary. Observations that could not 
be matched to a medcode in the symptom thesaurus were classified as 
potentially text-only and put forward for step 3.   
Step 3: Identifying true text-only recording 
This step checked to see if each potentially text-only record produced in step 2 
was the sole record of the patient’s attendance with the symptom, or whether 
the GP had in fact also used a code elsewhere in the notes (see Figure 6.2).  
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Figure 6.2 Step 3: Identifying true text-only recording 
 
 
To do this, for each symptom, the dataset of potentially text-only records 
created in step 2 was combined with that of the coded records of attendance 
(see Section 6.8.1) into a single file. Observations from the two datasets were 
matched on date. Potentially text-only records that were made on the same day 
as a coded record of attendance were classified as code-complementary, 
whereas unmatched observations were classified as true text-only records. Only 
true text-only records were retained for analysis.  
To illustrate steps 1–3, Table 6.4 lists some examples of text records, their 
paired medcode, date of recording as well as the intermediate and final 
classification. 
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Table 6.4 Examples of free text records for a single patient and their classification  
 Example number: 
1 2 3 4 
Event date 01/06/2010 31/06/2010 31/06/2010 07/07/2010 
Free text 
comment 
Presenting 
complaint was 
abdominal pain a 
Ongoing 
problems with 
abdo pain b 
Ongoing burning 
upper abdominal 
pain c 
Summary: 
Abdo pain d 
Paired 
medcode 
177 68 177 56 
Description Abdominal pain Chest infection Abdominal pain Seen in GP 
surgery 
Classification 
in Step 1 
Code-
complementary 
Potentially text 
only 
Code-
complementary 
Potentially 
true text 
only 
Final 
classification 
in Step 3 
Code-
complementary 
Code-
complementary 
Code-
complementary 
True text 
only 
a
 Free text record in column 1 was classified as code-complementary, because the paired 
medcode was also for abdominal pain. 
b
 Free text record in column 2 was classified as potentially text-only in step 2, because the 
paired medcode was not for abdominal pain, but a search of the whole record identified a 
separate medcode on the same day (31/06/2010) for abdominal pain (column 3), so the final 
classification in step 3 was code-complementary. 
c
 Free text record in column 3 was classified as code-complementary, because the paired 
medcode was also for abdominal pain. 
d 
A true text-only record, because a search of the whole record could not identify any codes for 
abdominal pain on that day for that patient. 
 
6.8.3 Identifying records of abnormal investigation results 
In the original studies, a three-step process was used to find coded records of 
abnormal investigation results for study participants in the analysis period. In 
160 
 
brief, this involved creating thesauri of medcodes for investigations related to 
cancer, looking up the results in the test files, and generating a binary variable 
to indicate whether the result was abnormal or not.  
I replicated this process when re-creating the datasets for my PhD, as it was a 
useful learning exercise and increased my understanding of the data.  
Step 1: creating ‘test’ thesauri 
Step 1 consisted of creating ‘test thesauri’ similar to symptom thesauri 
discussed above (see Section 6.8). A list of all blood tests relevant to the cancer 
under investigation was drawn up by the primary investigator and practising GP, 
Professor Willie Hamilton. Then all medcodes relating to these tests were 
identified and saved as separate ‘test thesaurus’ datasets, one for each test 
type. In the pancreatic cancer study, all hepatic enzyme tests were merged into 
a single composite variable. Similarly, tests for erythrocyte sedimentation rate, 
plasma viscosity and C-reactive protein were collated into a single variable 
called ‘raised inflammatory markers’.  
Step 2: getting the test results 
Step 2 consisted of extracting the test results from the test files (see Section 
6.5.2.6) and quantifying the amount of information recorded by each medcode 
in the thesaurus.  The ‘core’ medcodes were noted, i.e. those that collectively 
contributed 90% of the results. Any test medcode that contributed <1% of the 
total test results was dropped from the thesaurus as it was deemed 
unrepresentative. Next, the test value was compared with the normal range, 
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which was provided in the test file. If the normal range for core medcodes was 
missing, the value was imputed using the modal value for the test. If the normal 
range for a non-core medcode was not provided, the data were not used.  
Step 3: identifying abnormal test results 
Step 3 involved creating a binary variable denoting whether the patient had an 
abnormal test result. 
6.9 Variables  
This section describes the variables that were created for the features of 
cancer. 
6.9.1 Variables created from the coded records 
Categorical and binary variables were created to replicate those of the original 
studies, for all features of cancer, using the coded records; for example, 
haematuria, abdominal pain and jaundice.  
6.9.1.1 Binary variables 
Binary variables were created to identify patients who had attended at least 
once for haematuria, jaundice or abdominal pain during the analysis period. 
These variables were used to estimate the positive likelihood ratio (see Section 
6.12.3.4) and the positive predictive value (see Section 6.12.3.5) according to 
the coded record.  
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Note about variables 
Several variables for features of cancer were created to allow full investigation 
of the research questions outlined in Section 5. I have used fonts to clarify the 
recording method used (see Figure 6.3). 
Figure 6.3 Coded records were supplemented with text-only records to create variables 
reflecting the entire content of the electronic medical record 
 
Courier New denotes variables generated from codes, i.e. haematuria, 
abdominal pain and jaundice – these replicate the variables from the 
original study (and may or may not have a code-complementary text record). 
Underlined Lucida Handwriting is used for variables generated from the text 
only, i.e. haematuria, abdominal pain and jaundice. This is used to 
represent events that were never recorded in code. 
Underlined Courier New is used for the total record, where the variable is 
based on the code but is supplemented with records made solely in the text, 
e.g. haematuria is the sum of haematuria plus haematuria.  
163 
 
6.9.1.2 Binary variables 
Binary variables were created to identify patients who had attended at least 
once for haematuria, jaundice or abdominal pain during the analysis period. 
These variables were used to estimate the positive likelihood ratio (see Section 
6.12.3.4) and the positive predictive value (see Section 6.12.3.5) according to 
the coded record.  
6.9.1.3 Discrete, categorical variables  
Categorical variables were created that identified each patient’s attendance 
patterns for features of cancer where the event was recorded using a code. 
They took the form: 0: no attendance; 1: only one attendance; 2: only two 
attendances; …; n: n attendances or more, where n was determined as the last 
category that contained at least 5% of cases. In practice, the categorical 
variables were often equivalent to the binary variables described above, 
because it was rare for more than 5% of cases to attend for a feature more than 
once in the analysis period.  
The categorical variables were used as explanatory variables in the conditional 
logistic regression to get a measure of the association between attendances for 
these risk markers and a cancer diagnosis, as estimated from coded records. 
Where numbers permitted, these variables were also used to investigate 
whether re-attendance for a feature was clinically significant in terms of having 
different odds of a cancer diagnosis.  
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6.9.2 Variables created from the text-only records 
For the symptoms haematuria, abdominal pain and jaundice, categorical and 
binary variables were created from the text-only records.  
6.9.2.1 Binary variables 
The binary haematuria, abdominal pain and jaundice variables identified 
those patients who attended at least once for the symptom in the analysis 
period, but whose first five attendances for the symptom were made using the 
text only, i.e. the GP never used a code to record any of these attendances. 
This variable was used to identify under-reporting in the original studies of the 
total number of patients who attended for the symptom at least once in the year 
prior to the cancer diagnosis, which also relates to research questions 1 and 5 
(see Section 5).  
6.9.2.2 Discrete, categorical variables 
The categorical haematuria, abdominal pain and jaundice variables 
identified the attendance patterns for haematuria, abdominal pain or jaundice 
for those patients whose first five attendances were recorded in text only.  
The categorical variables were used as explanatory variables in the conditional 
logistic regression to get a measure of the association between attendance for 
the risk marker and cancer, as estimated from text-only records. This relates to 
research questions 1 and 5 (see Section 5).  
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Where numbers permitted, these variables were also used to investigate the 
clinical significance of re-attendance for a feature. 
6.9.3 From the combined text-only and coded records 
Binary and categorical variables – haematuria, abdominal pain and 
jaundice – were created using coded records supplemented with individual 
attendances recorded solely in the text (see Figure 6.3, above). 
6.9.3.1 Binary variables 
The binary variables identified the total number of patients who attended at 
least once for the symptom in the analysis period, as identified from coded or 
solely text-only records.  
These variables were used to re-estimate the positive likelihood ratio and 
positive predictive values for cancer in patients presenting with haematuria, 
abdominal pain or jaundice in light of all the information recorded by the GP 
about that patient. This relates to research questions 2 and 5 (see Section 5). 
6.9.3.2 Discrete, categorical variables 
The categorical variables identified the complete attendance pattern for a 
symptom whether it was recorded using a code or in the text. These variables 
were used as explanatory variables in conditional logistic regression. The 
association between attendance for a symptom and cancer was re-estimated in 
light of all the information recorded by the GP about that patient. This relates to 
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research questions 2 and 5 (Do the text data provide additional value to coded 
data?). 
6.9.4 Recording style variable 
For those patients who did attend at least once in the analysis period with 
haematuria, abdominal pain or jaundice, a binary variable was created to 
indicate the recording style used overall. ‘Coded’ meant that the GP had used a 
code for at least one of the attendances, whereas ‘text-only’ meant that the GP 
had always used text and never a code. This variable was used to examine 
whether there is an association between recording style and the type of 
symptom, the patient status or the context of presentation. This analysis relates 
to the following research questions: 
1. Are studies of coded data vulnerable to bias arising from the differential 
use of text and codes between comparison groups? 
2. Does recording style vary with type of symptom? 
3. Does the recording style vary with the context of presentation of a 
symptom? 
6.10 The final dataset 
6.10.1 Creating a baseline patient demographic dataset 
A baseline patient demographic dataset was created, in which there was one 
line of data per patient. This included the variables age, case/control status, 
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diagnosis date, gender and age at diagnosis. Finally, the binary variable that 
identified excluded patients was imported from the original studies, to ensure 
that I was studying exactly the same participants.  
6.10.2 Addition of variables for signs, symptoms and 
investigation results 
To construct the final dataset, the baseline demographic dataset was appended 
with each of the datasets containing evidence that patients attended in the 
analysis period for symptoms, and evidence of their investigation results. Before 
they were appended, the datasets were converted so that there was a single 
row of data per patient.  
Duplicate recordings made on the same day were identified and surplus 
observations were dropped.   
6.11 Missing data  
The General Medical Council requires that GPs document all important findings, 
both positive and negative, to create a record that ensures continuity of care.97 
Therefore, the assumption was made that a clinical event only occurred if there 
was evidence that it did. Consequently, missing data were interpreted as the 
equivalent of the absence of a sign or symptom, or that a test result would have 
been normal had it been carried out.  
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6.12 Analysis 
6.12.1 Threshold for inclusion of clinical features 
In the original studies, only symptoms, signs and test results that occurred in at 
least 5% of the cases or controls were studied. The frequency was examined in 
cases and in controls because, arguably, features presented preferentially by 
controls may have been protective for cancer. However, given that the study 
aims to identify risk markers, this seems relatively unlikely. In practice the 
features were all identified in the cases.  
To some extent this cut-off of 5% was arbitrary and requires justifying. At one 
extreme, a very low threshold increases the chances of identifying associations 
that, while statistically significant, are not clinically meaningful. This is akin to 
making a type I error, detecting an effect that is not actually present. However, 
raising the threshold too far the other way would increase the risk of missing 
those features that were clinically important, if not terribly frequent; in other 
words, making a type II error of failing to detect an effect that is present. A cut-
off of 5% was thought to represent a pragmatic balance between these two 
extremes.  
6.12.1.1 Using text data to examine the impact of a 5% threshold  
Rather fortuitously, inclusion of text data allowed the impact of applying this 5% 
threshold to be examined. Text records about haematuria were subdivided into 
those referring to its visible and non-visible forms (see Section 4.5.1.2). In the 
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original bladder cancer study, non-visible haematuria was recorded too 
infrequently (in 127/4,915 cases = 2.6%)a  to warrant inclusion in analysis.4 
Therefore, we took the opportunity to assess whether supplementing with text-
only records would increase the number of cases presenting with non-visible 
haematuria over the 5% threshold. If this turned out to be true, this would 
enable the first assessment of the risk of bladder cancer in patients presenting 
with non-visible haematuria. This was an exciting diversion, though still 
germane to the overall study question on the value of free text data. It was 
particularly timely, as the National Institute for Health and Care Excellence 
(NICE) were eager for evidence on this specific issue as they prepared to revise 
their guidelines on referral for cancer.57  
6.12.2 Outcome measures in event-level analysis 
6.12.2.1 Recording style preferences  
The preference for symptom recording style at the event level – coded (± a 
complementary text record) or text only – was reported regardless of case or 
control status. This analysis was designed to address research question 3: does 
recording style vary with type of symptom?   
                                            
a
 The investigations file was also searched for laboratory results of urine dipstick tests for blood 
(medcode 14561) and for red blood cells visible on urine microscopy (medcode 38204). No 
such tests had been carried out, confirming that this is an investigation carried out within GP 
surgeries, and not in the laboratory.  
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The total number of attendances was reported within cancers for alarm 
symptoms (visible haematuria for bladder cancer; jaundice for pancreatic 
cancer) and for non-alarm symptoms (abdominal pain for both cancers, non-
visible haematuria for bladder cancer) separately.  
6.12.2.2 Estimating diagnostic intervals  
These analyses relate to research question 5: Do the text data provide 
additional value to coded data? 
The diagnostic interval is estimated as the number of days between first 
attendance for a symptom and the date of cancer diagnosis (DIcoded). Studies 
that restrict their analysis to codes may underestimate the diagnostic interval, 
because it is possible that the GP recorded the symptom solely in the text at an 
earlier consultation. 
Analysis was restricted to cases (true bladder and pancreatic cancer patients) 
and diagnostic intervals were estimated for abdominal pain (bladder and 
pancreatic cancer datasets), haematuria (bladder cancer) and jaundice 
(pancreatic cancer).  
Determination of whether the diagnostic intervals followed a normal or 
asymmetrical distribution was made in several ways: first, using a box and 
whisker plot of the data; secondly, by regressing the quantiles of the data 
against the quantiles of a normal distribution with the same mean and variance 
as the sample being tested; and, thirdly, using the D’Agostino K-squared test of 
normality.124  
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Three approaches were taken to assess whether text data provide additional 
value to coded data when it comes to estimating diagnostic interval. 
First, the earliest coded record of attendance was used to estimate DIcoded for 
haematuria and abdominal pain in the bladder cancer dataset, and for jaundice 
and abdominal pain in the pancreatic cancer dataset. The coded records of 
attendance were augmented with text-only records and the diagnostic interval 
was re-estimated using the earliest recorded attendance for the symptom, be it 
recorded using a code or solely in the text (DIcoded/text). Some patients had both 
a coded and a text record, some had only a coded record and some only a text 
record. Therefore, there is no statistical test suitable for testing whether the 
diagnostic interval was altered by the addition of text-only records, because the 
data were neither fully matched nor completely unmatched. Therefore, just the 
summary statistics are reported as the median interval (in days) plus the 25% to 
75% interquartile range. 
Secondly, in matched analysis, the sign rank test for matched data was used to 
test the null hypothesis, H0, that DIcoded – DItext/coded = 0. To fulfil the requirement 
for matched data, analysis was restricted further, to those cases who had both 
coded and text records of attendance for the symptom. For example, they may 
have attended three times during the analysis period, and their first attendance 
was recorded in code, the second using both methods and the third attendance 
solely in the text. For each patient the diagnostic interval was estimated from 
the earliest coded record (DIcoded) and from the earliest record, which may have 
been coded or in the text (DItext/coded). The summary statistics are reported as 
172 
 
the median interval (in days) plus the 25% to 75% interquartile range. The 
significance level was set at p<0.05. 
Thirdly, in unmatched analysis, the Wilcoxon rank-sum (also known as Mann-
Whitney) test was used to test whether estimates of diagnostic intervals from 
coded (DIcoded) and from text (DItext) records are drawn from the same 
population. To fulfil the requirement for unmatched data, analysis was restricted 
to those with solely text records and to those with solely coded records. The 
summary statistics are reported as the median interval (in days) plus the 25% to 
75% interquartile range. The significance level was set at p<0.05. 
6.12.3 Outcome measures in patient-level analysis 
6.12.3.1 Recording style preferences 
The preference for recording style at the patient level – coded (± a 
complementary text record) or text onlya – was reported regardless of case or 
control status for alarm and non-alarm symptoms separately to address 
research question 3: does recording style vary with type of symptom?  
The total number of attendees was reported within cancers for alarm symptoms 
(visible haematuria for bladder cancer; jaundice for pancreatic cancer) and for 
                                            
a
 Note: Each patient was categorised by the style used to record their attendances for the 
symptom. ‘Coded’ was assigned if any record of a symptom was in coded form; conversely, 
‘text-only’ was designated only when all instances were noted solely in the text (see Section 
6.9.4). 
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non-alarm symptoms (abdominal pain for both cancers, non-visible haematuria 
for bladder cancer). 
The numbers of patients with a history of attendance for haematuria, jaundice or 
abdominal pain who were overlooked in the original studies because their 
records were lost in the hidden text were reported. 
6.12.3.2 Comparison of symptom recording style between cases and 
controls 
Evidence of an association between patient status (case or control) and 
recording style (coded or text-only record) was obtained using the χ2 test to 
address research question 2: are studies of coded data vulnerable to bias 
arising from the differential use of text and codes between comparison groups? 
For each symptom examined, the total number of patients attending at least 
once in the analysis period was determined from codes and text-only records. 
The proportion of the total attributable to each recording style was determined in 
cases and controls separately and displayed in a contingency table as well as 
graphically. The χ2 test was carried out for each symptom within each cancer 
dataset to test the null hypothesis that there is no association between patient 
status and recording style. The significance level was set at p<0.05.  
6.12.3.3 Test of the association between context of symptom 
presentation and recording style  
The association between context of symptom presentation and recording style 
was tested. Methods described in Sections 6.12.3.1 and 6.12.3.2 were repeated 
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for visible haematuria (the alarm symptom for bladder cancer) in the pancreatic 
dataset, and for jaundice (the alarm symptom for pancreatic cancer) in the 
bladder cancer dataset.  
As described in Section 4.5.3, the characteristics of abdominal pain vary with 
the site of origin. For this reason, the original studies each created a bespoke 
abdominal pain symptom thesaurus. Therefore, a generic symptom thesaurus 
for abdominal pain was created to allow comparison of recording of this ‘low-risk 
but not no-risk’ symptom across both datasets. These tests were carried out to 
address research question 4: does the recording style vary with the clinical 
context of presentation of a symptom?  
6.12.3.4 Likelihood ratios 
The likelihood ratio is a way of estimating the performance of a diagnostic test. 
In CAPER Studies, the positive likelihood ratio summarises how many times 
more likely cases are to have a clinical feature compared with controls. In other 
words, it is the probability that cases have a feature divided by the probability 
that controls have the same feature. It is calculated mathematically as 
)|(
)|(


DSp
DSp
 , where p(S+|D+) is the probability of symptom presence (S+) given 
(|) that cancer is present (D+) and p(S+|D−) is the probability of symptom 
presence given that cancer is not present. This calculation equates to sensitivity 
/ (1− specificity).  
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A likelihood ratio greater than 10 is considered as providing strong evidence of 
an association.125  
Confidence intervals for the positive likelihood ratio were calculated in Excel 
using the following equation: 
)
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  
Where, p1 is the sensitivity (number of cases with the feature, divided by the 
total number of cases) 
p2 is 1−specificity (where specificity is the number of controls without the feature 
divided by the total number of controls) 
n1 is the total number of cases 
n2 is the total number of controls 
6.12.3.5 Positive predictive value 
The positive predictive value (PPV) is another measure of diagnostic test 
performance. It estimates the probability that someone has a disease given that 
they have a positive test result, p (disease | positive test result), and is 
expressed as a percentage ‘chance’. The PPV was first applied to cancer 
diagnostics in primary care by Holtedahl in 1990,126 and was developed 
extensively by Hamilton.4,5,40,41,42,43,44,45,46,127,128 NICE recently lowered the 
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threshold for the PPV of symptoms that should trigger a cancer assessment 
from approximately 5% to 3%.9,129 
Arithmetically, the PPV can be calculated as the number of ‘true positives’ 
divided by the ‘total number of positives’ identified by the test, i.e. the sum of 
true positives and false positives. Unlike specificity and sensitivity, which remain 
fixed, arithmetically derived PPV varies with disease prevalence. This is 
because, unless the test’s specificity is 100%, decreasing prevalence must be 
accompanied by an increasing number of false-positives since the total number 
of test results remains constant. Consequently, it is inappropriate to estimate 
PPV arithmetically in case–control studies, which by their very nature arbitrarily 
fix the prevalence as well as the balance between cases and controls. The 
adjustment of prevalence occurs in two ways. First, the population is enriched in 
that there are generally many more cases in the study than would be expected 
in the population from which the cases derive. Secondly, there may be many 
controls per case.  
Instead, PPV was estimated using Bayes’ Theorem (see Appendix 5: Derivation 
of positive predictive value using Bayes’ theorem for full derivation and example 
for illustration):  
Posterior odds = (prior odds × f) × positive likelihood ratio   (1) 
The adjustment factor, f, was necessary because the likelihood ratio and the 
prior odds were each representative of different populations; namely, the 
consulting and the whole populations, respectively. Therefore, the prior odds 
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were adjusted to reflect the value in the consulting population to produce risk 
estimates that are meaningful to GPs. The adjustment factor, f, derived from the 
proportions of cases and of controls who consulted their GP during the period of 
the study: 
f =           (2)  
Where xc = the number of eligible cases who consulted in the study sample, xt = 
the total number of cases in the study sample, yc = the number of controls who 
consulted and yt = the number of controls overall. 
The assumption made here was that any patient who has not consulted the GP 
in the year prior to diagnosis did not have a positive indication of disease, i.e. 
their test results would have been normal or they did not attend for the symptom 
whose PPV was being estimated.  
Finally, the posterior odds were converted back to a probability to estimate the 
PPV: 
PPV = posterior odds / (1 + posterior odds)     (3) 
6.12.3.6 Odds ratios 
In the case–control studies, I estimated the strength of association between 
symptoms and a cancer diagnosis according to the ratio of the odds of a 
symptom in cases compared with the odds of the same symptom in controls.  
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For both univariable and multivariable analysis, odds ratios were estimated by 
Stata using conditional logistic regression to accommodate the matched study 
design and binary outcome. Using categorical explanatory variables, I estimated 
the odds ratio for specific numbers of attendances for each symptom in the 
analysis period; for example, only once, only twice and three or more.130 
I include below a short explanation of how odds ratios for cancer in patients with 
given symptoms are calculated manually. This will be referred to later on in the 
Discussion of how the odds ratio estimate is affected by bias that derives from 
the omission of text records from analysis. 
In case–control studies, to estimate the association between a symptom and 
cancer it is first necessary to calculate the probability of that symptom in the 
cases and controls separately, i.e. on the conditional presence of cancer. The 
conditional probabilities can be written using the same notation as that used in 
the derivation of PPV using Bayes’ Theorem (see Appendix 5: Derivation of 
positive predictive value using Bayes’ theorem), where D is the disease 
(cancer) under investigation and S is the symptom. Furthermore, D+ indicates 
that cancer is present (i.e. cases) and D− that it is not (i.e. controls); similarly, 
S+ and S− indicate symptom presence and absence, respectively. The lack of 
either reporting or recording of the symptom was assumed to mean there was 
no evidence that the symptom occurred (see Section 13.2.6 for Discussion of 
missing data).  The conditional probabilities are easily displayed in a 
contingency table; for example, the probability of symptom presence given 
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(denoted by ‘|’) that the patient has cancer (i.e. is a case) is represented as 
p(S+|D+): 
 Outcome 
Symptom present Symptom absent 
Exposure 
Cancer (cases) p(S+|D+) p(S−|D+) 
No cancer (controls) p(S+|D−) p(S−|D−) 
Knowing that odds = probability / (1 – probability) and that symptoms can only 
be present or absent, we can write: 
Odds of symptom presentation in cases = 
)|(
)|(


DSp
DSp
 
Odds of symptom presentation in controls = 
)|(
)|(


DSp
DSp
 
Therefore, the ratio of odds in the cases compared with the controls is: 
Odds ratio = 
)|()|(
)|()|(


DSpDSp
DSpDSp
 , which is simply the cross-product of the 
contingency table. 
Therefore, the odds ratio is vulnerable to bias in the estimates of symptom 
recording between cases and controls. 
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6.12.4 Regression analysis 
6.12.4.1 Univariable analysis to establish independent association 
between risk markers and cancer 
In the original studies, univariable analysis was used as the first step to 
modelling the presentation of cancer in primary care. It was carried out for each 
potential feature to assess whether it had an independent association with 
cancer. The z test was used to test whether the odds ratio was equal to 1 (i.e. 
no association) and the threshold p value for retention was p<0.1 to ensure that 
important variables were not omitted.  
It was not necessary to repeat univariable analysis in this study for all potential 
features of cancer. Rather, it was reserved only for those features included in 
the final models published in the original studies and for the new text-based 
variables.  
6.12.4.1.1 Post-estimation tests 
In my univariable analysis of the new text-based variables, the Wald test was 
used for each symptom to test the strength of its association with a cancer 
diagnosis. The level of significance was set at p<0.1 as in the original studies.  
To address research question 5 ‘Do the text data provide additional value to 
coded data?’ the Wald test was used to test whether code- and text-based 
variables gave similar estimates of the association between cancer and any of 
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the features abdominal pain, haematuria or jaundice.131 The significance level 
was set at p<0.05.  
Subsequently, code- and text-based variables were combined into a single, 
composite variable for regression analysis (see Figure 6.3 above).  
Where 5% of cases attended at least twice in the analysis period, the Wald test 
was used to test whether re-attendance was clinically significant in terms of 
association with cancer. The significance level was set at p<0.05.131  
6.12.4.2 Multivariable analysis to model the main features of cancer 
presentation 
The models derived in the original studies were adopted by this study; 
therefore, the processes carried out to determine the main features of cancer 
presentation were not replicated here. In brief, in the original studies, variables 
that passed univariable analysis were grouped on clinical grounds. Within each 
group, stepwise regression was carried out to select those features with the 
strongest association with cancer. The threshold value for retention was p<0.05 
(z test). Surviving variables were submitted to a final round of stepwise 
regression. The most significant features were retained in the final model using 
p<0.01 (z test).  
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6.12.4.3 Replication of the final model 
The final models of the original studies were replicated and post-estimation 
Wald tests were used to test whether re-attendance with a feature altered the 
odds ratio for cancer. The significance level was set at p<0.05.131  
6.12.4.4 Comparison of models with and without text-based variables 
The final models of the original studies were re-created using coded variables 
haematuria, jaundice and abdominal pain. The final models were 
compared with new models supplemented with text-only variables for 
abdominal pain (both cancers), and jaundice (pancreatic) or haematuria 
(bladder) (likelihood ratio test). This corrected for the underestimation of the 
number of patients presenting at least once with the symptom in the analysis 
period. If inclusion of text-based variables was significant, the coded variables 
haematuria, jaundice and abdominal pain were replaced with the 
composite variables haematuria, jaundice and abdominal pain. 
This analysis was carried out to investigate research question 5: do the text 
data provide additional value to coded data?  
6.12.4.5 Post-estimation tests 
Either the Wald or the likelihood ratio test could have been used as a post-
estimation test of whether the addition of text-based explanatory variables 
improved the fit of the model. There appears to be no clear indication as to 
which is superior, although many statisticians seem to prefer the likelihood ratio 
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test when both are suitable. Therefore, the likelihood ratio test was used to test 
nested models (one with and one without the text-based variables) in this 
study.131 The significance level was set at p<0.05. 
6.12.4.6 Testing for effect modification 
Evidence for effect modification was sought on clinical grounds; for example, 
between symptoms and diseases that were associated both with one another 
and the cancer – such as urinary tract infection and haematuria. This allowed us 
to ascertain the strengths of association between a risk marker and cancer 
separately for each level of the effect modifier. Evidence of effect modification is 
useful clinically, as it suggests to GPs what other information they should elicit 
when taking a history in order to assess the risk of cancer properly. 
Careful consideration was given to whether it was useful clinically to look for 
effect modification between the visible and non-visible forms of haematuria in 
the bladder cancer study. As discussed above (see Section 4.5.1.2), they are 
both defined as an abnormal presence of blood in the urine and lie on a 
continuum of one disease. Indeed, patients cannot have both visible and non-
visible forms of the disease simultaneously. Therefore, it was decided to be 
inappropriate to look for effect modification between these two forms of 
haematuria. 
6.12.4.7 Post-estimation tests 
A post-estimation Wald test was used to test for the significance of effect 
modification and the significance level was set at p<0.05.  
184 
 
6.12.5 Post-hoc analysis: modelling the outcome ‘text-only 
recording’ of visible haematuria in the bladder cancer 
dataset 
6.12.5.1 Introduction 
Finally, as post-hoc analysis, the outcome ‘text-only recording’ was modelled for 
visible haematuria using likely underlying causes (benign and malignant) as 
explanatory variables.  
When a patient consults in primary care because of visible haematuria, the GP 
has to consider a wide range of possible causes – from the benign through to 
the serious, including malignancy (see Section 4.5.1.5). Having considered the 
patient’s history and other presenting features, the GP must then decide how to 
record the consultation in the patient’s medical record.  
My study provided an opportunity for post-hoc analysis to test the hypothesis 
that GPs tend to use codes to record clinically significant events (e.g. indicative 
of cancer) and text for anything perceived not to be worrisome (e.g. benign and 
self-limiting pathology). This hypothesis arose following discussion of my results 
for visible haematuria with two of my supervisors (Professor Willie Hamilton and 
Dr Kevin Barraclough) and visiting academic, Dr Peter Hjertholm, all of whom 
are practising GPs – hence the post-hoc nature of the analysis.  
I tested for associations between the outcome ‘text-only recording of visible 
haematuria at the patient level’ and possible causes of visible haematuria, i.e. 
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benign (UTI, stones) and serious (bladder cancer). The modification of this 
association by gender was also explored, because UTIs are more common in 
women than men, while bladder cancer is more common in men than women. 
This post-hoc analysis also fits in well with research question 4: Does the 
recording style vary with the clinical context of presentation of a symptom?  
6.12.5.2 Mixed-effects logistic regression 
In this part of the analysis, the outcome variable was not case/control status; 
rather, it was whether a patient’s entire attendance for visible haematuria was 
made solely in the text, using the binary variable visible haematuria. This 
outcome was modelled using a mixed-effects logistic regression model 
adjusting for the random effect of clustering due to non-independence of 
observations within GP practices (as a result of matching). Choice of potential 
explanatory variables was based on possible causes of the symptom, which are 
discussed in Section 4.5.1.5. Visible haematuria in the cases was assumed to 
be attributable to bladder cancer, whereas visible haematuria in the controls 
was assumed to have a benign underlying pathology. Therefore, control–case 
status was used as a proxy for malignant vs benign cause. Other benign causes 
investigated included urinary tract infection and calculi.  
Evidence for possible reasons underlying each symptom was sought using the 
methods described in Section 6.8, including the compilation of medcode 
thesauri that were agreed with the lead investigator. 
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Univariable analysis was carried out to determine whether there was an 
independent association between each possible cause of the symptom and the 
outcome of text-only recording. Successful variables were submitted to 
multivariable analysis and stepwise regression was used to select the final 
model.  
6.12.5.3 Effect modification  
Effect modification by gender of the association between patient status (as a 
proxy for benign vs malignant cause of haematuria) and text-only recording of 
haematuria was investigated, because bladder cancer is more common in men 
than women.  
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7 Results: study participants 
7.1 Bladder study participants 
The participants of the bladder cancer study and their characteristics were 
determined in the original study.4 While the results in Subsection 7.1 are not 
strictly part of my PhD, they are presented at this point to enable complete 
interpretation of my extension of the original study.  
7.1.1 Bladder cancer study cases 
In total, 4,935 potential cases were identified as having a clinical or referral 
record of incident bladder cancer, as defined by the list of 20 Read codes 
agreed between the primary investigator (Professor Hamilton) and the CPRD 
research team (see Appendix 2: Disease thesauri).a 
7.1.1.1 Excluded cases 
After application of the exclusion criteria, 20 potential cases (n = 19 men, n = 1 
woman) were excluded from the study, for reasons given in Table 7.1. There 
were no cases who had not consulted their GP in the year prior to their 
diagnosis, leaving a total of 4,915 cases in the study. 
                                            
a
 Using the pre-1998 definition of bladder cancer. 
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7.1.2 Bladder cancer study controls 
In total, 24,098 patients were identified by the CPRD as eligible for 
consideration as controls. 
7.1.2.1 Excluded controls 
After application of the exclusion criteria, 2,380 potential controls (n = 1,958 
men, n = 422 women) were excluded from the study for reasons given in Table 
7.1.  
Table 7.1 Bladder cancer study exclusions 
Case 
or 
control 
Reason for exclusion Number of 
patients excluded 
Case No matched control identified 13 
Metastatic cancer present 7 
Subtotal 20 
Control Diagnosed with bladder cancer after the year 
2000 
125 
Diagnosed with bladder cancer before the year 
2000 
134 
No data recorded in their medical record in the 
analysis period 
2,086 
Matched to a case who was excluded because 
they had metastatic cancer 
35 
 Subtotal 2,380 
Total  2,400 
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7.1.3 Bladder cancer study matching 
After exclusions, there were 4,915 bladder cancer cases matched to 21,718 
controls on age, sex and GP practice, as reported in Table 7.2. The majority of 
cases were matched to at least four controls. 
Table 7.2 Bladder cancer study matching 
No. (%) of cases with:   
Total 1 control 2 controls 3 controls 4 controls 5 controls 
57 (1.2) 160 (3.3) 419 (8.5) 1,311 (26.7) 2,968 (60.4) 4,915  
 
7.1.4 Characteristics of the bladder cancer study participants 
7.1.4.1 Bladder cancer study participant demographics 
The age and gender of study participants are reported in Table 7.3.  
Table 7.3 Bladder cancer study participant demographics 
Age 
groupa 
Case (n = 4,915) Control (n = 21,718) 
 Male, n (%) Female, n 
(%) 
Male, n (%) Female, n 
(%) 
<60 years  417 (8.5) 140 (2.8) 1,631 (7.5) 639 (2.9) 
≥60 years 3,146 (64.0) 1,212 (24.7) 13,821 (63.6) 5,627 (25.9) 
Total 3,563 (72.5) 1,352 (27.5) 15,452 (71.1) 6,266 (28.9) 
a
The age group refers to the age at diagnosis in the case. 
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Overall, 3,563 of the 4,915 (72.5%) cases were men and 1,352 (27.5%) were 
women, reflecting the higher incidence of bladder cancer in the male population. 
Matching on gender ensured similar proportions in the control group: 15,452 
(71.1%) men and 6,266 (28.9%) women. The median age at diagnosis in the 
cases and in the matched controls was 74 (interquartile range: 66–80) years.   
7.2 Pancreatic cancer study participants 
The participants of the pancreatic cancer study and their characteristics were 
determined in the original study.5 While the results in Subsection 7.2 are not 
strictly part of my PhD, they are presented at this point to enable complete 
interpretation of my extension of the original study.  
7.2.1 Pancreatic cancer study cases 
In total, 3,647 potential cases were identified as having a clinical or referral 
record of incident pancreatic cancer, as defined by the list of 25 Read codes 
agreed between the primary investigator (Professor Hamilton) and the CPRD 
(see Appendix 2: Disease thesauri). 
7.2.1.1 Excluded cases 
After application of the exclusion criteria, 12 potential cases were excluded from 
the study, for reasons given in Table 7.4. There were no cases who had not 
consulted their GP in the year prior to their diagnosis, leaving a total of 3,635 
cases in the study. 
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7.2.2 Pancreatic cancer study controls 
In total, 17,977 patients were identified by the CPRD as eligible for 
consideration as controls. 
7.2.2.1 Excluded controls 
After application of the exclusion criteria, 1,518 potential controls were excluded 
from the study for reasons given in Table 7.4.  
Table 7.4 Pancreatic cancer study exclusions 
Case or 
control 
Reason for exclusion Number of patients 
excluded 
Case No matched control identified 2 
Tumour not originating in the pancreas 10 
Subtotal 12 
Control Diagnosis of pancreatic cancer 64 
 No data in the year before diagnosis 1,414 
 Case excluded 40 
 Subtotal 1,518 
Total  1,530 
 
7.2.3 Pancreatic cancer study matching 
After exclusions, there were 3,635 cases matched to 16,459 controls on age, 
sex and GP practice, as reported in Table 7.5. 
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 Table 7.5 Pancreatic cancer study matching  
No. of cases with:   
Total 1 control 2 controls 3 controls 4 controls 5 controls 
26 (0.7) 90 (2.5) 251 (6.9) 840 (23.1) 2,428 (66.8) 3,635 
 
7.2.4 Characteristics of the pancreatic cancer study 
participants 
7.2.4.1 Pancreatic cancer study participant demographics  
The age and gender of pancreatic cancer study participants are reported in 
Table 7.6. Overall, 1,743 of the 3,635 (48.0%) cases were men and 1,892 
(52.0%) were women. Matching on gender ensured similar proportions in the 
control group: 7,627 (46.3%) men and 8,832 (53.7%) women. The median age 
at diagnosis in the cases and in the matched controls was 73 (interquartile 
range: 65–80) years.   
Table 7.6 Pancreatic cancer study participant demographics 
Age groupa Case (n = 3,635) Control (n = 16,459) 
 Male, n (%) Female, n 
(%) 
Male, n (%) Female, n 
(%) 
<60 years  320 (18.4) 241 (12.7) 1,227 (16.1) 1,105 (12.5) 
≥60 years 1,423 (81.6) 1,651 (87.3) 6,400 (83.9) 7,727 (87.5) 
Total 1,743 (48.0) 1,892 (52.0) 7,627 (46.3) 8,832 (53.7) 
a
The age group refers to the age at diagnosis in the case. 
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8 Results: text string classification  
The accuracy and validity of the methods used to convert text strings to binary 
variables were assessed by comparing the final classification of a random 
sample of observations with that of the reference standard. Section 8.1 
describes the results relating to construction of the reference standard. The 
performance characteristics of the classification algorithm itself are reported 
later in Section 8.2. Other sources of uncertainty in text variables are reported in 
Section 8.3. Finally, the results of text string classification are reported in 
Section 8.4. 
8.1 The reference standard 
As described in the Methods (see Section 6.7), the reference standard was 
created in four stages: an initial one in which two raters independently classified 
a random sample of 100 text strings (the pilot study); a second stage where the 
raters clarified the criteria underpinning their decisions; and a third step in which 
the same sample was re-assessed. In the final stage, text strings were dropped 
if the raters could not agree to their meaning, or agreed that they were wholly 
uninterpretable.  
8.1.1 The pilot study results 
The results of independent assessments of the random sample of 100 text 
strings carried out by the two raters in the pilot study are displayed in Table 8.1.  
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The marginal totals for the three categories were symmetrically unbalanced: for 
both observers the prevalence of ‘current’ haematuria’ (74% for rater 1 and 77% 
for rater 2) greatly exceeded that of either ‘no current haematuria’ (12% for rater 
1 and 15% for rater 2) or ‘meaning unclear’ (14% for rater 1 and 8% for rater 2).  
Table 8.1 Results of independent assessments of the random sample of 100 text strings 
 Rater 1 Total 
Current 
haematuria 
Meaning 
unclear  
No current 
haematuria 
R
a
te
r 
2
 
Current 
haematuria 
68 7 2 77 
Meaning 
unclear  
4 2 2 8 
No current 
haematuria 
2 5 8 15 
Total 74 14 12 100 
 
The observed proportion of agreement between the raters was (68 + 2 + 8)/100 
(78%); however, this measure overestimated the true level of agreement as 
some of this will have arisen purely by chance. The chance-corrected weighted 
Kappa was 0.7 (95% CI: 0.6–0.9). In terms of inter-rater agreement, this is 
interpreted as fair to good by Landis and Koch,121 as good by Altman120 and as 
substantial by McGinn et al.122 The symmetrical imbalance within the sample in 
favour of ‘current haematuria’ means that the reported chance-corrected 
weighted Kappa is likely to underestimate the level of agreement. 
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Overall, raters 1 and 2 agreed that 2% of the observations were wholly 
uninterpretable.  
8.1.2 Clarification of category definitions 
As described in Section 6.6.2.2, most disagreements related to uncertainty over 
whether the record was referring to a symptom that was historical or 
contemporary; although, in some instances, the text was nonsensical (some 
examples were shown in Table 6.2 ).  
For clarity, the finally agreed definitions are repeated here: 
‘Symptom negative’ – used to describe those observations in which symptoms 
were explicitly or implicitly described as absent at the time the patient consulted 
the GP. 
‘Symptom positive’ – used to describe those observations in which symptoms 
were contemporary.  
‘Meaning unclear’ – used to describe when the patient’s status regarding the 
symptom could not be ascertained with certainty. 
 
8.1.3 Results after agreement of category definitions 
After discussion and agreement of the definitions for the three categories, the 
two raters independently re-assessed the same random set of observations. 
The results are reported in Table 8.2. The anticipation was that fewer 
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observations would be classed as ‘meaning unclear’. Rater 1 did tend to assign 
this category less frequently, with its percentage reducing from 14% to 3%. 
However, the use of this category by rater 2 remained fairly steady at 8% and 
then 11%. 
Table 8.2 Results of independent re-assessment of the random sample of 100 text strings  
 Rater 1 (revised) Total 
Current 
haematuria 
Meaning 
unclear  
No current 
haematuria 
R
a
te
r 
2
 (
re
v
is
e
d
) 
 
Current 
haematuria 
78 1 4 83 
Meaning 
unclear  
2 2 7 11 
No current 
haematuria 
0 0 6 6 
Total 80 3 17 100 
 
The re-assessment did not seem to improve the overall level of agreement, 
which remained similar to that in the pilot study. While the observed proportion 
of agreement rose to 86%, the chance-corrected weighted kappa remained 
similar to the value obtained previously, at 0.7 (95% CI: 0.5–0.9). The marginal 
totals for the three categories remained symmetrically unbalanced with the 
category ‘current haematuria’ dominant for both raters. Therefore, the weighted 
kappa still tended to underestimate the true level of agreement. 
Clarifying the definitions of each category did not affect the number of 
observations that were jointly classified as unclear, which remained at 2%.  
197 
 
In the re-assessment, raters 1 and 2 disagreed which category should be 
assigned to 14 observations in total (Table 8.3).  
Table 8.3 Changes in areas of disagreement following clarification of category definitions 
Source Number of observations 
affected 
Disagreement remained the same as per 
initial assessment  
 5 
New disagreement   3 
Raters both reversed their positions so that 
disagreement remained  
 6 
 
8.1.4 Finalising the reference standard 
Uninterpretable extracts (n=2) and extracts whose meaning the raters could not 
agree (n=14) were dropped. This left 84 extracts in the final reference standard, 
against which the performance of the classification system was assessed. 
8.2 Performance of the final classification against the 
reference standard 
The level of agreement between the final output of the classification process 
and the reference standard is reported in Table 8.4. As described in Section 
6.7.3, this was done to validate the classification process and to provide a 
measure of its potential as a source of misclassification of the text string.  
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The observed proportion of agreement between the classification system and 
the reference standard was (75+6)/84 = 96%. The chance-corrected weighted 
Kappa was 0.9 (95% CI: 0.7–1.1).  
Table 8.4 Two-way tabulation of the semi-automated classification procedure’s output against 
that of the reference standard 
 Reference standard Total 
Current 
haematuria 
No current 
haematuria 
Final 
classification 
output 
Current 
haematuria 
75 0 75 
Meaning 
unclear 
3 0 3 
No current 
haematuria 
0 6 6 
Total 78 6 84 
 
8.2.1 Sensitivity analyses 
A sensitivity analysis was carried out as illustrated by the purple and black lines 
in Table 8.4. The category ‘Meaning unclear’ in the final classification output 
was merged first with ‘Current haematuria’ and then with ‘No current 
haematuria’ to derive the following binary systems: 
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1. ‘Current haematuria’ or “Not ‘Current haematuria’” (i.e. merged groups 
‘No current haematuria’ and ‘Meaning unclear’). The black lines in Table 
8.4 above illustrate this. 
2. ‘No current haematuria’ or “Not ‘No current haematuria’” (i.e. merged 
groups ‘Current haematuria’ and ‘Meaning unclear’).  The purple lines in 
Table 8.4 above illustrate this. 
Two-way tabulation of the semi-automated classification procedure’s output 
against that of the gold standard is reported in Table 8.5, under sensitivity 
analysis 1.   
Table 8.5 Two-way tabulation of the semi-automated classification procedure’s output against 
that of the reference standard under sensitivity analysis 1 
 Reference standard Totals 
Current 
haematuria 
No current 
haematuria 
Final 
classification 
output 
Current 
haematuria 
75 0 75 
Not ‘Current 
haematuria’ 
3 6 9 
Totals 78 6 84 
In this analysis, the sensitivity is 75/78 (96%), the specificity and positive 
predictive value (PPV) are both 100%. The negative predictive value (NPV) is 
6/9 (67%).  
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Two-way tabulation of the semi-automated classification procedure’s output 
against that of the reference standard is reported in Table 8.6, under sensitivity 
analysis 2.  
Under this analysis, sensitivity, specificity, PPV and NPV were all 100%.  
Table 8.6 Two-way tabulation of the semi-automated classification procedure’s output against 
that of the reference standard under sensitivity analysis 2 
 Reference standard Totals 
Current 
haematuria 
Not ‘Current 
haematuria’ 
Final 
classification 
output  
Not ‘No 
current 
haematuria’ 
78 0 78 
No current 
haematuria 
0 6 6 
Totals 78 6 84 
 
8.3 Other sources of uncertainty in text-based variables 
Spelling and typographical errors made a minor contribution to uncertainty in 
text-based variables. The random sample contained 762 words, of which 5 were 
misspelt, representing an error rate of 0.7%. No instances of American instead 
of UK spelling – for example, ‘anemia rather than ‘anaemia’ – were found. 
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8.4 Results of text extract processing 
8.4.1 Raw data provided 
The numbers of extracts provided by the CPRD are reported in Table 8.7. The 
search terms identified a small number of extracts that were inappropriate (e.g. 
‘denies sphincteric symptoms’) – these were dropped from analysis (n = 9 in the 
pancreatic dataset; n = 8 in the bladder cancer dataset).  
Table 8.7 Raw text data supplied by the CPRD 
Cancer 
site 
Source No. of observations relating to: 
Haematuria Abdominal 
pain 
Jaundice 
Bladder Clinical file  4,631 1,926 293 
Referral file  32  17 10 
Subtotal 4,663 1,943 303 
Extract repeated on 
separate date 
8 6 1 
Total for 
classification 
4,671 1,949 304 
Pancreas Clinical file  480 3,538 2,737 
Referral file  16 78 77 
Subtotal 496 3,616 2,814 
Extract repeated on 
separate date 
0 2 1 
Total for 
classification 
496 3,618 2,815 
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The CPRD provided a single copy of each unique extract. Identifying the date of 
recording (Step 1 – see Section 6.8.2) revealed that sometimes GPs duplicated 
the exact wording on separate dates. Replicate copies were created to ensure 
that the dataset contained the actual number of records made – one for each 
date – and the totals requiring classification are reported in Table 8.7.  
8.4.2 Classification of text extracts 
Reminder about variables 
As a visual aid, fonts indicate the recording style used by the GP. 
 
Courier New denotes variables generated from Read codes, i.e. 
haematuria, jaundice and abdominal pain. 
Lucida Handwriting is used for variables generated from the text only, i.e. 
haematuria, jaundice and abdominal pain.  
Underlined Courier New is used for the total record, i.e. where the variable is 
based on the Read code but is supplemented with records made solely in the 
free text, i.e. haematuria, jaundice and abdominal pain. 
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For clarity, the results of haematuria text extract classification in the bladder 
cancer dataset are illustrated in detail in Figure 8.1, Figure 8.2 and Figure 8.3. 
The results following classification of all the text extracts (i.e. for all three 
symptoms) are summarised in Table 8.8 and Table 8.13, respectively, for the 
bladder and pancreatic cancer datasets.  
Figure 8.1 illustrates the results of initial classification of haematuria extracts by 
the algorithm and the numbers in each category after manual verification (see 
Section 6.8.2 for methods). The algorithm classified 3,780 observations as 
indicating current haematuria and 370 observations as ‘no haematuria’, leaving 
521 whose meaning was unclear (Figure 8.1(a)).  
Figure 8.1 Classification of text extracts: (a) by the algorithm and (b) after manual verification 
(a) 
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(b) 
 
*Only one copy of each unique text extract was supplied; however, GPs did enter exactly the same text on 
more than one occasion, so extracts were replicated to generate one copy for each date of recording.  
After manual verification, the final classification identified 3,839 records (82.2%) 
of haematuria from 2,196 patients. 'No current haematuria' was assigned with 
certainty to 774 (16.6%) extracts, as well as to the 58 (1.2%) extracts whose 
meaning could not be determined (Figure 8.1(b)). 
Figure 8.2 and Figure 8.3 illustrate the final steps of classification required to 
identify true text-only records of attendance for haematuria in the bladder 
cancer dataset (see Section 6.8.2 for the methods). Of the 3,839 attendances 
for haematuria identified from the text extracts, 2,699 were ‘hidden’ completely 
in the text as the GP had never recorded the attendance using a code.  
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Figure 8.2 Identifying the medcode paired with the text record (Step 1) and whether the paired 
medcode is related to the symptom discussed in the text (Step 2) 
 
Figure 8.3  Step 3: Identifying true text-only recording 
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8.4.2.1 Classification of text extracts in the bladder cancer dataset 
The details of classification of text extracts in the bladder cancer dataset are 
reported in Table 8.8. Potentially text-only records were identified for visible 
(n=3,188) and non-visible (n=311) haematuria, abdominal pain (n=1,208) and 
jaundice (n=105). The final numbers of true text-only records were 2,699 for 
visible and 298 for non-visible haematuria, 1,106 for abdominal pain and 88 for 
jaundice.  
Table 8.8 Text extract classification for visible and non-visible haematuria, abdominal pain and 
jaundice in the bladder cancer dataset 
Stage of classification No. of observations in the bladder cancer dataset 
relating to: 
Visible 
haematuria 
Non-visible 
haematuria 
Abdominal 
pain 
Jaundice 
By 
algorithm 
Current 
symptom  
3,780 314 1,356 149 
No current 
symptom  
370 3,836 341 95 
Unclear 521 521 252 60 
Total 4,671 4,671 1,949 304 
After 
manual 
check 
Current 
symptom 
3,839 314 1,394 118 
No current 
symptom  
774 4,299 538 178 
Unclear 58 58 17 8 
Total 4,671 4,671 1,949 304 
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Stage of classification No. of observations in the bladder cancer dataset 
relating to: 
Visible 
haematuria 
Non-visible 
haematuria 
Abdominal 
pain 
Jaundice 
Step 2 a 
Code-
complementa
ry 
c
 
651 3 186 13 
Potentially 
text only  
3,188 311 1,208 105 
Total 3,839 314 1,394 118 
Step 3 b Dropped –
paired 
medcode 
unidentifiable 
2 0 0 0 
Dropped –
duplicated 
record 
166 10 42 8 
Code-
complement
ary c 
321 3 60 9 
True text-
only 
record 
d
 
2,699 298 1,106 88 
 Total 3,188 311 1,208 105 
a Step 2: Identifying whether the paired medcode is related to the symptom discussed in the text 
(see Section 6.8.2). 
b
 Step 3: Identifying true text-only recording (see Section 6.8.2).
 
 c
 Code-complementary – the text extract was either paired with a medcode for the symptom, or 
the GP used a medcode to record the symptom on the same day elsewhere in the record.  
d
 Lucida Handwriting is used for variables generated from the text only, i.e. 
haematuria, jaundice and abdominal pain. 
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8.4.2.2 Medcodes paired with true text-only records 
The medcodes paired with the true text-only records were grouped into their 
appropriate Read code chapter, and are reported below for visible and non-
visible haematuria, abdominal pain and jaundice, respectively.  
8.4.2.2.1 Visible haematuria 
For visible haematuria, approximately half of true text-only records were 
paired with general administrative codes such as ‘Letter from specialist’ and 
‘Telephone encounter’ both in cases (1,264/2,462 = 51.3%) and controls 
(116/237 = 49.0%) (see Table 8.9). The next most frequent type of Read code 
in both patient groups was ‘History/Symptoms’, for example H/O: haematuria 
and dysuria. The text records paired with ‘H/O: haematuria’ were manually 
checked to see if they referred to a past rather than present occurrence of 
haematuria. If they did, this would suggest misclassification that required 
correction. In all cases the text suggested that haematuria was a current 
concern for the patient and that the classification was correct. 
For 44 of the 2,462 (1.8%) attendances made by cases, visible haematuria was 
recorded in a text note paired with a diagnostic code for bladder cancer. These 
44 attendances were made by 43 different cases (43/4,915 = 0.9%). 
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Table 8.9 Read code chapters associated with the medcode paired with the true text-only 
records of attendance for visible haematuria 
Patient  
group 
Read code chapter Frequency (%) 
C
o
n
tr
o
ls
 Administration  116 49.0 
History/Symptoms  40 16.9 
Genitourinary system disorders  27 11.4 
Other therapeutic procedures  15 6.3 
Preventive procedures  13 5.5 
Operations, procedures, sites  6 2.5 
Unspecified  5 2.1 
Examination/Signs  4 1.7 
[D]Symptoms  3 1.3 
Diagnostic procedures  2 0.8 
Laboratory procedures  2 0.8 
Endocrine, nutritional, metabolic and immunity 
disorders  
1 0.4 
Circulatory system diseases  1 0.4 
Skin and subcutaneous tissue diseases  1 0.4 
Musculoskeletal and connective tissue diseases  1 0.4 
Subtotal 237 100 
C
a
s
e
s
 Administration  1,264 51.3 
History/Symptoms  345 14.0 
Other therapeutic procedures  218 8.9 
Preventive procedures  167 6.8 
Genitourinary system diseases 116 4.7 
Unspecified  84 3.4 
Operations, procedures, sites  66 2.7 
Neoplasms  44 1.8 
Laboratory procedures  36 1.5 
[D]Symptoms  33 1.3 
Examination/Signs  25 1.0 
Diseases of blood and blood-forming organs  17 0.7 
Diagnostic procedures  6 0.2 
Radiology physics  6 0.2 
Occupation  5 0.2 
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Patient  
group 
Read code chapter Frequency (%) 
Circulatory system diseases  5 0.2 
Musculoskeletal and connective tissue diseases 
system 
5 0.2 
Mental disorders 4 0.2 
Nervous system and sense organ diseases 3 0.1 
Respiratory system diseases  3 0.1 
Digestive system diseases  3 0.1 
Causes of injury poison  3 0.1 
Endocrine, nutritional, metabolic and immunity 
disorders  
2 0.1 
Skin and subcutaneous tissue diseases  2 0.1 
 Subtotal 2,462 100 
Total  2,699 100 
 
8.4.2.2.2 Non-visible haematuria 
General administration was also the category of code most frequently paired 
with true text-only non-visible haematuria records; namely, in 30/50 (60%) of 
records in controls and in 116/248 (46.8%) of records in cases. The most 
frequently encountered general administrative codes were: ‘Seen in urology 
clinic’ (43/298 = 14.5%), ‘Letter from specialist' (32/298 = 10.8%), ‘Incoming 
mail NOS' (23/298 = 9.1%) and ‘Patient reviewed’ (20/298 = 6.7%). In the 
cases, codes related to genitourinary system diseases were paired with 36/248 
(14.5%) of the text-only records, whereas in the controls this category was used 
in only 2/50 (4%) of text-only records (see Table 8.10).  
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Table 8.10 Read code chapters associated with the medcode paired with the true text-only 
records of attendance for non-visible haematuria 
Patient group Read code chapter Frequency % 
Controls Administration 30 60 
History/Symptoms 7 14 
Preventive procedures 3 6 
Laboratory procedures 2 4 
Operations, procedures, sites 2 4 
Genitourinary system diseases 2 4 
[D]Symptoms 2 4 
Other therapeutic procedures 1 2 
Unspecified 1 2 
Sub-total 50 100 
Cases Administration 116 46.8 
Genitourinary system diseases 36 14.5 
History/Symptoms 28 11.3 
Preventive procedures 21 8.5 
Other therapeutic procedures 15 6.1 
Laboratory procedures 11 4.4 
Unspecified 11 4.4 
Operations, procedures, sites 4 1.6 
[D]symptoms 2 0.8 
Diagnostic procedures 1 0.4 
Mental disorders 1 0.4 
Respiratory system diseases 1 0.4 
Digestive system diseases 1 0.4 
Sub-total 248 100 
Total  298 100 
 
Within the ‘History/Symptoms’ category, 41/298 (13.8%) of the text-only records 
were paired with codes for haematuria. These text records were manually 
checked to see if they had been misclassified, but were confirmed as reporting 
that non-visible haematuria was a current concern, but that visible haematuria 
had occurred in the past.  
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8.4.2.2.3 Abdominal pain 
General administrative codes also accounted for the majority of medcodes 
paired with text-only abdominal pain records, both in cases (163/179= 42.9%) 
and controls (263/727= 36.2%) (Table 8.11). Indeed, the context of the 
consultation was important, with administrative codes such as ‘Patient 
reviewed’, ‘Telephone encounter’, and ‘Home visit’ accounting collectively for 
219/1,106 (19.8%) of all text-only records. History/Symptoms was the next most 
frequent type of code, used for 69/379 (18.2%) of records in the cases and for 
175/727 (24.1%) of records in the controls.  
Table 8.11 Read code chapters associated with the medcode paired with the true text-only 
records of attendance for abdominal pain 
Patient 
group 
Read code chapter  Frequency (%) 
C
o
n
tr
o
ls
 Administration 263 36.2 
History/Symptoms 175 24.1 
Preventive procedures 68 9.4 
Other therapeutic procedures 59 8.1 
Digestive system diseases  59 8.1 
Unspecified 40 5.5 
Genitourinary system diseases 10 1.4 
[D]Symptoms 9 1.2 
Examination/Signs 6 0.8 
Respiratory system diseases 6 0.8 
Infectious parasitic disease 5 0.7 
Musculoskeletal and connective tissue 
diseases 
5 0.7 
Circulatory system diseases 4 0.6 
Radiology physics 3 0.4 
Operations, procedures, sites 3 0.4 
213 
 
Patient 
group 
Read code chapter  Frequency (%) 
Diseases of blood and blood-forming organs 3 0.4 
Causes of injury poison 3 0.4 
Endocrine, nutritional, metabolic and immunity 
disorders 
2 0.3 
Occupation 1 0.1 
Mental disorders 1 0.1 
Nervous system and sense organ diseases 1 0.1 
Skin and subcutaneous disorders 1 0.1 
Sub-total 727 100 
C
a
s
e
s
 Administration 163 42.9 
History/Symptoms 69 18.2 
Other therapeutic procedures 37 9.7 
Genitourinary system diseases 32 8.4 
Preventive procedures 23 6.1 
Digestive system diseases 14 3.7 
Unspecified 13 3.7 
Examination/Signs 7 1.8 
[D]Symptoms 5 1.3 
Infectious parasitic disease 3 0.8 
Neoplasms 3 0.8 
Mental disorders 3 0.8 
Operations, procedures, sites 2 0.5 
Occupation 1 0.3 
Respiratory system diseases 1 0.3 
Skin and subcutaneous tissue diseases 1 0.3 
Musculoskeletal and connective tissue 
diseases 
1 0.3 
Causes of injury poison 1 0.3 
Sub-total 379 100 
Total  1,106 100 
 
8.4.2.2.4 Jaundice 
In the controls, Administration was the most frequent category of medcode 
paired with text-only jaundice records (24/26 = 38.7%), followed by 
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History/Symptoms (15/26 = 24.2%); however, for the cases, the two categories 
were used with similar frequency, i.e. 8/26 (30.8%) for History/Symptoms and 
7/26 (26.9%) for Administration (Table 8.12).  
Table 8.12 Read code chapters associated with the medcode paired with the true text-only 
records of attendance for jaundice 
Patient 
group 
Read code chapter Frequency % 
C
o
n
tr
o
ls
 Administration 24 38.7 
History/Symptoms 15 24.2 
Preventive procedures 4 6.5 
Other therapeutic procedures 4 6.5 
Unspecified 4 6.5 
Operations, procedures, sites 3 4.8 
[D]Symptoms 3 4.8 
Circulatory system diseases 2 3.2 
Digestive system diseases 2 3.2 
Neoplasms 1 1.6 
Sub-total 26 100 
C
a
s
e
s
 History/Symptoms 8 30.8 
Administration 7 26.9 
Preventive procedures 2 7.7 
Neoplasms 2 7.7 
Genitourinary system diseases 2 7.7 
Laboratory procedures 1 3.9 
Operations, procedures, sites 1 3.9 
Other therapeutic procedures 1 3.9 
Respiratory system diseases 1 3.9 
Digestive system diseases 1 3.9 
Sub-total 26 100 
Total  88 100 
 
8.4.2.3 Classification of text extracts in the pancreatic cancer dataset 
The details of classification of text extracts in the pancreatic cancer dataset are 
reported in Table 8.13.  
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Table 8.13 Text extract classification for jaundice, abdominal pain and haematuria in the 
pancreatic cancer dataset 
Stage of classification No. of observations in the pancreatic 
cancer dataset relating to: 
Jaundice Abdominal 
pain 
Visible 
haematuria 
Classification 
by algorithm 
Current 
symptom  
2,391   2,852 318 
No current 
symptom  
285 395 77 
Unclear 139 371 101 
Total 2,815 3,618 496 
Classification 
after manual 
verification 
Current 
symptom 
2,243 2,979 308 
No current 
symptom  
432 573 156 
Unclear 140 66 32 
Total 2,815 3,618 496 
Step 2 a Code-
complementary c 
308 458 39 
Potentially text 
only  
1,935 2,521 269 
Total 2,243 2,979 308 
Step 3 b Dropped (paired 
medcode 
unidentifiable) 
0 0 0 
Dropped 
(duplicated 
record) 
133 102 8 
Code-
complementary c 
163 204 10 
True text-only 
record 
1,639 2,215 251 
 Total 1,935 2,521 269 
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a Step 2: Identifying whether the paired medcode is related to the symptom discussed in the text 
(see Section 6.8.2). 
b
 Step 3: Identifying true text-only recording (see Section 6.8.2).
 
 c
 Code-complementary – the text extract was either paired with a medcode for the symptom, or 
the GP used a medcode to record the symptom on the same day elsewhere in the record.  
Potentially text-only records were identified for jaundice (n = 1,935), abdominal 
pain (n = 2,521) and visible haematuria (n = 269). The final numbers of true 
text-only records for jaundice, abdominal pain and visible haematuria 
were 1,639, 2,215 and 251, respectively.  
8.4.2.4 Medcodes paired with text-only records 
The medcodes paired with the true text-only records were grouped into their 
appropriate Read code chapter, and are reported below for jaundice, 
abdominal pain and visible haematuria, respectively.  
8.4.2.4.1 Jaundice 
Text-only jaundice records were most frequently paired with general 
administrative codes both in controls (19/35 = 54.3%) and cases (720/1,604 = 
44.9%). The second most common category of code was History/Symptoms, 
used for 7/35 (20.0%) of records in controls and 233/1,604 (14.5%) in cases 
(Table 8.14). This included 40 text-only jaundice records paired with codes 
indicating that the patient had a history of jaundice. The individual text snippets 
were re-checked and it was confirmed that they all indicated that jaundice was a 
current clinical concern for these patients, i.e. that the classification was correct. 
In the controls the remaining text-only records were paired with codes related to 
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the history, examination or other procedures, whereas in the cases codes for 
specific diseases and diagnoses tended to be used. For 83/1,604 (5.2%) of the 
attendances made by cases, jaundice was noted in a text record paired with a 
diagnostic code for pancreatic cancer. These 83 attendances were made by 77 
of the 3,635 (2.1%) cases. 
Table 8.14 Read code chapters associated with the medcode paired with the true text-only 
records of attendance for jaundice 
Patient 
group 
Read code chapter Frequency % 
C
o
n
tr
o
ls
 Administration 19 54.3 
History/Symptoms 7 20.0 
Other therapeutic procedures 3 8.6 
Preventive procedures 2 5.7 
[D]Symptoms 2 5.7 
Examination/Signs 1 2.9 
Laboratory procedures 1 2.9 
Sub-total 35 100 
C
a
s
e
s
 Administration 720 44.9 
History/Symptoms 233 14.5 
Other therapeutic procedures 162 10.1 
Preventive procedures 138 8.6 
Neoplasms 83 5.2 
Examination/Signs 57 3.6 
[D]Symptoms 42 2.6 
Unspecified 41 2.6 
Operations procedures sites 37 2.3 
Skin and subcutaneous tissue diseases 36 2.2 
Digestive system diseases 19 1.2 
Laboratory procedures 13 0.8 
Diagnostic procedures 4 0.3 
Radiology physics 3 0.2 
Infectious parasitic disease 3 0.2 
Genitourinary system diseases 3 0.2 
Endocrine, nutritional, metabolic and 
immunity disorders 
2 0.1 
Circulatory system diseases 2 0.1 
Musculoskeletal and connective tissue 2 0.1 
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Patient 
group 
Read code chapter Frequency % 
diseases 
Occupation 1 0.06 
Mental disorders 1 0.06 
Respiratory system diseases 1 0.06 
Causes of injury poison 1 0.06 
Sub-total 1,604 100 
Total  1,639 100 
 
8.4.2.4.2 Abdominal pain 
Text-only abdominal pain records were most frequently paired with 
administration codes (226/594 = 38.1% of records in controls, and 705/1,621 = 
43.5% of records in cases), followed once again by codes for History/Symptoms 
(controls: 147/594 = 24.8%; cases: 289/1,621 = 17.8%) (see Table 8.15).  
Table 8.15 Read code chapters associated with the medcode paired with the true text-only 
records of attendance for abdominal pain 
Patient  
group 
Read code chapter Frequency % 
C
o
n
tr
o
ls
 Administration 226 38.1 
History/Symptoms 147 24.8 
Other therapeutic procedures 52 8.8 
Digestive system diseases 45 7.6 
Preventive procedures 34 5.7 
[D]Symptoms 14 2.4 
Genitourinary system diseases 13 2.2 
Examination/Signs 12 2.0 
Unspecified 12 2.0 
Musculoskeletal and connective tissue diseases 7 1.2 
Laboratory procedures 6 1.0 
Operations, procedures, sites 6 1.0 
Infectious parasitic disease 6 1.0 
Causes of injury poison 3 0.5 
Diseases of blood and blood-forming organs 2 0.3 
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Patient  
group 
Read code chapter Frequency % 
Mental disorders 2 0.3 
Injury poison 2 0.3 
Neoplasms 1 0.2 
Nervous system and sense organ diseases 1 0.2 
Circulatory system diseases 1 0.2 
Respiratory system diseases 1 0.2 
Skin and subcutaneous tissue diseases 1 0.2 
Sub-total 594 100 
C
a
s
e
s
 Administration 705 43.5 
History/Symptoms 289 17.8 
Preventive procedures 188 11.6 
Other therapeutic procedures 150 9.3 
Unspecified 59 3.6 
Digestive system diseases 56 3.5 
[D]Symptoms 47 2.9 
Examination/Signs 43 2.7 
Neoplasms 18 1.1 
Genitourinary system diseases 11 0.7 
Laboratory procedures 10 0.6 
Musculoskeletal and connective tissue diseases 10 0.6 
Operations, procedures, sites 7 0.4 
Circulatory system diseases 5 0.3 
Occupation 4 0.3 
Skin and subcutaneous tissue diseases 4 0.3 
Radiology physics 3 0.2 
Endocrine, nutritional, metabolic and immunity 
disorders 
3 0.2 
Respiratory system diseases 2 0.1 
Diagnostic procedures 1 0.06 
Infectious parasitic disease 1 0.06 
Diseases of blood and blood-forming organs 1 0.06 
Mental 1 0.06 
Nervous system and sense organ diseases 1 0.06 
Injury poison 1 0.06 
Causes of injury poison 1 0.06 
Sub-total 1,621 100 
Total  2,215 100 
 
220 
 
8.4.2.4.3 Visible haematuria 
Text-only visible haematuria records were most frequently paired with 
medcodes from the administration category (controls: 68/151 = 44.7%; cases: 
43/100 = 43%), followed by History/Symptom codes (controls: 23/151 = 15.1%; 
cases: 19/100 = 19%).  
Table 8.16 Read code chapters associated with the medcode paired with the true text-only 
records of attendance for visible haematuria  
Patient group Read code chapter Frequency % 
C
o
n
tr
o
ls
 Administration 68 44.7 
History/Symptoms 23 15.1 
Other therapeutic procedures 17 11.2 
Genitourinary system diseases 17 11.2 
Preventive procedures 7 4.6 
[D]Symptoms 5 3.3 
Operations, procedures, sites 4 2.6 
Examination/Signs 2 1.3 
Laboratory procedures 2 1.3 
Circulatory system diseases 2 1.3 
Unspecified 1 0.7 
Diagnostic procedures 1 0.7 
Mental disorders 1 0.7 
Causes of injury poison 1 0.7 
Sub-total 151 100 
C
a
s
e
s
 Administration 43 43 
History/Symptoms 19 19 
Other therapeutic procedures 9 9 
Preventive procedures 8 8 
Genitourinary system diseases 8 8 
[D]Symptoms 4 4 
Neoplasms 2 2 
Unspecified 2 2 
Occupation 1 1 
Diagnostic procedures 1 1 
Laboratory procedures 1 1 
Diseases of blood and blood-forming organs 1 1 
Digestive system diseases 1 1 
Sub-total 100 100 
Total  251 100 
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9 Results: Recording style  
9.1 Event-level data 
In this analysis the aim was to identify the recording style of attendances for the 
symptoms. The analysis addresses research questions 1: ‘How much symptom 
information is documented in electronic medical records using text rather than a 
code?’ and 3: ‘Does recording style vary with type of symptom?’ (Section 5).  
The total numbers of attendances for each of haematuria, abdominal pain and 
jaundice were obtained by adding the number of text-only records of attendance 
to the numbers of coded records.  
9.1.1 Recording style at the event level in the bladder cancer 
dataset 
The method used to record attendances for visible and non-visible haematuria 
and abdominal pain is reported in Figure 9.1. The numbers of attendances 
recorded in code (i.e. visible and non-visible haematuria and 
abdominal pain) and solely in the text (i.e. visible and non-visible 
haematuria and abdominal pain) are tabulated at the bottom of Figure 9.1. 
The percentage of the total number of attendances obtained from coded and 
from text-only records is shown graphically at the top of the figure.  
Note these figures were obtained by re-using the symptom thesauri created for 
the original studies; therefore, ‘abdominal pain’ includes codes for abdominal 
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tenderness, rigidity and cramps, but not for epigastric pain, indigestion or 
dyspepsia (see Appendix 4: Symptom thesauri). 
Figure 9.1 Event-level data: method used to record attendances for visible and non-
visible haematuria and abdominal pain in the bladder cancer dataset 
 
Note: The percentages of the total number of attendances with a symptom are marked on the 
bars, and the raw numbers are tabulated beneath.   
As shown in Figure 9.1, while large numbers of text-only visible haematuria 
and abdominal pain records were made in the bladder cancer dataset, coding 
was the favoured method. Indeed, coded visible haematuria 
(4,603/7,302=63%) and abdominal pain (1,689/2,795=60%) records 
accounted for nearly two-thirds of the overall numbers of attendances for these 
symptoms. Lower numbers of attendance were observed for non-visible 
haematuria compared with both visible haematuria and abdominal pain. 
However, text-only was the preferred recording style, with non-visible 
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haematuria records accounting for nearly two-thirds of all the attendances for 
this feature (298/494=60%).  
9.1.2 Recording style at the event level in the pancreatic cancer 
dataset 
The method used to record attendances for jaundice and abdominal pain is 
reported in Figure 9.2. The numbers of attendances recorded in code (i.e. 
jaundice and abdominal pain) and solely in the text (i.e. jaundice and 
abdominal pain) are tabulated at the bottom of Figure 9.2. The percentage of 
the total number of attendances obtained from coded and from text-only records 
is shown graphically at the top of the figure. 
For jaundice there were similar numbers of jaundice (1,699/3,338 = 51%) and 
jaundice (1,639/3,338 = 49%) records, such that there was no overall 
preference for either recording style (Figure 9.2).  
As shown in Figure 9.2, large numbers of text-only abdominal pain records 
were made in the pancreatic cancer dataset. Despite this, coding was the 
preferred method, with abdominal pain records accounting for more than 
two-thirds (4,976/7,191 = 69%) of the attendances for this symptom.  
The coded abdominal pain records were obtained re-using the symptom 
thesaurus created in the original pancreatic cancer study. The thesaurus 
contained codes for epigastric pain, indigestion and dyspepsia, but not 
abdominal tenderness, rigidity or cramps (see Appendix 4: Symptom thesauri). 
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Figure 9.2 Event-level data: method used to record attendances for jaundice and 
abdominal pain in the pancreatic cancer dataset 
 
Note: The percentages of the total number of attendances with a symptom are marked on the 
bars, and the raw numbers are tabulated beneath.   
9.1.3 Medcodes used to record symptoms 
The symptom thesauri were deliberately comprehensive, in order to maximise 
the capture of all coded records of symptoms. The results below indicate how 
many of the medcodes included in the thesauri were actually used by the GPs. 
9.1.3.1 Visible and non-visible haematuria – bladder cancer 
Of the 26 medcodes included in the visible haematuria symptom thesaurus, 12 
were never selected by GPs in the bladder cancer dataset. In fact, the majority 
of coded visible haematuria records were made using a single medcode 
(507: ‘haematuria’), which accounted for 3,769 of the 4,603 (81.9%) 
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attendances in the analysis period (see Table 9.1). Six more medcodes were 
used to identify a further 18% of the coded records, leaving just a handful of 
matches for the remaining six medcodes that were ever selected.  
Table 9.1 Event-level data: codes used to document patient attendances for visible 
haematuria in the bladder cancer dataset 
Medcode  Description  Frequency (%) 
507  Haematuria  3,769 81.9 
7232  Frank haematuria  271 5.9 
6030  Haematuria - symptom  206 4.5 
6659  Blood in urine - haematuria  135 2.9 
9651  Painless haematuria  122 2.6 
6234  Blood in urine - symptom  66 1.4 
17060  Recurrent and persistent haematuria  24 0.5 
6901  Clot haematuria  4 0.1 
20357  Painful haematuria  2 0.04 
13915  RBCs- red blood cells in urine  1 0.02 
13929  Urine blood test = +  1 0.02 
13934  Urine blood test = ++  1 0.02 
19792  Urine blood test = +++  1 0.02 
Total   4,603 100 
Only one medcode for non-visible haematuria (277: microscopic haematuria) 
had been identified and included in the thesaurus for this symptom; therefore, 
this accounted for 100% of the attendances. 
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9.1.3.2 Jaundice – pancreatic cancer 
A small number of medcodes were used to document attendances for jaundice 
(Table 9.2). Indeed, just four medcodes identified 1,479 of the total 1,699 
(87.1%) attendances for this symptom. Only one medcode included in the 
symptom thesaurus was never used, i.e. [D]Jaundice (not of newborn) NOS. 
Table 9.2 Event-level data: codes used to document patient attendances for jaundice in 
the pancreatic cancer dataset 
Medcode  Description    Frequency (%) 
3121  Obstructive jaundice NOS  636 37.4 
6000  Jaundice - symptom  426 25.1 
2612  [D]Jaundice  210 12.4 
355  [D]Jaundice (not of newborn)  207 12.2 
5996  O/E - jaundiced  156 9.2 
25418  Yellow/jaundiced colour   43 2.5 
29488  O/E - jaundiced colour    9 0.5 
18019  Yellow - symptom    6 0.4 
18574  [D]Icterus NOS    6 0.4 
Total     1,699 100 
 
9.1.3.3 Abdominal pain 
As noted above, the original bladder and pancreatic cancer studies differed in 
their choice of codes used to identify attendances for abdominal pain (see 
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Appendix 4: Symptom thesauri). This was largely because, in the pancreatic 
cancer study, abdominal pain, dyspepsia and indigestion were all combined into 
a composite ‘abdominal’ symptom. In addition, pain from the bladder refers to 
the hypogastrium (aka suprapubic region), while pain from the pancreas refers 
to the left hypochondrium and epigastric region (see Section 4.5.3.4.4).  
The frequency of use of medcodes is reported separately for each dataset 
below.  
9.1.3.3.1 Bladder cancer dataset 
Two specific medcodes (177: abdominal pain and 1763: [D]abdominal pain) 
accounted for 1,244 of the total 1,689 (73.7%) attendances for abdominal pain 
in the bladder cancer dataset (Table 9.3). 
Table 9.3 Event-level data: codes used to document patient attendances for abdominal 
pain in the bladder cancer dataset 
Medcode  Description  Frequency (%) 
177  Abdominal pain  815 48.3 
1763  [D]Abdominal pain  429 25.4 
2383  Abdominal discomfort  139 8.2 
1976  Abdominal pain type  122 7.2 
7812  Colicky abdominal pain   27 1.6 
2056  [D]Abdominal colic   25 1.5 
22608  Lower abdominal pain   23 1.4 
5782  O/E - abdomen tender   22 1.3 
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Medcode  Description  Frequency (%) 
5960  Site of abdominal pain   17 1.0 
3338  Central abdominal pain   14 0.8 
4617  [D]Abdominal pain NOS   14 0.8 
716  [D]Abdominal cramps   12 0.7 
7726  [D]Right upper quadrant pain    6 0.4 
8436  [D]Upper abdominal pain    4 0.2 
3978  Right upper quadrant pain    3 0.2 
4771  Upper abdominal pain    3 0.2 
8362  [D]Left upper quadrant pain    3 0.2 
9695  [D]Nonspecific abdominal pain    3 0.2 
19283  [D]Umbilical pain    3 0.2 
2234  General abdominal pain-symptom    1 0.06 
9061  Generalised abdominal pain    1 0.06 
11070  [D]Abdominal tenderness    1 0.06 
16402  [D]Left lower quadrant pain    1 0.06 
24661  [D]Recurrent acute abdominal pain    1 0.06 
Total     1,689 100 
 
9.1.3.3.2 Pancreatic cancer dataset 
As with the bladder cancer dataset, a small number of medcodes accounted for 
the majority (4,168/4,976=83.8%) of the attendances for ‘abdominal pain’ in the 
analysis period (see Table 9.4). These codes were: 177 (abdominal pain), 257 
(dyspepsia), 1763 ([D]abdominal pain) and 290 (epigastric pain).  
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Table 9.4 Event-level data: codes used to document patient attendances for abdominal 
pain in the pancreatic cancer dataset 
Medcode  Description  Frequency (%) 
177  Abdominal pain    1,670 33. 6 
257  Dyspepsia  889 17.9 
1763  [D]Abdominal pain  835 16.8 
290  Epigastric pain  774 15.5 
1976  Abdominal pain type  273 5.5 
134  Indigestion  178 3.6 
5862  Indigestion symptoms  136 2.7 
2056  [D]Abdominal colic   50 1.0 
3338  [D]Abdominal pain NOS   37 0.7 
5960  Site of abdominal pain   32 0.6 
4617  Central abdominal pain   26 0.5 
542  [D]Epigastric pain   18 0.4 
15180  O/E - abdo. pain on palpation   11 0.2 
19283  [D]Nonspecific abdominal pain   10 0.2 
7623  Indigestion NOS    8 0.2 
43233  Undiagnosed dyspepsia    7 0.1 
24661  Generalised abdominal pain    6 0.1 
8697  Flatulent dyspepsia    4 0.08 
20640  O/E - epigastric pain on palp.    4 0.08 
14916  Indigestion symptom NOS    2 0.04 
37118  O/E -abd.pain on palpation NOS    2 0.04 
2234  O/E - abd. pain - epigastrium    1 0.02 
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Medcode  Description  Frequency (%) 
9061  Type of GIT pain NOS    1 0.02 
19223  [D]Left lower quadrant pain    1 0.02 
44484  [D]Recurrent acute abdominal pain    1 0.02 
Total  Total    4,976 100 
 
9.1.3.3.3 Using a generic abdominal pain thesaurus for both cancer sites 
The results in Figure 9.1 and Figure 9.2 suggested that the preference for 
coding abdominal pain was greater in the pancreatic (4,976/7,191 = 69%) than 
in the bladder (1,689/2,795 = 60%) cancer dataset.  
In separate analysis, a generic symptom thesaurus for abdominal pain was 
used to allow direct comparison of recording patterns between the two cancer 
datasets (Figure 9.3). 
Figure 9.3 Event-level data: abdominal pain recording, with coded records identified 
using the same symptom thesaurus in both cancer sites 
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In this analysis, the preference for coding was similar in the two datasets; 
namely, 2,148/3,239 (66%) in bladder, and 4,215/6,468 (65%) in pancreas.  
9.2 Patient-level data 
Event-level data (reported above) equate to the number of attendances for each 
symptom within the analysis period (including multiple attendances per patient). 
In contrast, patient-level data report the numbers of patients (attendees) 
attending at least once for the symptom of interest.  
The results in this section relate to research questions 1: ‘How much symptom 
information is documented in electronic medical records using text rather than a 
code?’; 2: Are studies of coded data vulnerable to bias arising from the 
differential use of text and codes between comparison groups’; 3: ‘Does 
recording style vary with type of symptom?’; and 4: ‘Does the recording style 
vary with the clinical context of presentation of a symptom’ (see Section 5).  
9.2.1 Overall recording style preference 
The recording style at the patient levela for alarm and non-alarm symptoms in 
the bladder and pancreatic cancer datasets is reported in Table 9.5. The 
numbers of patients attending at least once because of the symptom in question 
                                            
a
 Each patient was categorised by the overall style used to record their attendances for the 
symptom. ‘Coded’ was assigned if any record of a symptom was in coded form; conversely, 
‘text-only’ was designated only when all instances were noted solely in the text.  
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were obtained using the bespoke symptom thesauri created for the original 
studies.  
The results suggest that the original studies omitted at least 20% and as many 
as 59% of patients who had attended with haematuria (visible or non-visible), 
jaundice or abdominal pain, justifying our concerns about omitting text records 
from analysis.  
In the bladder cancer dataset, coded visible haematuria (2,787/3,483 = 
80%) and abdominal pain (1,142/1,762 = 65%) records identified a greater 
proportion of attendees for these symptoms compared with text-only visible 
haematuria (696/3,483 = 20%) and abdominal pain (620/1,762 = 35%) 
records (Figure 9.4 and Table 9.5).  
In contrast, text-only non-visible haematuria records (219/372 = 59%) 
identified more attendees for this symptom compared with coded non-
visible haematuria records (153/372 = 41%) (see Figure 9.4).  
In the pancreatic cancer dataset, coded records for both jaundice 
(1,112/1,596 = 70%) and abdominal pain (2,523/3,222 = 78%) identified a 
greater proportion of attendees for these symptoms compared with the text-only 
jaundice (484/1,596 = 30%) and abdominal pain (699/3,222 = 22%) records 
(see Figure 9.4).  
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Table 9.5 Symptom recording style for alarm symptoms (visible haematuria in bladder cancer; 
jaundice in pancreatic cancer) and non-alarm symptoms (abdominal pain for both cancers; non-
visible haematuria for bladder cancer), regardless of patient status 
Cancer site Feature Number (% of total) of patients attending 
at least once where the event was 
recorded using: 
Read code, 
n (%) 
Text-only, n 
(%) 
Total, n (%) 
Bladder Non-visible 
haematuria 
153 (41) 219 (59)  372 (100) 
Abdominal 
pain 
1,142 (65) 620 (35)  1,762 (100) 
Visible 
haematuria 
2,787 (80) 696 (20) 3,483 (100) 
Pancreas  Abdominal 
pain 
2,523 (78) 699 (22)  3,222 (100) 
Jaundice 1,112 (70) 484 (30) 1,596 (100) 
Figure 9.4 Graphical presentation of the recording style for symptoms within bladder and 
pancreatic cancer 
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9.2.2 Association between symptom recording style and patient 
factors  
In this analysis, the aim was to compare recording styles between cases and 
controls to address research question 2: ‘Are studies of coded data vulnerable 
to bias arising from the differential use of text and codes between comparison 
groups?’ (see Section 5).  
A second aim was to examine whether associations between recording style 
and patient status varied with gender, to address research question 4: ‘Does the 
recording style vary with the clinical context of presentation of a symptom?’  
9.2.2.1 In the bladder cancer dataset 
The recording styles that identified attendees for visible and non-visible 
haematuria and for abdominal pain are plotted in Figure 9.5, Figure 9.8 and 
Figure 9.10, respectively. The raw data are reported in Table 9.6.  
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Table 9.6 Numbers of patients attending at least once in the analysis period with abdominal 
pain or haematuria (visible or non-visible) grouped by recording style 
Clinical feature and 
its recording style a 
Number of cases (n = 4,915) and 
controls (n = 21,718) attending at 
least once in the analysis period for 
the feature 
Total, n (% of 
total with the 
symptom) 
Cases, n (% of 
cases) 
Controls, n (% of 
controls) 
Visible 
haematuria 
2,591 (52.7) 196 (0.9) 2,787 (80.0) 
Visible 
haematuria 
556 (11.3) 140 (0.6) 696 (20.0) 
Total: Visible 
haematuria 
3,147 (64.0) 336 (1.5) 3,483 (100) 
Non-visible 
haematuria 
127 (2.6) 26 (0.1) 153 (41.1) 
Non-visible 
haematuria 
185 (3.8) 34 (0.2) 219 (58.9) 
Total: Non-visible 
haematuria 
312 (6.4) 60 (0.3) 372 (100) 
Abdominal pain 358 (7.3) 784 (3.6) 1,142 (64.8)  
Abdominal pain 189 (3.8) 431 (2.0) 620 (35.2) 
Total: Abdominal 
pain 
547 (11.1) 1,215 (5.6) 1,762 (100) 
a
 Reminder that fonts are used to indicate recording style; for example, Visible haematuria 
– GP used a Read code for some or all attendances; Visible haematuria  – GPs used 
text-only to record all attendances; Visible haematuria – total record, i.e. codes plus text-
only records. 
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9.2.2.1.1 Visible haematuria 
There was strong evidence of an association between patient status (case or 
control) and the recording style that identified attendees for visible haematuria 
(χ2 test, p<0.0001). Coded visible haematuria records identified a greater 
proportion of the cases (2,591/3,147 = 82%) than of the controls (196/336 = 
58%) who had attended for visible haematuria during the analysis period.  
Figure 9.5 The number of patients who attended at least once in the analysis period for visible 
haematuria where the event was recorded using a code (dark red) or text-only (light red) in 
bladder cancer cases (n = 3,147/4,915) and controls (n = 336/21,718) separately 
 
This association between recording style and case/control status was markedly 
different in women than in men, as shown in Figure 9.6 and Figure 9.7, 
respectively. 
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In women, there was a strong association between recording style and 
case/control status (χ2 test, p<0.0001) (Figure 9.6). Coded records identified 
636 of the 791 (80.4%) female cases who had experienced at least one episode 
of visible haematuria – a proportion similar to that observed for the cases 
overall. In contrast, coded records identified only 19 of the 57 (33.3%) female 
controls who ever attended for this symptom.  
Figure 9.6 The number of women who attended at least once in the analysis period for visible 
haematuria where the event was recorded using a code (dark red) or text-only (light red) in 
bladder cancer cases (n = 791/1,352) and controls (n = 57/6,266) separately 
 
There was also a strong association between recording style and case/control 
status in men (χ2 test, p<0.0001). Compared with the female cases, coded 
records identified a similar proportion of male cases who attended at least once 
for visible haematuria (1,955/2,356 = 83.0%). For the controls, there was a 
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marked difference in recording style between men and women. Coded records 
identified 177 of the 279 (63.4%) male controls with visible haematuria. In other 
words, the extent of data hidden in text-only records for male controls was 
considerably less than that for the female controls.   
Figure 9.7 The number of men who attended at least once in the analysis period for visible 
haematuria where the event was recorded using a code (dark red) or text-only (light red) in 
bladder cancer cases (n = 2,356/3,563) and controls (n = 57/6,266) separately 
 
9.2.2.1.2 Non-visible haematuria 
In contrast with the visible form of haematuria, there was no evidence of an 
association between patient (men and women combined) status and recording 
style used to identify attendees for non-visible haematuria (χ2 test, p = 0.7). 
Text-only non-visible haematuria records predominated, identifying similar 
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proportions of cases (185/312 = 59%) and controls (34/60 = 57%) who had 
attended for non-visible haematuria during the analysis period.  
Figure 9.8 The number of patients who attended at least once in the analysis period for non-
visible haematuria where the event was recorded using Read codes (dark yellow) and text-only 
(light yellow) in bladder cancer cases (n = 312/4,915) and controls (n = 60/21,718) separately 
 
Examining the data for men and women separately indicated an association 
between recording style and case/control status in the women (p<0.05) but not 
the men (p = 0.5), although the numbers were small (see Figure 9.9).  
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Figure 9.9 The number of women (top panel) and men (bottom panel) who attended at least 
once in the analysis period for non-visible haematuria where the event was recorded using 
Read codes (dark yellow) and text-only (light yellow) in bladder cancer cases (women: n = 
86/1,352; men: n = 226/3,563) and controls (women: n = 16/6,266; men: n = 44/15,452) 
separately 
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The association led to greater loss of records in hidden text for the female 
cases compared with controls. Of the 16 female controls with at least one 
episode of non-visible haematuria, the records for 7 (43.8%) were made solely 
in the hidden text. This proportion increased in the female cases, where text-
only recording was used for 60/86 (69.8%) women with at least one episode of 
non-visible haematuria. 
9.2.2.1.3 Abdominal pain 
There was no evidence of an association between patient status (case or 
control) and recording style used to identify attendees for abdominal pain (χ2 
test, all patients combined: p = 0.7; male patients only: p = 0.98; female patients 
only: p = 0.5) (Figure 9.10).  
Figure 9.10 The number of patients who attended at least once in the analysis period for 
abdominal pain where the event was recorded using Read codes (dark green) or text-only (light 
green) in bladder cancer cases (n = 547/4,915) and controls (n = 1,215/21,718) separately  
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Over all patients, coded abdominal pain records predominated, identifying 
similar proportions of the cases (358/547 = 65%) and controls (784/1,215 = 
65%) who had attended for abdominal pain during the analysis period.   
9.2.2.2 In the pancreatic cancer dataset 
The recording styles that identified attendees for jaundice and abdominal pain in 
the pancreatic cancer dataset are plotted in Figure 9.11 and Figure 9.12, 
respectively, The raw data are reported in Table 9.7.  
Table 9.7 Numbers of patients attending at least once in the analysis period with abdominal 
pain or jaundice grouped by recording style 
Clinical feature and its 
recording style 
Number of cases (n = 3,635) 
and controls (n = 16,459) 
attending ≥ 1 in the analysis 
period for the feature 
Total, n (% of 
total with the 
symptom) 
Cases, n (%) Controls, n (%) 
Jaundice 1,102 (30.3) 10 (0.06) 1,112 (69.7) 
Jaundice 463 (12.7) 21 (0.1) 484 (30.3) 
Total: Jaundice 1,565 (43.1) 31 (0.2) 1,596 (100) 
Abdominal pain 1,527 (42.0) 996 (6.1)  2,523 (78.3) 
Abdominal pain 383 (10.5) 316 (1.9) 699 (21.7)  
Total: Abdominal pain 1,910 (52.5) 1,312 (8.0) 3,222 (100) 
9.2.2.2.1 Jaundice  
There was strong evidence of an association between patient status (case or 
control) and the recording style that identified attendees for jaundice (χ2 test, 
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p<0.0001) (Figure 9.11). Coded jaundice records identified a greater 
proportion of the cases (1,102/ 1,565 cases = 70%) than of the controls (10/31 
= 32%) who had attended for jaundice in the analysis period.  
Figure 9.11  The number of patients who attended at least once in the analysis period for 
jaundice where the event was recorded using Read codes (dark orange) or text-only (light 
orange) in pancreatic cancer cases (n = 1,565/3,635) and controls (n = 31/21,718) separately 
 
The association between recording style of jaundice and patient status was 
similar in men as in women. In men, coding identified 533/769 (69.3%) of the 
cases and 6/16 (37.5%) of the controls (χ2 test, p<0.0001). Similarly, in women, 
coding identified 569/796 (71.5%) of the cases and 4/15 (26.7%) of the controls 
(χ2 test, p<0.0001).  
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9.2.2.2.2 Abdominal pain 
There was also strong evidence of an association between patient status and 
recording style used to identify attendees for abdominal pain (χ2 test, p<0.001). 
Coded abdominal pain records predominated overall, but identified a slightly 
greater proportion of the cases (1,527/1,910 = 80%) than of the controls 
(996/1,312 = 76%) who had attended for abdominal pain during the analysis 
period (see Figure 9.12). Despite its statistical significance, the size of the 
preference was very small and of questionable clinical relevance.  
Figure 9.12 The number of patients who attended at least once in the analysis period for 
abdominal pain where the event was recorded using Read codes (dark green) or text-only (light 
green) in pancreatic cancer cases (n = 1,910/3,635) and controls (n = 1,312/16,459) separately 
 
In men, there was no association between recording style of abdominal pain 
and patient status (χ2 test, p = 0.3). Coding identified 750/927 (80.9%) of the 
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male cases and 431/548 (78.7%) of the male controls. In contrast, there was 
evidence of an association between recording style of abdominal pain and 
patient status in the women (χ2 test, p<0.05). Coding identified a slightly greater 
proportion of female cases with at least one episode of abdominal pain 
(777/983 = 79.0%), compared with 565/764 (74.0%) of the female controls. 
Again, despite its statistical significance, the size of the preference was very 
small and of questionable clinical relevance.  
9.2.3 Association between recording style and clinical context 
of symptom presentation  
In this analysis, the aim was to compare recording styles between cancer 
datasets to address research question 4: ‘Does the recording style vary with the 
clinical context of presentation of a symptom?’ (see Section 5). 
Three symptom thesauri of Read codes – one each for haematuria, jaundice 
and abdominal pain – were used to compare recording styles (coded or text-
only) between bladder and pancreatic cancer datasets (see Section 6.8 for 
methods). For haematuria and jaundice, respectively, I used the symptom 
thesauri from the bladder and pancreatic cancer studies. For abdominal pain, I 
used a ‘generic’ thesaurus consisting of a comprehensive list of all forms of 
abdominal pain rather than either of the bespoke thesauri created in the original 
studies (see Appendix 4: Symptom thesauri). For this reason, in this section the 
numbers of patients identified as attending for abdominal pain vary from those 
reported in the original studies. 
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9.2.3.1 General recording style 
The numbers of patients who attended at least once in the analysis period for 
each of the features is reported in Table 9.8 and in Figure 9.13, grouped by 
recording style.a  
Table 9.8 The effect of the context of presentation on symptom recording style for alarm and 
non-alarm symptoms. The same symptom thesauri were used to obtain data from both datasets 
Symptom Cancer site Number (% of total) of patients attending 
at least once where the events were 
recorded using: 
Read code, 
n (%) 
Text-only, n 
(%) 
Total, n (%) 
Visible 
haematuria 
Bladder 2,787 (80) 696 (20) 3,483 (100) 
Pancreas 199 (58) 142 (42) 341 (100) 
Jaundice Bladder 40 (47) 45 (53) 85 (100) 
Pancreas 1,112 (70) 484 (30) 1,596 (100) 
Abdominal 
pain 
Bladder 1,431 (71) 584 (29) 2,015 (100) 
Pancreas 2,195 (75) 720 (25) 2,915 (100) 
                                            
a
 Remember, that text-only is reserved for patients whose attendances were never recorded 
using a code. 
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Figure 9.13 Symptom recording styles for alarm and non-alarm symptoms in the bladder and 
pancreatic cancer datasets. The same symptom thesauri were used to obtain data from both 
datasets 
 
9.2.3.1.1 Visible haematuria 
Coded visible haematuria records identified a greater proportion of 
attendees compared with text-only visible haematuria records in both cancer 
datasets (Table 9.8 and Figure 9.13). While this preference was very strong in 
the bladder cancer dataset (2,787/3,483 = 80%), it was marginal in the 
pancreatic cancer dataset (199/341 = 58%).  
9.2.3.1.2 Jaundice 
In the pancreatic cancer dataset, coded jaundice records (1,112/1,596 = 
70%) identified more than twice the number of attendees for jaundice compared 
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with text-only jaundice records (484/1,596 = 30%). In the bladder cancer 
dataset, in contrast, coded jaundice (40/85 = 47%) and text-only jaundice 
records (45/85 = 53%) identified similar proportions of attendees.   
9.2.3.1.3 Abdominal pain 
Coded abdominal pain records identified the majority of attendees with this 
symptom in both datasets; namely 1,431 out of 2,015 attendees (71%) in the 
bladder, and 2,195/2,915 (75%) attendees in the pancreatic, cancer dataset.  
9.2.3.2 Association between recording style and case/control status for 
rare and common symptoms 
The results in this section relate to research questions 2: ‘Are studies of coded 
data vulnerable to bias arising from the differential use of text and codes 
between comparison groups?’ and 4: ‘Does the recording style vary with the 
clinical context of presentation of a symptom?’ (see Section 5). 
The association between patient status and recording style reported in Section 
9.2.2 did not hold when the context of symptom presentation was changed. The 
propensity for coded records to identify a greater proportion of cases than 
controls attending for alarm symptoms only occurred when the symptoms were 
presented in the context of their associated cancer.  
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9.2.3.2.1 Visible haematuria 
To recap, previously reported results (Section 9.2.3.1.1) indicated that, at the 
overall patient level, coded visible haematuria records identify a greater 
proportion of the attendees for this symptom compared with text-only visible 
haematuria records. This effect was more marked in the bladder (2,787/3,483 
= 80%) than in the pancreatic (199/341 = 58%) cancer dataset (see Figure 9.13 
and Table 9.8).  
My analysis in the bladder cancer dataset also showed that, at the level of 
cases and controls, coding identified a greater proportion of cases with visible 
haematuria compared with controls (see Figure 9.5). In contrast, in the 
pancreatic cancer dataset, there was marginal evidence of a reversal of the 
bias, in that coded visible haematuria records identified a greater 
proportion of controls than cases with a history of visible haematuria (χ2 test, p= 
0.05) (Figure 9.14).  
Looking at the pancreatic cancer controls first, the pattern was similar to that 
observed in the bladder cancer dataset. Coded visible haematuria 
records identified 147 of 238 controls (63%) with a history of the symptom, 
whereas text-only visible haematuria records identified only 91 of 238 (38%) 
attendees (see Table 9.9 and Figure 9.14). Therefore, this reversal in bias was 
driven wholly by a change in recording pattern for cases. Indeed, coded 
visible haematuria records identified a similar proportion of the cases 
(51/103=50%) as did the text-only visible haematuria records (52/103=50%).  
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Table 9.9 Numbers of patients presenting at least once with visible haematuria in the analysis 
period in the bladder and pancreatic datasets. The recording style (Read code or text only) is 
reported for cases and controls separately. The same symptom thesaurus was used for both 
cancer sites 
Cancer 
site 
Patient 
status 
Number (%) of total) of patients attending at least 
once estimated using: 
Visible 
haematuria 
Visible 
haematuria 
Visible 
haematuria 
Bladder*** Control 196 (58) 140 (42) 336 (100) 
Case 2,591 (82) 556 (18) 3,147 
(100) 
Total 2,787 (80) 696 (20) 3,483 
(100) 
Pancreas* Control 147 (62) 91 (38) 238 (100) 
Case 52 (50) 51 (50) 103 (100) 
Total 199 (58) 142 (42) 341 (100) 
***p< 0.0001, *p= 0.05; χ2 test of the null hypothesis that there is no association between patient status and recording 
style. 
Figure 9.14 Visible haematuria recording style in cases and controls compared in the 
contexts of bladder (left) and pancreatic (right) cancers  
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9.2.3.2.2 Jaundice 
As reported in Section 9.2.3.1.2, coded jaundice records (1,112/1,596 = 70%) 
identified a greater proportion of attendees for this symptom compared with 
text-only jaundice records (484/1,596 = 30%). This pattern was not apparent in 
the bladder cancer dataset (jaundice: 40/85 = 47%, jaundice: 45/85 = 53%). 
The propensity for coded records to identify attendees was more marked in 
patients who later transpired to have pancreatic cancer compared with controls 
(1,102/1,565 = 70% in cases vs 10/31 = 32% in controls; χ2 test, p<0.0001) 
(see Section 9.2.2.2.1, see also Table 9.10 and Figure 9.15).  
In contrast, in the bladder cancer dataset, there was marginal evidence 
suggesting a reversal of this bias. Coded jaundice records identified a greater 
proportion of controls than cases with a history of the symptom, although it 
should be noted that the numbers are small (χ2 test, p = 0.05).   
The reversal in bias was driven by both a loss of overall tendency for either 
recording style in the controls (jaundice: 30/64 = 47% vs jaundice: 34/64 = 
53%) and a loss of the tendency for coded jaundice records to identify cases 
(6/21 = 29%).  
The recording style patterns were not the same in the control groups for the 
bladder and pancreatic cancer datasets, which may be accounted for by the 
small numbers of these patients attending for jaundice.  
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Table 9.10 Numbers of patients presenting at least once with jaundice in the analysis period in 
the bladder and pancreatic datasets. The recording style (Read code or text only) is reported for 
cases and controls separately. The same symptom thesauri were used for both cancer sites 
Cancer site Patient 
status 
Number of patients attending at least once 
estimated using: 
Jaundice  Jaundice Jaundice 
Bladder* Control 34 (53) 30 (47) 64 (100) 
Case 6 (29) 15 (71) 21 (100) 
Total 40 (47) 45 (53) 85 (100) 
Pancreas*** Control 10 (32) 21 (68) 31 (100) 
Case 1,102 (70) 463 (30) 1,565 (100) 
Total 1,112 (70) 484 (30) 1,596 (100) 
***p< 0.0001, *p= 0.05; χ2 test of the null hypothesis that there is no association between patient status and recording 
style. 
Figure 9.15 Jaundice recording style in cases and controls compared in the contexts of bladder 
(left) and pancreatic (right) cancers  
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9.2.3.2.3 Abdominal pain 
As reported in Section 9.2.3.1.3, coded abdominal pain records identified a 
greater proportion of attendees for this symptom compared with text-only 
abdominal pain records, an effect that was similar in the bladder (1,431/2,015 
= 71%) and pancreatic (2,195/2,915 = 75%) cancer datasets.  
As described above (see Section 9.2.3.1.3), this effect was slightly more 
marked in patients who later transpired to have pancreatic cancer (1,527/1,910 
= 80%) compared with controls (996/1,312 = 76%) (χ2 test, p<0.001) (see Table 
9.11 and Figure 9.16).  
In contrast, there was no association between patient status and the recording 
style identifying attendees for abdominal pain in the bladder cancer dataset (χ2 
test, p=0.4). Coded abdominal pain records identified similar proportions of 
cases (419/600 = 70%) and controls (1,012/1,415 = 72%) (see Table 9.11 and 
Figure 9.16).  
The recording style pattern for abdominal pain was similar in the pancreatic and 
bladder cancer control groups – mirroring the results for visible haematuria 
recording style. 
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Table 9.11 Numbers of patients presenting at least once with abdominal pain in the analysis 
period in the bladder and pancreatic datasets. The recording style (code or text only) is reported 
for cases and controls separately. The same symptom thesaurus was used for both cancer sites 
Cancer site Patient 
status 
Number of patients attending at least once estimated 
using:  
Abdominal 
pain 
Abdominal 
pain 
Abdominal pain 
Bladder† Control 1,012 (72) 403 (28) 1,415 (100) 
Case 419 (70) 181 (30) 600 (100) 
Total  1,431 (71) 584 (29) 2,015 (100) 
Pancreas*** Control  803 (71) 323 (29) 1,126 (100) 
Case  1,392 (78) 397 (22) 1,789 (100) 
Total 2,195 (75) 720 (25) 2,915 (100) 
***p< 0.001, †p= 0.4; χ2 test of the null hypothesis: there is no association between patient status and recording style. 
Figure 9.16 Abdominal pain recording style in cases and controls compared in the contexts of 
pancreatic and bladder cancers. The same symptom thesaurus was used in both datasets  
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10 Results: effect of recording style bias on risk 
estimates for cancer 
10.1 Bladder cancer 
10.1.1 Estimates of positive predictive value and positive 
likelihood ratio from coded records 
The features of bladder cancer presentation in primary care were identified in 
the original study extended by my PhD. The numbers of cases and controls with 
coded records of attendance for each of these features is reported in Table 
10.1. Also presented are the positive likelihood ratio and positive predictive 
value (PPV) for bladder cancer.a The results are from my re-construction and 
re-analysis, and numbers of patients and positive likelihood ratios largely 
matchedb those of the original study.4 The positive predictive values for the 
                                            
a
 As defined before the International Classification of Disease (ICD) for Oncology created 
separate diagnostic codes for carcinoma in situ of bladder (D09.0) and neoplasm of uncertain 
behaviour of bladder (D41.4), removing them from code C67 (bladder cancer). 
b
 The discrepancies in numbers of patients were essentially trivial, and reflected very slight 
differences in definitions of some variables, such as that for raised inflammatory markers. 
Furthermore, I assumed that two similar codes on the same day (e.g. Read codes K197300 
‘Frank haematuria’ and K197199 ‘Painful haematuria’) reflected a single event. The positive 
predictive values reported in the original study are lower than those reported in my PhD 
because they were estimated using a prior odds for the post-1998 definition of bladder cancer. 
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post-1998 definition of bladder cancer are given in an appendix (see Appendix 
6: Risk estimates for the post-1998 definition of bladder cancer (C67)). 
In terms of frequency of attendance, visible haematuria was the most 
notable feature, with coded records indicating that 2,591/4,915 (52.7%) of cases 
attended at least once in the analysis period. Urinary tract infection 
was the next most significant feature (in 835/4,915 = 17.0% of cases), followed 
by raised creatinine (in 660/4,915 = 13.4% of cases) and then dysuria 
(in 444/4,915 = 9.0% of cases). Non-visible haematuria was recorded as 
a code in only 127 (2.6%) of cases and 26 (0.1%) of controls (data not shown). 
This feature therefore failed to meet the 5% threshold for inclusion in univariable 
analysis (the justification for setting this threshold at 5% is given in Section 
6.12.1). 
Of all the features, visible haematuria was the most strongly predictive of 
bladder cancer, associated with a 3.98% (3.47–4.571%) chance of the disease. 
Indeed, patients with bladder cancer were 58.41 (50.69–67.32) times more 
likely to have visible haematuria compared with controls. However, in all age 
groups combined, the positive likelihood ratio values and PPVs for all other 
features, when considered in isolation, were unremarkable.  
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Table 10.1 The positive likelihood ratio and PPV for bladder cancer (pre-1998 definition) in 
patients aged ≥40 years presenting with clinical features associated with the disease (codes) 
Feature of 
bladder cancer 
Number of patients 
attending at least once: 
Positive 
likelihood 
ratio (95% CI) 
PPV (%) 
(95% CI)ab 
Cases n (% 
of n = 4,915 
cases) 
Controls, n 
(% of n = 
21,718 
controls) 
Abdominal 
pain 
358  
(7.3) 
784  
(3.6) 
2.01  
(1.79–2.28) 
0.14  
(0.13–0.16) 
Constipation 286  
(5.8) 
708  
(3.3) 
1.78  
(1.56–2.04) 
0.13  
(0.11–0.14) 
Visible 
haematuria 
2,591  
(52.7) 
196  
(0.9) 
58.41c  
(50.69–67.32) 
3.98  
(3.47–4.57) 
Dysuria 444  
(9.0) 
209  
(1.0) 
9.39  
(7.99–11.03) 
0.66  
(0.56–0.78) 
Urinary 
tract 
infection 
835  
(17.0) 
705  
(3.2) 
5.23  
(4.76–5.76) 
0.37  
(0.34–0.41) 
Raised 
inflammatory 
markers 
332  
(6.7) 
809  
(3.7) 
1.81  
(1.58–2.06) 
0.13  
(0.11–0.15) 
High white 
cell count 
251  
(5.1) 
401  
(1.8) 
2.75  
(2.36–3.22) 
0.19  
(0.17–0.23) 
Raised 
creatinine 
660  
(13.4) 
1,668  
(7.7) 
1.75  
(1.61–1.90) 
0.12  
(0.11–0.13) 
a 
PPV values are adjusted for the consulting population (see Section 6.12.3.5). 
b
 PPV values estimated using Bayes’ Theorem (see Section 6.12.3.5), assuming a prior odds of 0.000646 
based on 2008 UK national incidence data. See Section 15.5.1 for a worked example of how to calculate 
PPV using Bayes’ theorem. 
c
 Positive likelihood ratio >10. 
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10.1.2 Effect of supplementation with text-only records on 
positive likelihood ratio and PPV  
Detailed analysis of GPs’ choice of recording style was presented in Section 9 
(see Table 9.6). This section focuses on whether supplementing codes with text 
records alters the risk estimates for bladder cancer in patients with haematuria 
or abdominal pain. This relates to research questions 2 (Are studies of coded 
data vulnerable to bias arising from the differential use of text and codes 
between comparison groups?) and 5 (Do the text data provide additional value 
to coded data?) (see Section 5). 
The numbers of patients attending at least once for abdominal pain or 
haematuria obtained from coded records in the original study were updated with 
information from the text. These revised binary abdominal pain, visible 
haematuria and non-visible haematuria variables were used to re-
examine the predictive power of these symptoms for bladder cancer (Table 
10.2). Where earlier results suggested that the frequency of text-only records 
was different in men than in women, revised risk estimates were calculated for 
men and women separately.  
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Table 10.2 Positive likelihood ratio and PPV for bladder cancer in patients of all ages presenting 
with abdominal pain, visible or non-visible haematuria estimated from coded and from coded 
plus text-only records 
Clinical 
feature and 
recording 
style  
Number of patients 
attending at least once: Positive 
likelihood 
ratio 
(95% CI) 
PPV (%) 
(95% CI) a 
 
Cases n 
(% of n = 
4,915 
cases) 
Controls, n 
(% of n = 
21,718 
controls) 
  
Abdominal 
pain  
358  
(7.3) 
784  
(3.6) 
2.02   
(1.79–2.28) 
0.14  
(0.13–0.16) 
Abdominal 
pain 
542 
(11.0) 
1,217 
(5.6) 
1.97   
(1.79–2.17) 
0.14   
(0.13–0.15) 
Visible 
haematuria
 
 
2,591  
(52.7) 
196  
(0.9%) 
58.41   
(50.69–67.32) 
 3.98   
(3.47–4.57) 
Visible 
haematuria 
3,147 
(64.0) 
336  
(1.5) 
41.39   
(37.14–46.11) 
2.85 
(2.57–3.17) 
Non-
visible 
haematuria
 
 
127  
(2.6) 
26  
(0.1) 
n/a n/a 
Non-
visible 
haematuria 
312  
(6.3) 
60  
(0.3) 
22.98   
(17.46–30.24) 
1.60   
(1.22–2.10) 
 
a
 PPV values are adjusted for the consulting population (see Section 6.12.3.5). PPV values 
estimated using Bayes’ Theorem (see Section 6.12.3.5), assuming a prior odds of 0.000646 
based on 2008 UK national incidence data. 
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10.1.2.1 Abdominal pain 
The 95% confidence intervals suggested that supplementing coded abdominal 
pain records with text-only records did not alter the positive likelihood ratio 
(abdominal pain: 2.02, 95% CI: 1.79–2.28 vs abdominal pain: 1.97, 95% 
CI: 1.79–2.17) or the PPV (abdominal pain:   0.14, 95% CI: 0.13–0.15 vs 
abdominal pain:  0.14, 95% CI: 0.13–0.15) (Table 10.2). Risk estimates 
were similar in men and women, and were unaffected by addition of text-only 
records (data not reported).  
10.1.2.2 Visible haematuria 
In contrast, supplementing the coded visible haematuria record with text-
only records reduced the positive likelihood ratio from 58.41 (95% CI: 50.69–
67.32) (visible haematuria) to 41.39 (95% CI: 37.14–46.11) (visible 
haematuria). Similarly, the PPV fell from 3.98% (95% CI: 3.47–4.57%) 
(visible haematuria) to 2.85% (95% CI: 2.57–3.17%) (visible 
haematuria) (Table 10.2).  
The risk of bladder cancer associated with visible haematuria is reported for 
men and women separately in Table 10.3. The estimates of PPV in men and in 
women from coded records were greater than those estimated for men and 
women combined. For men, this was due to their greater prior odds for bladder 
cancer (0.001002 for men compared with 0.000646 for men and women 
combined). For women, this was due to their relatively high likelihood ratio 
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(155.14, 95% CI: 98.67–243.92 in women compared with 58.41, 95% CI: 
50.69–67.32 for all patients combined). 
Table 10.3 Positive likelihood ratio and PPV for bladder cancer in men and women separately, 
aged over 40 years, presenting with visible haematuria estimated from coded and from coded 
plus text-only records 
Visible haematuria 
recording style  
Number (%) of 
patients attending 
at least once: 
Positive 
likelihood 
ratio 
(95% CI) 
PPV (%) 
(95% CI) a 
Cases, 
n (% of 
cases) 
Controls, 
n (% of 
controls) 
Men (n=3,563 cases, n=15,452 controls) 
Visible 
haematuria
 
 
1,955 
(54.9) 
177 
(1.1) 
47.90 
(41.25–55.62) 
5.14 
(4.46–5.93) 
Visible 
haematuria 
2,356 
(66.1) 
279 
(1.8) 
36.62 
(32.53–41.23) 
3.97 
(3.54–4.46) 
Women (n=1,352 cases, n=6,266 controls) 
Visible 
haematuria
 
 
636 
(47.0) 
19 
(0.3) 
155.14 
(98.67–243.92) 
5.10 
(3.30–7.80) 
Visible 
haematuria 
791 
(58.5) 
57 
(0.9) 
64.32 
(49.48–83.60) 
2.17 
(1.68–2.81) 
a
 PPV values are adjusted for the consulting population (see Section 6.12.3.5). PPV values 
estimated using Bayes’ Theorem (see Section 6.12.3.5), assuming prior odds of 0.001002 for 
men and of 0.000323 for women, based on 2008 UK national incidence data. 
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Looking at the 95% confidence intervals, addition of text-only records of 
attendance for visible haematuria reduced the risk estimates both in men and 
women. However, the extent of the correction brought about by addition of text-
only records was much more marked in the women than in the men. The PPV 
from coded records in men was 5.14% (95% CI: 4.46–5.93%), and addition of 
text-only records reduced the PPV to 3.97% (95% CI: 3.54–4.46%). In women, 
however, the PPV from coded records was 5.10% (95% CI: 3.30–7.80%), and 
was reduced to 2.17% (95% CI: 1.68–2.81%) after addition of text-only records.  
10.1.2.3 Non-visible haematuria 
The probability of bladder cancer in patients according to non-visible 
haematuria was 1.60% (95% CI: 1.22–2.10%), and cases were approximately 
23 times more likely to experience non-visible haematuria than controls 
(likelihood ratio 22.98, 95% CI: 17.46–30.24) (Table 10.2). There were no 
comparison data from the original study, as non-visible haematuria did not meet 
the 5% threshold for inclusion in analysis. 
10.1.3 Estimates of odds ratios in univariable analyses 
from coded records 
The frequency of attendance for each feature included in the final model of the 
original study4 is reported in Table 10.4 along with its odds ratio for disease in 
univariable analysis. The results are from my re-construction and re-analysis, 
and largely matched those of the original study.  
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Table 10.4 Frequency of attendance for features included in the final model of the original 
study,
4
 plus the univariable analysis  
Feature of 
bladder cancer 
n
a
 Number of participants  Odds ratio in 
univariable 
analysis (95% 
CI) 
p
b
 
Cases, n (% of 
n = 4,915 
cases) 
Controls, n (% 
of n = 21,718 
controls) 
Abdominal pain 0 4,557 (92.7) 20,934 (96.4) – – 
≥1 358 (7.3) 784 (3.6) 2.1 (1.9–2.4) 0.0001 
Constipation 0 4,629 (94.2) 21,010 (96.7) – – 
≥1 286 (5.8) 708 (3.3) 1.9 (1.6–2.2) 0.0001 
Visible 
haematuria
 c
 
0 2,324 (47.3) 21,522 (99.1) – – 
1 1,301 (26.5) 133 (0.6) 100.5 (78.1 – 
129.3) 
0.0001 
2 721 (14.7) 39 (0.2) 240.4 (157.8–
366.5) 
0.0001 
≥3 568 (11.6) 24 (0.11) 308.6 (186.4–
510.9) 
0.0001 
Dysuria 0 4,471 (91.0) 21,509 (99.0) – – 
≥1 444 (9.0) 209 (1.0) 10.6 (8.9–12.6) 0.0001 
Urinary tract 
infection 
d
 
0 4,080 (83.0) 21,013 (96.8) – – 
1 511 (10.4) 503 (2.3) 5.9 (5.1–6.7) 0.0001 
≥2 324 (6.6) 202 (0.9) 10.1 (8.3–12.3) 0.0001 
Raised 
inflammatory 
markers 
0 4,583 (93.3) 20,909 (96.3) – – 
≥1 332 (6.7) 809 (3.7) 2.0 (1.8–2.3) 0.0001 
High white 
cell count 
0 4,664 (94.9) 21,317 (98.2) – – 
≥1 251 (5.1) 401 (1.8) 3.1 (2.6–3.6) 0.0001 
Raised 
creatinine 
0 4,255 (86.6) 20,050 (92.3) – – 
≥1 660 (13.4) 1,668 (7.7) 2.1 (1.9–2.3) 0.0001 
 
Notes: 95% CI = 95% confidence interval. 
a 
n is the number of times the patient attended for the feature in the analysis period. 
b
 Wald test of the null hypothesis that the odds ratio is 1. 
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c 
Strong evidence that the association between visible haematuria and bladder cancer varied with 
number of attendances (χ
2
= 1,794.5, 3 d.f., p<0.0001). 
d
 Strong evidence that the association between urinary tract infection and bladder cancer varied 
with number of attendances (χ2= 22.6, 1 d.f., p<0.0001). 
10.1.3.1 Strength of association with bladder cancer 
Visible haematuria was the most significant feature in terms of strength of 
association with bladder cancer in univariable analysis. The odds of bladder 
cancer in patients who attended only once with visible haematuria was 100.5 
times (95% CI: 78.1–129.3, Wald test p<0.0001) higher than in patients for 
whom there was no evidence from codes that they had attended for this 
symptom. Dysuria had the second strongest association with bladder cancer 
(odds ratio = 10.6, 95% CI: 8.9–12.6 for at least one presentation, p<0.0001), 
followed by urinary tract infection (odds ratio = 5.9, 95% CI: 5.1–6.7 
for a single attendance, p<0.0001). Abdominal pain, constipation, a 
high white cell count, a high creatinine level or raised 
inflammatory markers were all less strongly associated with bladder 
cancer, with odds ratios at or below 3 for at least one attendance.  
10.1.3.2 The significance of re-attendance for a feature 
There was strong evidence that re-attendance for visible haematuria was 
significantly associated with cancer. The association between bladder cancer 
and visible haematuria varied with the number of attendances in the 
analysis period (χ2=1,794.5, 3 d.f., Wald test p<0.0001), with further episodes 
increasing the odds of disease. Similarly, the odds of bladder cancer increased 
with repeat attendance for urinary tract infection (χ2=22.6, 1 d.f., 
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p<0.0001). The significance of re-attendance for abdominal pain, 
constipation or dysuria could not be assessed, as too few patients 
attended more than once in the analysis period. Similarly, GPs did not re-order 
tests in enough patients for inflammatory markers, creatinine or a 
white cell count to allow assessment of the significance of repeat testing.  
10.1.4 Effect on odds ratios in univariable analyses of 
supplementation with text-only records  
The odds ratios for bladder cancer after addition of text-only records of 
attendance for non-visible and visible haematuria and for abdominal pain are 
reported below.  
10.1.4.1 Non-visible haematuria 
Descriptors in the text allowed separate identification of visible and non-visible 
forms of haematuria, enabling re-assessment of the frequency of attendance for 
the latter (see Table 10.5). As described above, there were insufficient coded 
non-visible haematuria records to meet the threshold for inclusion in 
univariable analysis. Similarly, text-only non-visible haematuria records failed 
the 5% threshold for inclusion in univariable analysis, amounting to 184 of 4,915 
(3.8%) of cases. Despite this, non-visible haematuria and non-visible 
haematuria were both significantly associated with bladder cancer (Table 
10.5), with respective odds ratios of 28.4 (95% CI 17.5–46.1, Wald test, 
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p<0.0001) and 27.7 (95% CI: 18.8–40.8) (p<0.0001) for at least one 
attendance.  
Table 10.5 Numbers of cases and controls attending with non-visible haematuria in the analysis 
period, according to the recording style, and independent association with bladder cancer in 
univariable analysis 
Recording 
style  a 
n b Number (%) of patients 
presenting with non-
visible haematuria 
Odds ratio 
(95% CI) in 
univariable 
analysis 
 p 
value c 
Cases (n 
= 4,915) 
Controls (n = 
21,718) 
Non-visible 
haematuria 
0 4,788 
(97.4) 
21,692 (99.9) – – 
≥1 127 (2.6) 26 (0.1) 28.4 (17.5–
46.1)d 
0.0001 
Non-visible 
haematuria 
0 4,730 
(96.2) 
21,684 (99.8) – – 
≥1 185 (3.8) 34 (0.2) 27.7 (18.8–
40.8)d 
0.0001 
Non-visible 
haematuria 
0 4,603 
(93.6) 
21,658 (99.7) – – 
≥1 312 (6.4) 60 (0.3) 28.0 (20.7–
37.9) 
0.0001 
Notes: 
a 
Non-visible haematuria – some or all attendances recorded as a code; Non-visible 
haematuria  – all attendances recorded as text only; Non-visible haematuria – total, i.e. 
coded record supplemented with text-only records. 
b
 Number of attendances in the analysis period.  
c
 Wald test that the odds ratio is 1. 
d 
No evidence that association between non-visible haematuria and bladder cancer varies with recording 
style (χ2 = 0.01, 1 d.f., p = 0.936). 
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There was no evidence that the association between bladder cancer and non-
visible haematuria varied with recording style (Wald test, χ2 = 0.01, 1 d.f.. p = 
0.936).  
Supplementation with text-only records increased the total number of patients 
identified as attending at least once for non-visible haematuria to 312 (6.4% of 
4,915 cases). Thus, the 5% threshold was exceeded, permitting estimation of 
the odds ratio in univariable analysis (OR 28.0, 95% CI: 20.7–37.9, p<0.0001). 
Therefore, non-visible haematuria was later included as an explanatory 
variable in multivariable analysis. 
10.1.4.2 Visible haematuria 
There was also significant recording of visible haematuria in text-only records 
(Table 10.6), easily exceeding the 5% threshold for inclusion in univariable 
analysis. Of the 4,915 cases, 556 (11.3%) attended at least once where this 
was never documented as a code. The text-only records indicated that patients 
did re-attend for visible haematuria; however, the numbers were too low to 
permit meaningful analysis of its significance in terms of association with 
bladder cancer.   
In contrast with non-visible haematuria, there was strong evidence that the 
association between visible haematuria and bladder cancer varied with the 
recording style (χ2 = 75.8, 3 d.f., p<0.0001). The odds ratio for bladder cancer 
from visible haematuria records was 21.0 (95% CI: 17.1–25.6) (Wald test, 
p<0.0001) for at least one attendance. However, it was 100.5 (95% CI: 78.1–
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129.3) for a single attendance according to the coded visible haematuria 
records.  
Table 10.6 Numbers of cases and controls attending with visible haematuria in the analysis 
period, according to the recording style, and independent association with bladder cancer in 
univariable analysis 
Recording 
style a 
na
b Number (%) of patients 
attending: 
Odds ratio (95% 
CI) 
p 
valuec 
Cases  
(n = 4,915) 
Controls (n 
= 21,718) 
Visible 
haematuria 
0 2,324 (47.3) 21,522 (99.1) – – 
1 1,301 (26.5) 133 (0.6) 100.5 (78.1–129.3) 0.0001 
2 721 (14.7) 39 (0.2) 240.4 (157.8–366.5) 0.0001 
≥3 569 (11.6) 24 (0.11) 308.6 (186.4–510.9) 0.0001 
Visible 
haematuria 
0 4,359 (88.7) 21,548 (99.4) – – 
≥1 556 (11.3) 140 (0.6) 21.0 (17.1–25.6) 0.0001 
Visible 
haematuria 
0 1,768 (36.0) 21,382 (98.5) – – 
1 1,306 (26.6) 229 (1.1) 75.9 (60.9–94.6) 0.0001 
2 910 (18.5) 64 (0.3) 223.3 (156.4–318.7) 0.0001 
≥3 931 (18.9) 43 (0.2) 473.6 (306.2–732.3) 0.0001 
a
 Strong evidence that the association between bladder cancer and visible haematuria varied with the 
recording style (χ2= 75.8, 3 d.f., p<0.0001).
  
b 
Number of attendances in the analysis period (the maximum number of attendances examined was that 
level containing no fewer than 5% of cases). 
c
Wald test of the null hypothesis that the OR is 1. 
The odds ratio for the combined variable   visible haematuria was 75.9 
(95% CI: 60.9–94.6, p<0.0001) for a single attendance. The effect of re-
attendance with visible haematuria was highly significant (χ2= 77.97, 2 d.f, 
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p<0.0001), with the odds ratio rising to 473.6 (95% CI: 306.2–732.3, p<0.0001) 
for three or more attendances.      
10.1.4.3 Abdominal pain 
There was a significant amount of text-only abdominal pain recording (see 
Table 10.7), which identified that 189 of the 4,915 (3.8%) cases attended at 
least once in the analysis period. However, the numbers were insufficient for it 
to meet the 5% threshold for inclusion in univariable analysis. Despite this, 
abdominal pain was independently associated with bladder cancer, with an 
odds ratio of 2.1 (1.7–2.5) (Wald test, p<0.0001).  
There was no evidence that the association between bladder cancer and 
abdominal pain varied with the recording style (χ2= 1.0, 1 d.f., p = 0.99). The 
odds ratios in univariable analysis were similar for abdominal pain (2.1, 
95% CI: 1.9–2.4, p<0.0001), abdominal pain (2.1, 95% CI: 1.7–2.5, 
p<0.0001) and the combined abdominal pain (2.2, 95% CI: 2.0–2.4, 
p<0.0001) variables. The significance of re-attendance with abdominal pain in 
the analysis period could not be assessed, owing to small numbers. 
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Table 10.7 Frequency of attendance for abdominal pain in the analysis period in cases and 
controls grouped by recording style, and independent association with bladder cancer in 
univariable analysis 
Recording 
stylea d 
na
b Number (%) of patients 
attending for abdominal pain  
Odds ratio 
(95% CI) 
p 
valuec 
Cases (n = 
4,915) 
Controls (n = 
21,718) 
Abdominal 
pain 
0 4,557 (92.7) 20,934 (96.4) – – 
≥1 358 (7.3) 784 (3.6) 2.1 (1.9–2.4) 0.0001 
Abdominal 
pain 
0 4,726 (96.2) 21,287 (98.0) – – 
≥1 189 (3.8) 431 (2.0) 2.1 (1.7–2.5) 0.0001 
Abdominal 
pain 
0 4,368 (88.9) 20,503 (94.4) – – 
≥1 547 (11.1) 1,215 (5.6) 2.2 (2.0–2.4) 0.0001 
Notes: 
a 
Abdominal pain – some or all attendances recorded as a code; Abdominal pain  – all 
attendances recorded as text only; Abdominal pain  – total, i.e. coded record supplemented with 
text-only records. 
b
 Number of attendances in the analysis period.  
c
 Wald test that the odds ratio is 1. 
d 
No evidence that the association between abdominal pain and bladder cancer varies with recording style 
(χ2 = 1.0, 1 d.f., p = 0.99). 
10.1.5 Multivariable analyses  
10.1.5.1 The basic model estimated using coded records 
The multivariable conditional logistic regression analysis of the presenting 
features of bladder cancer, as identified in the original study,4 was re-run using 
solely code-based variables to replicate the basic model (see Table 10.8).  
Visible haematuria was the feature most strongly associated with bladder 
cancer. According to the coded records, the odds of bladder cancer were 107.5 
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(95% CI: 82.9–139.3) (Wald test, p<0.0001) times higher in patients who 
attended once with the symptom compared with those who never attended. The 
strength of association with bladder cancer varied with further episodes of 
visible haematuria (χ2 = 25.01, 2 d.f., p<0.0001), rising to an odds ratio of 
345.7 (95% CI: 198.6–601.7) (p<0.0001) for three or more attendances in the 
analysis period (Table 10.8).  
Of the remaining features of bladder cancer, dysuria had the strongest 
association with bladder cancer, with an odds ratio of 6.7 (95% CI: 5.2–8.7) 
(Wald test, p<0.0001). Re-attendance for urinary tract infection 
increased the odds of bladder cancer, from 4.4 (95% CI: 3.6–5.3) to 6.8 (95% 
CI: 5.1–9.1) (χ2 = 5.7, 1 d.f., p<0.05) (see Table 10.8).  
Abdominal pain was also associated with bladder cancer, albeit less strongly 
than visible haematuria. The odds ratio for patients attending at least 
once with abdominal pain was 2.0 (95% CI: 1.7–2.5) (Wald test, p<0.0001) 
(Table 10.8). Insufficient numbers of patients re-attended with the symptom to 
investigate the significance of further episodes of abdominal pain. 
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Table 10.8 Frequency of attendance for features of bladder cancer in the year before analysis 
and odds ratio in multivariable conditional logistic regression analysis; estimates were obtained 
from coded records 
Feature of bladder 
cancer 
n
a
 Number of: Odds ratio (95% 
CI) 
Cases, n 
(% of n = 
4,915 cases) 
Controls, n 
(% of n = 
21,718 
controls) 
S
y
m
p
to
m
s
 
Abdominal 
pain 
0 4,557 (92.7) 20,934 (96.4) – 
≥1 358 (7.3) 784 (3.6) 2.0 (1.7–2.5)*** 
Constipation 0 4,629 (94.2) 21,010 (96.7) – 
≥1 286 (5.8) 708 (3.3) 1.5 (1.2–1.8)** 
Visible 
haematuria  
0 2,324 (47.3) 21,522 (99.1) – 
1 1,301 (26.5) 133 (0.6) 107.5  
(82.9–139.3)*** 
2 721 (14.7) 39 (0.2) 275.0  
(176.6–428.2)*** 
≥3 569 (11.6) 24 (0.1) 345.7  
(198.6–601.7)*** 
Dysuria 0 4,471 (91.0) 21,509 (99.0) – 
≥1 444 (9.0) 209 (1.0) 6.7 (5.2–8.7)*** 
D
is
e
a
s
e
 
Urinary 
tract 
infection 
0 4,080 (83.0) 21,013 (96.8) – 
1 511 (10.4) 503 (2.3) 4.4 (3.6–5.3)*** 
≥2 324 (6.6) 202 (0.9) 6.8 (5.1–9.1)*** 
In
v
e
s
ti
g
a
ti
o
n
s
 
Raised 
inflammatory 
markers 
0 4,583 (93.2) 20,909 (96.3) – 
≥1 332 (6.8) 809 (3.7) 1.5 (1.2–1.9)*** 
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Feature of bladder 
cancer 
n
a
 Number of: Odds ratio (95% 
CI) 
Cases, n 
(% of n = 
4,915 cases) 
Controls, n 
(% of n = 
21,718 
controls) 
High white 
cell count 
0 4,664 (94.9) 21,317 (98.2) – 
≥1 251 (5.1) 401 (1.8) 2.1 (1.6–2.8)**** 
Raised 
creatinine 
0 4,255 (86.6) 20,050 (92.3) – 
≥1 660 (13.4) 1,668 (7.7) 2.0 (1.7–2.3)*** 
**p<0.001, ***p<0.0001, Wald test of the null hypothesis that the OR is 1. 
a
n, Number of attendances in the analysis period. 
 
10.1.5.2 Goodness of fit with and without text-only records  
The effect of adding the new, text-based, variables abdominal pain, visible 
haematuria and non-visible haematuria to the original model was 
highly significant (nested models, likelihood ratio χ2 = 1,420.76, 3 d.f., 
p<0.0001). Therefore, text-only records were included for all three symptoms in 
the revised final model (see Table 10.9 below). 
10.1.5.3 Effect modification  
The original study did not report any significant effect modification in the model; 
however, this was revisited and sought on clinical grounds. Significant 
antagonistic effect modification was found between urinary tract 
infection and each of visible haematuria (Wald test, χ2 = 128.38, 6 
d.f., p<0.0001), dysuria (χ2 = 14.55, 2 d.f., p<0.001) and non-visible 
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haematuria (χ2 = 16.97, 2 d.f., p<0.001). The individual odds ratios for effect 
modification are reported in Table 10.9.  
10.1.6 Revised final model 
The revised final model, including the text-only records and effect modification, 
is reported in Table 10.9.  
Table 10.9 Conditional logistic regression analysis of the final model of bladder cancer 
presentation 
Feature of 
bladder cancer 
na Number of: Odds ratio (95% 
CI) 
Cases 
 (n = 4,915) 
Controls  
(n = 21,718) 
S
y
m
p
to
m
s
 
Abdominal 
pain 
0 4,368 (88.9) 20,503 (94.4) – 
≥1 547 (11.1) 1,215 (5.6) 2.0 (1.7–2.4)*** 
Constipation 0 4,629 (94.2) 21,010 (96.7) – 
≥1 286 (5.8) 708 (3.3) 1.4 (1.1–1.8)* 
Visible 
haematuria  
0 1,768 (36.0) 21,382 (98.5) – 
1 1,306 (26.6) 229 (1.1) 96.6 (75.0–124.5) 
*** 
2 910 (18.5) 64 (0.3) 312.4 (204.6–
477.0) *** 
≥3 931 (18.9) 43 (0.2) 644.5 (384.9–
1,079.1) *** 
Dysuria 0 4,471 (91.0) 21,509 (99.0) – 
≥1 444 (9.0) 209 (1.0) 7.9 (5.6–11.1) *** 
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D
is
e
a
s
e
 
Urinary 
tract 
infection 
0 4,080 (83.0) 21,013 (96.8) – 
1 511 (10.4) 503 (2.3) 4.7 (3.7–6.1) *** 
≥2 324 (6.6) 202 (0.9) 9.2 (6.4–13.2) *** 
In
v
e
s
ti
g
a
ti
o
n
s
 
Raised 
inflammatory 
markers 
0 4,583 (93.2) 20,909 (96.3) – 
≥1 332 (6.8) 809 (3.7) 1.7 (1.3–2.1) *** 
High white 
cell count 
0 4,664 (94.9) 21,317 (98.2) – 
≥1 251 (5.1) 401 (1.8) 1.8 (1.3–2.5) *** 
Raised 
creatinine 
0 4,255 (86.6) 20,050 (92.3) – 
≥1 660 (13.4) 1,668 (7.7) 2.0 (1.6–2.4) *** 
Non-visible 
haematuria 
0 4,603 (93.6) 21,658 (99.7)  
≥1 312 (6.4) 60 (0.3) 28.5 (16.4–49.6) 
*** 
*** p<0.0001(Wald test of null hypothesis that odds ratio = 1). 
* p<0.05 (Wald test of null hypothesis that odds ratio = 1). 
Effect modification interaction terms Odds ratio 
(95% CI) 
p value 
Visible 
haematuria 
× UTI 
 Overall: 
0.0001 
1  1 0.1 (0.06–0.2) 0.0001 
2  0.2 (0.06–0.6) 0.005 
≥3 0.2 (0.05–0.5) 0.001 
1 ≥2  0.04 (0.02–0.08) 0.0001 
2  0.05 (0.02–0.1) 0.0001 
≥3 0.2 (0.04–1.4) 0.1 
Dysuria 
× UTI 
 Overall: 
0.001 
≥1 1  0.4 (0.2–0.9) 0.02 
≥2 0.3 (0.1–0.6) 0.001 
Non-visible 
haematuria 
× UTI 
 Overall: 
0.001 
≥ 1 1  0.08 (0.02–0.3) 0.0001 
≥2 0.2 (0.03–0.9) 0.04 
a
n, Number of attendances in the analysis period. 
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The revised model was a significantly better fit than the model estimated using 
coded records alone (likelihood ratio test χ2 = 1,546.71, 11 d.f., p<0.0001). The 
most noteworthy result of adding text-only records to the model is that bladder 
cancer is strongly associated with non-visible haematuria, with an odds 
ratio of 28.5 (95% CI: 16.4–49.6) (p<0.0001) for one or more attendance. 
The effect of adding text-only records of attendance for visible haematuria was 
generally unremarkable, other than to increase the odds ratio for bladder cancer 
in patients attending three or more times in the analysis period. The odds ratio 
for three or more attendances was estimated to be 345.7 (95% CI: 198.6–
601.7) (p<0.0001) from coded visible haematuria records (see Table 
10.8), compared with 644.5 (95% CI: 384.9–1,079.1) (p<0.0001) from the 
supplemented visible haematuria records (see Table 10.9).  After 
supplementation with text-only records, the odds for bladder cancer significantly 
rose with re-attendance for visible haematuria (Wald test, χ2 = 60.67, 2 d.f., 
p<0.0001), starting at 96.6 (95% CI: 75.0–124.5) for a single visit, rising to 
644.5 (95% CI: 384.9–1,079.1) for three or more.  
Adding text-only records of attendance for abdominal pain had no effect on the 
odds ratio for bladder cancer; namely, 2.0 (95% CI: 1.7–2.5) (p<0.001) from 
abdominal pain records (see Table 10.8) compared with 2.0 (95% CI: 1.7–
2.4) (p<0.001) from abdominal pain records (see Table 10.9). 
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10.2 Pancreatic cancer 
10.2.1 Estimates of positive predictive value and positive 
likelihood ratio from coded records 
The features of pancreatic cancer presentation in primary care were identified in 
the original study.5 The numbers of cases and controls with coded records of 
attendance for each of these features are reported in Table 10.10, along with 
the positive likelihood ratio and positive predictive value for pancreatic cancer. 
The results are from my re-construction and re-analysis,a and largely replicated 
those of the original study.5  
In terms of frequency of attendance, two features predominated: abdominal 
pain (in 1,527/3,635 = 42.0% of cases) and jaundice (in 1,102/3,635 = 
30.3% of cases). Jaundice was clearly the most strongly predictive of 
pancreatic cancer, associated with a 12.77% (95% CI: 7.25–21.58%) chance of 
the disease. Indeed, patients with pancreatic cancer were 498.98 (95% CI: 
268.00–929.02) times more likely to be jaundiced compared with controls. 
However, in all age groups combined, the positive likelihood ratio values and 
positive predictive values for all other features considered in isolation were 
unremarkable, even abdominal pain which was recorded quite frequently. 
                                            
a
 The discrepancies were essentially trivial, and reflected very slight differences in definitions of 
some variables.  
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Table 10.10 The positive likelihood ratio and positive predictive value for pancreatic cancer in 
patients aged ≥40 years presenting with clinical features associated with the disease (codes))  
Feature of 
pancreatic 
cancer 
Number of patients 
attending at least once: 
Cases n 
(% of n = 
3,635 
cases) 
Controls, n 
(% of 16,459 
controls) 
 
Positive 
likelihood 
ratio  
(95% CI) 
PPV (%) (95% 
CI)ab 
Diarrhoea 381 (10.5) 534 (3.2) 3.23 (2.85–
3.67) 
0.09 (0.08–
0.11) 
Nausea 
and/or 
vomiting 
572 (15.7) 350 (2.1) 7.40 (6.51–
8.41) 
0.21 (0.19–
0.24) 
Back pain 458 (12.6) 1,028 (6.2) 2.02 (1.82–
2.24) 
0.06 (0.05–
0.06) 
Weight loss 354 (9.7) 105 (0.6) 15.27 (12.31–
18.92) c 
0.44 (0.36–
0.55) 
Malaise 187 (5.1) 197 (1.2) 4.30 (3.53–
5.23) 
0.12 (0.10–
0.15) 
New-onset 
diabetes 
380 (10.5) 436 (2.7) 3.95 (3.46–
4.51) 
0.11 (0.10–
0.13) 
Jaundice 1,102 (30.3) 10 (0.06) 498.98 
(268.00–
929.02) c 
12.77 (7.25–
21.58) 
Constipation 428 (11.8) 557 (3.4) 3.48 (3.08–
3.93) 
0.10 (0.09–
0.11) 
Abdominal 
pain 
1,527 (42.0) 996 (6.1) 6.94 (6.46–
7.45) 
0.20 (0.19–
0.22) 
 
a 
PPV values are adjusted for the consulting population (see Section 6.12.3.5). 
b
 PPV values estimated using Bayes’ theorem (see Section 6.12.3.5), assuming a prior odds of 
0.0002671 based on 2008 UK national incidence data. 
c
 Positive likelihood ratio >10. 
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10.2.2 Effect of supplementation with text-only records on 
positive likelihood ratio and PPV  
Detailed analysis of GPs’ choice of recording style was presented in Section 9 
(see Table 9.8). This section focuses on whether supplementing codes with text 
records alters the risk estimates for pancreatic cancer in patients with jaundice 
or abdominal pain. This relates to research question 5: ‘Do the text data provide 
additional value to coded data?’ (see Section 5). 
The numbers of patients attending at least once for abdominal pain or jaundice 
determined using coded records in the original study were updated with records 
from the text. These revised binary abdominal pain and jaundice variables 
were used to re-examine the predictive power of these symptoms for pancreatic 
cancer (Table 10.11). 
10.2.2.1 Abdominal pain 
The 95% confidence intervals suggested that supplementing coded records of 
abdominal pain with text-only records did not alter the positive likelihood ratio 
(abdominal pain: 6.94, 95% CI: 6.46–7.45 vs abdominal pain: 6.59, 95% 
CI: 6.21–7.0) or the PPV (abdominal pain: 0.20%, 95% CI: 0.19–0.22% vs 
abdominal pain: 0.19%, 95% CI: 0.18–0.20%). 
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Table 10.11 Positive likelihood ratio and PPV for pancreatic cancer in patients of all ages 
presenting with abdominal pain or jaundice 
Clinical 
feature and 
recording 
style  
Number of patients 
attending at least 
once: 
Cases n 
(% of n = 
3,635 
cases) 
Controls 
n (% of 
16,459 
controls) 
 
Positive 
likelihood 
ratio 
(95% CI) 
Positive 
predictive value 
(%) 
(95% CI) 
Abdominal 
pain 
1,910  
(52.5) 
1,312  
(8.0) 
6.59  
(6.21–7.0) 
0.19  
(0.18–0.20) 
Abdominal 
pain 
1,527  
(42.0) 
996  
(6.1) 
6.94  
(6.46–7.45) 
0.20  
(0.19–0.22) 
Jaundice 1,565  
(43.1) 
31  
(0.2) 
228.59  
(160.49–325.58) 
6.25  
(4.46–8.68) 
Jaundice  1,102  
(30.3) 
10  
(0.06) 
498.98  
(268.00–929.02)  
12.77  
(7.25–21.58) 
a 
 PPV values are adjusted for the consulting population (see Section 6.12.3.5). PPV values 
estimated using Bayes’ theorem (see Section 6.12.3.5), assuming a prior odds of 0.0002671 
based on 2008 UK national incidence data. 
 
10.2.2.2 Jaundice 
In contrast, supplementing the coded jaundice record with text-only jaundice 
records reduced the positive likelihood ratio from 498.98 (95% CI: 268.0–929.0) 
(jaundice) to 228.59 (95% CI: 160.49–325.58) (jaundice). Similarly, the 
PPV fell from 12.77% (95% CI: 7.25–21.58%) (jaundice) to 6.25% (95% CI: 
4.46–8.68%) (jaundice).  
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10.2.3 Estimates of odds ratio in univariable analysis from 
coded records 
The frequency of attendance for each feature included in the final model of the 
original study is reported in Table 10.12 along with its odds ratio for disease in 
univariable analysis. The results are from my re-construction and re-analysis, 
and largely match those of the original study. 
10.2.3.1 Strength of association with pancreatic cancer 
Jaundice was the feature most strongly associated with pancreatic cancer in 
univariable analysis – the odds of pancreatic cancer in patients who attended at 
least once for jaundice were 712.9 times (95% CI: 339.0–1,499.0, Wald test 
p<0.0001) higher than in non-attenders.  Weight loss had the second strongest 
association with pancreatic cancer (odds ratio = 17.4, 95% CI: 13.8–21.9, for at 
least one attendance, p<0.0001), followed by nausea and/or vomiting (odds 
ratio = 9.2, 95% CI: 7.9–10.6, p<0.0001) and then abdominal pain (odds ratio = 
7.1, 95% CI: 6.2–8.0 for a single attendance, p<0.0001). Diarrhoea, back pain, 
malaise, new-onset diabetes and constipation were all less strongly associated 
with pancreatic cancer, with odds ratios below 5 for at least one attendance.  
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Table 10.12 Frequency of attendance for features included in the final model of the original 
study, plus the univariable analysis  
Feature of 
pancreatic 
cancer 
n
a
 Number of participants Odds ratio in 
univariable analysis 
(95% CI) 
p
b
 
Cases, n (% 
of n = 3,635 
cases) 
Controls, n (% 
of n = 16,459 
controls) 
Diarrhoea                       0 3,254 (89.5) 15,925 (96.8) – – 
≥1 381 (10.5) 534 (3.2) 3.6 (3.1–4.1) 0.0001 
Nausea 
and/or 
vomiting    
0 3,063 (84.3) 16,109 (97.9) – – 
≥1 572 (15.7) 350 (2.1) 9.2 (7.9–10.6) 0.0001 
Back pain 
c
 0 3,177 (87.4) 15,431 (93.8) – – 
1 270 (7.4) 742 (4.5) 1.8 (1.6–2.1) 0.0001 
≥2 188 (5.2) 286 (1.7) 3.3 (2.7–4.0) 0.0001 
Weight loss                     0 3,281 (90.3) 16,354 (99.4) – – 
≥1 354 (9.7) 105 (0.6) 17.4 (13.8–21.9) 0.0001 
Malaise                           0 3,448 (94.9) 16,262 (98.8) – – 
≥1 187 (5.1) 197 (1.2) 4.8 (3.9–5.9) 0.0001 
New-onset 
diabetes 
0 3,255 (89.5) 16,023 (97.4) – – 
≥1 380 (10.5) 436 (2.6) 4.5 (3.9–5.3) 0.0001 
Jaundice  0 2,533 (69.7) 16,449 (99.9) – – 
≥1 1,102 (30.3) 10 (0.06) 712.9 (339.0–1,499.0) 0.0001 
Constipation 0 3,207 (88.2) 15,902 (96.6) – – 
≥1 428 (11.8) 557 (3.4) 4.0 (3.5–4.6) 0.0001 
Abdominal 
pain 
d
 
0 2,108 (58.0) 15,463 (93.9) – – 
1 621 (17.1) 673 (4.1) 7.1 (6.2–8.0) 0.0001 
≥2 906 (24.9) 323 (2.0) 21.8 (18.7–25.3) 0.0001 
95% CI = 95% confidence interval. 
a 
n is the number of times the patient attended for the feature in the analysis period. 
b
 Wald test of the null hypothesis that odds ratio is 1. 
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c 
Strong evidence that the association between back pain and pancreatic cancer varied with number of 
attendances (χ
2
= 25.72, 1 d.f., p<0.0001). 
d Strong evidence that the association between abdominal pain and pancreatic cancer varied with 
number of attendances (χ
2
= 149.5, 1 d.f., p<0.0001). 
 
10.2.3.2 The significance of re-attendance for a feature 
There was strong evidence that re-attendance for abdominal pain was 
significant. The association between pancreatic cancer and abdominal pain 
varied with the number of attendances in the analysis period (χ2= 149.5, 1 d.f., 
Wald test p<0.0001), with further episodes increasing the odds of disease to 
21.8 (95% CI: 18.7–25.3) (p<0.0001). Similarly, the odds of pancreatic cancer 
increased with repeat attendance for back pain (χ2= 25.72, 1 d.f., p<0.0001). 
The significance of re-attendance for diarrhoea, nausea and/or vomiting, weight 
loss, malaise, jaundice diabetes and constipation could not be assessed, 
because too few patients attended more than once to allow meaningful 
analysis. 
10.2.4 Odds ratios in univariable analysis after 
supplementation with text-only records 
The odds ratios for pancreatic cancer in patients attending for jaundice and 
abdominal pain, after supplementation with text-only records, are reported 
below.  
10.2.4.1 Jaundice 
There were high numbers of text-only jaundice records (Table 10.13), easily 
exceeding the 5% threshold for inclusion in univariable analysis. Indeed, 463 of 
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3,635 (12.7%) of cases attended at least once where this was never 
documented as a code. The text-only records indicated that patients did re-
attend for jaundice; however, the numbers were too low to permit meaningful 
analysis in terms of association with pancreatic cancer. 
Table 10.13  Frequency of presentation with jaundice in the analysis period in cases and 
controls, according to the recording style, and independent association with pancreatic cancer 
Recording 
style a na
b 
Number (%) of patients 
attending: 
Odds ratio (95% CI) 
p 
value 
c 
Cases (n = 
3,635) 
Controls (n 
= 16,459) 
Jaundice 0 2,533  
(6.97) 
16,449  
(99.9) 
– – 
≥1 1,102  
(30.3) 
10  
(0.06) 
712.9  
(339.0–1,499.0) 
0.0001 
Jaundice 0 3,172  
(87.3) 
16,438  
(99.9) 
– – 
≥1 463  
(12.7) 
21  
(0.1) 
130.3  
(79.2–214.6) 
0.0001 
Jaundice 0 2,070  
(56.7) 
16,428  
(99.8) 
– – 
≥1 1,565  
(43.1) 
31  
(0.2) 
640.4  
(353.9–1,158.9) 
0.0001 
a
 Strong evidence that the association between pancreatic cancer and jaundice varied with the recording 
style (χ2= 7.63, 1 d.f., p<0.01). 
b 
Number of attendances in the analysis period (the maximum number of attendances examined was that 
level containing no fewer than 5% of cases). 
c
Wald test of the null hypothesis that the odds ratio is 1. 
 
There was strong evidence that the association between jaundice and 
pancreatic cancer varied with the recording style (Wald test, χ2= 7.63, 1 d.f., 
p<0.01). The odds ratio for pancreatic cancer from coded (jaundice) records 
was 1,132.4 (95% CI: 506.1–2,533.8) (Wald test, p<0.0001) for at least one 
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attendance, whereas it was 314.4 (95% CI: 156.5–631.4) (p<0.0001) according 
to the text-only (jaundice) records.  
The odds ratio for the combined variable jaundice was 640.4 (95% CI: 353.9–
1,158.9) for at least one attendance. The numbers re-attending with jaundice 
were too low to permit meaningful analysis of its significance in terms of altered 
association with pancreatic cancer. 
10.2.4.2 Abdominal pain 
There was a significant amount of text-only abdominal pain recording: 383 of 
3,635 cases (10.5%) attended at least once, meeting the 5% threshold for 
inclusion in univariable analysis (see Table 10.14). There was strong evidence 
that the association between pancreatic cancer and abdominal pain varied with 
the recording style (χ2= 151.44, 2 d.f., p<0.0001), although the size of the 
difference was of questionable clinical significance. The odds ratio for 
pancreatic cancer from text-only abdominal pain records was 6.5 (95% CI: 
5.5–7.6) (Wald test, p<0.0001) for at least one attendance, whereas it was 7.1 
(95% CI: 6.2–8.0) (p<0.0001) for a single attendance according to the coded 
abdominal pain records. 
The odds ratio for the combined variable abdominal pain was 7.3 (95% CI: 
6.5–8.2, p<0.0001) for a single attendance. The effect of re-attendance for 
abdominal pain in the analysis period was highly significant (χ2= 229.31, 1 d.f., 
p<0.0001), with the odds ratio rising to 26.3 (95% CI: 22.8–30.3) (p<0.0001) for 
two or more attendances.  
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Table 10.14 Frequency of attendance for abdominal pain in the analysis period in cases and 
controls grouped by recording style, and independent association with pancreatic cancer 
Recording 
stylea  na
b 
Number (%) of patients 
attending for abdominal pain 
Odds ratio (95% 
CI) p 
valuec 
Cases    
(n = 3,635) 
Controls  
(n = 16,459) 
Abdominal 
pain 
0 2,108  
(58.0) 
15,463  
(94.0) 
– – 
1 621  
(17.1) 
673  
(4.1) 
7.1  
(6.2–8.0) 
0.0001 
≥2 906  
(24.9) 
323  
(2.0) 
21.8  
(18.7–25.3) 
0.0001 
Abdominal 
pain 
0 3,252  
(89.5) 
16,143  
(98.1) 
– – 
≥1 383  
(10.5) 
316  
(1.9) 
6.5  
(5.5–7.6) 
0.0001 
Abdominal 
pain 
0 1,725  
(47.5) 
15,147  
(92.0) 
– – 
1 734  
(20.2) 
891  
(5.4) 
7.3  
(6.5–8.2) 
0.0001 
≥2 1,176  
(32.4) 
421  
(2.6) 
26.3  
(22.8–30.3) 
0.0001 
a 
Strong evidence that the association between abdominal pain and pancreatic cancer varied with 
recording style (χ2= 151.44, 2 d.f., p<0.0001). 
b
 Number of attendances in the analysis period.  
c
 Wald test that the odds ratio is 1. 
 
10.2.5 Multivariable analysis 
10.2.5.1 The basic model estimated using coded records 
The multivariable conditional logistic regression analysis of the presenting 
features of pancreatic cancer, as identified in the original study,5 was run using 
solely code-based variables to replicate the basic model (Table 10.15). 
Jaundice was the feature most strongly associated with pancreatic cancer. 
The odds of pancreatic cancer were 1,306.1 (95% CI: 599.9–2,843.7) (Wald 
287 
 
test, p<0.0001) times higher in patients who attended at least once with this 
feature compared with non-attenders. The significance of re-attendance for 
jaundice could not be assessed, owing to small numbers of controls.  
Abdominal pain was also associated with pancreatic cancer, albeit less 
strongly than jaundice. The odds of disease in patients attending once with 
abdominal pain were 7.9 (95% CI: 6.6–9.5) (Wald test, p<0.0001). There was 
strong evidence that the association between abdominal pain and 
pancreatic cancer varied with repeat attendance (χ2= 78.18, 1 d.f., p<0.0001). 
The odds of disease increased from 7.9 (95% CI: 6.6–9.5) for a single visit to 
23.4 (95% CI: 18.9–28.8) for two or more. 
Also strongly associated with pancreatic cancer in multivariable analysis were 
weight loss (odds ratio 19.3, 95% CI: 13.7–27.1, p<0.0001) and nausea 
and/or vomiting (6.2, 95% CI: 4.9–7.8, p<0.0001). The remaining features 
were less strongly associated with pancreatic cancer (odds ratio lower than 5).  
Two or more attendances for back pain were more significant than a single 
episode (χ2= 8.42 1 d.f., p<0.01).   
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Table 10.15 Frequency of attendance for symptoms of pancreatic cancer in the year before 
analysis and odds ratio in multivariable conditional logistic regression analysis; estimates were 
obtained from code-based variables  
Feature of 
pancreatic 
cancer 
na Number of: Odds ratio (95% CI) 
Cases 
(n = 3,635) 
Controls  
(n = 16,459) 
Diarrhoea 0 3,254 (89.5) 15,925 (96.8) – 
≥1 381 (10.5) 534 (3.2) 2.4 (1.9–3.1)*** 
Nausea 
and/or 
vomiting 
0 3,063 (84.3) 16,109 (97.9) – 
≥1 572 (15.7) 350 (2.1) 6.2 (4.9–7.8)*** 
Back pain 0 3,177 (87.4) 15,431 (93.8) – 
1 270 (7.4) 742 (4.5) 1.3 (1.1–1.7)* 
≥2 188 (5.2) 286 (1.7) 2.4 (1.7–3.3)*** 
Weight loss 0 3,281 (90.3) 16,354 (99.4) – 
≥1 354 (9.7) 105 (0.6) 19.3 (13.7–27.1)***  
Malaise 0 3,448 (94.9) 16,262 (98.8) – 
≥1 187 (5.1) 197 (1.2) 2.9 (2.1–4.1)*** 
New-onset 
diabetes 
0 3,255 (89.5) 16,023 (97.4) – 
≥1 380 (10.5) 436 (2.7) 4.2 (3.4–5.4)*** 
Jaundice 0 2,533 (69.7) 16,449 (99.9) – 
≥1 1,102 (30.3) 10 (0.06) 1,306.1  
(599.9–2,843.7)*** 
Constipation 0 3,207 (88.2) 15,902 (96.6) – 
≥1 428 (11.8) 557 (3.4) 2.1 (1.7–2.7)*** 
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Feature of 
pancreatic 
cancer 
na Number of: Odds ratio (95% CI) 
Cases 
(n = 3,635) 
Controls  
(n = 16,459) 
Abdominal 
pain 
0 2,108 (58.0) 15,463 (94.0) – 
1 621 (17.1) 673 (4.1) 7.9 (6.6–9.5)*** 
≥2 906 (24.9) 323 (2.0) 23.4 (18.9–28.8)*** 
a
Number of attendances in the analysis period. 
**p<0.01, ***p<0.0001, Wald test of the null hypothesis that the odds ratio is 1. 
 
10.2.5.2 Goodness of fit with and without text-based variables 
The effect of adding the new, text-based variables abdominal pain and 
jaundice was highly significant (nested models, likelihood ratio χ2 = 1,246.10, 
2 d.f., p<0.0001). Therefore, text-only records were included for both features in 
the revised final model (see Table 10.16).  
10.2.5.3 Effect modification 
There was significant and antagonistic effect modification between abdominal 
pain and jaundice (Wald test, χ2 = 22.1, 2 d.f., p<0.0001).  In addition, there 
was also significant and antagonistic effect modification between constipation 
and abdominal pain (Wald test, χ2 = 21.51, 2 d.f., p<0.0001). The individual 
interaction terms for effect modification are reported in Table 10.16. 
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10.2.6 Revised final model 
The revised final model, including the text-only records and effect modification, 
is reported in Table 10.16. The revised model was a significantly better fit than 
the model estimated using coded records alone (likelihood ratio text χ2 = 
1,322.95, 4 d.f., p<0.0001). 
The addition of text-only records for jaundice and abdominal pain did not 
appreciably alter the odds ratios for these features. Jaundice remained the most 
strongly associated with pancreatic cancer, whether the odds ratio was 
estimated using coded jaundice records (main effects odds ratio: 1,306.1, 
95% CI: 599.9–2,843.7, Wald test, p<0.0001) (see Table 10.15) or the 
supplemented jaundice records (1,969.7, 95% CI: 918.2–4,225.3, p<0.0001) 
records (see Table 10.16). While the point estimate from the jaundice records 
appears larger than that from the jaundice records, the wide confidence 
intervals for both estimates suggests that there is no difference between them.   
Similarly, supplementing with text records of abdominal pain attendance did not 
appreciably alter the association between this symptom and pancreatic cancer. 
The odds ratio was estimated to be 7.9 (95% CI: 6.6–9.5, p<0.0001) for a single 
attendance from coded abdominal pain records (see Table 10.15) compared 
with 7.2 (95% CI: 5.9–8.8, p<0.0001) from abdominal pain records (see 
Table 10.16).  
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Re-attendance for abdominal pain was significant (χ2= 127.54, 1 d.f., 
p<0.0001) with the odds ratio rising to 35.6 (95% CI: 27.9–45.3) for two or more 
attendances (see Table 10.16 on the next page). 
In the final model, the significance of a single attendance for back pain was 
lost, the symptom only becoming significant upon the second attendance, with 
an odds ratio of 2.6 (95% CI: 1.8–3.7) (p<0.0001). 
The odds ratios for the rest of the features of pancreatic cancer were only 
adjusted slightly by the addition of text-only records for jaundice and abdominal 
pain. 
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Table 10.16 Conditional logistic regression analysis of the final model of pancreatic cancer 
presentation 
Feature of 
pancreatic 
cancer 
na Number of: Odds ratio (95% 
CI) 
Cases 
(n = 3,635) 
Controls  
(n = 16,459) 
Main effects 
Diarrhoea 0 3,254 (89.5) 15,925 (96.8) – 
≥1 381 (10.5) 534 (3.2) 1.5 (1.1–2.0)* 
Nausea 
and/or 
vomiting 
0 3,063 (84.3) 16,109 (97.9) – 
≥1 572 (15.7) 350 (2.1) 5.3 (4.1–7.0)*** 
Back pain 0 3,177 (87.4) 15,431 (93.8) – 
1 270 (7.4) 742 (4.5) 1.3 (1.0–1.7)† 
≥2 188 (5.2) 286 (1.7) 2.6 (1.8–3.7)*** 
Weight loss 0 3,281 (90.3) 16,354 (99.4) – 
≥1 354 (9.7) 105 (0.6) 27.5 (18.2–
41.5)***  
Malaise 0 3,448 (94.9) 16,262 (98.8) – 
≥1 187 (5.1) 197 (1.2) 2.3 (1.6–3.5)*** 
New-onset 
diabetes 
0 3,255 (89.5) 16,023 (97.4) – 
≥1 380 (10.5) 436 (2.7) 4.6 (3.5–6.0)*** 
Jaundice 0 2,070 (57.0) 16,428 (99.8) – 
≥1 1,565 (43.0) 31 (0.2) 1,969.7  
(918.2–
4,225.3)*** 
Constipation 0 3,207 (88.2) 15,902 (96.6) – 
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≥1 428 (11.8) 557 (3.4) 3.0 (2.2–4.2)*** 
Abdominal 
pain 
0 1,725 (47.5) 15,147 (92.0) – 
1 734 (20.2) 891 (5.4) 7.2 (5.9–8.8)*** 
≥2 1,176 (32.4) 421 (2.6) 35.6 (27.9–
45.3)*** 
Effect modification interaction terms 
Odds ratio (95% 
CI) 
p value 
Abdominal 
pain 
× Jaundice  0.001 
1  1 0.1 (0.05–0.5)  
≥2  1 0.1 (0.05–0.2)  
Abdominal 
pain 
× Constipation  0.0001 
1  1 0.4 (0.2–0.8)  
≥2  1 0.3 (0.2–0.5)  
a
 Number of attendances in the analysis period. 
†p = 0.06, *p<0.01, ***p<0.0001 Wald test that odds ratio is 1. 
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11 Results: Comparison of diagnostic intervals 
estimated from coded and from text-only records 
The diagnostic interval is estimated as the number of days between first 
attendance for a symptom and the date of cancer diagnosis. This analysis of 
diagnostic intervals estimated from coded and text-only records of attendance 
for symptoms relates to research question 5: Do the text data provide additional 
value to coded data? The methods are described in Section 6.12.2.2. 
11.1.1 Summary statistics for diagnostic interval data 
The change in diagnostic interval following the addition of text-only records of 
attendance for haematuria, abdominal pain and jaundice is reported in Table 
11.1. As explained in Section 6.12.2.2, there are no suitable methods for testing 
whether there is a statistical difference between the diagnostic interval as 
estimated from the earliest coded record (DIcoded) and that estimated from the 
earliest ever record (whether recorded as a code or in the text, DItext/coded). This 
is because the data are neither fully matched nor completely unmatched. The 
wide interquartile range suggests that there is no difference in the point 
estimates of diagnostic interval regardless of the recording method used.  
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Table 11.1 Diagnostic interval data (median, 25% to 75% interquartile range, IQR) 
estimated before and after addition of text-only records of attendance for haematuria, 
abdominal pain and jaundice 
Cancer 
site 
Symptom ncoded DIcoded, days 
(25% to 75% 
IQR) 
ntext/coded DItext/coded, days 
(25% to 75% IQR) 
B
la
d
d
e
r 
Visible 
haematuria 
2,595 −65  
(−122 to −35) 
3,147 −69  
(−130 to −36) 
Non−visible 
haematuria 
127 −77  
(−131 to −41) 
312 −65  
(−114 to −33) 
Abdominal pain 358  −134  
(−249 to −54) 
547 −123  
(−244 to −47) 
P
a
n
c
re
a
s
 Jaundice 1,110 −27 
(−50 to −13) 
1,565 −25  
(−49 to −12) 
Abdominal pain 1,527 −85  
(−175 to −42) 
1,910  −78 
(−172 to −37) 
Note: ncoded: number of patients identified from coded records as having attended at least once 
for the symptom in the analysis period.  
ntext/coded: number of patients identified from coded or text records as having attended at least 
once for the symptom in the analysis period.  
 
11.1.1.1 Testing for normality 
None of the diagnostic interval data reported in Table 11.1 followed a normal 
distribution (D’Agostino K-squared test of normality, p<0.001 for each symptom 
before or after addition of text-only records). The box-and-whisker plots are 
shown in Figure 11.1. Therefore, non-parametric methods were used in the 
matched and unmatched analysis reported below. 
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Figure 11.1 Box and whisker plot of diagnostic interval for visible (top left), non-visible (top right) 
haematuria and abdominal pain (middle left) in bladder cancer and for abdominal pain (middle right) 
and jaundice (bottom) in pancreatic cancer. Estimates were made using the first coded record 
(DIcoded, blue) and the first ever record (DItext/code, pink)  
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11.1.1.2 Matched analysis 
The results of matched analysis are reported in Table 11.2. Patients were 
included in the analysis if they had both coded and text records of attendance 
for a symptom. For each patient the diagnostic interval was estimated from the 
earliest coded record (DIcoded) and from the earliest record, which may have 
been coded or in the text (DItext/coded).  
There was strong evidence that the diagnostic interval for each symptom was 
lengthened by the addition of text-only records of attendance.a This was most 
marked for abdominal pain in the bladder cancer dataset, where the coded 
records estimated diagnostic interval as −130.5 (25% to 75% interquartile 
range: −249 to −68) days compared with −147.5 (25% to 75% interquartile 
range: −260 to −81) as estimated after addition of text-only records. The change 
in diagnostic interval was smallest for jaundice in pancreatic cancer, where the 
difference in median estimates of diagnostic interval was only 3 days. 
 
 
                                            
a
 It would be impossible for addition of text-only records to shorten diagnostic intervals. 
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Table 11.2 Matched analysis of diagnostic interval data – patients who had both a coded and a 
text record of attendance 
Site Symptom ncoded+text DIcoded, days 
(25% to 75% 
IQR) 
DItext/coded (25% 
to 75% IQR) 
pa 
B
la
d
d
e
r 
Visible 
haematuria 
1,438 −67.5 
(−119 to −35) 
−77  
(−137 to −41) 
<0.0001 
Non-visible 
haematuria 
30 −76.5  
(−128 to −41) 
−82.5 
(−135 to −55) 
<0.01 
Abdominal 
pain 
138 −130.5 
(−249 to −68) 
−147.5 
(−260 to −81) 
<0.0001 
P
a
n
c
re
a
s
 
Jaundice 695 −28  
(−53 to −14) 
−31  
(−59 to −16) 
<0.0001 
Abdominal 
pain 
739 −95  
(−196 to −48) 
−105  
(−222 to −54) 
<0.0001 
Notes: 
a
 Sign rank test of the null hypothesis DIcoded−DItext/coded =0 in matched pairs. 
ncoded+text: number of bladder or pancreatic cancer cases with a coded and a text record of the 
symptom. 
DIcoded: number of days from the earliest coded record of the symptom and diagnosis with 
bladder or pancreatic cancer. 
DItext/coded: number of days from the earliest text or coded record of the symptom and diagnosis 
with bladder or pancreatic cancer. 
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11.1.1.3 Unmatched analysis 
The results of unmatched analysis are reported in Table 11.3. Apart from visible 
haematuria in the bladder cancer dataset, the results suggest that diagnostic 
intervals from coded (DIcoded) and from text (DItext) records are not drawn from 
the same population (Wilcoxon rank-sum test, p<0.01 to p<0.0001).  
The unmatched data analysis suggests that the diagnostic interval estimated 
from the first coded record is greater than that estimated from the first text-only 
record. This contrasts with the results in matched analysis, where addition of 
text-only records lengthened the diagnostic interval. 
The difference in median values of diagnostic interval was greatest for 
abdominal pain in bladder cancer; namely, −136.5 (25% to 75% interquartile 
range: −249 to −48) days (coded records) and −90 (−210 to −34) days (text-
only records). The difference in median values was least for jaundice in 
pancreatic cancer, i.e. −23 (25% to 75% interquartile range: −47 to −11) days 
(coded records) and −19 (−36 to −7) days (text-only records).  
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Table 11.3 Unmatched analysis of diagnostic interval data 
Site Symptom ncoded ntext DIcoded, days 
(25% to 75% 
IQR) 
DItext (25% to 
75% IQR) 
pa 
B
la
d
d
e
r 
Visible 
haematuria 
1,157 552 −63  
(−125 to −35) 
−60  
(−111.5 to −29) 
0.07 
Non-visible 
haematuria 
97 185 −77  
(−132 to −42) 
−56  
(−100 to −30) 
0.015 
Abdominal 
pain 
220 189 −136.5  
(−249 to −48) 
−90  
(−210 to −34) 
0.018 
P
a
n
c
re
a
s
 
Jaundice 415 455 −23  
(−47 to −11) 
−19  
(−36 to −7) 
0.0035 
Abdominal 
pain 
788 383 −76  
(−163 to −36) 
−46  
(−106 to −19) 
<0.0001 
Notes: 
a
 Wilcoxon rank-sum (Mann-Whitney) test of the null hypothesis that DIcoded and DItext are drawn 
from the same population. 
ncoded: number of bladder or pancreatic cancer cases with solely a coded record of the symptom. 
ntext: number of bladder or pancreatic cancer cases with solely a text record of the symptom. 
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12 Results: Modelling the outcome ‘text-only recording’ 
of visible haematuria in the bladder cancer dataset 
This post-hoc analysis was conducted to explore the hypothesis that GPs tend 
to use codes to record clinically significant events and text for anything 
perceived to be less worrisome. This also relates to research question 4: Does 
the recording style vary with the clinical context of presentation of a symptom? 
The methods used are described in Section 6.12.5. 
12.1 Relationship between recording style and cause of 
visible haematuria  
For those patients who attended at least once for visible haematuria in the 
analysis period, the recording style used was tabulated against the possible 
cause; namely, bladder cancer and urinary tract infection (Table 12.1, with 
graphical presentation in Figure 12.1).a b There were insufficient numbers of 
patients with calculi to allow meaningful analysis (n = 12).  
  
                                            
a
 Note that text-only recording status was reserved for just those patients whose visible 
haematuria was only ever documented in the text. 
b
 As explained in Methods, patient case–control status was used as a proxy for malignant 
versus benign cause. 
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Table 12.1 Recording style of visible haematuria tabulated against possible cause and patient 
gender  
Explanatory variable No. (%) of patients attending at least once 
estimated using: a 
Visible 
haematuria 
Visible 
haematuria 
Visible 
haematuria 
Benign 
cause vs 
bladder 
cancer b 
Control  196 (58.3) 140 (41.7) 336 (100) 
Case 2,591 (82.3)    556 (17.7) 3,147 (100) 
Total 2,787 (80.0) 696 (20.0) 3,483 (100) 
Urinary 
tract 
infection c, 
d 
Attended ≥1  450 (72.0) 175 (28.0) 625 (100) 
No 
attendance 
2,337 (81.8) 521 (18.2) 2,858 (100) 
Total 2,787 (80.0) 696 (20.0) 3,483 (100) 
Gender e Male 2,132 (80.9) 503 (19.1) 2,635 (100) 
Female 655 (77.2) 193 (22.8) 848 (100) 
Total 2,787 (80.0) 696 (20.0) 3,483 (100) 
a
 Visible haematuria – GP used a Read code for some or all attendances; Visible 
haematuria – GPs used text-only to record all attendances; Visible haematuria – total 
record. 
b
 Strong evidence against the null hypothesis that there is no relationship between recording style and 
benign vs malignant cause of haematuria (Pearson χ2, 1 d.f., = 109.4, χ2 test: p<0.0001).
 
c
 Strong evidence against the null hypothesis that there is no relationship between recording style and 
attendance for urinary tract infection (Pearson χ2, 1 d.f., = 30.6, χ2 test: p<0.0001).
 
d
 Occurrences of urinary tract infection and visible haematuria were not matched on date. 
e
 Moderate evidence against the null hypothesis that there is no relationship between recording style and 
gender (Pearson χ2, 1 d.f., = 5.4, χ2 test: p<0.05). 
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As reported above (see Section 9.2.2.1), recording style varied with patient 
case/control status (χ2 test: p<0.0001). The preference for text-only recording 
was greater in controls (140/336 = 41.7%) – whose haematuria is assumed to 
have a benign cause – than in patients diagnosed with bladder cancer within 
the year (i.e. the cases, 556/3,147 = 17.7%) (Table 12.1).  
Recording style also varied according to whether patients had attended for a 
urinary tract infection (χ2 test: p<0.0001): text-only recording was more highly 
favoured in patients with a history of urinary tract infection (175/625 = 28.0%) 
than in those who had no record of attendance for this (521/2,858 = 18.2%) 
(Table 12.1). 
Figure 12.1 Recording style of visible haematuria plotted as a function of possible cause and 
patient gender  
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12.2 Relationship between recording style and gender  
There was moderate evidence (χ2 test: p<0.05) of a small variation of recording 
style with gender (cases and controls combined), with the GP preference for 
text-only recording being slightly more marked in women (193/848 = 22.8%) 
than in men (503/2,635 = 19.1%) (Table 12.1 and Figure 12.1). The results of 
earlier analysis (see Figure 9.6) show that this is particularly marked for female 
controls, where the records of attendance for visible haematuria were lost in the 
hidden text for 38 of the 57 (66.7%) female controls.  
12.3 Univariable analysis 
In univariable analyses, benign vs malignant cause (i.e. control vs case status) 
(p<0.001), attendance for a urinary tract infection (p<0.001) and gender 
(p<0.05) were all independently associated with the outcome ‘text-only 
recording’ (mixed-effects logistic regression) (Table 12.2). 
Table 12.2 Univariable analysis for the outcome ‘text-only recording of visible haematuria’ 
(mixed-effects logistic regression, controlling for random effects of clustering within GP practice) 
Explanatory variable  Odds ratio 
(univariable 
analysis)  
95% CI p value d 
Benign vs malignant cause 
(control vs case)a 
3.6 2.8–4.7 0.0001 
Urinary tract infection (≥1 
attendance vs no attendance) b 
1.9 1.5–2.4 0.0001 
Gender (females vs males) c 1.3 1.0–1.5 0.02 
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a
 Random effect of clustering within GP practice was significant (χ2= 29.9, p<0.0001). 
b 
Random effect of clustering within GP practice was significant (χ2= 32.8, p<0.0001). 
c 
Random effect of clustering within GP practice was significant (χ2= 27.9, p<0.0001). 
d
 z-test that the odds ratio is not 1. 
12.4 Modification of the effect of benign vs malignant 
causes by gender 
Initial analysis involved looking for evidence of an association between benign 
versus malignant causes and text-only recording within gender. For men, the 
preference for text-only recording of haematuria was greater in the controls 
(presumed to have a benign cause) (102/279 = 36.6%) than in the cases 
(presumed to be due to bladder cancer) (401/2,356 = 17.0%) (χ2 test, 
p<0.0001). The preference for text-only recording in controls was more marked 
in the women (38/57 = 66.7% in controls vs 155/791 = 19.6% in cases) (χ2 test, 
p<0.0001) (see Table 12.3 and Figure 12.2).  
These results justified testing, in the final model, whether the association 
between the suspected cause of haematuria (benign versus malignant) and its 
recording solely in the text was different in male compared with female patients.  
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Table 12.3 Overall numbers of patients in the bladder cancer dataset presenting at least once 
with visible haematuria recorded as a Read code or solely in the text, grouped by cause of 
visible haematuria within gender 
Gender  Benign 
cause vs 
bladder 
cancer 
Number of patients (%) attending at least once 
estimated using: 
Visible 
haematuria 
Visible 
haematuria 
Visible 
haematuria 
Male a Benign 
(controls)  
177 (63.4) 102 (36.6) 279 (100)  
Bladder 
cancer 
(cases)  
1,955 (83.0) 401 (17.0) 2,356 (100)  
Subtotal 2,132 (80.9) 503 (19.1) 2,635 (100)  
Female 
b 
Benign 
(controls)  
19 (33.3) 38 (66.7) 57 (100) 
Bladder 
cancer 
(cases)  
636 (80.4) 155 (19.6) 791 (100)  
Subtotal 655 (77.2) 193 (22.8) 848 (100)  
Total  2,787 (80.0) 696 (20.0) 3,483 (100) 
a χ2 test: p<0.0001 – strong evidence to reject the null hypothesis that, within men, there is no association 
between benign vs malignant cause of visible haematuria and recording style. 
b
 
 
χ2 test: p<0.0001 – strong evidence to reject the null hypothesis that, within women, there is no 
association between benign vs malignant cause of visible haematuria and recording style. 
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Figure 12.2 Overall numbers of patients in the bladder cancer dataset presenting at least once 
with visible haematuria recorded as a Read code or solely in the text, grouped by gender within 
cause of visible haematuria 
 
 
12.5 Modification of the effect of urinary tract infection by 
gender   
For male patients there was a greater tendency for their attendance for visible 
haematuria to be recorded solely in the text if they had a history of a urinary 
tract infection (107/384 = 27.9%) than if they did not (396/2,251 = 17.6%). A 
similar pattern was observed in the women (68/241 = 28.2% in women with a 
history of a urinary tract infection, compared with 125/607 = 20.6% in women 
with no such history) (Table 12.4 and Figure 12.3). Indeed, the results 
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suggested an association between recording style and a history of urinary tract 
infection in men (χ2 test, p<0.0001) and women (χ2 test, p<0.05). 
These results justified testing, in the final model, for modification of the effect of 
urinary tract infection by gender.  
Table 12.4 Overall numbers of patients in the bladder cancer dataset presenting at least once 
with visible haematuria recorded as a Read code or as text only, grouped by a history of urinary 
tract infection (UTI)  within gender 
Gender UTI  Number of patients (%) attending at least once 
estimated using: 
Visible 
haematuria 
Visible 
haematuria 
Visible 
haematuria 
Male No UTI 1,855 (82.4) 396 (17.6) 2,251 (100) 
UTI 277 (72.1) 107 (27.9) 384 (100) 
Subtotal 2,132 (80.9) 503 (19.1) 2,635 (100) 
Female No UTI 482 (79.4) 125 (20.6) 607 (100) 
UTI 173 (71.8) 68 (28.2) 241 (100) 
Subtotal 655 (77.4) 193 (22.6) 848 (100) 
Total  2,787 (80.0) 696 (20.0) 3,483 (100) 
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Figure 12.3 Overall numbers of patients in the bladder cancer dataset presenting at least once 
with visible haematuria recorded as a Read code or as text only, grouped by history of urinary 
tract infection (UTI) within gender 
 
12.6 Multivariable analysis – main effects 
The main effects of patient case/control status,a attendance for urinary tract 
infection and gender were significant in multivariable analysis (see Table 12.5). 
Patient case/control status was most strongly associated with the outcome ‘text-
only recording of visible haematuria’ (odds ratio 3.7, 95% CI: 2.8–4.7, 
p<0.0001), followed by urinary tract infection (odds ratio 1.9, 95% CI: 1.8–2.2, 
p<0.0001). Women were more likely than men to have their haematuria 
recorded in the text (odds ratio: 1.2, 95% CI: 1.0–1.5, p<0.05). Clustering within 
                                            
a
 Note this is a proxy for cause of haematuria, i.e. assumed to be benign in the controls and 
bladder cancer in the cases. 
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GP practice was significant and adjustment for this was retained (likelihood ratio 
test, p<0.001).  
Table 12.5 Multivariable analysis for the outcome ‘text-only recording of visible haematuria’ 
(mixed-effects logistic regression, controlling for random effects of clustering within GP practice) 
Explanatory variable  Odds ratio 
(multivariable 
analysis) a 
95% CI p 
value b 
Control–case status (benign cause 
vs bladder cancer) 
3.7 2.8–4.7 0.0001 
Gender (female vs male) 1.2 1.0–1.5 0.04 
Urinary tract infection (≥1 
attendance vs no attendance) 
1.8 1.4–2.2 0.0001 
Constant 0.2 0.1–0.2 0.0001 
a
 Random effect of clustering within GP practice was significant (χ2= 34.7, p<0.0001). 
b
 z-test of the null hypothesis that the odds ratio is 1. 
12.6.1 Effect modification  
There was no evidence that the effect of a history of urinary tract infection on 
text-only recording of visible haematuria was different in men and women 
(interaction term not significant, p = 0.4).  
In contrast, the effect of benign versus malignant cause of visible haematuria on 
the style used by GPs to record the symptom was markedly different in men 
and women (interaction term 3.1, 95% CI: 1.6–6.2, p<0.001); therefore, this was 
retained in the final model (Table 12.6).  
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12.6.2 The final model 
The final model is reported in Table 12.6. Suspicion of an underlying benign 
pathology was positively associated with text-only recording of visible 
haematuria. This was most strongly observed in female controls attending for 
visible haematuria, for whom the odds ratio of text-only recording was 9.3 (95% 
CI: 5.0–17.4, p<0.0001). In male controls, the odds ratio was less, at 3.0 (95% 
CI: 2.2–4.0, p<0.0001). For this reason, the main effect of gender was retained 
in the final model, despite the fact that it was not significant (p=0.4). The odds 
that GPs would record attendance for visible haematuria solely in the text were 
1.8 times (95% CI: 1.4–2.3, p<0.0001) higher if patients had a history of urinary 
tract infection. The random effect of clustering within GP practice (the estimated 
standard deviation in the intercept on the logit scale is 0.4, 95% CI: 0.3–0.7) 
was significant (χ2 = 34.8, p<0.0001). 
Table 12.6 Multivariable analysis for the outcome ‘text-only recording of visible haematuria’ 
(mixed-effects logistic regression, controlling for random effects of clustering within GP practice) 
Explanatory variable Odds ratio 
(multivariable 
analysis) 
95% Confidence 
interval 
P 
valuea 
Benign cause vs bladder 
cancer (in men) 
3.0 2.2–4.0 0.0001 
Benign cause vs bladder 
cancer (in women) 
9.3 5.0–17.4 0.0001 
UTI vs no UTI 1.8 1.4–2.3 0.0001 
Female vs male 1.1 0.9–1.4 0.4 
Constant 0.2 0.1–0.2 0.0001 
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Note to Table 12.6: 
a z-test that the odds ratio is not 1. 
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13 Discussion  
This was primarily a methodological study, albeit with some clinical implications, 
using the Clinical Practice Research Datalink (CPRD) primary care database. 
The methodological objectives were devised to investigate recently developed 
research methods for cancer diagnosis that use electronic general practice 
databases; for example, methods underpinning the derivation of QCancer7 and 
risk assessment tools.4,5 This is important, because many studies using these 
techniques informed recently updated guidance from the National Institute for 
Health and Care Excellence (NICE) on cancer referral from primary care. 
Indeed, the recommendations in these guidelines influence NHS spending 
approaching £1bn annually.9 
To carry out the study, two datasets used to characterise the presentation of 
bladder4 and pancreatic5 cancer in primary care were re-created and then 
augmented with previously unavailable, ‘hidden’, text records of attendance for 
haematuria, jaundice and abdominal pain. This newly acquired information 
allowed me to identify – and, to an extent, quantify – methodological problems 
inherent in symptom-based studies that use such databases but omit text 
records from analysis.  
This chapter starts with a discussion of the validity of the methods used in this 
thesis (Section 13.1), as well as their strengths and limitations (Section 13.2). 
Discussion of my study’s methodological findings follows next (see Section 
13.3), including an outline of their implications for future research using data 
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from the CPRD. The impact of the methodological findings on clinical outcome 
measures is discussed in Section 13.4. Finally, the new clinical findings of this 
study are discussed in Section 13.5.  
13.1 Choice of study design 
To a large extent, the study design was governed by decisions made by 
researchers who planned the original studies that were extended by my PhD.4,5 
The case–control designs, set in the CPRD, were chosen because they 
permitted the study of prospective medical records of a sufficiently large number 
of patients diagnosed with the cancers of interest. The study design also 
enabled multiple symptoms and signs reported by the patients to be 
investigated.  
My study design has a number of strengths and limitations, which are discussed 
below. 
13.2 Study strengths and limitations 
13.2.1 Setting  
A shared aim of the original studies was to improve the selection of primary 
care patients referred to secondary care for investigation of possible cancer. 
Therefore, the CPRD – generally regarded as the gold standard of primary care 
databases – was the ideal setting for those studies.1  
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The strengths of the CPRD were discussed in detail in Section 2.4, and include 
its large size, high data quality and the fact that it is a probability samplea of the 
UK population. Indeed, during the recruitment period of this study, more than 
500 GP surgeries in England, Northern Ireland, Scotland and Wales were 
registered with the CPRD, covering approximately 5% of the UK population. 
Therefore, inferences can be drawn from the results of this study to the UK 
population as a whole. 
13.2.2 Case finding 
In order to identify and quantify recording style bias between cases and controls 
it was paramount to identify cancer patients (the cases) and healthy patients 
(the controls) accurately.  
As discussed in Section 3.2.2, more cases of urinary tract and pancreatic 
cancers were recorded on the National Cancer Data Repository than in the 
CPRD.25 In total, this affected a relatively small number of cases in that study; 
namely, 20 urinary tract cancer cases (so, presumably an even smaller number 
of bladder cancer cases) and 23 pancreatic cancer cases that were recorded in 
the cancer registry but not in the CPRD.  
                                            
a
 Probability sampling means that every person in the population has a known – and non-zero – 
probability of being included in the sample selected for study. It is valid to make inferences 
about population parameters from probability sample estimates.   
316 
 
A recent population-based cohort study validated diagnoses of colorectal, lung, 
gastroesophageal and urological cancers in England recorded in the CPRD by 
comparison with Cancer Registry data. The study period – 1 January 2001 to 31 
December 2007 – coincided with my study’s recruitment period.132 Validation of 
CPRD diagnoses was reported in terms of their positive predictive value (PPV) 
(namely the proportion of CPRD cancers confirmed in the Cancer Registry), 
their sensitivity (i.e. the proportion of cancers correctly identified in the CPRD) 
and specificity (i.e. the proportion of patients identified as cancer-free in the 
CPRD). While neither bladder nor pancreatic cancer was investigated 
specifically, the study reported that the PPV of a CPRD diagnosis was 92% for 
urinary tract cancers and 96% for gastroesophageal cancers. The sensitivity 
was 85% for urological and 92% for gastroesophageal cancers. The specificity 
was also high – at 99% for both cancer sites – suggesting low numbers of false-
positives within the CPRD. Urological and gastroesophageal cancer diagnoses 
were recorded a median of 4 days (interquartile range −22 to +13 days) and 9 
(−29 to +7) days later, respectively, in the CPRD than in the Cancer Registry.  
The authors noted study limitations, such as use of a convenience samplea and 
restriction to CPRD practices in England with linkage to the Cancer Registry. 
Therefore, inferences about the CPRD overall should be made with caution.132 
                                            
a
 Convenience samples are non-probability samples that are drawn from a population purely 
because they are close to hand and readily available.  
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Overall, the findings of both studies are reassuring that cancer diagnoses 
recorded in the CPRD can be viewed as valid and accurate approximately 90% 
of the time.25,132 
13.2.3 Symptom identification  
In order to identify recording style bias between cases and controls accurately, 
it was important to identify all coded and text records of each of the symptoms 
studied. My study has several strengths and some limitations in this regard, 
which are now discussed.   
13.2.3.1 Symptom thesauri 
An undoubtable strength of the study was the comprehensive nature of the 
symptom thesauri compiled to identify the frequency of patient attendance, 
where this had been recorded.  
There were two main indications that the symptom thesauri were sufficiently 
comprehensive to identify all coded records of attendance for haematuria, 
jaundice and abdominal pain.  
First, it appears that, despite having the choice of a variety of codes for each 
symptom within the Read code system, GPs consistently used a relatively small 
selection (see Section 9.1.3). The rare or ‘doubtful’ codes that were retained in 
the thesaurus were used very sparsely, or never at all.  
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Secondly, identifying the codes that were paireda with text-only records of 
attendance for haematuria, jaundice or abdominal pain incidentally afforded the 
opportunity to examine the scope of the symptom thesauri to identify all coded 
attendances for those symptoms. None of the paired codes were identified as 
having been overlooked for inclusion in the symptom thesauri. This was 
reassuring, particularly for abdominal pain where we had decided against 
including codes for abdominal discomfort and abdominal tenderness (see 
Section 6.8.1).  
Strictly, identifying these paired codes does not wholly exclude the possibility 
that the thesauri had still omitted some codes that GPs had used to document 
the symptoms. However, it would be on the very unlikely condition that the GP 
had never commented further on the symptom in the paired text box. 
It is, of course, possible that GPs omitted to record symptoms reported by 
patients and that patients themselves did not report symptoms they were 
experiencing. This study was limited in that it could not assess the extent of 
these unrecorded or unvoiced symptoms.  
Despite the above-mentioned caveat, it is reassuring that the methods used to 
compile the symptom thesauri – adopted in all CAPER studies (Section 4.2) – 
were thorough. My study confirms that most, if not all, coded records of 
                                            
a
 Reminder: In ViSion, the main IT program used by GP practices contributing to the CPRD, a 
text record can only be made once a code has been selected – hence, all text records must 
have a ‘paired’ coded entry.  
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attendance for symptoms that were both reported and recorded were extracted 
consistently and reliably in CAPER studies.40,41,42,43,44,45,46  
13.2.3.2 Symptom identification from text records 
There were some limitations to the methods used to identify text records of 
attendance for the symptoms examined in my study.  
First, the CPRD methods used to identify extracts from the text fields will have 
missed any references to symptoms made using incorrect or US spelling. This 
is particularly relevant to haematuria, the American spelling of which is 
hematuria. Reassuringly, we found no American English spelling elsewhere in 
the text extracts (e.g. estrogen rather than oestrogen) and a very low 
typographical error rate of 0.64%. Even so, the frequency of attendance 
identified from text records is probably very slightly underestimated.  
Secondly, only the search phrase plus three words either side was available for 
analysis. This sometimes made it difficult to decide whether the symptom was a 
current concern or not. For example, two practising GPs could not agree as to 
the meaning of 14 out of 100 randomly selected text extracts, and agreed that a 
further two extracts were uninterpretable. I decided to err on the side of caution 
and categorise patients as not having a symptom if there was any uncertainty. 
Therefore, the frequency of attendance from text records is likely to be 
underestimated.  
Thirdly, the study did not examine whether the use of text-only recording 
changed over the course of the recruitment period, i.e. from 1 January 2000 to 
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31 December 2009, In hindsight, given the knowledge that the CPRD is no 
longer able to collect text data or allow access to historical text data, it would 
have been valuable to explore trends in text-only data recording over this 10-
year period.  
13.2.4 Lifestyle factors 
Lifestyle factors, such as smoking and obesity, were not included as possible 
explanatory variables in the original studies. This was deliberate, as the studies 
were seeking to model the prodromal symptoms of bladder and pancreatic 
cancer rather than to identify risk factors for developing these diseases. 
It is possible that a GP would consider cancer more likely in symptomatic 
patients with known risk factors than in symptomatic patients without these risk 
factors. If the summated perceived risk of cancer affected the recording style, 
then information about these risk factors would be helpful. That said, even if the 
smoking and obesity data were reliable and available, my case–control study 
design is not optimal for investigating the effect of these lifestyle factors on 
recording style bias. The direct investigation of factors that contribute to a GP's 
decision of whether to record a patient's symptom using a code or solely in the 
text would require a separate study, in which the outcome was the recording 
style rather than a cancer diagnosis.  
I carried out some post-hoc analyses (see Section 13.3.9 for the discussion of 
these findings) to explore the potential of this approach for future studies. 
However, a moratorium on the collection of text data by the CPRD was 
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introduced in 2013, reducing the practicability of this as a future avenue of 
research.  
In reality, the recording of body mass index tends to be opportunistic, occurring 
when patients attend for another reason or because it is directly relevant to the 
patient's current clinical condition. Furthermore, the body mass index changes 
over time; therefore, even if this information were recorded in the CPRD, it may 
not accurately reflect the patient's status at the time the GP was assessing the 
likelihood of cancer.  Bhaskaran et al133 assessed the completeness of body 
mass index recording in the CPRD in a random sample of 1 million patients 
aged 16 years or older. They reported that a recent value of body mass index 
(i.e. in the previous 3 years) had been recorded for only 34% of their sample in 
the years 2000–2004 and for 51% in the period 2005–2011, indicating the poor 
availability of this data type in the CPRD.  
An incentive to record smoking status was introduced with the Quality and 
Outcomes Framework in 2004.47 Booth et al (2013) conducted a validation 
study of smoking records in the CPRD between 2007 and 2011. They reported 
that, of their sample (n = 279,682) of patients from English practices, 226,568 
(81%) had at least one record indicating their smoking status, suggesting that 
recording levels are high. In addition, there was good agreement between 
smoking prevalence estimates in the CPRD and in the Health Survey for 
England.134 This suggests that it would be feasible to design a study to 
investigate the effect of smoking status on recording style bias, although it 
would have to be set prior to 2013 to match the period of text record availability. 
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Even so, such a design would require establishing each patient's past (rather 
than current) smoking habits to determine their level of exposure to this risk 
factor.  
13.2.5 Possible sources of bias within the study 
13.2.5.1 Recall bias 
Recall bias is a common concern for case–control studies, which generally rely 
on participants’ memories of past exposure to risk factors. While the analysis 
was conducted retrospectively, the consultations themselves were recorded 
prospectively; therefore, recall bias was eliminated from both this and the 
original studies.4,5  
13.2.5.2 Reporting bias 
Matching on each of sex, age and GP practice minimised the potential for 
reporting bias. However, one could argue that patients in the early presentation 
stage of cancer might be starting to become worried about their health and have 
a lower threshold for attending the GP than controls. In the original studies this 
was examined by looking for differences in attendance between cases and 
controls for fractures. This was based on the concept that the more frequently 
patients attended the surgery, the greater their opportunity to voice unrelated 
items in addition to those that prompted the consultation. Fractures were 
chosen because they were thought to be equally likely across the entire study 
population, given that incident rather than metastatic cancer was investigated. 
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Neither of the original studies reported evidence of differential reporting patterns 
between cases and controls for fractures.  
The choice of fractures may be criticised, however, because they are 
unambiguous diagnoses requiring the patient to seek treatment and follow-up in 
fracture clinic. Arguably, a fracture is unrepresentative of ‘low-risk but not no-
risk’ symptoms such as abdominal pain, the reporting of which may vary with a 
patient’s individual tolerance, capacity for self-management or knowledge of the 
symptom’s significance.  
A study of the presentation of cancer in childhood, carried out in association 
with our group, used attendance patterns for head lice and acne rather than 
fractures to examine differential reporting between patient groups.135 There was 
no evidence from either of these ‘control’ conditions to indicate reporting bias 
between the cases and controls. 
13.2.5.3 Detection bias 
In my study, the non-visible haematuria records are vulnerable to detection 
bias.136 This is because non-visible haematuria is only detected by specific 
dipstick testing of the urine. As described in Table 4.6, specific indications for 
urine dipstick testing include screening for (and monitoring of) diabetes mellitus 
and the diagnosis of renal disease. Therefore, patients with diabetes mellitus or 
renal disease, such as glomerulonephritis, may be over-represented in the 
group identified as having non-visible haematuria. There is no reported 
association between diabetes mellitus or glomerulonephritis and bladder 
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cancer, suggesting that testing is likely to be equally spread between cases and 
controls. However, urine dipstick testing may also be prompted where the GP 
suspects urological disease (including bladder cancer), leading to preferential 
testing in cases over controls.  
The detection bias probably leads to an underestimation of the total number of 
patients with non-visible haematuria. In addition, the effect is likely to be 
unequal between the cases and controls. This suggests that any detection bias 
present in my study may inflate the risk estimates for bladder cancer in patients 
with non-visible haematuria.  
13.2.5.4 Selection bias 
Another limitation of the study is that it did not identify whether the recording 
style bias was caused by the recording behaviour of a small number of GP 
practices. However, it was felt important to include data from all contributing 
practices in order to obtain a measure of bias in CPRD studies overall. This is 
because the CPRD does not provide quality measures about the quantity of 
data recorded in hidden text – arguably they should be encouraged to do so at 
the practice level. This is particularly important now that text data are no longer 
collected and will not be available in future studies. 
13.2.6 Missing data 
This was an observational study of electronic medical records made during 
routine clinical practice; therefore, information about particular symptoms of 
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interest was not specifically sought by GPs, generating much missing data. 
Missing data is an acknowledged limitation of the CPRD.2  
In my study, the lack of either reporting or recording of a symptom was 
interpreted as no evidence that the symptom occurred. Altman and Bland 
caution against this approach,137 presumably because it risks introducing 
misclassification, particularly for binary outcomes. Including text records goes 
some way to correcting for any such misclassification, although it cannot correct 
for errors that arise when patients either do not voice their symptoms, or GPs 
do not record them by any method.  
Herrett et al acknowledge that the approach taken in my study is the only 
workable option when faced with missing Read codes for binary variables in 
CPRD studies.2 An alternative is imputation, but this is only suitable for 
continuous variables. Even then, patterns of 'missingness' vary and are 
complex in the CPRD, making it difficult to impute the missing values of 
continuous variables accurately. Herrett et al cite the examples of body mass 
index, which is more likely to be recorded in patients with ill health, and of blood 
pressure, which is recorded more frequently in those with cardiovascular 
disease. Another alternative is to restrict analysis to patients with complete 
data; however, this would drastically reduce the power of the study and 
introduce a bias in favour of patients who have ill health and who attend 
frequently.2 
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13.3 Discussion of methodological findings 
This section starts with a brief overview of the symptoms to frame the ensuing 
discussion of the quantity of information about the symptoms recorded in hidden 
text at the event level and the consequences of this at the patient level.  
13.3.1 The symptoms – a brief overview of their clinical 
significance 
13.3.1.1 Jaundice 
Jaundice has a variety of causes in adults, including gallstones and life-
threatening malignancies such as pancreatic cancer. Gallstones typically 
present in women over 40 years old, who are both overweight and have a 
history of several pregnancies85; therefore, they were unlikely to be a common 
cause of jaundice in the pancreatic cancer study.a 
As jaundice may indicate the presence of a serious condition, it is generally 
viewed as a worrying – ‘alarm’ – symptom in adults, particularly in those free 
both of gallstones and alcoholic disease, because of the possibility of pancreatic 
cancer.9,93  
Jaundice has no reported association with bladder cancer.  
                                            
a
 Indeed, in my reanalysis of the pancreatic cancer dataset, I identified that only 138/20,094 
(0.7%) of the patients had a history of gallstones, of whom 83 (60%) were women. 
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13.3.1.2 Visible haematuria 
Visible haematuria is also an alarm symptom with a variety of causes, ranging 
from urinary tract infections and calculi to serious malignancies such as bladder 
cancer. Benign nephrological causes, for example calculi, generally present in 
patients younger than those recruited to my study, who were aged 40 years or 
over.a In contrast, urinary tract infection is common in women, owing to their 
short urethra, and older women are particularly susceptible because their 
oestrogen levels fall after the menopause.85 This is exemplified by the fact that, 
in the bladder cancer study, of the patients who experienced a urinary tract 
infection in the analysis period, nearly half were women, even though they only 
made up about one-quarter of the overall study population.b Urinary tract 
infection was associated with bladder cancer strongly enough to be included in 
the final model of risk markers of the disease (see Table 10.9). 
Visible haematuria is also viewed as a serious clinical symptom, particularly in 
patients who either present with other features of urological tract malignancies 
or in those confirmed as not having a nephrological cause, urinary tract infection 
or stones.72 The updated NICE guidelines recommend referral for patients for 
                                            
a
 In my reanalysis of the bladder cancer dataset, I identified that only 12/26,633 (0.05%) of the 
patients had an episode of calculi during the analysis period. 
b
 Of the 1,540 patients who had a urinary tract infection in the analysis period in the bladder 
cancer study, 707 (46%) were women, which is high considering that women comprised only 
7,618/26,633 (28.6%) of the study population.  
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suspected bladder cancer if they are aged 45 years and over and have 
unexplained visible haematuria without a urinary tract infection, or persistent 
visible haematuria that recurs after successful treatment of a urinary tract 
infection.9  
There are similarly no reported associations between visible haematuria and 
pancreatic cancer.  
13.3.1.3 Abdominal pain 
In contrast with these alarm symptoms, abdominal pain is a ‘low-risk but not no-
risk’ symptom associated with both the cancers studied. In isolation, abdominal 
pain does not merit investigation for either bladder or pancreatic cancer; 
however, the updated NICE guidelines recommend that patients should be 
referred for possible pancreatic cancer if they present with abdominal pain in 
association with weight loss.9 
Abdominal pain was the only symptom studied that was common to both cancer 
sites. Usage of text-only recording for this ‘low-risk but not no-risk’ symptom first 
appeared to be inconsistent between the cancers. Using the bespoke symptom 
thesauri from the original studies, text-only recording was used for a higher 
proportion of attendances in the bladder (1,106/2,795 = 40%) than in the 
pancreatic (2,215/7,191= 31%) cancer dataset. ‘Abdominal pain’, however, was 
defined far more broadly in the symptom thesaurus developed for the original 
pancreatic study compared with that created for the bladder cancer one, as it 
included codes for dyspepsia and indigestion. In contrast, identical search 
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criteria were used to extract the text records of abdominal pain from both cancer 
sites. As a consequence, text-only recording will have accounted for a smaller 
proportion of total abdominal pain records in the pancreatic, compared with the 
bladder cancer, study. Subsequent analysis using a generic symptom thesaurus 
for both cancers revealed that this 9% discrepancy in text-only recording 
between the cancer sites was an artefact, entirely accounted for by the 
differences in the bespoke symptom thesauri.  
13.3.1.4 Non-visible haematuria 
Non-visible haematuria is mostly associated with benign conditions such as 
glomerulonephritis, which generally present in patients younger than the 
participants recruited to my studies.77 
In terms of cancer diagnosis, non-visible haematuria is viewed as another ‘low-
risk but not no-risk’ symptom. Nevertheless, the NICE guidelines were recently 
updateda to include a new recommendation that patients who are aged ≥60 
years and who have unexplained non-visible haematuria and either dysuria or a 
raised white cell count on a blood test are referred for suspected bladder 
cancer.9  
                                            
a
 Using evidence in a paper published from this thesis. 
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13.3.2 Quantity of information recorded in hidden text at 
the event level 
At the event level, differing (and large) numbers of attendances for each of the 
four symptoms – haematuria (visible and non-visible), jaundice and abdominal 
pain – were recorded solely in hidden text (see Figure 9.1 and Figure 9.2). 
Therefore, the original studies could not have been aware of the reported and 
recorded occurrences of these symptoms.4,5  
13.3.2.1 Clinical significance of the symptom 
The amount of text-only recording was independent of the symptom’s clinical 
significance in terms of malignancy. Take, for example, the recording patterns 
for non-visible haematuria and jaundice – polar opposites in this regard.72,77,93 
Text-only recording was used frequently for both these symptoms, documenting 
well over half of the attendances for non-visible haematuria (298/494 = 60%) 
and for approximately half of the attendances for jaundice (1,639/3,338 = 49%). 
In contrast, a far lower proportion of attendances for visible haematuria – 
another alarm symptom, albeit of lower risk than jaundice72 – was recorded 
solely in the text (2,699/7,302 = 37%).   
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13.3.2.2 What are GPs coding in preference to the symptom itself?  
13.3.2.2.1 The source of information 
Analysis of the code paireda with the text-only recording suggested that, at the 
event level, documenting the source of symptom information (frequently ‘Letter 
from Specialist’) using a readily retrievable method (i.e. codes) is an important 
factor for GPs. 
Good-practice guidelines – current during the study period – were drawn up to 
advise GP practices as they migrated over to paperless systems. These 
guidelines give some insight into why GPs frequently gave priority, in terms of 
retrievability, to the information source over the information itself. Specifically, 
Sections 4.13 and 4.14 in the guidance stipulate the requirement to ensure that 
contacts, encounters and interventions that take place outside the GP surgery 
are clearly recorded using location codes.138 This information is undoubtedly 
important, as it presents a complete picture of the care received by a patient.  
13.3.2.2.2 The context of the consultation 
At the event level, text-only records for all symptoms were also frequently 
paired with codes describing the context of the consultation. This may be 
                                            
a
 Reminder: In ViSion, the main IT program used by GP practices contributing to the CPRD, a 
text record can only be made once a code has been selected – hence, all text records must 
have a ‘paired’ coded entry.  
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because GPs want to initiate the medical record at the outset of the consultation 
(which, in ViSion, requires selection of a code) and are unable to select an 
appropriate clinical code until they have taken the history.  
In some cases, it may be that documenting the context of the consultation in a 
clear and easily retrievable way reflects defensive medical record-keeping 
practices, with GPs ensuring that they have defined the limits of their clinical 
interaction with the patient. The frequent pairing of ‘Telephone encounter’, for 
example, with text-only records of all symptoms likely reflects the importance for 
GPs of logging that fact that their ability to carry out a full and thorough 
examination was diminished.  
13.3.2.3 The increasing importance of ‘retrievability’ 
When medical records were entirely paper-based,a there was no choice but to 
retrieve information manually. The issue of ‘retrievability’ has grown in 
importance with the increasing computerisation of medical records. This is not 
only because computer searches can be used to automate, quickly and at 
reduced cost, the retrieval of anything recorded using a code. It is also because, 
when they are creating the electronic medical record, GPs now have to consider 
what information needs to be easily retrievable (i.e. coded), by whom and to 
what end.  
 
                                            
a
 In primary care, paper records were stored in ‘Lloyd George Envelopes’. 
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13.3.2.3.1 Updated best practice recommendations for record-keeping 
The recommendations for good record-keeping that were in place during the 
study period138 were updated in 2011, and have elevated the importance of 
‘retrievability’.139 The updated guidelines state that ‘where information can be 
adequately recorded using codes and structured data entry it is generally better 
to do so, but where this is not possible free-text clinical narrative can be used 
instead of or to clarify structured data entry.’139 In this context, ‘clear 
documentation’ means ‘coding’, as this is the only recording method that 
ensures the information is readily retrievable in a computerised search. It is, of 
course, moot whether GPs ever read, let alone adhere to, such lengthy 
documents.  
The updated recommendations reiterate the importance of clearly documenting 
the source of all clinical information, to capture that which comes from outside 
the practice. Acknowledging the impracticality of processing what may be large 
quantities of information, the guidelines recommend recording key data using a 
code.139  
Finally, the updated guidelines place increased emphasis on the importance of 
documenting the context of all encounters between GPs and their patients, both 
within and outside the GP surgery. The guidelines state: ‘when information is 
recorded that is likely to be shared with others working in a different setting, 
particular care needs to be taken to ensure that important context is made as 
explicit and unambiguous as possible’.139 This assists care where patients are 
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often seen by a number of different healthcare professionals or GPs within a 
practice.  
13.3.2.3.2 Medico-legal factors 
An increasingly litigious atmosphere is also driving GPs to ensure that medico-
legally important information is readily retrievable (i.e. coded) from the 
electronic medical record. 
The numbers of complaints and medico-legal claims against GPs is increasing 
year on year.140 In addition, the Criminal Justice and Courts Act 2015, which 
came into force in April 2015, extended the remit of the criminal offence of ‘ill-
treatment or wilful neglect’ from children and people who lack capacity to cover 
competent adults.141 An important aspect of this extension is that a patient need 
only complain about aspects of the clinical care, or about a near miss, for the 
event to be considered a possible ‘crime’. While the Medical Defence Union 
anticipates that the offence of ill-treatment or wilful neglect will be prosecuted 
rarely, they predict an increase in criminal investigations of GPs.  
In addition, new legislation was introduced in 2014, placing a statutory 
requirement on all doctors to have relevant insurance or professional indemnity 
to cover their medical practice. The majority of doctors had already made such 
provision, but its profile was raised by the legislation’s granting of power to the 
General Medical Council to remove a doctor’s licence to practise if such cover is 
not in place.142 This adds further impetus to the legalistic view of the medical 
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consultation, and its subsequent recording. The maxim ‘if it isn’t written down, it 
didn’t happen’ is at risk of mutating into ‘if it isn’t coded, it didn’t happen.’ 
13.3.2.4 Summary and implications  
The growing pressures to prioritise the documentation of ‘governance-type’ 
events in a readily retrievable way raise a serious concern that increasing 
quantities of important clinical information about patients will be unavailable in 
the future to both clinical audit and researchers because its recording is 
‘relegated’ to the hidden text.  
The above discussion has centred on the recording of symptoms at the event 
level, and how text-only recording may lead to underestimation of the number of 
episodes of a symptom. Re-attendance at the GP practice offers patients 
another opportunity to voice their symptoms and for the GP to record them in a 
retrievable manner using a code. This brings me to the discussion of my 
analysis at the patient level.   
13.3.3 Quantity of information recorded in hidden text at 
the patient level 
My study shows that GPs frequently and consistently recorded attendances for 
haematuria, jaundice or abdominal pain in the hidden text. For some patients, 
this occurred to such an extent that their entire record of attendance for that 
symptom was concealed from the original studies, which had analysed just the 
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coded records.4,5 This led to their underestimating the numbers of patients with 
a history of these symptoms.  
13.3.3.1 The importance of a symptom’s clinical significance 
Moving on from event-level to patient-level analysis,a a pattern appeared in the 
bladder cancer study suggesting the importance of a symptom’s clinical 
significance. This contrasts with event-level data, where text-only recording 
appeared to be independent of clinical significance, driven rather by the source 
of symptom information and the context of the consultation.  
The results from the bladder cancer study suggested that underestimation of 
the number of patients with a history of a symptom was inversely proportional to 
the risk of bladder cancer associated with that symptom. Compare, for example, 
visible and non-visible haematuria – conventionally perceived as contrasting 
symptoms in terms of bladder cancer risk. Within bladder cancer, for nearly 
60% of the attendees for the low-risk, non-visible form of haematuria, all their 
records of attendance for the feature were concealed in the text,77 compared 
with only 20% of all attendees for the ‘alarming’ visible form.72 The 35% of 
attendees for ‘low-risk but not no-risk’ abdominal pain identified solely by text 
records lay between these values (see Figure 9.4).  
                                            
a
 Reminder: Each patient was categorised by the overall style used to record their attendances 
for the symptom. ‘Coded’ was assigned if any record of a symptom was in coded form; 
conversely, ‘text-only’ was designated only when all instances were noted solely in the text.  
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These findings are entirely consistent with the hypothesis that doctors 
preferentially record clinical features substantiating what they think is the correct 
diagnosis and, furthermore, that they are more likely to use codes than text for 
alarm symptoms (see Section 5). This was also explored in post-hoc analysis 
(see Section 12), the results of which are discussed below in Section 13.3.9. 
In contrast, the results from the pancreatic cancer study were not in keeping 
with the above-mentioned hypothesis, and possible reasons for this are 
discussed below. 
13.3.3.2 In the pancreatic cancer study 
The pattern of recording in the pancreatic cancer study was not consistent with 
the hypothesis that doctors preferentially record clinical features substantiating 
what they think is the correct diagnosis, and that they are more likely to use 
codes than text for alarm symptoms.  
Rather, records for 30% of patients attending for jaundice (a ‘red flag’ for 
pancreatic cancer) in the analysis period were concealed in the text, compared 
with records for 22% of patients attending for abdominal pain (see Figure 9.4).  
There are several possible explanations which, collectively, may account for this 
discrepancy between cancer sites, as discussed below.  
First, for 77 cases (77/3,635 = 2.1%), their only documented presentation with 
jaundice coincided with their diagnosis with pancreatic cancer. For these 77 
patients, it was the diagnosis that was codified into the electronic medical 
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record – the jaundice was noted solely in the accompanying text field. Arguably 
this reflects the greater significance of the diagnosis compared with its 
symptomatic manifestation. In contrast, a smaller proportion of cases in the 
bladder cancer study (43/4,915= 0.9%) had a single episode of visible 
haematuria that not only coincided with their date of diagnosis but was also 
noted solely in the text. Conceivably the difference between the cancer sites 
here reflects the fact that jaundice is generally a late feature of pancreatic 
cancer.143  
Secondly, the symptom thesaurus for abdominal pain was broader in the 
pancreatic than in the bladder cancer study, including as it did codes for 
dyspepsia and indigestion. In contrast, identical search terms were used across 
the two studies to extract text records of the symptom. Therefore, by default, the 
proportion of attendees for ‘abdominal pain’ in the pancreatic cancer study 
identified by text-only records will be artefactually low. Indeed, using the generic 
symptom thesaurus for abdominal pain increased the proportion of attendees 
whose entire record was documented in the text in the pancreatic cancer study 
from 22% to 25%.  
Finally, re-attendance for abdominal pain was far more common in the 
pancreatic than in the bladder cancer study. This is likely to reduce the 
proportion of attendees whose entire history of the symptom was documented 
solely in the text, simply because re-attendance for a symptom increases the 
number of opportunities for GPs to codify the symptom into the electronic 
medical record. It may, however, also reflect the fact that GPs are recognising 
339 
 
the increased clinical significance of the abdominal pain with re-attendance, and 
deliberately ensuring its documentation in a retrievable manner using a code.  
This brings us to the importance of the context of presentation. 
13.3.3.3 Context of presentation 
The ‘context of presentation’ includes considerations such as the likelihood that 
the patient’s symptom(s) manifest serious disease, the constellation of other 
signs and symptoms presented by patients during a consultation, as well as 
patient characteristics such as their age.  
If the context of presentation played no role in determining how symptoms were 
recorded at the patient level, one would predict that their recording patterns 
would be identical across the bladder and pancreatic cancer studies.  
13.3.3.3.1 Age  
The age profiles of the participants in the two cancer studies were very similar: 
both studies shared the same age criteria for recruitment, i.e. cases had to be at 
least 40 years old, and the controls were matched with the cases on age. 
Furthermore, the median age of diagnosis was 74 (95% CI: 66–80) years for 
bladder cancer cases and 73 (65–80) years for pancreatic cancer cases. 
Therefore, any difference in context of presentation between the studies is 
unlikely to be due to variation in the age profiles of their respective participants.   
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13.3.3.3.2 Alarm symptoms 
One-fifth of attendees (696/3,483 = 20%) for visible haematuria had their entire 
history of attendance for the symptom during the analysis period documented 
solely in the text in the bladder cancer study. This fraction more than doubled 
for the same symptom in the pancreatic cancer study (142/341= 42%). A similar 
pattern was observed for jaundice in the pancreatic and bladder cancer studies, 
respectively (see Figure 9.13).  
The results suggest that, once easily explicable causes have been excluded, 
the GPs are making strong clinical judgements that the possibility of pancreatic 
or bladder cancer has increased in patients presenting with jaundice or visible 
haematuria, respectively. Once they have recognised the seriousness of this 
possibility, GPs may ensure that this is documented in a readily retrievable 
manner in the patient’s notes, hence the increased preference for coding.139 
This discussion is expanded below, where patient factors are explored at the 
level of cases and controls (see Section 13.3.4). 
13.3.3.3.3 ‘Low-risk but not no-risk’ abdominal pain 
The trend for abdominal pain recording was similar in direction – but not 
magnitude – to that described above for visible haematuria and jaundice. Of the 
two cancer sites, the bladder cancer study had the greatest proportion of 
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patients with a history of abdominal pain concealed in the hidden text, reflecting 
the comparatively weaker association between them (see Figure 9.13).a  
In contrast with the alarm symptoms, however, this effect was small in size (4% 
difference between cancer sites). Consequently, despite its reaching statistical 
significance, it was of questionable clinical relevance. One possible explanation 
for the reduced effect seen for abdominal pain, compared with the alarm 
symptoms, relates to the fact that abdominal pain is such a non-specific 
complaint, particularly in the primary care setting.85  
13.3.4 Are studies of coded data vulnerable to bias arising 
from the differential use of text and codes between 
comparison groups? 
Unbiased estimates of clinical features in diseased and healthy groups require 
that GPs are equally likely to record information reported by the two comparison 
groups. Not only that, the accessibility of information within the electronic 
medical record must be the same for both groups. As discussed in detail above, 
                                            
a
 The same, generic, abdominal symptom library was used to compare how abdominal pain was 
recorded at the patient level between the bladder and pancreatic cancer studies. This is 
because re-using the bespoke symptom thesauri created for the bladder and pancreas studies 
generated a spurious difference in usage of text-only recording of abdominal pain at the event 
level between the cancer sites. 
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in the CPRD, only the coded records are readily and routinely available to 
researchers, the text being generally withheld (see Section 2.2). I have 
discussed the impact of this at the event and patient level, and now move on to 
discuss patient factors in greater depth by examining differences between 
comparison groups, i.e. cases and controls.  
A common assumption made by studies using electronic primary care data is 
that GPs have no systematic tendency to alter their recording style according to 
a patient’s later-designated case/control status4,5,40,41,42,43,44 – an assumption 
this study was specifically designed to test.  
The results reinforce the earlier proposed hypothesis (see Section 5) that GPs 
are making strong clinical judgements (driven by clinical context) about the 
probable significance of symptoms in patients. GPs appear to preferentially 
code clinical features they consider significant to a diagnosis, while tending to 
use hidden text to record those that they think are not. Therefore, studies of 
coded data are likely to be vulnerable to bias arising from the differential use of 
hidden text and codes between comparison groups, depending on the nature of 
the symptom being investigated and the context of its presentation. 
13.3.4.1 For alarm symptoms 
As discussed above (see Section 13.3.3), the original studies of bladder4 and 
pancreatic5 cancer considerably underestimated the numbers of patients 
attending during the analysis period for the alarm symptoms of visible 
haematuria and jaundice. Here I discuss how this extended to their obtaining 
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biased estimates of the numbers of cases and controls attending the GP for an 
alarm symptom associated with that cancer. While the mechanism of bias was 
slightly different in each cancer dataset, the net result in both instances was the 
same: the original studies obtained more complete information about alarm 
symptoms in their cases than in their controls.  
As discussed above, a greater proportion of attendees for visible haematuria in 
the bladder cancer study were identified by codes than by hidden text. This 
effect was more marked in the cases (with codes identifying 2,591/3,147 = 82% 
of attendees) than in the healthy controls (196/336 = 58%). Consequently, 
compared with the cases, a greater proportion of the visible haematuria records 
of control patients were lost in the hidden text.  
An even greater bias towards preferentially identifying cases over controls with 
a history of jaundice was observed in the pancreatic cancer study. The increase 
in bias was driven by the greater propensity of GPs to ‘relegate’ jaundice to the 
hidden text in the control patients, to the extent that coding only identified one-
third (10/31= 32%) of these patients, compared with 1,102/1,565 (70%) of the 
cases. This was a particularly revealing finding, given that the overall patient-
level analysis in the pancreatic cancer dataset had initially appeared 
inconsistent with the hypothesis that GPs are preferentially coding symptoms 
that substantiate their working diagnosis (see Figure 9.4 and Section 13.3.3.2).  
These results strongly suggest that GPs were correctly identifying the clinical 
significance of the alarm symptom (visible haematuria or jaundice) in the cases 
– all diagnosed with an associated cancer within the year – and preferentially 
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coding this into the medical record. Consequently, these recording style 
decisions introduced a bias that exacerbated the difference in burden of the 
alarm symptom between the comparison groups.  
The repercussions of these findings for outcome measures such as the positive 
predictive value and odds ratio are discussed below (see Section 13.4). 
13.3.4.2 For ‘low-risk but not no-risk’ symptoms 
The original studies also underestimated the numbers of patients who had 
attended for the ‘low-risk but not no-risk’ symptom of abdominal pain, because, 
for large numbers of patients, the entire record of attendance for the symptom 
was made solely in the text. That said, there was no evidence that omitting text-
only records from analysis led to biased estimates of the numbers of cases and 
controls with a history of abdominal pain. A similar pattern was observed for 
non-visible haematuria in the bladder cancer study. 
Abdominal pain is common to many diseases, and is not exclusively associated 
with either bladder or pancreatic cancer. Therefore, this lack of bias between 
cases and controls does not refute the hypothesis that GPs are correctly 
identifying the clinical significance of the symptom and opting to codify it in the 
electronic medical records. 
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13.3.5 Does the recording style vary with the clinical 
context of presentation of a symptom? 
As discussed in Section 5, GPs draw on their knowledge and experience to 
formulate a working diagnosis that best fits the patient’s presentation. This led 
to the hypothesis that doctors preferentially record any clinical features 
substantiating the working diagnosis, as opposed to everything reported by the 
patient. Analysis of recording methods allowed me to take this further and 
deduce that doctors preferentially ‘code’ those clinical features that substantiate 
their working diagnosis, rather than record them in the hidden text.  
The results at the patient level (Section 13.3.3.3) support the hypothesis that 
such recording behaviour leads to bias in the capture of information about 
symptoms based on their perceived likelihood of presentation in a particular 
context (Section 5). The bias caused the original studies to obtain more 
complete information about the alarm symptom in their cases than in their 
controls. 
More detailed analysis at the level of cases and controls further supports and 
develops the conclusions drawn from results at the general patient level. Not 
only are GPs accurately identifying when alarm symptoms are manifestations of 
their associated cancer, they are also recognising when the alarm symptoms 
are symptomatic of a pathology other than cancer.  
Take the recording patterns of visible haematuria as an example: the proportion 
of controls whose attendance(s) for the symptom was recorded using a code 
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was similar in the bladder (196/336 = 58%) and pancreatic (147/238 = 62%) 
cancer datasets. In contrast, the proportion of cases whose attendance(s) for 
the symptom was recorded using a code was far greater in the bladder 
(2,591/3,147= 82%) than in the pancreatic (52/103= 50%) cancer dataset. This 
loss of preference for coding visible haematuria in the pancreatic cancer cases 
actually reversed the recording style bias to the extent that more complete 
information was obtained about the alarm symptom in the controls than in the 
cases. A similar reversal of bias was observed for jaundice in the bladder 
cancer dataset. 
13.3.5.1 Summary 
The results at the patient level strongly support the hypothesis that GPs 
consider the constellation of signs and symptoms presented by patients to 
formulate a working diagnosis. Subsequently, they preferentially record in code 
any clinical features that substantiate this working diagnosis. This introduces a 
recording style bias into clinical research studies whose analysis is restricted to 
coded records. Of course, GPs also consider the patient's test results, but these 
are automatically coded into the patient's record such that these data are not 
vulnerable to any recording style bias. 
The next section proposes a framework of factors that are likely to influence 
GPs when deciding whether to record symptoms using a code or in the text. It is 
suggested that this framework may be used by researchers to anticipate the 
size and direction of any recording style bias in studies of CPRD coded data or 
similar datasets. 
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13.3.6 Recording method choices reflect the balance 
between several pressures  
The recording method decisions made by GPs can be considered in light of the 
strategies they take to arrive at a diagnosis.108 The following discussion will 
focus on gut feelings,144,145,146,147 heuristics,110 hypothetico-deductive reasoning 
versus pattern recognition109,148 and Kahneman’s two-system approach to how 
humans form judgements and make decisions.149,150 149 
13.3.6.1 Gut feelings 
Gut feeling is defined as a feeling of unease that something is wrong in the 
absence of specific indicators. In a small qualitative study, Stolper suggested 
that GPs experience two kinds of gut feelings during consultations. The first is a 
‘sense of alarm’, even about patients without specific signs or symptoms 
indicative of serious disease, while the second is a ‘sense of reassurance’ when 
GP feels secure about the prognosis and therapy.145  
Van Den Bruel et al.151 devised a triage instrument for assessing serious 
infections in children and reported that the gut feeling that 'something is wrong' 
proved to be the best clinical indicator that a child was really sick, although it 
was unclear upon which signs and symptoms the physicians were basing their 
decisions.   
The above studies suggest that even a ‘sense’ of alarm may encourage GPs 
towards investigation or referral, in effect lowering their threshold for taking 
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action. However, it is difficult to anticipate how this would influence what and 
how GPs record in the medical record, given that their gut feeling is not 
dependent on the presence of specific signs or symptoms. 
13.3.6.2 Heuristics 
Heuristics are simple decision strategies that focus on a small number of 
relevant signs or symptoms that are predictive of a diagnosis, ignoring some of 
the information available. Medical decision-making heuristics commonly follow a 
'fast-and-frugal' model, whereby doctors' decisions are guided by the answers 
to a number of mostly subliminal, sequential, yes/no questions. 110  
Heuristics are based on three rules: 
1. The search rule: this specifies what information is sought (i.e. a clinical 
predictor) and in what order of clinical priority.  
2. The stop rule: this determines when the clinician can stop seeking new 
information (i.e. when sufficient clinical predictors have been obtained). 
3. The decision rule: this determines the decision to be made, according to 
the value of the clinical predictor(s).   
It is conceivable that these rules influence a GP's choice of what to code into 
the patient's medical record, with preference given to high-priority clinical 
indicators. Indeed, the results of my thesis support this hypothesis: visible 
haematuria and jaundice are both high-priority clinical indicators – the former for 
bladder cancer, the latter for pancreatic cancer – while abdominal pain is a 'low-
risk but not no-risk' symptom of both cancers.  
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While heuristics may be useful to doctors working in time-pressured 
environments, they may also lead to errors in diagnosis or management. 152  
For this reason, it is important that any heuristic frameworks should be validated 
and only used if they are shown to have a high sensitivity; however, this may 
come at the expense of a low positive predictive value, which has the potential 
to lead to over-investigation.144 
Heuristic frameworks have many attractions; for example, their degree of 
accuracy can be validated, and they are transparent and easy to apply in 
appropriate settings. Furthermore, they may lead to cost savings, if shown to be 
as, or more, accurate than complex alternatives. 110 However, as acknowledged 
in the recently updated NICE guidelines for suspected cancer,9 they are too 
simplistic to use in isolation,108 and should be used in conjunction with a range 
of clinical decision-making skills, including hypothetico-deductive reasoning and 
pattern recognition, which are discussed next.  
13.3.6.3 Hypothetico-deductive reasoning and pattern recognition 
When assessing patients, a hypothetico-deductive reasoning strategy may be 
adopted by GPs, in which they decide upon a number of possible diagnoses 
early on in a consultation and then test them through focused examination and 
history-taking. An alternative is pattern recognition, in which GPs readily 
recognise a patient's presentation and make a 'spot' diagnosis. Under these 
circumstances, GPs may consider it unnecessary to 'test their hypothesis', 
reserving this strategy only for more complex or atypical presentations.108,148 
When assessing the probability of a diagnosis using either hypothetico-
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deductive reasoning or pattern recognition, GPs's decisions are vulnerable to a 
number of cognitive biases, which may lead to diagnostic errors, including148,153: 
1. Availability bias: where GPs are more likely to consider diagnoses that 
are more easily retrieved from memory 
2. Representativeness bias: where GPs place too much emphasis on the 
typical features of a disease and miss an atypical presentation 
3. Confirmation bias: where GPs only seek information to confirm their 
hypothesis, rather than also testing whether it might be incorrect  
4. Premature closure: where GPs come to a decision too soon, before 
eliciting enough information (this is also pertinent to heuristic models) 
5. Base rate neglect: where GPs neglect the true rate of a diagnosis and 
focus on a possible, but unlikely, diagnosis. 
These biases, particularly confirmation bias, may also influence GPs' decisions 
about what to record in a patient's medical record, and whether they record it 
using a code or in the text (see Section 6.5.1.2).  
Hypothetico-deductive reasoning and pattern recognition build on tangible 
clinical information obtained when GPs take a history and perform a clinical 
examination. They fit well with the work of Kahneman, which is discussed 
below.  
13.3.6.4 Kahneman’s two-system approach  
In his book, Thinking, Fast and Slow, Daniel Kahneman uses a ‘metaphor of 
two agents’ – which he names System 1 and System 2 – to characterise mental 
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thinking broadly as either intuitive or deliberate. He proposes that thought 
processes in System 1 occur automatically and quickly, with little or no effort 
and no sense of voluntary control. System 1, he says, underlies many of our 
inherent skills, ranging from the ability to judge distance to the recognition of 
stereotypes.  
In contrast, System 2 is used for complex mental effort and when checking facts 
or logic, such as when testing hypotheses. Indeed, tasks carried out using 
System 2 are disrupted when a person’s attention is diverted to something else, 
at the expense of performance of the task in hand. 
Systems 1 and 2 both function while we are awake, but it is System 1 that 
automatically determines our impressions, intuitions, intentions and feelings 
related to events or situations we encounter. Through an iterative process, 
System 2 reviews the interpretations made by System 1, and intuitions or 
impressions that are ‘approved’ by System 2 are reinforced to the extent that 
they become beliefs. Similarly, intentions and feelings that are substantiated by 
System 2 turn into impulses and eventually become voluntary actions.  
In Kahneman’s model, Systems 1 and 2 are coordinated efficiently to minimise 
effort while at the same time optimising performance. Indeed, most of the time 
System 2 is not very active – it is only alerted when something happens that 
‘violates the model of the world that System 1 maintains’. In other words, it is 
mobilised when System 1 does not have a ready explanation for what is going 
on around us.150  
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Kahneman’s theory of System 1 and System 2 fits well with the above-
discussed concepts of clinical reasoning, with System 1 equating to ‘pattern 
recognition’ and System 2 to ‘hypothetico-deductive reasoning’.148,149,152  
During consultations, GP’s decision-making is likely to be dominated by pattern 
recognition (System 1), in part because short appointments do not allow for the 
slow thought processes of System 2. Indeed, through repeated learning and 
development of expertise and specialist knowledge, doctors have gained, 
through System 1, the ability to store patterns of association in memory that are 
then accessed and recalled without intention or effort. Hypothetico-deductive 
reasoning (System 2) is reserved for complex patients, whose symptoms and 
history do not fit into an immediately recognisable pattern.148,154 Some 
commentators, for example Marcum,154 have suggested that there is a third 
process involved – termed ‘metacognition’ – in which doctors reflect on their 
thinking and decisions, particularly when there is a conflict between Systems 1 
and 2. I suggest that metacognition plays a minor role in the short and 
pressured consultation itself; rather, it is more likely to occur later when GPs are 
pondering over difficult cases, or sharing them with colleagues. 
Knowledge of the many cognitive influences described above on GPs during the 
patient consultation will help researchers to predict the presence and direction 
of any recording style bias at the patient level. My results strongly suggested 
the importance, at the patient level, of a symptom’s clinical significance in 
relation to the disease under study. 
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GPs are mindful of alarm symptoms because pattern recognition alerts them of 
their association with serious disease (‘Framing & norms’ in Figure 13.1). 
Indeed, referral for alarm symptoms alone is encouraged by heuristics such as 
NICE guidance for cancer (‘Dogma’ in Figure 13.1).9 Independently of national 
guidelines, GPs are likely to feel uneasy (‘Affect heuristic’) about patients who 
present with alarm symptoms, and worry about the consequences – for them 
and their patient – of their missing or delaying a serious diagnosis (‘Loss 
aversion’). Repeat attendance for a symptom, particularly if an innocent 
explanation has been excluded, will exacerbate these feelings.  
A symptom that is considered to be ‘low-risk but not no-risk’ will not be 
associated with such strong ‘framing & norms’ effects and so will not engender 
the same degree of uneasiness and loss aversion as an alarm symptom.  
All of the above suggest that alarm symptoms, rather than ‘low-risk but not no-
risk’ symptoms, will provoke GPs to take action, diverting doctors away from a 
watch-and-wait approach. Procedural requirements associated with that action, 
such as form-filling, may encourage GPs to record the headline symptom or 
administrative procedure using a code. Once this has been done, everything 
else may be recorded quickly in hidden text, including symptoms that are 
irrelevant to, or less critical for, the working diagnosis. 
There are a number of external factors that may also influence what GPs decide 
to record in the medical record. For example, the Quality and Outcomes 
Framework and IT factors. 
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13.3.6.5 Quality and Outcomes Framework 
GPs are incentivised to code anything covered by The Quality and Outcomes 
Framework (QoF).47 The QoF was introduced as part of the new GP contract in 
April 2004. Its purpose was to improve the quality of general practice by 
rewarding GPs financially for implementing ‘good practice’. While participation is 
voluntary, it is widely adopted as a means of securing income. Much of what it 
entails is classic System 1 thinking, which translates into a recording style that 
must enable the ready retrieval of that clinical information, i.e. coding rather 
than text. Evidence of compliance with QoF requires GPs to code clinical events 
that fall within named domains, of which there were four in 2004: clinical, 
organisational, patient experience and additional services. The symptoms I 
studied – haematuria, jaundice and abdominal pain – were not included in any 
of these domains and so their coding will not have been encouraged specifically 
by QoF.155  
I suggest that researchers using CPRD datasets should first consider whether 
the symptoms they are studying were covered by QoF at the time of data 
collection. If they were, the researcher can be more confident that the majority 
of symptom occurrences will be coded consistently for all patients. Therefore, 
their estimates of both the frequency of symptoms and the number of patients 
affected by them will be good. Indeed, studies spanning the introduction of QoF 
may see a change in data recording quality, as suggested by a paper on 
ovarian cancer.156 
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For symptoms that are not covered by QoF, researchers should acknowledge 
the strong possibility that they will underestimate symptom frequency if they 
restrict their analysis to coded records. The reason for this is likely to be related 
to IT factors, which are discussed below. 
13.3.6.6 IT factors 
For anything outside QoF, time pressures encourage GPs to select the simplest 
method of recording it in the patient’s notes (IT factors in Figure 13.1 below). 
This will vary with the GP’s familiarity with the software, which could not be 
elucidated in this study. It will also vary with the utility of the software itself, 
which in most CPRD practices is ViSion. ViSion requires GPs to enter a code 
before the text box becomes available; therefore, at least one code must be 
selected for a consultation to be recorded. The event-level analysis suggested 
that researchers should not assume that the importance of a symptom will 
outweigh the importance of coding either the source of the information or the 
context of the consultation. Indeed, medico-legal factors will encourage GPs to 
document not only the symptom, but also its source and the context of the 
consultation, in a readily retrievable manner (i.e. as a code) at the event 
level.139  
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Figure 13.1 Recording style decisions: System 1 and System 2 factors  
 
  
13.3.6.7 System 2 factors 
Diagnoses rely not on a single symptom, but usually on a constellation. This is 
particularly so in cancer. I suggest that System 2 steps in to help GPs spot 
when an alarm symptom is a ‘red herring’ rather than a ‘red flag’. This may be 
because something else in the patient’s presentation contradicts the ‘typical’ 
diagnosis in patients presenting with that alarm symptom. Alternatively, it may 
simply be that the other signs and symptoms do not wholly fit with the 
recognised pattern of that disease. It may also be because the GP has a gut 
feeling of reassurance that the patient does not have serious disease,146 
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although electronic medical recording systems do not offer an obvious 
mechanism for recording this. My results suggest that, in this scenario, 
recording style bias is reversed in favour of obtaining information about the 
symptom in the controls rather than the cases.  
This underlines the importance for researchers to relate the clinical significance 
of a symptom to the disease they are studying. It is difficult to envisage a 
scenario in which researchers studying a particular disease would want to 
investigate the frequency of alarm symptoms that are not known to be 
associated with that disease. In the unlikely event that they did, they should 
anticipate the presence of a recording style bias in favour of identifying 
symptom occurrence in the controls over the cases.  
13.3.7 Added value of text data 
This part of the discussion relates to research question 5: Do the text data 
provide additional value to coded data? The discussion starts with the value of 
text data in increasing the identification of symptom frequency, with particular 
reference to the 5% threshold that symptoms are required to exceed to be 
included in univariable analysis in some CAPER studies. 
The discussion then continues by examining the ‘research quality’ of code- and 
text-based variables. 
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13.3.7.1 Threshold for inclusion in univariable analysis 
As described in Section 6.12.1, only those symptoms, signs and test results that 
had occurred in at least 5% of the cases or controls were included in analysis. 
This somewhat arbitrary threshold was chosen as a pragmatic compromise. If it 
were any lower, the chances of identifying clinically meaningless associations 
were increased; any higher, and the chances of missing associations between 
important, yet infrequent, symptoms were raised.  
In the original bladder cancer study extended by my PhD,4 the frequency of 
non-visible haematuria (127/4,915 cases = 2.6%) failed the threshold for 
inclusion in analysis. Supplementing with text-only records for this feature 
revealed that its actual frequency was 312 in the 4,915 cases (6.4%) – above 
the 5% threshold. Therefore, inclusion of text-only records enabled the first 
study of the risk of bladder cancer in patients presenting with non-visible 
haematuria in primary care. The results from this thesis were published in The 
British Journal of General Practice8 and used by the National Institute for Health 
and Care Excellence in their revision of the guidelines for recognition and 
referral for suspected cancer. A new recommendation was introduced to refer 
people for suspected bladder cancer if they are 60 years of age or more and 
have unexplained non-visible haematuria and either dysuria or a raised white 
blood cell count.9 This is a direct demonstration of the added value of text-only 
records to research. These clinical findings are discussed in further detail below 
(see Section 13.5). 
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Arguably, one could also avoid missing such important features of cancer by 
lowering the threshold for inclusion to below 3%. Indeed, this has been done in 
other CAPER studies; for example, when determining the risk of breast cancer 
in symptomatic patients presenting to primary care.42 However, this still leaves 
the risk estimates vulnerable to any recording style bias between cases and 
controls and is a less satisfactory solution. 
13.3.7.2 The errors associated with code- and text-based variables 
An undeniable disadvantage of the text-based variables compared with their 
coded counterparts is their relatively high degree of uncertainty. There were two 
main sources of this uncertainty. First, not all the text that had been written was 
accessible, just the search term and three words either side. The second source 
of uncertainty was the accuracy with which the text extracts were converted to 
binary variables, i.e. whether they denote a symptom’s absence or presence. 
Several steps were taken both to minimise and quantify the degree of 
uncertainty associated with text-based variables. 
13.3.7.3 Minimising the degree of uncertainty introduced by text 
variables 
The classification of text extracts was carried out using a semi-automated 
process that ensured the consistent application of a set of classification ‘rules’ 
using an algorithm, and also allowed the flexibility of individual assessment 
where necessary. The arguments of the algorithm were underpinned by a solid 
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understanding both of syntax and the theory of negation (see Appendix 3: 
Algorithm construction).112  
The main source of uncertainty in interpreting text extracts was whether the 
symptom was a current or historical concern for the patient. This was 
sometimes difficult to discern, but was important to establish for the purposes of 
the study, which was designed to estimate the risk of cancer in patients with a 
current symptom. The category ‘symptom absent’ was assigned if the meaning 
could not be ascertained with certainty, to minimise the number of false-
positives in the dataset.  
Increasing the number of words in the text extracts from three to five either side 
of the search term would improve the chances of being able to interpret the 
meaning accurately. At 5p per word, this would incur a considerable extra cost, 
for limited, if any, benefit.  
13.3.7.4 Quantifying the degree of uncertainty 
The performance of the semi-automated classification process was assessed 
by comparison of its output with that of a rigorously constructed gold standard, 
using a test set of 100 randomly selected text extracts.113 Additional analyses 
were conducted to obtain maximum and minimum measures of sensitivity and 
specificity. Negation of the symptom in the text was rare, resulting in nearly all 
(90% in the randomly selected test set) the text extracts confirming its 
presence. This created an imbalanced contingency table, and rendered 
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interpretation of the sensitivity (which ranged from 96% to 100%) and of the 
specificity (100%) essentially meaningless.  
A further indication of the degree of uncertainty in text-based variables was 
obtained during construction of the reference standard. This entailed two GPs 
independently rating a random sample of 100 text extracts, blind to whether 
they were from the medical records of cases or controls. The final level of 
agreement for all 100 extracts was 0.71 (95% CI 0.53–0.89), which, while not 
perfect, is interpreted as good by Altman120 and as substantial by McGinn et 
al.122 Furthermore, this value is likely to be an underestimate of the true level of 
agreement, because of the imbalance in the number of text extracts assigned to 
each category – far more were categorised as indicating the symptom’s 
presence than its absence. For 16 of the 100 text extracts, the two independent 
raters could either not agree their meaning, or agreed that they were 
uninterpretable (these extracts were not included in the final reference 
standard). This in itself is an indication of the degree of uncertainty in the text-
based variables.  
13.3.7.5 The ‘research quality’ of code- and text-based variables 
13.3.7.5.1 Modelling the presentation of cancer 
Text- and code-based variables gave similar measures of association (i.e. odds 
ratio) between ‘low-risk but not no-risk’ symptoms and cancer. In contrast, the 
text-based variables gave smaller – but still significant – measures of 
association between recognised alarm symptoms and cancer (see Table 10.6 
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and Table 10.13). This fall in odds ratio was most likely to be an artefact related 
to the biased recording of alarm symptoms between cases and controls, 
wherein coded records obtain more complete information about the symptom 
history from cases than they do from controls. Therefore, the decision was 
made to combine the code- and text-based variables for each symptom into a 
single composite variable. This illustrates the value of text-based variables, as 
they ‘correct’ both for any recording style bias and underestimation of symptom 
frequency.   
Further evidence of the added value of text-based variables was illustrated by 
the observation that their addition significantly improved the fit of the final 
models both of bladder (see Table 10.9) and pancreatic (see Table 10.16) 
cancer presentation.  
13.3.7.5.2 Estimating the risk of cancer 
Similarly, further value of text-based variables was apparent in their correction 
of the likelihood ratio and hence positive predictive value for those symptoms 
affected by recording style bias. This is discussed in greater detail below (see 
Section 13.4). 
13.3.7.5.3 Diagnostic interval data  
From the summary statistics and wide interquartile ranges, it appeared that 
adding text-only records had little impact on the estimate of diagnostic intervals 
(see Table 11.1). However, matched analysis of patients whose symptoms had 
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been recorded using both methods suggested that the addition of text-only 
records lengthened the diagnostic interval for all the symptoms in the cancer 
sites investigated (see Table 11.2). This was most marked for 'low-risk but not 
no-risk' abdominal pain in pancreatic cancer, where the median diagnostic 
interval increased by 17 days after addition of text-only records. It was least 
notable, and of questionable clinical significance, for the alarm symptom of 
jaundice in pancreatic cancer. Here, the median diagnostic interval increased by 
only 3 days.  
Unmatched analysis was conducted using data from patients whose symptoms 
had been recorded only in the text or only as a code. The results were 
somewhat counterintuitive on first glance, given the results of the matched 
analysis. However, this probably simply reflects the fact that adding text-only 
records can either have no effect on the estimate of diagnostic interval, or 
lengthen it – it cannot shorten it. The unmatched analysis tells us whether 
diagnostic interval estimates from coded and text-only records are drawn from 
the same population. 
The unmatched analysis suggested that coded records tended to be made 
earlier than text-only records for all symptoms, except visible haematuria in 
bladder cancer whose diagnostic interval estimates were the same regardless 
of recording style. As in the matched analysis, the difference in median values 
was smallest for jaundice in pancreatic cancer. At 4 days, the clinical 
significance of this change is questionable. The difference in median values 
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was greatest for abdominal pain, at 46.5 days in the bladder and 30 days in the 
pancreatic cancer datasets.  
Overall, this suggests that, for alarm symptoms, the text-only records provide 
little added value in terms of estimating diagnostic interval. For 'low-risk but not 
no-risk' abdominal pain, however, the estimate of diagnostic interval is more 
accurate after the addition of text-only records.      
To my knowledge, Hayward et al157 is the only other comparable study. They 
reported that respiratory symptoms were recorded significantly earlier in the text 
than as a code. For example, the median diagnostic interval for the first coded 
symptom for breathlessness or wheeze was 44 (95% CI: 9–139) weeks, 
increasing to 149 (95% CI: 44–275) weeks after addition of text-only records. As 
far as I can tell from the paper, no statistical test was used to assess the 
strength of evidence of a real difference between these median values.  Indeed, 
the large confidence intervals suggest to me that, while the point estimates 
appear different, there was in fact no difference between the two median values 
owing to the large variability inherent in the measurement. This finding certainly 
matches my observations of the raw data, as described above (see Table 11.1). 
I conclude that, for the assessment of diagnostic intervals, text-based variables 
provide added value over coded records for 'low-risk but not no-risk' symptoms. 
In contrast, they provide little added value for the alarm symptoms. 
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13.3.8 Summary of methodological findings 
My study shows that large numbers of individual symptom records are made 
solely in the hidden text. This suggests that researchers restricting their analysis 
of CPRD data to just the coded records need to acknowledge that their event-
level reports of symptom frequency will be underestimated considerably. This 
study was unable to elucidate a framework that might be used to predict the 
extent and direction of this underestimation, as no association between use of 
hidden text and clinical significance was apparent.  
Researchers should also acknowledge that this underestimation persists at the 
patient level, but may be compounded by a recording style bias between 
comparison groups. This is greatest for alarm symptoms strongly associated 
with the disease under investigation, where the bias preferentially obtains 
information from the cases compared with controls. For ‘low-risk but not no-risk’ 
symptoms that are not strongly associated with the disease under investigation, 
little or no recording style bias is anticipated. 
The implications of these biases for clinical outcome measures are discussed 
below, but before that I would like to discuss the findings of my post-hoc 
analysis. 
13.3.9 Discussion of post-hoc analysis 
The post-hoc analysis was prompted by the finding that recording style bias for 
visible haematuria differed between men and women (see Section 9.2.2.1.1). It 
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also relates to the hypothesis that GPs tend to use codes for significant 
symptoms and text for less worrisome symptoms. 
The post-hoc analysis suggested that patients were more likely to have their 
haematuria recorded solely in the text if they had a urinary tract infection. This is 
entirely consistent with the hypothesis that symptoms that commonly arise from 
benign pathology are more likely to be noted in the text fields than as a code. 
Since urinary tract infections are more common in women than in men, effect 
modification by gender of the association between urinary tract infection and 
text-only recording was anticipated, with GPs having a raised suspicion of a 
benign cause in women. The interaction term was not significant, however, 
which seemed counterintuitive. On reflection, this finding may indicate that GPs 
are only recording confirmed, rather than suspected, diagnoses of urinary tract 
infection.  
Also consistent with the hypothesis was the observation that control patients – 
whose cause of visible haematuria was presumed to be benign – were more 
likely than bladder cancer cases to have their symptom recorded solely in the 
text. Here there was an effect modification by gender, with female control 
patients being three times more likely than male control patients to have their 
visible haematuria recorded solely in the text (see Table 12.6). Therefore, 
something about the women – but seemingly not the presence of a urinary tract 
infection – is increasing the likelihood that their records of attendance for visible 
haematuria are lost in the hidden text.  
Possible reasons for this are now discussed. 
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13.3.9.1 GPs’ perceptions of the risk of bladder cancer in women with 
visible haematuria 
The finding of gender-based bias in use of text-only recording was specific to 
haematuria and was not observed for abdominal pain or jaundice. This 
observation may be explained by differences in GPs’ perceptions of the risk of 
bladder cancer in men compared with women with visible haematuria.  
For example, Lyratzopoulos et al reported evidence that GPs interpret the 
seriousness of haematuria differently in men than in women, suggesting that 
GPs are less likely to suspect a diagnosis of bladder cancer in women than in 
men. Furthermore, they found that women were more likely than men to have a 
delayed diagnosis of bladder cancer.158 Their study was carried out using data 
on 740 patients with bladder cancer from the English National Audit of Cancer 
Diagnosis in Primary Care (2009–2010). One outcome measure used as 
evidence of gender inequality was the ‘primary care interval’. This is the time 
interval between the first presentation to the GP with a symptom and the 
patient’s first specialist referral for further investigation for cancer. There was 
only a small difference in the median primary care interval between men (4 
days, n = 525) and women (6 days, n = 196). At the tail of the distributions, 
however, the difference was substantial. The primary care interval at the 75th 
centile was 15 days for men whereas it was 32.5 days for women, and at the 
90th centile the difference was greater still, at 39 days for men and 103 days for 
women. In addition, women were more likely than men (odds ratio 3.29, 95% 
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CI: 2.06–5.25, p<0.001) to have visited the GP on three or more occasions 
before referral.158   
A limitation of the latter study is that it did not report whether the ‘excess’ 
consultations by the women were for possible symptoms of cancer. Therefore, it 
is possible that some of the results could be accounted for by baseline 
differences in consultation rates between men and women. Unfortunately, 
Lyratzopoulos et al did not report a detailed age profile of the patients in their 
study, other than saying that 91% of the patients with bladder cancer were older 
than 55 years. As discussed in Section 6.4.1, aggregated data from 
QResearch® suggest that men aged 55–59 years consult the GP five times per 
year, compared with a figure of nearly seven for women.101 In contrast, a THIN-
based study reported that, in patients older than 58 years of age, there was 
little, if any, gender difference in consultation rates.102 Gender-specific 
differences in baseline consultation rates are more likely to account for the 
‘excess’ consultations by women observed in Lyratzopoulos et al’s study if they 
occurred over a long time period. If, however, they all happened shortly before 
the referral was made, one could be more confident that the ‘excess’ 
consultations in women truly reflected a gender bias in the GPs’ interpretation of 
the seriousness of the patient’s condition. Unfortunately, the intervals between 
consultations were not reported for this assessment to be made.  
13.3.9.2 Misattributed vaginal bleeding 
The women recruited to my study were all over 40 years old. Approximately 
one-tenth (639/6,266 = 10.2%) of the controls were between 40 and 59 years of 
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age, and likely to have been experiencing symptoms of the menopause during 
the study (see Table 7.3). One such symptom is abnormal and chaotic vaginal 
bleeding, which cannot always be distinguished from visible haematuria of 
urological origin.  
It is not possible for GPs to verify the source of blood apparently observed in 
the urine (vaginal or urological) after the event, although the presence (or, 
equally, the absence) of other presenting features may raise their suspicion of 
misattribution of vaginal bleeding. Under these circumstances, it is possible, but 
I think unlikely, that the GP may record the patient’s report of ‘haematuria’ in the 
text rather than as a code.  
13.3.9.3 Summary 
The results of the post-hoc analysis support the hypothesis that GPs tend to 
use codes to record visible haematuria when they suspect that they underlying 
pathology is serious, and text when they feel reassured of a benign cause. This 
effect was greater in women than in men, although a single reason for this 
gender bias could not be established.  
The implications of the methodological findings in my main and post-hoc 
analysis for clinical outcome measures are now discussed. 
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13.4 Effect of recording style bias on clinical outcome 
measures 
13.4.1 Likelihood ratio 
This discussion is best started with a reminder of how the likelihood ratio was 
calculated (see Section 6.12.3.4 for more detail). In cancer diagnostics, the 
positive likelihood ratio summarises how many more times likely patients with 
cancer are to experience a symptom compared with healthy patients free of 
cancer. It is calculated using the following formula:   
)|(
)|(


DSp
DSp
          (1) 
Where p(S+|D+) is the probability that cases (i.e. patients who have a positive 
diagnosis of disease D, denoted as D+) have a symptom S (S+), and p(S+|D−) 
is the probability that controls (i.e. patients who are not diagnosed with that 
cancer: D−) have the same feature, S+. 
At the event level, use of hidden text in the electronic medical record conceals a 
considerable number of occurrences of all symptoms from researchers 
examining just the coded data. This persists with repeat attendance by 
individual patients, to the extent that the complete history of attendance for that 
symptom is also concealed from researchers at the patient level. Therefore, 
both p(S+|D+) and p(S+|D−) are likely to be underestimated for all symptoms.  
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13.4.1.1 For ‘low-risk but not no-risk’ symptoms 
Similar proportions of cases and controls with abdominal pain and non-visible 
haematuria in the bladder cancer study were lost to research because their 
entire history for the feature was recorded solely in hidden text. In other words, 
the degree of underestimation of abdominal pain and non-visible haematuria 
was the same in cases as in controls. Therefore, the likelihood ratio estimate 
was unaffected by recording style bias; for example, the biased estimate for 
abdominal pain in the bladder cancer study was 2.02 (95% CI: 1.79–2.28) and 
the corrected estimate was 1.97 (1.79–2.17) (see Table 10.2). There was a 
small bias in estimates of abdominal pain in favour of identification of the 
symptom in the cases over the controls in the pancreatic cancer study. 
However, this was so small as to have a negligible impact on the likelihood 
ratio, the ‘biased’ estimate of which was 6.94 (95% CI: 6.46–7.45) compared 
with the corrected value of 6.59 (6.21–7.0) (see Table 10.11). 
From both research and clinical perspectives, it is most reassuring to know that 
outcome measures for ‘low-risk but not no-risk’ symptoms are not likely to be 
affected by recording style bias. 
13.4.1.2 For alarm symptoms in their associated cancer 
When an alarm symptom is investigated in the context of a cancer with which it 
has a strong association, recording style bias leads to the preferential 
obtainment of information from the cases compared with controls. In terms of 
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equation (1) above, this means that p(S+|D−) is underestimated to a greater 
extent than p(S+|D+), inflating the likelihood ratio artefactually.  
From a research perspective, studies should acknowledge that their likelihood 
ratios for recognised alarm symptoms of disease are likely to be overestimates. 
For example, in the bladder cancer study, the biased estimate of the likelihood 
ratio for visible haematuria was 58.41 (95% CI 50.69–67.32). Correcting for 
recording style bias by adding in the text-only records reduced this to 41.39 
(37.14–46.11) (see Table 10.2). This also translates to an overestimation of the 
positive predictive value, as discussed below (see Section 13.4.2).  
13.4.1.3 For alarm symptoms in unconnected cancers  
It is unlikely that researchers will want to estimate the likelihood ratio of an 
alarm symptom in an unconnected cancer (see Section 13.3.6.7). If they were, 
researchers should be aware that recording style bias is likely to lead to the 
preferential obtainment of information from the controls compared with the 
cases. This means, in terms of equation (1), that p(S+|D+) will be 
underestimated to a greater extent than p(S+|D−), reducing the likelihood ratio 
artefactually. 
13.4.2 Positive predictive value 
As discussed in Section 6.12.3.5, the positive predictive value (PPV) was 
calculated from the posterior odds [PPV = posterior odds / (1 + posterior odds)], 
which was estimated using Bayes’ Theorem: 
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Posterior odds = (prior odds × f) × positive likelihood ratio   (2) 
The adjustment factor, f, derives from the proportions of cases and of controls 
who consulted their GP for any reason during the period of the study. Therefore, 
it is independent of recording style bias related to individual symptoms. The 
value of prior odds is generally estimated from national incidence data, which 
again is independent of recording style bias. Therefore, the impact of recording 
style bias on PPV derives totally from its effect on the positive likelihood ratio 
(see Section 13.4.1).  
The results strongly suggest that recording style bias is likely to inflate the PPV 
of alarm symptoms, but only for cancers with which they are associated. In 
contrast, recording style bias is unlikely to affect the PPV of ‘low-risk but not no-
risk’ symptoms of cancer.  
13.4.3 Odds ratio 
In case–control studies, the strength of association between a symptom and 
cancer is estimated by the odds ratio: the greater the odds ratio, the greater the 
association between the symptom and cancer. Section 6.12.3.6 describes how 
the odds ratio is calculated using the formula: 
Odds ratio = 
)|()|(
)|()|(


DSpDSp
DSpDSp
      (3) 
Where: 
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p(S+|D+) = the probability that symptom S occurs (S+) in patients with cancer D 
(the cases, D+) 
p(S−|D−) = the probability that symptom S does not occur (S−) in patients who 
do not have cancer D (the controls, D−) 
p(S−|D+) = the probability that symptom S does not occur (S−) in the cases 
(D+) 
p(S+|D−) = the probability that symptom S occurs (S+) in controls (D−) 
This was an observational study based on electronic medical records made 
during every-day clinical practice, i.e. information about the symptoms of 
interest was not sought specifically. Symptom absence was assumed if there 
was no evidence to the contrary (see Section 13.2.6 for discussion of the 
handling of missing data). Therefore, values for S− were derived entirely from 
the estimates of S+ and the number of cases and controls. 
From equation (3), it can be seen that a recording style bias favouring 
obtainment of information about symptoms from cases over controls inflates the 
odds ratio, because p(S+|D−) will be underestimated to a greater extent than 
p(S+|D+). Therefore, the results strongly suggest that, in CPRD studies 
restricting analysis to coded records, the association between recognised alarm 
symptoms and cancer will be inflated by biased estimates of the odds ratio. For 
example, in the bladder cancer study, the biased odds ratio for cancer in 
patients following a single episode of visible haematuria was 100.5 (95%CI: 
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78.1–129.3). After correcting for recording style bias the odds ratio was 
estimated at 75.9 (60.9–94.6) (Table 10.6). 
In contrast, the association between ‘low-risk but not no-risk’ symptoms and 
cancer, as assessed by the odds ratio, is unlikely to be unaffected by recording 
style bias. Indeed, this was the case for abdominal pain in the bladder cancer 
study, where the odds ratio of 2.1 (95% CI: 1.9–2.4) was unaltered by the 
addition of text records (2.2, 95% CI: 2.0–2.4) (Table 10.7).  
The effect of recording style bias in terms of modelling the symptomatic 
presentation of cancer in the original studies is discussed below for univariable 
and multivariable analysis separately.4,5  
13.4.3.1 In univariable analysis 
Discussion of the loss of symptom information in the hidden text generally and 
the resulting failure of a symptom to meet the pre-specified (though arguably 
arbitrary) 5% threshold for inclusion in univariable analysis was discussed 
separately above (see Section 13.3.7.1). 
Symptoms meeting the 5% threshold for inclusion in univariable analysis level 
were assessed individually as to whether they had an independent association 
with cancer (z test of whether the odds ratio differs significantly from 1). My 
study shows that recording style bias either has no effect on (for ‘low-risk but 
not no-risk’ symptoms) or inflates (recognised alarm symptoms) the odds ratio. 
Furthermore, to ensure that important variables were not omitted, the p value 
for retention on the z test was set to 0.1. Therefore, researchers can be 
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reassured that recording style bias, even if present, has little effect at the 
univariable analysis stage.  
13.4.3.2 In multivariable analysis 
In contrast, researchers in the field of cancer diagnostics should be aware that 
recording style bias may have an impact on the final selection of which 
symptoms best characterise the presentation of the cancer being investigated. 
This is because the modelling method entails using sequential regressions at 
the multivariable analysis stage to select those features with the strongest 
association with cancer. Recording style bias favours the retention of 
recognised alarm symptoms over ‘low-risk but not no-risk’ symptoms, because it 
selectively inflates the odds ratios of the former but not the latter. A ‘low-risk but 
not no-risk’ symptom would be falsely rejected if its odds ratio (an accurate 
estimate) were caused to fall below the selected p-value for retention indirectly, 
through the inflated odds ratio of an alarm symptom. Strictly, this would only 
happen if loss of records of attendance for the alarm and ‘low-risk but not no-
risk’ symptoms in the hidden text predominantly affected the same cases. If this 
requirement were satisfied, the association between the low-risk symptom and 
cancer could fall to a level low enough that the symptom were rejected from the 
model. It is unlikely this happened, given that the proportion of cases whose 
entire records for a high-risk symptom were lost in the hidden text was in the 
order of 20% (visible haematuria in bladder cancer) to 30% (jaundice in 
pancreatic cancer). Therefore, this gives some reassurance that recording style 
bias between cases and controls has rarely led to the inappropriate omission of 
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symptoms from a final model of the clinical features of cancer.4,5 Indeed, the 
CAPER studies can, and do, check the omitted variables against the final 
model, to confirm that their exclusion is appropriate.   
13.4.3.3 Summary 
To summarise, recording style bias is likely to inflate outcome measures for 
recognised alarm symptoms in CPRD studies of diseases strongly associated 
with that alarm symptom. In contrast, outcome measures for ‘low-risk but not 
no-risk’ symptoms are not affected by recording style bias. 
Perversely, this may not always matter in cancer diagnostics; for example, even 
after correction for recording style bias, the PPV for jaundice in pancreatic 
cancer still considerably exceeded the current 3% PPV threshold for referral for 
investigation (reducing from 12.77%, 95% CI: 7.25–21.58% to 6.25%, 4.46–
8.68%).5  
A more important concern is that recording style bias potentially introduces a 
positive feedback effect between research and recording practice. I propose 
that the selective inflation of risk estimates for alarm symptoms has two effects. 
First, it reinforces clinicians’ views of the (already known) importance of these 
symptoms, increasing the chances that they will be recorded using a code. 
Secondly, it further marginalises clinicians’ views of the importance of ‘low-risk 
but not no-risk’ symptoms, increasing the chances that their recording is 
relegated to the hidden text. The net effect is to increase recording style bias 
still further.  
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The discussion now moves on to exploring the potential impact of recording 
style bias beyond the CPRD.  
13.4.4 Impact of recording style bias for NICE guidance for 
suspected cancer 
In the recent update of NICE guidance,9 one of the original studies extended by 
this PhD – Stapley et al (2012) – was the sole source used to assess evidence 
of pancreatic cancer in patients with jaundice.5  
Regarding the evidence of bladder cancer in patients with visible haematuria, 
the NICE committee decided to omit Shephard et al from its meta-analysis 
because of its case–control design.4 
The potential impact of loss of records in the hidden text and associated bias of 
the positive predictive value (PPV) of visible haematuria for bladder cancer in 
the five studies6,66,67,68,69 in the NICE meta-analysis65 is discussed below. 
It should be noted that direct comparison of my PPV values with the individual 
values reported in the five studies in the NICE meta-analysis is limited by 
between-study differences in disease prevalence.159 This is not just because 
PPV itself is dependent on disease prevalence, but also because some of the 
studies were conducted before and some after the change in definition of 
bladder cancer in 1998.62 Therefore, I limit the discussion to the direction of 
change that would be observed if correction of recording style bias were made. 
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13.4.4.1 Jones et al – CPRD study 
Jones et al69 carried out a cohort study using coded CPRD data. Therefore, it 
will be vulnerable to biased recording of visible haematuria, favouring 
identification of the symptom in patients who receive a diagnosis of bladder 
cancer compared with healthy patients in the cohort.  
As to the potential effect of recording style bias on the positive predictive value 
(PPV), it is first necessary to review how this was calculated. As it was a cohort 
design, the PPV was estimated arithmetically in a contingency table and quoted 
for a particular cancer incidence. As described in Section 6.12.3.5, the PPV is 
the number of patients with visible haematuria who also had cancer (i.e. the 
‘true-positives’) divided by the total number of patients who had visible 
haematuria, whether they had cancer or not (i.e. the sum of true-positives and 
false-positives). Loss of records of attendance for visible haematuria in the 
hidden text will lead to underestimation of both the numbers of true-positives 
and false-positives. Recording style bias similar to that observed in my study 
will inflate the PPV, because the number of false-positives will be 
underestimated to a greater extent than the number of true-positives.  
I suggest that the degree of recording style bias for visible haematuria in Jones’ 
cohort study is greater than in my case-control study, despite the fact that both 
were conducted using CPRD data. This is related to differences in study design 
and consequently the characteristics of the patients recruited to each study. 
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My study had a case–control design, in which cases were matched to controls 
on age, sex and GP practice. The increased incidence of bladder cancer in men 
compared with women led to a gender imbalance of 19,017/26,633 (71%) men 
and 7,618/26,633 (29%) women in my study. In contrast, Jones followed a 
cohort design and selected all 923,605 patients who were registered with a 
CPRD practice between 1 January and 31 December 1994. While the gender 
balance is not reported, it is likely to be roughly 50% male and 50% female. 
My results indicate that recording style bias for visible haematuria is more 
marked in women than in men. This resulted in a greatly overestimated PPV for 
bladder cancer (pre-1998 definition) in women with bladder cancer of 5.10% 
(95% CI: 3.30–7.80%), which was corrected to 2.17% (95% CI: 1.68–2.81%) 
after hidden records for the female controls were unmasked by examination of 
the text records (see Table 10.3). In contrast, the overestimation of the PPV for 
bladder cancer in men was less marked. The coded records suggested a value 
of 5.14% (95% CI: 4.46–5.93%), which was ‘corrected’ down to 3.97% (95% CI: 
3.54–4.46%) by addition of text-only records.  
This was further supported by my post-hoc analysis, which suggested that when 
the GP suspected that the visible haematuria had a benign cause, they were 
more likely to use the free text than a code to record the symptom. This effect 
was much greater for female than for male patients (odds ratio of text-only 
recording was 9.3, 95%CI: 5.0–17.4, p<0.0001 for women, and 3.0, 95% CI: 
2.2–4.0, p<0.0001 for men). 
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My study yielded a biased PPV of visible haematuria for bladder cancer in all 
patients over 40 years old of 3.98% (95% CI: 3.47–4.57), which was ‘corrected’ 
to 2.85% (95% CI: 2.57–3.17%) after addition of text-only records. This 
suggests a correction factor for recording style bias of 1.4 (Table 10.2) in my 
case–control study. The comparatively large number of healthy female control 
patients in the Jones et al cohort study means that this correction factor will be 
unable to correct the attendant recording style bias fully. Therefore, his reported 
PPV in all patients of 4.2% (95% CI: 3.8–4.6%) is likely to be considerably 
inflated.  
13.4.4.2 In the QResearch® study 
Hippisley-Cox et al carried out a cohort study using the QResearch® database 
of electronic medical records. The aim was to derive an algorithm for assessing 
the risk of urinary tract cancer in patients presenting to primary care, named 
QCancer® (Renal).6  
13.4.4.2.1 Potential for loss of records in hidden text in QResearch® 
QResearch® is based on medical records obtained in every-day general 
practice using what was then known as Egton Medical Information Systems 
(EMIS) software.a In terms of recording clinical information, EMIS and ViSion 
(the software used by the majority of practices that contribute to the CRPD) 
differ fundamentally. ViSion requires GPs to select an appropriate Read code 
                                            
a
 Egton Medical Information Systems is now known as EMIS Health. 
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before they can access the free text comments box. In contrast, in EMIS GPs 
start recording the consultation by typing in the text box, and then have the 
option to select Read codes that are suggested based on character matches 
with the free text the GP is typing. So in ViSion every consultation must be 
accompanied by at least one Read code, while in EMIS the entire clinical 
encounter can be recorded in the hidden text.  
Clinical events included in the Quality and Outcomes Framework (QoF) (see 
Section 13.3.6.5) are likely to be recorded using a code in EMIS. However, for 
anything outside QoF, there is little incentive for GPs to break their train of 
thought mid-typing in order to select a suggested Read code. Indeed, one could 
argue that GPs who are unable to touch-type may even be unaware of the 
range of Read code choices on offer, because their attention will be focused on 
the keyboard rather than the screen.  
For these reasons, the Hippisley-Cox study is likely to have underestimated the 
prevalence of visible haematuria (which is not covered by QoF) reported by her 
cohort of patients, regardless of whether they receive a cancer diagnosis. 
Evidence of this would suggest that studies based in EMIS are, at the very 
least, more vulnerable than CPRD studies to loss of data to research through 
use of the hidden text to record clinical events. Greater underestimation of the 
frequency of symptoms will not affect recording style bias if the excess loss of 
symptom information due to EMIS’ ready access to text fields is the same in 
patients with cancer as in the healthy cohort, but it was not possible to test this 
in my study. 
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13.4.4.2.2 Frequency of visible haematuria  
Testing for excess loss of data in QResearch® compared with CPRD studies 
would require a direct comparison of Hippisley-Cox’s estimate of the frequency 
of visible haematuria with that obtained in my study. This is complicated by 
differences in our study design. On the one hand, mine is a case–control study 
of 26,633 patients over 40 years of age, resulting in a population that is 
artificially enriched with bladder cancer patients.61 On the other hand, the 
Hippisley-Cox study studied over 3.5 million patients, who, at the time of the 
study, were between 30 and 84 years old and did not have a renal tract cancer 
diagnosis.  
Hippisley-Cox et al reported a crude incidence rate of 298 per 100,000 person-
years. These figures suggest that a maximum of 0.3% of patients in the whole 
cohort (including healthy patients and those who received a renal tract cancer 
diagnosis during the study) experienced an episode of haematuria. This ignores 
the possibility of repeat attendance by individual patients, which would lower the 
figures still further.  
The symptom thesaurus for visible haematuria used in my study and by 
Shephard et al4 identified that, in our healthy controls alone, 196/21,718 (0.9%) 
had visible haematuria.  
These findings support the hypothesis that studies based on coded records 
from EMIS underestimate the frequency of symptoms through increased use of 
the hidden text to records symptoms. At the very least, the increased number of 
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‘false-negatives’ (i.e. cancer patients whose symptoms were recorded solely in 
the text) will lead to the misleading conclusion that too high a percentage of 
cases are asymptomatic.  
13.4.4.2.3 Study population factors 
As discussed above in relation to Jones et al69 (see Section 13.4.4.1), my 
analysis shows that women are three times more likely than men to have their 
visible haematuria recorded solely in the text when the GP suspects that there 
is a benign cause. In contrast to my study, which had a gender imbalance of 
approximately 2.5 men to every woman, Hippisley-Cox et al used a cohort 
design and recruited more than 3 million patients with similar numbers of men 
and women. Therefore, compared with my case–control study, the Hippisley-
Cox et al study had a far greater proportion of control healthy patients who were 
women.  
This suggests that the Hippisley-Cox study was highly vulnerable to recording 
style bias that favoured identification of visible haematuria in the patients who 
were diagnosed with bladder cancer. This would lead to biased estimates of the 
PPV, as is discussed below.  
13.4.4.2.4 Positive predictive value 
The Hippisley-Cox cohort study reported a PPV for bladder cancer of 6.48% 
(95% CI: 6.1–6.8%) at an incidence rate of 70 per 100,000 person-years for all 
urological cancers (of which 79% were bladder cancer). This value was at the 
385 
 
upper end of the PPV estimated in the meta-analysis of five studies considered 
by NICE (5.1%, 95% CI: 3.2–8.0%).  
I suggest that two factors are acting in the Hippisley-Cox et al study to inflate 
this estimate considerably above the true value. First and foremost, the cohort 
design results in the inclusion of a high proportion of healthy female controls, 
whose visible haematuria is three times more likely to be recorded solely in the 
text compared with healthy male controls. Secondly, it is feasible that the 
recording style bias in QResearch® studies is even greater than that in CPRD 
studies, owing to the GPs’ easy access to text fields.  
13.4.4.3 In The Health Improvement Network (THIN) study 
The Collins and Altman67 study was cohort in design, carried out using data 
from the THIN database of electronic medical records to validate Hippisley-
Cox’s QCancer® (Renal) study discussed above. Practices that contribute data 
to THIN share the same IT system as the CPRD, namely ViSion. Therefore, the 
Collins and Altman study is likely to be affected by recording style bias to the 
same extent as a CPRD study. Collins and Altman reported a PPV for bladder 
in patients with visible haematuria of 4.35% (95% CI: 4.1–4.6%), which again is 
likely to be an overestimate given the data’s vulnerability to recording style bias.  
Like Hippisley-Cox et al,6 Collin and Altman67 recruited similar numbers of men 
and women; therefore, the degree of recording style bias is likely to be even 
greater than that observed in my study, owing to their greater prevalence of 
healthy female controls.  
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13.4.4.4 In the Network of Sentinel General Practitioners in Belgium 
The Bruyninckx et al study was carried out using primary care data from the 
Network of Sentinel General Practitioners in the Belgian Healthcare System.66  
Participants in the Bruyninckx et al study were those patients who had received 
a diagnosis of urological cancer in the period 1993–1994. Patients were asked 
specifically if they had complained to their GP about visible haematuria prior to 
their diagnosis. Therefore, while the study is vulnerable to recall bias, the 
estimates of PPV are not likely to be inflated by the recording style bias 
identified in my thesis.  
13.4.4.5 In the Vanderbilt University Medical Center Research 
Derivative 
Friedlander et al was a billing study was conducted using data from the 
Vanderbilt University Medical Center Research Derivative.68 This is a database 
containing complete administrative and clinical information about every patient 
treated in the Vanderbilt Health System (a private healthcare facility in 
Tennessee, USA), in which coding is strongly driven by billing.  
Patient data were managed using a platform called REDCap (Research 
Electronic Data Capture), which strongly discourages the use of free text fields 
(confirming that they do exist) as their content is difficult to analyse.160 The 
presence of haematuria was confirmed either by urinalysis (for which coding is 
obligatory), or by the presence of a diagnostic code. The classification of 
haematuria as a diagnosis means that it would almost certainly always be 
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recorded as a code, for billing purposes. Therefore, it is highly unlikely that 
recording style bias affected the outcomes measures.  
13.4.4.6 Summary 
The NICE meta-analysis reported a summary PPV of visible haematuria for 
bladder or renal cancer in patients aged 15–100 years old of 5.1% (95% CI: 
3.2–8.0%).65 Three6,67,69 of the five studies used in this meta-analysis65 are 
vulnerable to recording style bias that inflates estimates of PPV. The recording 
style bias in these three studies is likely to be at least at the level observed in 
my study, and probably greater owing to their cohort design. This relates to the 
three-fold propensity of GPs to record visible haematuria in the hidden text 
when female (rather than male) patients present and have what the GP 
suspects is a benign cause of their symptom. The cohort studies, which 
recruited equal numbers of men and women, were even more vulnerable to 
recording style bias than my case–control design, which had a male : female 
ratio of 2.5 : 1.  
13.4.5 Comparison with existing literature 
Just one study, to the best of my knowledge, has analysed the content of text 
fields in the CPRD to identify how much symptom information is stored there 
and not as codes.33 This work was reported in conference proceedings and has 
not been published in a peer-reviewed journal. I have identified no CPRD 
studies that report on differential recording styles in comparison groups or on 
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the association between use of codes vs text and perceived symptom 
significance.  
13.5 Discussion of clinical findings: the risk of bladder 
cancer in patients with non-visible haematuria 
My study is the first report of the risk of bladder cancer in primary care patients 
with non-visible haematuria. For the pre-1998 definition of bladder cancer,a the 
risk was 1.60% (95% CI: 1.22–2.10%) for all patients of 40 years or older (see 
Table 10.2). This is just over one-half the risk estimated in patients with visible 
haematuria, after correction for recording style bias (2.85%, 95% CI: 2.57–
3.17%), and more than twice that of the next highest risk symptom – dysuria 
(0.66%, 95% CI: 0.56–0.78%).  
My estimation of the risk of bladder cancer in patients with non-visible 
haematuria was most timely, as it coincided with revision of the guidelines on 
referral for suspected cancer by The National Institute for Health and Care 
Excellence (NICE). As a consequence, my risk estimates for the post-1998 
definition of bladder cancerb were used by NICE. The data in the over-60s were 
particularly pertinent, putting the risk of bladder cancer at 1.66% (95% CI: 1.22–
                                            
a
 Including carcinoma in situ of bladder (ICD10 code D09.0) and neoplasm of uncertain 
behaviour of bladder (D41.4). 
b
 ICD10 code C67, excluding carcinoma in situ of bladder (ICD10 code D09.0) and neoplasm of 
uncertain behaviour of bladder (D41.4). 
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2.26%) (see Table 16.2). This is approximately half the risk estimated in 
patients with visible haematuria (3.03%, 95% CI: 2.67–3.44%, see Table 16.2), 
but much greater than that in patients presenting with any of the single features 
of bladder cancer identified. Dysuria was the next highest risk symptom in the 
over-60s, with a positive predictive value of 0.61% (95% CI: 0.50–0.74%).  
In light of these findings, NICE included a new recommendation to refer patients 
aged over 60 who have unexplained non-visible haematuria and either dysuria 
or a raised white cell count on a blood test.9 
There are no comparison studies estimating the risk of bladder cancer in 
patients presenting to primary care with non-visible haematuria. Some studies 
have estimated the positive predictive value of non-visible haematuria for 
urological malignancy in a secondary care setting. For example, Edwards et al 
conducted a prospective analysis of 4,020 patients attending a haematuria clinic 
in the UK between October 1998 and August 2003. They identified 94 
malignancies (renal cell carcinoma and transitional cell carcinoma) in 1,949 
patients with non-visible haematuria, yielding a positive predictive value of 4.8% 
for all age groups combined.161 In the UK, however, not all patients with non-
visible haematuria are referred for investigation; therefore, studies conducted in 
secondary care are not generalisable to the primary care setting, owing to 
selection bias. Indeed, Edwards et al recruited patients from a haematuria clinic, 
to which referral is only made after urinary tract infection has been excluded.  
A limitation of the study is the detection bias discussed in Section 13.2.5.3. This 
is likely to mean that I have underestimated the frequency of non-visible 
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haematuria in cases and controls. It is possible that this has inflated the positive 
predictive value, because the levels of underestimation are likely to be greater 
in controls than in cases.  
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14 Conclusion 
This thesis has studied a neglected area of research; namely, the potential for 
systematic bias in studies of electronic medical records that restrict their 
analysis to codes, omitting anything recorded in the text. 
To conclude, I address my original research questions. 
14.1 How much symptom information is documented in 
electronic medical records using text rather than a 
code? 
My study shows that a considerable amount of symptom information is 
documented in electronic medical records using text rather than a code. At the 
event level, the amount of text-only recording varied, from as much as 60% 
(298/494) for non-visible haematuria in bladder cancer to 31% (2,215/7,191) for 
abdominal pain in pancreatic cancer.  
Use of text recording persists with repeat visits to the GP such that, for some 
patients, their entire record of attendance for the symptom is lost in the hidden 
text. In numerical terms, non-visible haematuria was shown to be affected the 
most (219/372=59%); visible haematuria, the least (696/3,483=19%).  
Therefore, studies restricting their analysis to coded records underestimate both 
the frequency of attendance for symptoms, and the number of affected patients.  
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14.2 Are studies of coded data vulnerable to bias arising 
from the differential use of text and codes between 
comparison groups? 
The answer to this is a qualified yes. GPs have an increased tendency to code 
attendance for alarm symptoms in those patients later diagnosed with a cancer 
that is strongly associated with the symptom. This leads to recording style bias 
that affects studies whose analysis is restricted to codes. This is because codes 
detect more complete information about symptoms from the cases than from 
the controls. This inflates not only the measures of association between 
recognised alarm symptoms and cancer, but also the risk estimates for cancer.  
14.3 Does recording style vary with type of symptom? 
The answer to this depends on whether you are looking at the event or the 
patient level.  
At the event level, there is no evidence of an association between recording 
style and the type of symptom.  
At the patient level, however, an association becomes apparent. As just 
discussed, GPs are more likely to code alarm symptoms than use the text when 
the alarm symptoms are presented by patients later diagnosed with a strongly 
associated cancer.  
In contrast, for features that do not have a strong association with malignant 
pathology, GPs' recording style is similar whether the patient is later diagnosed 
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with cancer or remains free of the disease. Therefore, studies restricting their 
analysis to codes will produce unbiased measures of association between these 
features and cancer, and unbiased risk estimates.  
14.4 Does the recording style vary with the clinical context 
of a symptom's presentation?  
The answer to this is yes. As described above, GPs have an increased 
tendency to code attendance for alarm symptoms in patients later diagnosed 
with a cancer that is strongly associated with the symptom. However, this strong 
preference for coding is not retained for alarm symptoms presented by patients 
later diagnosed with an unconnected cancer. This suggests that GPs tend to 
code attendance for alarm symptoms when they suspect that the cause is an 
underlying malignancy. 
The patient's gender affects the recording style of visible haematuria in 
particular. GPs are more likely to use the text to record attendance for visible 
haematuria for female than for male patients where they suspect that the 
underlying cause is benign.  
14.5 Do text data provide additional value to coded data? 
The answer to this is yes, on a number of grounds. First, including text records 
permits a more accurate estimation of both the frequency of attendance for a 
symptom, and the number of patients affected. Including text records enabled 
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the first estimate of the risk of bladder cancer in patients presenting with non-
visible haematuria8 – a direct illustration of their added value.  
Secondly, studies that include text data produce: unbiased measures of 
association between alarm symptoms and cancer; unbiased risk estimates of 
cancer in symptomatic patients; and unbiased estimates of the timing of first 
symptom presentation. 
14.6 Summary  
Inclusion of text records increases the accuracy of outcome measures in 
studies of observational data from electronic medical records. This is important 
because electronic medical records are increasingly used in epidemiological 
research, and provide much of the evidence on which national guidelines are 
based.  
Regrettably, it is no longer permissible for the CPRD to collect text records 
made by GPs. Therefore, future studies of CPRD records will be limited to 
anticipating the size and direction of the recording style in their data. My study 
suggests that researchers should consider the following factors when assessing 
their study's vulnerability to recording style bias. 
First, researchers should identify whether the symptom is included as part of the 
Quality and Outcomes Framework. If it is, the researcher can be confident that 
symptom occurrence will be coded consistently for all patients, with minimal 
recording style bias.  
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Second, for symptoms that are not included in the Quality and Outcomes 
Framework, researchers should consider the symptom's clinical significance. 
Our findings suggest that GPs preferentially code clinical features they consider 
significant to a diagnosis, while tending to use hidden text to record those that 
they think are not. 
For alarm symptoms, researchers should anticipate recording style bias that 
favours detection of a history of the symptom in patients later diagnosed with a 
disease with which the symptom is strongly associated. In contrast, for 'low-risk 
but not no-risk' symptoms, recording style bias is likely to be minimal or absent. 
While the risk estimates for the latter symptoms are unaffected, compared with 
the inflated estimates for alarm symptoms, they appear to be relatively low and 
unimportant, which inappropriately marginalises them in the clinicians’ eyes. 
Therefore, recording style bias introduces a positive feedback loop between 
research and clinical practice. The inflated risk estimates for symptoms 
reinforces clinicians’ views of the symptom’s importance, further increasing the 
amount of recording style bias introduced by GPs when they make the medical 
record.  
I understand that the CPRD is lobbying hard to overturn the current moratorium 
on the collection and availability of text data for research. I support them in their 
endeavours because, as this thesis shows, text records are a rich and valuable 
resource that improves the accuracy of epidemiological research.  
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15 Appendices 
15.1  Appendix 1: Literature search tables 
Table 15.1 The search terms and number and details of references found. The 
Boolean/Phrase search mode was chosen and the study period was 1946 to May 2014 
Search terms Number and details of 
references found 
‘General Practice Research Database’ AND ‘unstructured 
text’ 
328,118,162 
‘General Practice Research Database’ AND ‘free text’ 111,22,23,24,28,30,31,118,162,163,164 
‘GPRD’ AND ‘free text’ 71,22,23,24,28,162,163 
‘GPRD’ AND ‘unstructured text’ 228,162 
‘free text’ AND ‘electronic health records’ AND ‘UK’ 913,15,28,32,165,166,167,168,169 
‘free text’ AND ‘electronic medical record’ AND ‘UK’ 0 
‘unstructured text’ AND ‘electronic health records’ AND 
‘UK’ 
128 
‘unstructured text’ AND ‘electronic medical record’ AND 
‘UK’ 
0 
‘uncoded text’ AND ‘electronic health records’ AND ‘UK’ 0 
‘uncoded text’ AND ‘electronic medical record’ AND ‘UK’ 0 
‘Clinical Practice Research Datalink’ AND ‘validation’ 725,27,170,171,172,173,174 
‘General Practice Research Database’ AND ‘validation’ 2810,17,20,21,22,23,25,26,175,176,177,1
78,179,180,181,182,183,184,185,186,187,1
88,189,190,191,192,193,194 
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Table 15.2 Reasons for study exclusion 
Reason Study 
Uncoded 
data not 
examined   
10,164,165,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,188,189,190,191,192,19
3,194 
 
Not 
GPRD/CPR
D 
17,167,169,187 
Used to 
develop 
natural 
language 
processing 
tool 
1,118,162,168 
Publication 
unavailable 
163
 
Protocol 
for 
systematic 
review 
166
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15.2 Appendix 2: Disease thesauri 
Table 15.3 Bladder cancer (cancer site 1) disease thesaurus codes 
Medcode Description Read 
code 
779 Malignant neoplasm of urinary bladder B49..00 
6436 [M]Transitional cell carcinoma NOS BB43.00 
7187 Carcinoma in situ of bladder B837.00 
9712 [M]Papillary transitional cell carcinoma BB4A.00 
16926 Neoplasm of unspecified nature of bladder BA04.00 
19162 Malignant neoplasm of anterior wall of urinary bladder B493.00 
21652 [M]Transitional cell carcinoma in situ BB42.00 
22146 Secondary malignant neoplasm of bladder B581100 
28241 Malignant neoplasm of ureteric orifice B496.00 
31102 Malignant neoplasm of urinary bladder NOS B49z.00 
35963 Malignant neoplasm of lateral wall of urinary bladder B492.00 
36949 Malignant neoplasm of other site of urinary bladder B49y.00 
38862 Malignant neoplasm of trigone of urinary bladder B490.00 
41571 Malignant neoplasm of bladder neck B495.00 
42012 Malignant neoplasm of posterior wall of urinary bladder B494.00 
42023 Malignant neoplasm of urachus B497.00 
44996 Malignant neoplasm of dome of urinary bladder B491.00 
47801 Malignant neoplasm, overlapping lesion of bladder B49y000 
58798 [M]Transitional cell carcinoma, spindle cell type BB47.00 
97091 [X]2ndry malignant neoplasm/bladder+oth+unsp urinary 
organs 
ByuC500 
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Table 15.4 Pancreatic cancer (cancer site 12) disease thesaurus codes 
Medcode Description Read code 
8166 Malignant neoplasm of pancreas B17..00 
8771 Malignant neoplasm of head of pancreas B170.00 
9224 [M]Insulinoma NOS BB5B200 
10949 Malignant neoplasm of ampulla of Vater B162.00 
16931 Carcinoma in situ of pancreas B80z000 
21792 Carcinoma in situ of ampulla of Vater B808600 
26858 [M]Gastrinoma and carcinomas BB5C.00 
32294 [M]Glucagonoma, malignant BB5B500 
34388 Malignant neoplasm of pancreas NOS B17z.00 
35535 Malignant neoplasm of pancreatic duct B173.00 
35718 [M]Gastrinoma NOS BB5C000 
35795 Malignant neoplasm of Islets of Langerhans B174.00 
39870 Malignant neoplasm of tail of pancreas B172.00 
40810 Malignant neoplasm of body of pancreas B171.00 
43594 [M]Gastrinoma or carcinoma NOS BB5Cz00 
48537 Malignant neoplasm of other specified sites of pancreas B17y.00 
49629 [M]Gastrinoma, malignant BB5C100 
55675 Endocrine tumour of pancreas B717011 
58022 [M]Glucagonoma NOS BB5B400 
63102 [M]Islet cell carcinoma BB5B100 
95609 [M]Insulinoma, malignant BB5B300 
95783 Malignant neoplasm of specified site of pancreas NOS B17yz00 
96635 Malignant neoplasm of ectopic pancreatic tissue B17y000 
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Medcode Description Read code 
97875 Malignant neoplasm, overlapping lesion of pancreas B175.00 
98825 [M]Mixed islet cell and exocrine adenocarcinoma BB5B600 
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15.3 Appendix 3: Algorithm construction 
15.3.1 Grammar – a quick tour 
15.3.1.1 Introduction 
A sentence is defined as consisting of a subject and predicate, where the 
predicate contains the verb and gives information about the subject. The 
number of grammatically correct sentences that can be formed from a group of 
words is far less than the number of possible combinations. For example, there 
are 5! (= 120) ways of arranging the five words ‘man’, ‘ball’, ‘a’, ‘the’ and 
‘kicked’; however, only six of these form grammatically correct sentences and 
not all of these are meaningful.195 Plainly then there must be rules governing 
how words can be arranged to form phrases, clauses and sentences.  
15.3.1.2 Constituent phrases of a sentence  
In linguistics, the set of rules governing how words can be arranged 
grammatically in a sentence is called syntax.  Syntactically, sentences are 
thought to consist of a noun phrase (defined as a group of words that behave 
as a noun) and a verb phrase (defined as the main verb and its auxiliaries) 
(see Figure 15.1).  
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Figure 15.1 The basic structure of a sentence (S) can be shown using a syntax tree diagram. 
Abbreviations: NP, noun phrase; VP, verb phrase. (Image generated using Syntax Tree 
Generator Copyright © 2011 by Miles Shang mail@mshang.ca) 
 
Delving deeper into syntax gives a framework on which to build an algorithm 
that can interpret and assign a particular meaning to phrases, clauses and 
sentences.  
15.3.1.2.1 Noun phrase 
As Figure 15.2 shows, the constituent parts of a noun phrase are the 
determiner, adjective, noun and prepositional phrase, of which only the noun is 
obligatory. A determiner is a word used before a noun to show which particular 
example of the noun is meant; for example, articles (e.g. the), possessives (e.g. 
my), quantifiers (e.g. no) and demonstratives (e.g. these). A prepositional 
phrase is one that both follows and modifies the noun.  
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Figure 15.2 A syntax tree can be used to show the constituent parts of a noun phrase. 
Abbreviations: NP, noun phrase; Det, determiner; A, adjective; N, noun; PP, prepositional 
phrase.  Parentheses enclose those parts of speech that are optional and an asterisk indicates 
where there is no upper limit for the number of words that can be included in the sentence. 
(Image generated using Syntax Tree Generator Copyright © 2011 by Miles Shang 
mail@mshang.ca) 
 
15.3.1.2.2 Verb phrase 
The constituent parts of the verb phrase, shown in Figure 15.3, are the verb 
(obligatory), noun phrase and a modifying prepositional phrase.  
Figure 15.3 A syntax tree can be used to show the constituent parts of a verb phrase. 
Abbreviations: VP, verb phrase; V, verb; NP, noun phrase; PP, prepositional phrase. 
Parentheses enclose those parts of speech that are optional. (Image generated using Syntax 
Tree Generator Copyright © 2011 by Miles Shang mail@mshang.ca) 
 
Verbs are classed as either auxiliary or main, where the auxiliary form 
determines the mood, tense or aspect the main verb that follows. For example, 
in the sentence ‘The patient bleeds’, ‘bleeds’ is a main verb; whereas, in the 
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sentence ‘The patient does bleed’, ‘does’ is an example of an auxiliary verb 
determining the mood of main verb ‘bleed’. Auxiliary verbs are particularly 
important when it comes to reversing the meaning of a phrase, as explained 
below. 
15.3.1.2.3 Adjective and adverb phrases 
Sentences can also include optional adjectives (or adjective phrases). As 
shown in Figure 15.4, the adjective phrase consists of an obligatory adjective, 
which can be modified by a prepositional phrase.  
Figure 15.4  A syntax tree can be used to show the constituent parts of an adjective phrase. 
Abbreviations: AP, adjective phrase; A, adjective; PP, prepositional phrase; P preposition; Det, 
determiner; N, noun. Only the adjective is obligatory. (Image generated using Syntax Tree 
Generator Copyright © 2011 by Miles Shang mail@mshang.ca) 
 
Finally, adverbs impart information about their associated verbs, adjectives or 
other adverbs.  
Negation is the denial of the truth of a clause or statement. From the figures 
above, I worked out where negation can fall within the sentence, and used 
these rules to generate the search terms of my algorithm. As shown in Figure 
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15.1, basic sentence construction involves a noun phrase and a verb phrase. 
Bearing in mind that one negative will negate another, the negation can be 
placed in one or other of these phrases and not both at the same time.  
15.3.1.3 Negation of the noun phrase 
15.3.1.3.1 Using the determiner 
A noun phrase consists of an obligatory noun plus the optional determiner, 
adjective(s) and prepositional phrase (Figure 15.2). In my algorithm, I was 
looking to identify negative reports of symptoms in patients; therefore, the 
obligatory noun in the noun phrase will be either the symptoms themselves or 
the patient. The determiner also allows the introduction of negation, through the 
use of words such as ‘no’ and ‘none’ (Figure 15.5): 
Figure 15.5 Negation of a noun phrase is introduced by the determiner. (Image generated using 
Syntax Tree Generator Copyright © 2011 by Miles Shang mail@mshang.ca) 
    
The text strings provided by the CPRD are of one-to-one consultations between 
a patient and their GP, during which it is unlikely that the GP will negate the 
patient (i.e. no patient…); therefore, I thought it reasonable to ignore this option. 
 
406 
 
This gives me my first rule for the algorithm:  
 
Algorithm rule 1 
negative determiners placed before the symptom, for example 
 ‘no’ + ‘symptom’ 
 ‘nil’ + ‘symptom’ 
 ‘no more’ + ‘symptom’a 
 ‘no further’ + ‘symptom’b 
 
15.3.1.3.2 Using affixes 
Combining nouns with the affixes ‘un-‘, ‘a-‘, ‘de-‘, ‘dis-‘, ‘in-‘, ‘-less’ and ‘mis-’ will 
reverse their sense. In this study I was searching for the following symptoms: 
haematuria, jaundice, icterus and abdominal pain, none of which have negated 
forms created using the above affixes. Therefore, this rule has no application 
here, but it may be useful in others so I’ll include it:  
                                            
a
 This form indicates that the patient has experienced the symptom in the past, but is free of it at 
the time of consultation. 
b
 This form indicates that the patient has experienced the symptom in the past, but is free of it at 
the time of consultation. 
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Algorithm rule 2 
affixes negating symptoms, for example: 
 amenorrhoea 
 
15.3.1.3.3 Using the preposition 
Words such as ‘without’ can be used before the symptom to indicate their 
absence, giving me rule 3: 
 
Algorithm rule 3 
negative prepositions negating the symptom, for example: 
 without + (any) + ‘symptom’ 
 
15.3.1.4 Negation of the verb phrase 
A verb phrase consists of an obligatory verb, and optional noun and 
prepositional phrases (Figure 15.3). Negation of a verb can take several forms, 
which are described below. 
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15.3.1.4.1 Using ‘not’  
A commonly used construction is the negative adverb ‘not’, which reverses the 
sense of a positive verb.196 It is important to remember that verbs are classified 
as auxiliary and/or main (see Section 15.3.1.2.2). 
1. Auxiliary verbs: ‘Not’ sandwiched between auxiliary and main verbs 
reverses the meaning of the latter112 (p 15) 195 (p 152); for example, ‘The 
patient does not present with blood in his urine’. ‘Not’ must be used with 
auxiliary verbs, so the opposite of this is ‘The patient presents with blood 
in his urine’. In other words, negation cannot take the form ‘The patient 
presents not with blood in his urine’.  This gives me my fourth rule: 
 
Algorithm rule 4 
‘auxiliary verb’ + ‘not’ + ‘main verb’ + (any) + ‘symptom’, for example: 
  ‘not’ + ‘have’ + (any) + ‘symptom’ 
 ‘not’ + ‘got’ + (any) + ‘symptom’ 
 ‘not’ + ‘complain(ing)/(ed)’ + ‘of’ + (any) + ‘symptom’ 
 ‘not’ + ‘present(ing)/(ed)’ + ‘with’ + (any) + ‘symptom’ 
 ‘not’ + ‘encounter(ed)’ + (any)  + ‘symptom’ 
 ‘not’ + ‘exhibit(ed)’ + (any)  + ‘symptom’ 
 ‘not’ + ‘notice(d)’ + (any) + ‘symptom’ 
 ‘not’ + ‘reveal’ + (any) + ‘symptom’ 
 ‘not’ + ‘see(n)’ + ‘symptom’ 
 ‘not’ + ‘suggest’ + (any) + ‘symptom’ 
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2. Infinitive verbs 195 (p 163): ‘not’ can be placed before an infinitive to 
negate its meaning, giving me rule 5: 
 
Algorithm rule 5 
‘not’ + ‘infinitive verb’ + ‘symptom’, for example: 
 ‘not’ + ‘to be’ + ‘symptom’ 
 
15.3.1.4.2 Using ‘no longer’a 
Algorithm rule 6 
‘noun phrase’ + ‘negative adjective’  + ‘verb phrase’, for 
example: 
 patient + no longer + has + (any)+  ‘symptom’ 
 patient + no longer + complains of + (any) + ‘symptom’ 
 
15.3.1.4.3 Using negative verbs 
Where a verb has a negative meaning, no other form of negation is required. 
This is most likely to occur when the patient is the noun (rule 7a), although it 
                                            
a
 This form indicates that the patient has experienced the symptom in the past, but is free of it at 
the time of consultation. 
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can be used in the present perfect tense when the symptom is the noun 
(rule 7b): 
 
Algorithm rule 7a 
 ‘patient’ + ‘negative verb’ + ‘symptom’, for example: 
 patient denies + (any) 
 patient denied + (any) 
 patient refutes + (any) 
 patient refuted + (any) 
Algorithm rule 7b 
‘symptom’ + ‘negative verb’, for example: 
 haematuria has 
ceased/stopped/cleared/resolved/gone/settleda 
 
15.3.1.5 Negation of the adjective phrase 
15.3.1.5.1 Using ‘not’, ‘never’, ‘no longer’ 
When ‘not’, ‘never’ or ‘no longer’ is placed before a positive adjective it negates 
it, giving me my eighth rule: 
                                            
a
 This form indicates that the patient has experienced the symptom in the past, but is free of it at 
the time of consultation. 
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Algorithm rule 8 
‘noun phrase’ + ‘is’ + ‘not’ + ‘adjective, for example: 
 ‘symptom’ + ‘(is)’ + ‘not’ + present 
 ‘symptom’ + ‘(is) + ‘no longer’ + presenta 
 ‘symptom’ + ‘(is)’ + ‘not’ + applicable 
 ‘symptom’ + ‘(is)’ + ‘not’ + indicated 
Note: in notes, doctors may omit the verb here and just write ‘haematuria not 
present’, for example. 
 
15.3.1.5.2 Using negative adjectives 
Searching for negative adjectives used to describe a symptom gives me my 
ninth rule: 
 
Algorithm rule 9 
‘noun phrase’ + ‘is’ + ‘negative adjective’, for example: 
                                            
a
 This form indicates that the patient has experienced the symptom in the past, but is free of it at 
the time of consultation. 
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 ‘symptom’ + ‘(is)’+ absent/ruled out/negative (-ve)/ 
excluded/ rejected/ denied 
 ‘patient’ + ‘(is)’ + asymptomatic/free of  
 
15.3.1.6 Word patterns that introduce ambiguity  
1. Any: a determiner used before a noun that is defined ‘as some, or even the 
smallest amount or number of’:  
a. ‘if any’ indicates an ambiguous observation and requires further 
investigation to determine the context. 
 
Algorithm rule 11 
‘if any’ + ‘symptom’ 
Classify these occurrences as ‘ambiguous and needing manual classification’ 
 
b. ‘any XXX or symptom.’ (where XXX is another symptom) coming at 
the end of a string of text is ambiguous and requires further 
investigation to determine the context (caught by rule 12 below).  
2. Or: a conjunction placed before a noun to connect different possibilities. It is 
also often used after a negative verb to mean neither one thing nor another, 
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which is the most likely use in this context. An alternative to 'or' is the solidus 
with variable spacing. 
 
Algorithm rule 12 
‘or’ + ‘symptom’ 
‘/’ + ‘symptom 
Classify these occurrences as ‘ambiguous and needing manual classification’ 
 
3. If: conjunction to mean ‘that a particular thing can or will happen only after 
something else happens or becomes true’. When used before a symptom, 'if' 
indicates the possibility of that symptom and not a definite occurrence. 
 
Algorithm rule 13 
‘if’ + ‘symptom’ 
Classify these occurrences as ‘ambiguous and needing manual classification’ 
 
4. Ago: adverb meaning ‘back in time from the present’. This may mean that 
the symptom occurred in the past but is not a current concern. I deliberately 
sought the presence of this word in the text snippets and marked 
observations containing it as requiring manual assessment.  
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Algorithm rule 14 
‘ago’  
Classify these occurrences as ‘ambiguous and needing manual classification’ 
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15.4 Appendix 4: Symptom thesauri 
Table 15.5 Abdominal pain symptom thesauri 
Medcode Description Thesaurus type: 
Bladder Pancreas Generic 
2056 [D] Abdominal colic X X X 
716 [D] Abdominal cramps X  X 
2383 Abdominal discomfort X   
17762 [D] Abdominal migraine   X 
2861 Abdominal migraine   X 
6433 Abdominal migraine - symptom   X 
1763 [D] Abdominal pain X X X 
177 Abdominal pain X X X 
3338 [D] Abdominal pain NOS X X X 
1976 Abdominal pain type X X X 
16402 [D] Abdominal tenderness X   
29352 Abdominal wall pain X X X 
54385 [D] Acute abdomen   X 
17586 Angina - abdominal   X 
15908 Appendicular colic X  X 
930 Biliary colic   X 
6285 Biliary colic   X 
7306 Biliary colic symptom   X 
4617 Central abdominal pain X X X 
1239 [D] Colic NOS   X 
7812 Colicky abdominal pain X  X 
257 Dyspepsia  X  
542 [D] Epigastric pain  X X 
290 Epigastric pain  X X 
23756 [D] Evening colic X   
8697 Flatulent dyspepsia  X  
28285 [D] Gas pain (abdominal) X X X 
11070 General abdominal pain-symptom X X X 
24661 Generalised abdominal pain X X X 
17324 Griping pain   X 
1336 [D] Groin pain   X 
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Medcode Description Thesaurus type: 
Bladder Pancreas Generic 
628 [D] Hypochondrial pain   X 
421 Iliac fossa pain X  X 
134 Indigestion  X  
7623 Indigestion NOS  X  
37118 Indigestion symptom NOS  X  
5862 Indigestion symptoms  X  
2982 Left iliac fossa pain   X 
9061 [D] Left lower quadrant pain X X X 
8362 [D] Left upper quadrant pain X X X 
22608 Lower abdominal pain X  X 
5691 Non-colicky abdominal pain X X X 
19283 [D] Nonspecific abdominal pain X X X 
19223 O/E - abd. pain - epigastrium  X X 
42211 O/E - abd. pain - hypogastrium  X X 
21583 O/E - abd. pain - L.iliac   X 
25630 O/E - abd. pain - L.lumbar   X 
11647 O/E - abd. pain - R. iliac  X X 
36558 O/E - abd. pain - R.lumbar   X 
24627 O/E - abd. pain - umbilical X  X 
37101 O/E - abd.pain-L.hypochondrium  X X 
12639 O/E - abd.pain-R.hypochondrium   X 
15180 O/E - abdo. pain on palpation  X X 
5782 O/E - abdomen tender X   
50590 O/E - abdominal rigidity X   
73235 O/E - abdominal rigidity NOS X   
20640 O/E - epigastric pain on palp.  X X 
42235 O/E - guarding - epigastrium   X 
56084 O/E - guarding - hypogastrium   X 
62933 O/E - guarding - umbilical X  X 
24584 O/E - guarding of abdomen   X 
56094 O/E - guarding-L.hypochondrium   X 
42195 O/E - guarding-R.hypochondrium   X 
62934 O/E - rebound - epigastrium   X 
62927 O/E - rebound - umbilical X  X 
17451 O/E - rebound tenderness   X 
56091 O/E - rebound tenderness NOS   X 
62965 O/E - rebound-R.hypochondrium   X 
17636 O/E - umbilical pain on palp. X  X 
14916 O/E -abd.pain on palpation NOS  X X 
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Medcode Description Thesaurus type: 
Bladder Pancreas Generic 
52402 [X] Other and unspecified abdominal pain  X X 
31062 [D] Other specified abdominal pain X X X 
16868 [D] Pain in left iliac fossa   X 
16806 [D] Pain in right iliac fossa   X 
50662 [X] Pain localized to other parts of lower abdomen   X 
3869 Psychogenic dyspepsia  X  
2234 [D] Recurrent acute abdominal pain X X X 
15201 [D] Renal colic, unspecified   X 
1181 Right iliac fossa pain   X 
19360 [D] Right lower quadrant pain X X X 
7726 [D] Right upper quadrant pain X  X 
9695 Right upper quadrant pain X  X 
51337 Shoulder pain from abdomen   X 
5960 Site of abdominal pain X X X 
25118 Site of GIT pain   X 
29922 Site of GIT pain NOS  X X 
6357 Subcostal pain   X 
20475 [D] Suprapubic pain   X 
7300 Suprapubic pain   X 
70357 [D] Tympanites (abdominal) X   
14989 Type of GIT pain   X 
6395 Type of GIT pain - symptom   X 
44484 Type of GIT pain NOS  X X 
4771 [D] Umbilical pain X  X 
43233 Undiagnosed dyspepsia  X  
8436 [D] Upper abdominal pain X  X 
3978 Upper abdominal pain X  X 
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Table 15.6 Symptom thesaurus for visible haematuria 
Medcode Description 
507 Haematuria 
6030 Haematuria - symptom 
6234 Blood in urine - symptom 
6659 Blood in urine - haematuria 
6901 Clot haematuria 
7164 Recurrent benign haematuria syndrome 
7232 Frank haematuria 
9651 Painless haematuria 
13913 Blood in urine test 
13915 RBCs- red blood cells in urine 
13919 Urine: trace non-haemol. blood 
13929 Urine blood test = +++ 
13932 Urine: trace haemolysed blood 
13934 Urine blood test = + 
17060 Recurrent and persistent haematuria 
19361 Traumatic haematuria 
19792 Urine blood test = ++ 
20357 Painful haematuria 
29463 Urine microscopy:RBC's present 
35555 Urine: red - blood 
44541 Recurrent and persistent haematuria, dense deposit disease 
47228 Essential haematuria 
60856 Recur+persist haematuria difus crescentic glomerulonephritis 
61317 Recur+persist haematuria difus membranous glomerulonephritis 
68364 Recur+persist haematuria, focal+segmental glomerular lesions 
95546 Recurrent+persistnt haematuria minor glomerular abnormality 
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Table 15.7 Symptom thesaurus for jaundice 
Medcode Description 
355 [D]Jaundice (not of newborn) 
2612 [D]Jaundice 
3121 Obstructive jaundice NOS 
5996 O/E - jaundiced 
6000 Jaundice - symptom 
18019 Yellow - symptom 
18574 [D]Icterus NOS 
25418 Yellow/jaundiced colour 
29488 O/E - jaundiced colour 
38877 [D]Jaundice (not of newborn) 
NOS 
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15.5 Appendix 5: Derivation of positive predictive value 
using Bayes’ theorem 
The positive predictive value (PPV) estimates the probability that someone has 
a disease given that they have a positive test result, p (disease | positive test 
result). Where arithmetical calculation is inappropriate, PPV can be estimated 
using Bayes’ Theorem. Here is the derivation: 
Let D be the disease (cancer) under study and S be a positive indication of 
disease (e.g. positive test result or presence of a symptom). From conditional 
probability: 
The probability of disease D, given there is a positive indication (S) of disease, 
is:  
p(D|S)= p(D and S)/p(S)        (1) 
Equally, the probability of S, given the presence of disease D, is: 
p(S|D)= p(D and S)/p(D)        (2) 
So,  
p(D and S)= p(D|S)× p(S) = p(S|D) × p(D)     (3) 
Substituting for p(D and S) in (1): 
p(D|S)= [p(S|D) × p(D)]/p(S)       (4) 
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= Bayes’ theorem in probability format 
If D+ is ‘disease positive’, then the alternative is ‘disease negative’ (D−); 
similarly, S+ and S− are symptom-positive and symptom-negative, respectively. 
You can write (4) in terms of the ratio of posterior probabilities: 
)()|(
)()|(
)|(
)|(





DpDSp
DpDSp
SDp
SDp
       (5) 
As far as a disease is concerned, at any one time a patient can either have it or 
not have it, so p(D+)= 1−p(D−).  This allows us to convert the above equation 
as odds, where odds = probability / (1 − probability): 
)|
)|(
)()|(



DpS
DSp
DoddsSDodds        (6) 
Odds(D+) represents the prior odds of having the disease and can be estimated 
from external sources; in the CAPER studies, from national incidence data. The 
second term in the right-hand side of the above equation is the positive 
likelihood ratio (see Section 6.12.3.4). Therefore, equation (6) can be written in 
words as: 
Posterior odds = prior odds × positive likelihood ratio    (7)  
Adjustment must be made for the fact that the likelihood ratio and the prior odds 
are each representative of different populations; namely, the consulting and the 
whole populations, respectively. To produce risk estimates that are meaningful 
to GPs, the prior odds have to be adjusted to reflect the value in the consulting 
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population. The adjustment factor derives from the proportions of cases and of 
controls who consulted their GP during the period of the study: 
Posterior odds = (prior odds × f) × positive likelihood ratio   (8) 
Where f = , in which xc = the number of eligible cases who consulted in the 
study sample, xt = the total number of cases in the study sample, yc = the 
number of controls who consulted and yt = the number of controls overall. 
The assumption made here was that any patient who has not consulted the GP 
in the year prior to diagnosis did not have a positive indication of disease, i.e. 
their test results would have been normal or they did not attend for the symptom 
whose PPV was being estimated. 
Finally, to estimate the PPV the posterior odds are converted back to a 
probability, as probability = odds / (1 + odds). 
15.5.1 Example for illustration 
I have worked through an example to illustrate the method, using coded records 
of visible haematuria in the bladder cancer study. We would like to estimate the 
probability that a patient with visible haematuria has bladder cancer. From 
equation (8) above, we know that: 
Posterior odds of having bladder cancer = (prior odds of bladder cancer × f) × 
positive likelihood ratio of visible haematuria for bladder cancer  (9) 
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15.5.1.1 Estimating prior odds of bladder cancer 
National incidence data from the UK give us an estimate of the prior probability 
of having the disease, which we can convert to prior odds using the formula: 
Odds = probability/(1−probability)       (10) 
The original bladder cancer study used UK population and bladder cancer 
incidence data published by the Office for National Statistics from 2008 to 
obtain the prior probability.197  In 2008 in England, of the 25,101,400 men and 
women aged 40 years and over, there were 8,735 new diagnoses of bladder 
cancer, giving a prior probability of having bladder cancer equal to 0.00034799.  
Substituting this in equation (10) gives us: 
Odds = 0.00034799/(1−0.00034799)) 
= 0.0003481 
Therefore, in the national population, the prior odds of having bladder cancer is 
0.0003481 – and gives us the value to use in equation (9). 
15.5.1.2 Adjusting the prior odds to be representative of the 
consulting population 
The prior odds value is derived from national population data, and is not 
representative of the consulting population. The adjustment factor, f = , (see 
above for definitions) corrects for this. 
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In the bladder cancer study, all 4,915 eligible and recruited cases consulted the 
GP in the study period; therefore, xc/xt = 1. However, of the 24,098 controls who 
met the inclusion criteria, 2,086 did not consult the GP in the study period; 
therefore, yc/yt = (23,804−2,086)/23,804 = 0.912.
a  
This gives a final adjustment factor, f, to use in equation (9): 
f  = 1/0.912  
= 1.096 
15.5.1.3 Estimating positive likelihood ratio 
The positive likelihood ratio for visible haematuria is 
)|(
)|(


DSp
DSp
 , i.e. the 
probability of visible haematuria in bladder cancer cases divided by the 
probability of visible haematuria in the controls.  
Coded records identified that visible haematuria occurred in 2,591 of the 4,915 
(= 52.7%) cases, and in 196 of the 21,718 (0.6%) of the controls. Assuming that 
patients whose records contained no codes for visible haematuria never 
experienced the symptom, this gives us the value of the positive likelihood ratio 
to use in equation (9): 
                                            
a
 These 2,086 patients met the exclusion criteria, as did a further 294 controls because they 
either received a bladder cancer diagnosis or were matched to an excluded case, leaving a final 
number of 21,718 controls recruited to the study (see Table 7.1). 
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Positive likelihood ratio  = (2,591/4,915) / (196/21,718)  
= 58.4 1 
This figure is representative of CPRD patients who had consulted the GP, 
rather than of the CPRD population as a whole.  
15.5.1.4 Estimating the posterior odds 
From the above figures, we can estimate the posterior odds of bladder cancer in 
patients who have visible haematuria using equation (9): 
Posterior odds  = 0.0003481 × 1.096 × 58.41 
= 0.02228 
This is converted to the PPV using the formula below: 
Probability (PPV) = odds / (1 + odds) 
Therefore: 
PPV    = 0.02228 / (1 + 0.02228) 
= 0.0218, or 2.18%. 
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16 Appendix 6: Risk estimates for the post-1998 
definition of bladder cancer (C67) 
This section reports the risk estimates in symptomatic patients for bladder 
cancer, as defined by International Classification of Disease for Oncology 
category C67.  
Table 16.1 The positive likelihood ratio and PPV for bladder cancer (post-1998 diagnosis) in 
patients aged ≥40 years presenting with clinical features associated with the disease 
Feature of 
bladder cancer 
Number of patients 
attending at least once: 
Positive 
likelihood 
ratio (95% CI) 
PPV (%) 
(95% CI)ab 
Cases n (% 
of n = 3,565 
cases) 
Controls, n 
(% of n = 
15,850 
controls) 
Abdominal 
pain 
c
 
251 (7.0) 581 (3.7) 1.92 (1.66–
2.22) 
0.07 (0.06–
0.08) 
Abdominal 
pain
 d
 
389 (10.9) 896 (5.6) 1.93 (1.72–
2.16) 
0.07 (0.07–
0.08) 
Constipation
 
c
 
205 (5.7) 507 (3.2) 1.80 (1.53–
2.10) 
0.07 (0.06–
0.08) 
Visible 
haematuria
 c
 
1,953 (54.7) 135 (0.9) 64.26 (54.19–
76.22) 
2.40 (2.03–
2.83) 
Visible 
haematuria
 d
 
2,369 (66.4) 239 (1.5) 44.03 (38.74–
50.04) 
1.66 (1.46–
1.88) 
Dysuria
 c
 321 (9.0) 159 (1.0) 8.97 (7.44–
10.81) 
0.34 (0.28–
0.41) 
Urinary 
tract 
infection
 c
 
623 (17.5) 507 (3.2) 5.46 (4.88–
6.10) 
0.21 (0.19–
0.23) 
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Feature of 
bladder cancer 
Number of patients 
attending at least once: 
Positive 
likelihood 
ratio (95% CI) 
PPV (%) 
(95% CI)ab 
Cases n (% 
of n = 3,565 
cases) 
Controls, n 
(% of n = 
15,850 
controls) 
Raised 
inflammatory 
markers
 c
 
229 (6.4) 1,248 (7.9) 0.82 (0.71–
0.93) 
0.03 (0.03–
0.04) 
High white 
cell count
 c
 
189 (5.3) 294 (1.8) 2.86 (2.39–
3.42) 
0.11 (0.09–
0.13) 
Raised 
creatinine
 c
 
229 (6.4) 590 (3.7) 1.72 (1.49–
2.00) 
0.07 (0.06–
0.08) 
Non-visible 
haematuria
 d
 
242 (6.8) 46 (0.3) 23.37 (17.09–
31.96) 
0.88 (0.65–
1.21) 
 
a 
PPV values are adjusted for the consulting population (see Section 6.12.3.5). 
b
 PPV values estimated using Bayes’ Theorem (see Section 6.12.3.5), assuming a prior odds of 0.000348 
based on 2008 UK national incidence data of C67 diagnoses. See Section 15.5.1 for a worked example of 
how to calculate PPV using Bayes’ Theorem. 
c
 Estimated from coded records only. 
d
 Estimated from coded plus text-only records. 
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Table 16.2 The positive likelihood ratio and PPV for bladder cancer (post-1998 diagnosis) in 
patients aged ≥60 years presenting with clinical features associated with the disease 
Feature of 
bladder cancer 
Number of patients 
attending at least once: 
Positive 
likelihood ratio 
(95% CI) 
PPV (%) (95% 
CI)ab 
Cases n (% of 
n = 3,182 
cases) 
Controls, n 
(% of n = 
14,2702 
controls) 
Abdominal 
pain 
c
 
218 (6.9)  538 (3.8) 1.82 (1.56–2.12) 0.14 (0.12–
0.16) 
Abdominal 
pain
 d
 
350 (11.0) 839 (5.9) 1.87 (1.66–2.11) 0.14 (0.13–
0.16) 
Constipation
 
c
 
197 (6.2) 491 (3.4) 1.80 (1.53–2.11) 0.14 (0.12–
0.16) 
Visible 
haematuria
 c
 
1,735 (54.5) 132 (0.9) 58.95 (49.59–
70.06) 
4.33 (3.67–
5.11) 
Visible 
haematuria
 d
 
2,108 (66.2) 232 (1.6) 40.75 (35.78–
46.41) 
3.03 (2.67–
3.44) 
Dysuria
 c
 272 (8.5) 152 (1.1) 8.03 (6.61–9.75) 0.61 (0.50–
0.74) 
Urinary 
tract 
infection
 c
 
567(17.8) 487 (3.4) 5.22 (4.65–5.86) 0.40 (0.35–
0.45) 
Raised 
inflammatory 
markers
 c
 
212 (6.7) 555  (3.9) 1.71 (1.47–2.00) 0.13 (0.11–
0.15) 
High white 
cell count
 c
 
171 (5.4) 279 (2.0) 2.75 (2.28–3.31) 0.21 (0.17–
0.25) 
Raised 
creatinine
 c
 
483 (15.2) 1,229 (8.6) 1.76 (1.60–1.94) 0.13 (0.12–
0.15) 
Non-visible 
haematuria
 d
 
226 (7.1%) 46 (0.3%) 23.03 (16.08–
30.18) 
1.66 (1.22–
2.26) 
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18 Glossary of terms 
Haematuria, visible The abnormal presence of red blood cells in urine in 
sufficient quantities to be readily recognised by the patient. Synonyms: frank, 
gross, macroscopic 
Haematuria, non-visible The abnormal presence of red blood cells in urine in 
an amount so small that it requires detection by urine dipstick testing or 
microscopy. Synonyms: invisible, dipstick-positive, microscopic  
Medcode The numeric form of the alphanumeric Read code, generated 
exclusively by the CPRD to facilitate data management, storage and 
manipulation in software packages such as Stata (see Read codes) 
Noun phrase A word or group of words containing a noun and functioning 
in a sentence as subject, object, or prepositional object. 
Read codes A thesaurus of clinical events, each with a unique alphanumeric 
code, that has been used in the NHS since 1985. There are two versions: 
version 2 (v2) and version 3 (CTV3 or v3). Read codes provide a standard 
vocabulary for clinicians to record patient findings and procedures in health and 
social care IT systems across primary and secondary care (e.g. General 
Practice surgeries and pathology reporting of results). For more information see 
http://systems.hscic.gov.uk/data/uktc/readcodes. The CPRD receive data from 
contributing practices in the form of alphanumeric Read codes, and map them 
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1:1 to numeric medcodes, purely for ease of data management, storage and 
manipulation in software packages such as Stata (see Medcodes) 
Syntax The arrangement of words and phrases to create well-formed 
sentences in a language. 
Verb phrase A verb with another word or words indicating tense, mood, or 
person. 
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